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Abstract 
 
An estimated 2.5 million neonates die every year, with preterm birth being the leading cause. 
Sub-Saharan Africa and southern Asia account for 78% of neonatal deaths. The WHO 
recommends kangaroo mother care (KMC) for stabilised newborns ≤2000g; however, most deaths 
occur before stabilisation. An evidence gap exists regarding KMC for this population.  
 
The overall aim of this PhD was to inform the design of a trial of KMC initiated before 
stabilisation in a sub-Saharan African context. The first part focused on assessing facility 
readiness and quantifying neonatal mortality risk. Cascade models were developed and used to 
assess 23 East African facilities. A logistic model was derived and validated using data from 187 
UK hospitals and one Gambian hospital. The final model, including three parameters, 
demonstrated very good performance. The score requires further validation in low-resource 
contexts, but has potential to improve neonatal resource allocation. 
 
The second part of this PhD focused on evaluating the feasibility of initiating KMC before 
stabilisation and designing the trial. This study showed it was feasible to monitor and provide care 
in the KMC position, and found the intervention was acceptable to parents and providers. 
Launched in 2020, the OMWaNA trial will determine the mortality impact of this intervention 
within 7 days relative to standard care at four Ugandan hospitals. Process and economic 
evaluations will explore causal pathways for clinical effects, estimate incremental cost and cost-
effectiveness, and examine barriers and facilitators to inform uptake and sustainability. 
 
This PhD has developed a cascade model to assess facility readiness, validated a score to assess 
individual risk, and demonstrated the feasibility of initiating KMC before stabilisation. These 
studies have informed the design of a trial evaluating the mortality impact of this intervention in 
Uganda. The findings are expected to have broad applicability to low-resource hospitals and 
important policy implications.  
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Definitions 
 
Adverse event: any untoward medical occurrence in a patient or clinical investigation subject 
administered an experimental therapy, which does not necessarily have to have a causal 
relationship with this therapy1 
 
Apgar score: system for assessing newborns and response to neonatal resuscitation at the time of 
delivery; includes 5 components: 1) colour, 2) heart rate, 3) reflexes, 4) muscle tone, 5) 
respiration; each component is scored 0 to 2 at 1 and 5 minutes post-birth, and at 5-minute 
intervals thereafter up to 20 minutes for infants scoring <72 
 
Apnoea of prematurity: a pause of breathing lasting >15–20 seconds, or accompanied by oxygen 
desaturation (SpO2 ≤80% for ≥4 seconds) and bradycardia (HR <2/3 of baseline for ≥4 seconds), 
in a preterm infant3 
 
Breastmilk feeding: process of feeding a mother's breastmilk to her infant, either directly from the 
breast or by expressing milk from the breast and feeding it to the infant by nasogastric tube, 
bottle, cup, or spoon, to provide calories, macronutrients, and micronutrients4 
 
Hypoglycaemia: blood glucose concentration <2.6 mmol/L; increased risk in newborns who are 
preterm, small-for-gestational age, or sick, and those born to diabetic mothers; highest risk within 
first 24 hours after birth, as newborns transition to extrauterine life; failure to achieve or maintain 
normoglycaemia may be related to inadequate glycogen stores, immature glycogenolytic or 
gluconeogenic pathways, and/or poor endocrine adaptation (e.g., transient hyperinsulinism)5  
 
Hypothermia: body temperature below the normal range (36.5°C – 37.5°C); low birthweight and 
sick newborns are at higher risk because they regulate body temperature less well than normal 
birthweight babies; can be sub-categorised as follows:6 
Mild hypothermia: 36.0°C – 36.4°C 
Moderate hypothermia: 32.0°C – 35.9°C 
Severe hypothermia: <32.0°C 
 
Intraventricular haemorrhage: complication of prematurity characterised by bleeding within the 
ventricles (fluid-filled areas) inside the brain, typically originating from the periventricular 
germinal matrix (a highly vascular collection of neuronal-glial precursor cells); majority of 
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affected infants are asymptomatic; diagnosis is based on screening cranial ultrasound; severity 
ranges from grade 1 (mild) to grade 4 (severe)7 
 
Kangaroo mother care: Package of care that consists of prolonged skin-to-skin contact (SSC) 
between neonate and caregiver, usually the mother; promotion of exclusive breast milk feeding; 
early hospital discharge; and adequate support and close follow-up at home8 
Continuous KMC: SSC between baby and caregiver for at least 18h/day 
Intermittent KMC: SSC between baby and caregiver for periodic sessions of ≥1h duration 
 
Length of stay: duration of hospitalisation 
 
Low birthweight: live newborn with birthweight <2500g; can be sub-categorised as follows:9 
 Very low birthweight: birthweight <1500g 
 Extremely low birthweight: birthweight <1000g 
 
Neonatal mortality rate: number of neonates dying before reaching 28 days of age, per 1,000 live 
births in a year10 
 
Neonatal period: first 28 days post-birth; can be sub-categorised as follows:11 
 Early neonatal period: 0-6 days post-birth 
 Late neonatal period: 7-28 days post-birth 
 
Preterm: live birth before 37 completed weeks gestation; can be sub-categorised as follows:12 
Extremely preterm: birth at <28 weeks 
Very preterm: birth at 28 to <32 weeks 
Moderate to late preterm: 32 to <37 weeks 
 
Serious adverse event: any untoward medical occurrence that 1) results in death, 2) is life 
threatening, 3) requires prolongation of hospitalisation, 4) results in persistent or significant 
disability/incapacity, or 5) is a congenital anomaly/birth defect1 
 
Thermal protection of the newborn: series of measures taken at birth and during first few days 
post-birth to ensure newborns maintain normal body temperature of 36.5-37.5°C6 
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1. Background and rationale 
 
1.1. Global neonatal mortality 
 
Between 1990 and 2015, the mortality rate amongst children under 5 years of age declined by 
53% globally. Despite this accomplishment, the global community failed to achieve the two-thirds 
reduction targeted by Millennium Development Goal (MDG) 4.13 Slower progress in reducing 
neonatal deaths (deaths within 28 days of birth) largely explains why this target was not reached. 
Despite a 3-fold increase in donor assistance for maternal, newborn, and child health projects and 
a 34-fold increase for programmes including newborns in the target population,14 the annualised 
rate of reduction (ARR) for all-cause neonatal mortality between 2000 and 2015 (3.1%) was 
much lower than that for children aged 1–59 months (4.7%).15 Consequently, the proportion of 
neonatal deaths increased from 39% to 45% over the same period.15  
 
Post-2015, the global health community witnessed a shift from the MDGs to the Sustainable 
Development Goals (SDG), including a central focus on closing the equity gap (“leave no one 
behind”).16 In line with this priority, the SDGs include a target neonatal mortality rate of ≤12 per 
1000 livebirths and an under-5 mortality rate of ≤25 per 1000 livebirths in all countries by 2030.17 
Growing recognition of the global burden of neonatal death and disability, including adverse 
effects on human capital and wellbeing, led to the development of the United Nations (UN) 
Secretary General’s Every Newborn Action Plan (ENAP).18 Endorsed at the World Health 
Assembly in 2014, the ENAP is a country-led, multi-partner initiative that aims to end 
preventable newborn deaths and stillbirths, with national targets of ≤10 neonatal deaths per 1000 
livebirths and ≤10 stillbirths per 1000 total births by 2035.19 The ENAP neonatal mortality target 
was selected in consideration of the corresponding under-5 target of ≤25 deaths per 1000 
livebirths in the SDGs. Based on trends between 2000 and 2012, a global ARR of 4.3% will be 
required to achieve the SDG and ENAP neonatal mortality targets by 2030 (Figure 1-1).18  
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Figure 1-1. Mortality trends from 1990 to 2012, and neonatal mortality targets by 2030 set by the 
Every Newborn Action Plan  
 
Source: Lawn et al, 2014.18 Estimates for under-5 mortality rate (U5MR) and neonatal mortality rate (NMR) to 2012 
based on data from the UN Interagency Group for Child Mortality Estimation (UN-IGME). Projections to 2035 based 
on ARRs for 2000-2012, with global numbers representing aggregation of country-specific numbers and projections.  
 
An estimated 2.5 million neonatal deaths occurred in 2018, accounting for 47% of under-5 
deaths.20 The neonatal mortality rate was estimated at 18 per 1000 livebirths globally (2018).20 
The neonatal period represents the time of highest mortality risk amongst children and 
adolescents aged <15 years. Within the neonatal period, 36% of deaths occur within 24 hours (h) 
of birth and 73% occur in the early neonatal period, defined as the first 7 days of life.11 Between 
1980 and 2015, early neonatal mortality decreased more slowly than all other categories of under-
5 deaths (Figure 1-2).21 Complications of preterm birth, defined as birth before 37 completed 
weeks of gestation, are the leading cause, accounting for 35% of neonatal deaths and 16% of 
under-5 deaths (Figure 1-3).20 
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Figure 1-2. Global age pattern of under-5 mortality, 1980-2015  
 
Source: Global Burden of Disease Child Mortality Collaborators, 2015.21 
 
Figure 1-3. Global distribution of under-5 and neonatal deaths by cause, 2018  
 
Source: UN Interagency Group for Child Mortality Estimation, 2019.20 Estimates from WHO and the Maternal and 
Child Epidemiology Estimation Group, based on cause fractions for 2017 applied to UN-IGME estimates for 2018. 
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1.2. Mortality in preterm and low birthweight neonates 
 
Globally, 14.8 million babies are born preterm and 20.5 million are born with low birthweight 
[LBW, <2500 grams (g)] every year.22,23 Over 80% of neonatal deaths occur in LBW babies, 
among which two-thirds are preterm and one-third are term and small-for-gestational age 
(SGA).23–25 Neonatal mortality is 15-fold higher in SGA preterm babies relative to babies with 
either characteristic alone.24 Major mortality reduction could be achieved by improving inpatient 
care in LMICs.18,26–28 In such settings, 50% of neonates born at 32-34 weeks’ gestation, a time 
when nearly all should survive, die because adequate care is not available.26,29   
 
1.3. Neonatal mortality in sub-Saharan Africa, Kenya, and Uganda 
 
Nearly 80% of neonatal deaths occur in sub-Saharan Africa and southern Asia.20 Compared to 
other regions, sub-Saharan Africa has experienced slow progress in reducing newborn deaths, 
particularly those due to complications of prematurity.15,30 The ARR for all-cause neonatal 
mortality in sub-Saharan Africa between 2000 and 2018 (2.1%) was nearly 50% lower than that 
for children aged 1–59 months (3.8%).20 This disparity is likely related to higher rates of preterm 
birth and LBW,18,22,23 poor coverage of facility-based neonatal care,26,29,31,32 and health system 
capacity issues, including physical and human resource deficiencies.33–36 Further, many 
interventions are introduced without adequate evidence of their effectiveness in related LMIC 
contexts.26,37  
 
In Kenya and Uganda, neonatal mortality rates were estimated at 19.6 and 19.9 per 1000 
livebirths, respectively, with a resultant 28,911 and 32,296 deaths in 2018.20 Complications of 
prematurity were a leading cause of neonatal deaths in Kenya and Uganda with estimated cause-
specific mortality rates of 5.8 and 5.4 per 1000 live births, respectively, approximately two-fold 
higher than that of the Americas and three-fold higher than that of Europe (Figure 1-4).38 
Paralleling the global trend, 37% of neonatal deaths in sub-Saharan Africa occur on the day of 
birth and 74% occur in the first week.11  
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Figure 1-4. Causes of neonatal death (2017): Worldwide, Europe, the Americas, Kenya, and Uganda  
 
Source of data: WHO and the Maternal and Child Epidemiology Estimation Group, 2018.38 
 
1.4. Levels of neonatal inpatient care  
 
In an effective health system, neonatal care is typically delivered across three levels (Figure 1-
5).34 Essential newborn care, which should be provided to all babies, includes bag-mask 
resuscitation (for babies who do not breathe at birth), thermal support (drying, warming), hygienic 
cord and skin care, and early initiation of exclusive breastfeeding.26 Special care refers to a 
package of facility-based interventions for small and sick newborns, which includes bag-mask 
resuscitation and overhead heaters (for neonates requiring stabilisation); thermal support with 
kangaroo mother care (KMC); feeding support with intravenous (IV) fluids and nasogastric tubes; 
infection prevention and treatment with antibiotics; oxygen therapy and pulse oximetry 
monitoring for respiratory distress; and phototherapy for jaundice.26,34 Estimates suggest that 
achieving 95% coverage of these interventions in 81 high-burden countries could prevent 747,400 
neonatal deaths in 2030, and reduce prematurity-, intrapartum-, and infection-related causes of 
mortality by 86%, 76%, and 74%, respectively (Figure 1-6).39 Located in tertiary hospitals, 
neonatal intensive care units (NICU) are staffed by providers with specialised neonatal skills and 
additionally offer continuous positive airway pressure (CPAP) or mechanical ventilation, 
surfactant therapy (for preterm babies with severe respiratory distress),26,40 24h laboratory 
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support, and systems for transport and referral.34 A recent survey of clinicians and programme 
professionals working in newborn health identified a subset of neonatal interventions or services 
as ‘transitional’ between special and intensive care. These included CPAP, seizure management, 
blood and exchange transfusion, retinopathy screening and treatment for preterm infants, and 
specialised follow-up for high-risk infants.41 
 
Figure 1-5. Levels of inpatient neonatal care, with health system requirements for each level  
 
Source: Moxon et al, 2015.34 Red text indicates tracer for health system bottleneck analysis.  
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Figure 1-6. Scenarios to 2030 for 81 high-burden countries: current neonatal mortality rate 
trajectory; trajectory required to meet SDG target 3.2; and projection if every newborn covered by 
universal health coverage 
 
Source: World Health Organisation, 2019.39 
 
1.5. Overview of thermal care for preterm and LBW neonates 
 
1.5.1. Kangaroo mother care  
 
KMC is an intervention consisting of early skin-to-skin contact, usually with the mother; 
promotion of exclusive breastmilk feeding; early hospital discharge; and adequate support and 
close follow-up at home.8 Figure 1-7 shows the optimal KMC position with infant upright and 
skin-to-skin between the mother’s breasts.  
 
Figure 1-7. Optimal positioning for kangaroo mother care 
 
Source: World Health Organisation, 2003.8 
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The latest Cochrane review (21 trials) and a meta-analysis (124 studies) demonstrated that KMC 
among stable neonates ≤2000g is associated with decreased mortality,42,43 sepsis,42,43 
hypothermia,43 hypoglycaemia,43 and length of stay (LOS)42 compared to standard care. World 
Health Organisation (WHO) guidelines recommend KMC for “routine care of newborns weighing 
≤2000g… initiated as soon as newborns are clinically stable;”44 where stability has been defined 
as vital functions (breathing, circulation) not requiring “continuous medical support and 
monitoring,” and not being “subject to rapid and unexpected deterioration.”8  
 
1.5.2. Incubator care 
 
Incubators are the standard alternative to KMC for thermal care in preterm and LBW neonates. 
Due to high purchase cost and poor routine maintenance practices, hospitals in low-resource 
settings often lack an adequate quantity of functional incubators (Figure 1-8).45–48 Potential risks 
associated with incubator care include hypothermia;49,50 hyperthermia;51 nosocomial infections 
related to lack of effective cleaning standards;52–54 and cross-infection from other neonates when 
incubators are shared, a common practice in low-resource facilities. Failure of incubators to 
properly regulate temperature may be related to malfunction (over-heating or under-heating),51,54–
57 loss of electrical supply,45 poor understanding of set-point regulation,51 and environmental 
factors.55  
 
Figure 1-8. Incubators in newborn special care units, Iganga District, Uganda 
  
Source of images: Melissa Medvedev, 2016. 
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1.6. Rationale for thesis 
 
In LMIC settings, provision of high-quality inpatient care for small and sick newborns is often 
precluded by limited availability of skilled providers, especially nurses, and shortages of essential 
drugs, supplies, and equipment.33–36 These health system bottlenecks must be recognised and 
addressed to accelerate progress in reducing the burden of death and disability following neonatal 
conditions. Existing scoring systems to quantify neonatal illness severity and mortality risk have 
primarily been developed for high-income contexts, using laboratory-derived and therapy-derived 
measures that are typically unavailable (e.g., blood gas, oxygenation index) or observations that 
are not routinely collected or reliably measurable (e.g., urine output, gestational age) in resource-
constrained facilities.58,59 Assessing individual risk, using a simplified score feasible for LMIC 
settings, and monitoring facility readiness are imperative to help address the aforementioned 
health system bottlenecks and promote improved quality of care for small and sick newborns. 
 
WHO guidelines recommend initiation of KMC once newborns are clinically stable.44 However, 
the majority of neonatal deaths occur within 48h of birth,11 prior to stabilisation. The only 
randomised controlled trial (RCT) of KMC initiated before stabilisation, which reported mortality 
outcomes, was conducted in Ethiopia and enrolled 123 newborns ≤2000g. It reported a 43% 
reduction in mortality; however, 66% of deaths and the major difference between arms occurred 
within 12h of birth.37,60 Further, this trial excluded >50% of eligible newborns, failed to utilise 
allocation concealment, and had an apparent group imbalance at baseline (favouring KMC),60 
compromising robustness. Analyses adjusting for this imbalance were not presented and outcome 
data were selectively reported, raising the likelihood of reporting bias.61 Thus, the effect of KMC 
initiated before stabilisation remains an unaddressed research priority and a well-designed RCT is 
warranted to examine mortality impact relative to standard care, particularly in settings where 
neonatal intensive care is not available.37,62   
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2. Aim and Objectives 
 
2.1. Overall aim 
 
The overall aim of this PhD is to improve risk prediction amongst small and sick newborns and  
inform the design of a RCT of KMC initiated before stabilisation in a sub-Saharan African 
context.  
 
2.2. Objectives 
 
1. To develop clinical cascades to evaluate facility readiness for neonatal care, and utilise these 
to assess 23 health facilities in Kenya and Uganda. 
2. To develop and validate a risk score to predict in-hospital neonatal mortality amongst 
newborns ≤2000g (NMR-2000) within 24h of birth, which is applicable for low-resource 
settings.  
3. To evaluate the feasibility of KMC initiated prior to clinical stabilisation amongst neonates 
≤2000g at Jinja Regional Referral Hospital in Uganda. 
4. To apply the findings from objectives 1-3 to inform the design of a RCT, which will 
determine the effect of KMC initiated before stabilisation relative to standard care on 
mortality within 7 days amongst neonates ≤2000g at four hospitals in Uganda. 
5. To synthesise the implications of this thesis for policy, programmes, and research for newborn 
care in East Africa and beyond. 
 
2.3. Thesis structure 
 
This thesis follows the research paper style, with four of the chapters being papers that have been 
published in peer-reviewed journals. An overview of the component chapters is provided below. 
Further details are provided in section 2.4, including related objectives, research themes and 
questions, and methods. 
 
Chapter 1 provides a background on the global burden of neonatal mortality, mortality in preterm 
and LBW neonates, neonatal mortality in the sub-Saharan African context, the levels of neonatal 
inpatient care, and an overview of KMC and incubators for thermal care of preterm and LBW 
neonates. The rationale for the thesis is included. 
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Chapter 2 (this chapter) includes the aim, objectives, and details regarding ethical approvals and 
funding for the work contained within the thesis. 
 
Chapter 3 addresses Objective 1 and details the development and utilisation of a clinical cascade 
model to assess the physical readiness of 23 health facilities in Kenya and Uganda to identify and 
manage common neonatal conditions. Chapter 3 has been published in a peer-reviewed journal 
(PLoS One). 
 
Chapter 4 addresses Objective 2. It describes the development and validation of a risk score 
practicable for LMIC settings to predict mortality amongst hospitalised newborns ≤2000g within 
24h of birth, using datasets from the United Kingdom (UK) and The Gambia. Chapter 4 has been 
published in a peer-reviewed journal (The Lancet Child and Adolescent Health). 
 
Chapter 5 includes a literature review of the existing evidence regarding KMC, including 
duration, time of initiation, effect on mortality and other important clinical outcomes, and 
potential causal pathways for these clinical effects. 
 
Chapter 6 addresses Objective 3 and describes the findings of a mixed methods study that 
determined the proportion of admitted neonates meeting proposed instability criteria, assessed the 
feasibility of providing KMC to unstable neonates, and evaluated the acceptability of this 
intervention to parents and providers at Jinja Regional Referral Hospital in Uganda. Chapter 6 has 
been published in a peer-reviewed journal (Journal of Global Health). 
 
Chapter 7 addresses Objective 4 and provides a detailed overview of the protocol for a four-
centre, open-label, individually randomised, superiority trial, which aims to determine the effect 
of KMC initiated before stabilisation relative to standard care on mortality within 7 days amongst 
neonates ≤2000g in Uganda. Chapter 7 has been published in a peer-reviewed journal (Trials). 
 
Chapters 8 and 9 address Objective 5. Chapter 8 draws together lessons learnt from Objectives 1 
through 4 and provides an overall summary of the work, including implications. Chapter 9 
provides recommendations for policy, programmes, and research. 
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2.4. Table of overview of thesis chapters, objectives, methods, and papers 
 
Table 2-1. Overview of thesis chapters, objectives, methods, and papers 
Chapter number and title Objective Sub-objectives Methods Paper 
1 Background and rationale To provide context and describe 
rationale for this PhD thesis 
Describe global burden of neonatal 
mortality, including sub-Saharan Africa, 
Kenya, and Uganda 
Provide overview of the levels of 
neonatal inpatient care 
Provide overview of KMC and 
incubator care for thermal support 
Targeted literature 
review 
 
 
2 Aim and objectives     
3 Clinical cascades as a 
novel way to assess 
physical readiness of 
facilities for the care of 
small and sick neonates in 
Kenya and Uganda 
Objective 1: To develop clinical 
cascades to evaluate facility 
readiness for neonatal care and 
utilise these to assess 23 health 
facilities in Kenya and Uganda 
1.1 Develop clinical cascades for six 
common neonatal conditions 
1.2 Utilise the clinical cascades to assess 
23 health facilities in Kenya and 
Uganda 
1.3 Determine changes in resources 
availability over time by facility 
Review of WHO 
clinical guidelines 
 
Estimation of mean 
readiness, readiness 
loss   
McNemar’s test 
Clinical cascades as a novel 
way to assess physical 
readiness of facilities for the 
care of small and sick 
neonates in Kenya and 
Uganda, published in PLoS 
One63 
4 Development and 
validation of a simplified 
score to predict neonatal 
mortality risk among 
neonates weighing 2000g 
or less: an analysis using 
data from the UK and The 
Gambia 
Objective 2: To develop and 
validate a risk score feasible for 
low-resource settings to predict 
in-hospital mortality amongst 
newborns ≤2000g within 24h of 
birth 
2.1 Evaluate existing neonatal illness 
severity and mortality risk scores to 
select candidate variables 
2.2 Develop and validate a score to 
predict in-hospital neonatal 
mortality risk amongst newborns 
≤2000g (NMR-2000)  
2.3 Compare the performance of the 
novel score (NMR-2000) with that 
of an existing score (CRIB-II) 
Literature review 
 
 
Logistic regression, 
prediction model 
 
 
Comparison of areas 
under the receiver 
operating characteristic 
curves 
Development and validation 
of a simplified score to 
predict neonatal mortality 
risk among neonates 
weighing 2000g or less: an 
analysis using data from the 
UK and The Gambia, 
published in The Lancet 
Child and Adolescent 
Health64 
*Table A1-1 provides a detailed overview of my role in each component of this thesis 
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Chapter number and title Objective Sub-objectives Methods Paper 
5 Current evidence regarding 
duration, timing, clinical 
impact, and causal 
pathways for clinical 
effects of kangaroo mother 
care: literature review 
To review existing evidence 
regarding KMC, including 
duration, time of initiation, effect 
on mortality and other clinical 
outcomes, and potential causal 
pathways for these effects  
 Literature review  
6 Kangaroo Mother Care for 
clinically unstable 
neonates: is it feasible at a 
hospital in Uganda? 
Objective 3: To evaluate the 
feasibility of KMC initiated prior 
to stabilisation amongst neonates 
≤2000g at Jinja Hospital in 
Uganda 
 
 
3.1 Determine the proportion of 
admitted neonates meeting proposed 
instability criteria 
3.2 Assess the feasibility of monitoring 
and providing interventions to 
unstable neonates ≤2000g in the 
KMC position 
3.3 Evaluate the acceptability of KMC 
for unstable neonates ≤2000g to 
parents and healthcare providers 
Chart review 
 
Estimation of KMC 
duration and number of 
concurrent therapies 
 
Semi-structured 
interviews, thematic 
content analysis 
Kangaroo Mother Care for 
clinically unstable neonates: 
is it feasible at a hospital in 
Uganda?, published in 
Journal of Global Health65 
7 Operationalising kangaroo 
Mother care before 
stabilisation amongst low 
birth Weight Neonates in 
Africa (OMWaNA): 
protocol for a randomised 
controlled trial to examine 
mortality impact in 
Uganda 
Objective 4: To apply the 
findings of objectives 1-3 to 
inform the design of a RCT, 
which will determine the effect 
of KMC initiated before 
stabilisation relative to standard 
care on mortality within 7 days 
amongst neonates ≤2000g at four 
hospitals in Uganda 
Provide a detailed overview of the 
protocol for a four-centre, open-label, 
individually randomised, superiority 
trial that aims to determine the effect of 
KMC initiated before stabilisation 
relative to standard care on mortality 
within 7 days amongst neonates ≤2000g 
in Uganda 
 Operationalising kangaroo 
Mother care before 
stabilisation amongst low 
birth Weight Neonates in 
Africa (OMWaNA): protocol 
for a randomised controlled 
trial to examine mortality 
impact in Uganda, published 
in Trials66 
8 Discussion and 
implications 
To discuss the main findings of 
the thesis and outline key 
implications  
Discuss overall strengths and limitations    
9 Recommendations and 
conclusion 
Objective 5: To describe the 
implications of these findings for 
policy, programmes, and research 
in East Africa and beyond 
Summarise recommendations for policy, 
programmes, and future research 
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2.5. Ethics 
 
Facility readiness assessment work in Kenya and Uganda (chapter 3) was covered as part of the 
broader research efforts of the University of California San Francisco (UCSF) Preterm Birth 
Initiative-East Africa, which received approval from the ethics committees of UCSF, Makerere 
University, the Uganda National Council for Science and Technology (UNCST), and the Kenya 
Medical Research Institute. Where required, ethical approval for other work included in this thesis 
was obtained from the Research Ethics Committee (REC) of the London School of Hygiene and 
Tropical Medicine (LSHTM). Ethical approval for risk score development and validation (chapter 
4) was also obtained from the North West–Preston REC, the UK Health Research Authority, and 
the REC of the Gambian Government/Medical Research Council Unit The Gambia at LSHTM. 
The KMC feasibility study (chapter 6) was additionally approved by the RECs of Makerere 
University and UNCST, and the OMWaNA trial (chapter 7) by the RECs of the Uganda Virus 
Research Institute and UNCST. All approval letters are included in the annex. Further details 
regarding ethical considerations, including informed consent, are described in individual chapters.  
 
2.6. Funding 
 
Funding for PhD tuition was received from the UCSF Preterm Birth Initiative as part of a 
postdoctoral fellowship at UCSF from 2015 to 2017. Costs of travelling to London for PhD work 
were supported by the UCSF Preterm Birth Initiative fellowship award and a grant from the 
Eunice Kennedy Shriver National Institute of Child Health and Human Development of the 
National Institutes of Health (Grant ID: K23HD092611). Work on the facility readiness cascades 
and the cost of using data from the UK National Neonatal Research Database for the mortality 
risk score work were funded by the Bill & Melinda Gates Foundation through a grant to the 
UCSF Preterm Birth Initiative (Grant ID: OPP 1107312). Work on the risk score was supported 
by a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human 
Development (Grant ID: K23HD092611) awarded to Melissa Medvedev and a Wellcome Trust 
Fellowship (Grant ID: 2000116) awarded to Helen Brotherton. The KMC feasibility study was 
funded by the UCSF Preterm Birth Initiative (as part of postdoctoral fellowship award) and the 
Thrasher Research Fund (Grant ID: 13388). The OMWaNA trial is funded by the Joint Global 
Health Trials scheme of the Department of Health and Social Care, Department for International 
Development, Medical Research Council, and The Wellcome Trust (Grant ID: MR/S004971/1) 
awarded to Joy Lawn. Funding from the Eunice Kennedy Shriver National Institute of Child 
Health and Human Development (Grant ID: K23HD092611) also supported my work on the trial.   
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3. Clinical cascades as a novel way to assess physical readiness of facilities for 
the care of small and sick neonates in Kenya and Uganda (Paper A) 
 
3.1. Scope of this chapter 
 
Chapter 3 presents the first research paper entitled, “Clinical cascades as a novel way to assess 
physical readiness of facilities for the care of small and sick neonates in Kenya and Uganda.” This 
paper describes an innovative approach utilising clinical cascades for six common neonatal 
conditions/emergencies to assess facility readiness across three stages of care (identification, 
treatment, monitoring-modifying treatment), which is employed to assess 23 health facilities in 
Kenya and Uganda. While the focus of this paper is on physical readiness for neonatal inpatient 
care more broadly, this work is included as the first paper of this PhD to illustrate the current 
context for such care in East Africa and to demonstrate the facility-level resource issues that must 
be recognised and addressed to facilitate safe and effective provision of evidence-based 
interventions in this vulnerable patient population. 
 
This work was published in PLoS One as an open access article in November 2018. See Appendix 
A.3.1 for the copyright.  
 
3.2. List of figures 
 
Figure 1- Comparison of overall readiness estimates by stage of care for the essential newborn 
care, neonatal resuscitation, and poor feeding-hypothermia clinical cascades in 2016 
and 2017 
Figure 2- Comparison of overall readiness estimates by stage of care for the respiratory distress-
apnea, infection-convulsions, and jaundice clinical cascades in 2016 and 2017 
Figure 3- Neonatal resuscitation clinical cascade, 2017 
Figure 4- Infection-convulsions clinical cascade, 2016 
 
3.3. List of tables 
 
Table 1- Facility characteristics by facility level 
Table 2- Neonatal care readiness for the essential newborn care, neonatal resuscitation, and poor 
feeding-hypothermia clinical cascades, 2016 and 2017 
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Table 3- Neonatal care readiness for the respiratory distress-apnea, infection-convulsions, and 
jaundice clinical cascades, 2016 and 2017 
Table 4- Readiness loss by clinical cascade and stage of care, 2016 and 2017 
Table 5- Comparison of readiness in facilities with and without newborn special care units, 2016 
and 2017 
 
3.4. Citation 
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Abstract
Background
Globally, there were 2.7 million neonatal deaths in 2015. Significant mortality reduction
could be achieved by improving care in low- and middle-income countries (LMIC), where the
majority of deaths occur. Determining the physical readiness of facilities to identify and man-
age complications is an essential component of strategies to reduce neonatal mortality.
Methods
We developed clinical cascades for 6 common neonatal conditions then utilized these to
assess 23 health facilities in Kenya and Uganda at 2 time-points in 2016 and 2017. We cal-
culated changes in resource availability over time by facility using McNemar’s test. We esti-
mated mean readiness and loss of readiness for the 6 conditions and 3 stages of care
(identification, treatment, monitoring-modifying treatment). We estimated overall mean
readiness and readiness loss across all conditions and stages. Finally, we compared readi-
ness of facilities with a newborn special care unit (NSCU) to those without using the two-
sample test of proportions.
Results
The cascade model estimated mean readiness of 26.3–26.6% across the 3 stages for all
conditions. Mean readiness ranged from 11.6% (respiratory distress-apnea) to 47.8%
(essential newborn care) across both time-points. The model estimated overall mean
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readiness loss of 30.4–31.9%. There was mild to moderate variability in the timing of readi-
ness loss, with the majority occurring in the identification stage. Overall mean readiness
was higher among facilities with a NSCU (36.8%) compared to those without (20.0%).
Conclusion
The cascade model provides a novel approach to quantitatively assess physical readiness
for neonatal care. Among 23 facilities in Kenya and Uganda, we identified a consistent pat-
tern of 30–32% readiness loss across cascades and stages. This aggregate measure could
be used to monitor and compare readiness at the facility-, health system-, or national-level.
Estimates of readiness and loss of readiness may help guide strategies to improve care, pri-
oritize resources, and promote neonatal survival in LMICs.
Introduction
Globally, there were 2.7 million neonatal deaths in 2015 [1]. The leading causes were preterm
birth, defined as birth before 37 completed weeks of gestation (16%), intrapartum-related
events (11%), and sepsis or meningitis (7%) [1]. Deaths in the neonatal period are responsible
for 45% of all deaths in children under age 5, with preterm birth being the leading cause [1].
Major mortality reduction could be achieved by improving care in low- and middle-income
countries (LMIC) [2–5]. Within the neonatal period, 36% of deaths occur on the day of birth
and 73% occur in early neonatal period, defined as the first 7 days [2]. Between 1980 and 2015,
early neonatal mortality has decreased more slowly than all other age-categories of under-5
mortality [6]. Thus, the immediate postnatal and early neonatal periods represent critical win-
dows of opportunity to improve neonatal survival globally.
Facility-based care of small and sick neonates, including neonatal resuscitation, kangaroo
mother care (KMC), intravenous (IV) fluids, feeding support, oxygen, antibiotics, and photo-
therapy, could avert an estimated 580,000 neonatal deaths annually [7]. Estimates suggest that
provision of available interventions in facilities could decrease prematurity, intrapartum, and
infection-related causes of neonatal mortality by 58%, 79%, and 84%, respectively [7]. Con-
versely, some of these interventions also carry a risk of harm when administered by inade-
quately trained staff or without proper equipment. For example, provision of oxygen therapy
in the absence of pulse oximetry monitoring increases the risk of retinopathy and subsequent
visual impairment in preterm neonates [8,9]. Although an estimated 72% of deliveries globally
occurred in facilities from 2012 to 2017 [10], lack of access to delivery and postnatal care
remains a challenge in LMICs [11–13]. Further, essential interventions are not successfully
implemented in many LMICs due to an array of underlying constraints, including shortages of
skilled providers, inadequate funding, poor distribution of newborn care services, and weak
referral systems [14]. To better understand such barriers and ultimately address the functional-
ity of a health system as a whole, facility-level capacity limitations must first be identified.
However, analyzing facility capacity has been an ongoing focus of public health for decades
and competing theories exist on how to best approach such an analysis. To develop and further
standardize an approach, the United Nations Children’s Fund (UNICEF) and the World
Health Organization (WHO) published guidelines describing “signal functions” related to
facility readiness for provision of Essential Obstetric Care (EOC) [15]. These signal functions
represent a selection of key interventions used to treat obstetric complications, which classify
and monitor the level of care (basic or comprehensive) being provided by a facility, rather than
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listing all EOC services that should be provided [15]. In 2009, EOC was replaced by Emergency
Obstetric and Newborn Care (EmONC), and the list of signal functions was expanded to
include neonatal resuscitation (with a bag and mask) at facilities providing basic or compre-
hensive levels of care [16]. Availability, use, and quality of EmONC have been suggested as
pragmatic indicators to monitor and evaluate the progress of health systems towards reducing
maternal and neonatal mortality [16–21], yet there have been few attempts to develop addi-
tional signal functions for neonates. One study evaluated indicators for the quality of pediatric
hospital care in LMICs and found broad support among experts for several newborn indictors,
including availability of tetracycline, vitamin K, parenteral antibiotics, and drugs for the pre-
vention of mother-to-child transmission (PMTCT) of HIV [22]. In 2012, new signal functions
were proposed for routine and emergency newborn care, including KMC, IV fluids, cup feed-
ing, oxygen, antibiotics, and PMTCT [18]; however, these have not been widely adopted glob-
ally. A recent study delineated over 600 structural characteristics, including infrastructure,
equipment, drugs, providers and guidelines, for facility readiness to deliver care for small and
sick newborns, and work is currently underway to finalise recommendations for newborn sig-
nal functions [23].
Notably, the signal function approach is subject to limitations and recommendations for
alternative approaches have led researchers to the rethink the analysis of capacity. Potter and
Brough emphasized that the key components of a functioning health system (i.e., facility/staff,
skills, tools) are hierarchical in nature, and depend greatly upon the availability and functional-
ity of each other [24,25]. Applied to a clinical context, a medical intervention can only be effec-
tively administered if the necessary infrastructure, staff, and tools are first in place. Through
precise identification of resource shortages, capacity needs can be tied to specific gaps found
within each step of the hierarchy [24]. The HIV treatment cascade was developed as a tool to
identify gaps in care delivery and to prioritize resources with the goal of improving public
health [26–28]. At each step of the cascade (e.g., diagnosis, linkage to care), patients may be
lost to follow-up and, as a result, fail to access or benefit from available health interventions.
The cascade approach has subsequently been applied to other areas of public health, including
PMTCT [29], hepatitis C [30], diabetes [31], hypertension [32] and, most recently, emergency
obstetric care [33]. The latter introduced the clinical cascade model, which highlights the fact
that multiple resources are required sequentially or simultaneously in order to provide real-
time patient care [33]. For example, a provider can effectively treat a sick neonate requiring
immediate care only when all resources needed to identify and treat the underlying condition
are simultaneously present in the facility. In the obstetric cascade study, Cranmer and col-
leagues assessed 44 primary care facilities in Kakamega County, Kenya and found that 39–
100% had the resources required for identification, 7–57% had resources for treatment, and
0–2% had resources to monitor or modify treatment across five common maternal emergen-
cies [33].
Informed by Potter and Brough’s capacity pyramid and based on the obstetric emergency
cascade [24,33], we aimed i) to develop clinical cascades to evaluate facility readiness to care for
small, sick neonates and ii) to utilize these to assess 23 health facilities in Kenya and Uganda.
Methods
Study setting
In Kenya and Uganda, annual neonatal mortality rates have slowly decreased over the last
decade, but remain high at 21 and 20 deaths per 1,000 live births, respectively (2017) [34]. Esti-
mated preterm birth rates are 12% for Kenya and 14% for Uganda [35]. We conducted facility
assessments at 23 health facilities- 17 in Migori County, Kenya and 6 in Busoga Region,
Clinical cascades to assess facility readiness for neonatal care
PLOS ONE | https://doi.org/10.1371/journal.pone.0207156 November 21, 2018 3 / 22
Uganda. In Kenya, facilities included 1 county referral hospital, 10 sub-county hospitals, 2 mis-
sion hospitals, and 4 health centers. In Uganda, facilities included 1 regional referral hospital, 3
district hospitals, and 2 mission/private non-for-profit (PNFP) hospitals. All of the facilities
were intervention sites for a larger Preterm Birth Initiative study focused on data strengthen-
ing and provider skills training.
Study procedures
Cascade development. Using the WHO Guidelines for the Management of Common
Childhood Illnesses [36], researchers (MM, DW) developed a list of evidence-based treatments
for 6 common neonatal conditions/emergencies: essential (routine) newborn care (for all new-
borns); neonatal resuscitation; poor feeding-hypothermia; respiratory distress-apnea of pre-
maturity; infection-convulsions; and jaundice. We also reviewed local guidelines, which were
available for a subset of these conditions, and found them to be congruent with the WHO
Guidelines [36]. Researchers (MM, HN, GMN, GN, PW, PO, DW) then developed and refined
lists of essential supplies, including drugs, needed at each stage of the facility readiness cas-
cades: identification of the condition/emergency (stage 1), treatment (stage 2), and monitoring
and modifying treatment as clinically indicated (stage 3). Supplies considered infeasible for
routine use in LMIC settings [IV epinephrine; X-ray machine; laboratory testing supplies (e.g.,
for bacterial culture, complete blood count, blood type, Coombs test); supplies for lumbar
puncture and exchange transfusion)] were not included in the final cascades. Readiness was
defined by the presence of all required supplies/drugs for each clinical cascade and stage of
care, and overall across the 3 stages for all 6 conditions. Within each clinical cascade, readiness
for individual supplies required the simultaneous presence of all preceding supplies in that cas-
cade. Within each stage, individual supplies were organized sequentially in the order in which
they would be required to to provide real-time care.
Facility assessments. We conducted facility assessments at two time-points, approxi-
mately nine months apart, in 2016 and 2017, to determine if any changes in supply availability
occurred over time. Further, as all of the facilities were intervention sites for a larger study, it
was important to monitor supply availability in order to establish any potential impacts on the
ongoing project. All assessments were conducted by in-country project staff with a back-
ground in either clinical care or monitoring and evaluation. Data collectors confirmed the
presence and functionality of items located in neonatal units, labor rooms, and maternity
wards through visual identification. Data collectors verbally inquired with a pharmacist or
other pharmacy staff member to determine the availability of drugs. Staff recorded the pres-
ence or absence of items during facility assessments using a mobile application tool on the
OpenDataKit platform (https://opendatakit.org). Using this tool, data collectors could also
record any additional notes of interest.
Statistical analysis
We described facility characteristics and neonatal care variables with standard descriptive sta-
tistics, including mean, standard deviation (SD), median, interquartile range (IQR), frequency,
and proportion. Point estimates for resource availability across all facilities at each time-point
were summarized as counts and proportions. Changes in resource availability over time by
facility were calculated using McNemar’s test. Since the dataset had fewer than 100 observa-
tions or data were not normally distributed, non-parametric statistics with two-sided tests of
significance were used for all analyses. Loss of readiness was calculated by subtracting readi-
ness at a given stage from readiness in the preceding stage. In the identification stage, readiness
loss was calculated by subtracting readiness from 100%. Means were used to estimate overall
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readiness and loss of readiness because these measures were based on few observations, thus
medians would not accurately capture the range of observations. Variability was summarized
using the absolute range and SD since resource availability varied greatly. Readiness loss
between stages was quantified with percentages. Since resource requirements differ based
upon the expected level of care provision [8,18,37], we estimated readiness for each clinical
cascade and stage of care by facility level as well as by country. In the sub-analysis of health
clinics, we excluded items that are not expected to be available at this level of facility [37]. Fur-
ther, we compared the readiness of facilities with a functional newborn special care unit
(NSCU) to those without using the two-sample test of proportions. All statistical analyses were
carried out using Stata 15.1 (StataCorp LP, College Station, Texas, United States of America).
Ethics
We obtained ethical approval from the Institutional Review Boards of Makerere University,
the Uganda National Council for Science and Technology, the Kenya Medical Research Insti-
tute, and the University of California San Francisco. The facility assessment data did not
require individual informed consent.
Results
Facility characteristics
Among the 23 facilities assessed, the median monthly delivery volume was 52 (IQR: 29–160;
Table 1). Delivery volumes were highest among facilities at the regional, district, or county
level (median: 212, IQR: 188–427) and lowest among facilities at the health center level
(median: 25, IQR: 21–30). Eight (35%) facilities had a functional NSCU, with a median
monthly admission volume of 35 (IQR: 24–108; Table 1). Notably, 6 (100%) of Ugandan facili-
ties had a functional NSCU relative to only 2 (12%) of Kenyan facilities.
Across all 23 facilities, there were a median of 0 pediatricians, 1 general doctor, 0 clinical
officers, and 8 nurse-midwives working in neonatal care (Table 1). Pediatricians were only
available at 2 (9%) facilities, both of which were regional- or district-level hospitals in Uganda.
All 6 Ugandan facilities had�1 general doctor working in neonatal care. Among the 17 Ken-
yan facilities, 6 had�1 general doctor, 6 had�1 clinical officer, and 5 had only nurse mid-
wives working in neonatal care.
Neonatal care resource availability
Across the 2 time-points, there was wide variability in the availability of durable goods (range:
4–91%; S1 Table) and consumable supplies (range: 17–96%; S2 Table). Availability of clean
cloth or towels (-34.8%, p = 0.0325), resuscitation area with warmer (-22%, p = 0.0253), and
glucometers (-30%, p = 0.0082) by facility significantly decreased over time (S1 Table). No sig-
nificant changes in the availability of consumable supplies by facility were identified (S2
Table). Wide variability also existed for newborn special care tracer items [8], including oxy-
gen (78%), pulse oximeters (22–44%), IV fluids [Ringers lactate or half normal saline/5% dex-
trose (91%)], and nasogastric tubes (57%; S1 and S2 Tables). The majority of facilities had
dextrose (78–96%) and aminophylline (78–91%; S2 Table). A much lower proportion stocked
calcium gluconate (39%) and ceftriaxone or cefotaxime (57–65%; S2 Table).
Clinical cascade estimates of neonatal care readiness
Overall, the cascade model estimated mean readiness of 27% (SD: 23) in 2016 and 26% (SD:
28) in 2017 across the 3 stages of care for all 6 conditions. In 2016, mean readiness was 51%
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(SD: 17) in the identification stage, 20% (SD: 12) in the treatment stage, and 9% (SD: 15) in the
monitoring-modifying stage across the 6 cascades. In 2017, mean readiness was 57% (SD: 24)
in the identification stage, 17% (SD: 14) in the treatment stage, and 4% (SD: 6) in the monitor-
ing-modifying stage. Across both time-points, mean readiness by cascade ranged from 12%
(respiratory distress-apnea) to 48% (essential newborn care; Tables 2 and 3; Figs 1 and 2).
In 2017, 14 of 23 facilities (61%) had the resources necessary to identify a non-vigorous neo-
nate requiring resuscitation, including water and soap (or hand disinfectant), stethoscope, and
disposable gloves (Table 2; Fig 3). Of those, 12 (52%) had a resuscitation area with heat lamp,
Table 1. Facility characteristics by facility level.
All
facilities,
N = 23
Regional/district/ county level,
n = 5
Mission/PNFP level,
n = 4
Sub-county level,
n = 10
Health center level,
n = 4
Delivery and newborn unit admission volume
Monthly delivery volume, median (IQR)a 52 (29–160) 212 (188–427) 108 (61–145) 44 (27–63) 25 (21–30)
Functional newborn special care unit
(NSCU), n (%)b
8 (35) 5 (100) 3 (75) 0 (0) 0 (0)
Monthly NSCU admissions, median (IQR)c 35 (24–
108)d
39 (35–108) 28 (24–32)e N/A N/A
Human resources for neonatal care
Pediatrician, median (IQR) 0 (0–0) 0 (0–1) 0 (0–0) 0 (0–0) 0 (0–0)
Any pediatrician, n (%) 2 (9) 2 (40) 0 (0) 0 (0) 0 (0)
General doctor, median (IQR) 1 (0–1) 1 (1–1) 3 (2–4) 0 (0–1) 0 (0–0)
Any general doctor, n (%) 12 (52) 5 (100) 4 (100) 3 (30) 0 (0.0)
Clinical officer, median (IQR) 0 (0–1) 0 (0–0) 0 (0–0) 1 (0–1) 2 (1–3)
Any clinical officer, n (%) 6 (26) 0 (0) 0 (0) 3 (30) 3 (75)
Nurse midwife, median (IQR) 8 (6–12) 14 (14–15) 10 (9–12) 7 (5–8) 6 (5–8)
Any nurse-midwife, n (%) 23 (100) 5 (100) 4 (100) 10 (100) 4 (100)
a Calculated as the number of deliveries per month, averaged over 12 months (September 2016 to August 2017), by facility level.
b NSCUs are expected to provide feeding support for small and sick infants (including IV fluids and nasogastric tubes); infection prevention and management
(including antibiotics); oxygen therapy (with pulse oximetry); phototherapy; incubators or radiant warmers; and space for neonatal resuscitation and KMC. Tertiary
facilities offering neonatal intensive care are expected to additionally provide CPAP, mechanical ventilation, surfactant therapy, and 24-hour laboratory support [8].
c Calculated as the number of admissions to NSCU per month, averaged over 12 months (September 2016 to August 2017), by facility level.
d Figure reflects data from all 6 Ugandan facilities and 1 of the 2 Kenyan facilities with a functional NSCU; these data are not routinely collected in Kenyan facilities
below the county level.
e Figure reflects data from the 2 Ugandan facilities; this data is not routinely collected in Kenyan facilities below the county level.
https://doi.org/10.1371/journal.pone.0207156.t001
Table 2. Neonatal care readiness for the essential newborn care, neonatal resuscitation, and poor feeding-hypothermia clinical cascades, 2016 and 2017 (N = 23
facilities).
Stage Item 2016
n (%)a
2017
n (%)a
Essential Newborn Care Identify Water and soap, or hand disinfectant 18 (78) 19 (83)
Treat Clean blade / cord tiesb[38] 18 (78) 17 (74)
Vitamin K (IM) 10 (44) 8 (35)
Tetracycline eye ointment 9 (39) 8 (35)
PMTCT in line with national policyc
Monitor-Modify Newborn weighing scale 9 (39) 6 (26)
Guidelines: referral of sick newborns 9 (39) 3 (13)
(Continued)
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10 (44%) had a ventilation bag, and 8 (35%) had an appropriately-sized mask and suction
device. Only 1 facility (4%) also had guidelines for referral of sick newborns, which should be
Table 2. (Continued)
Stage Item 2016
n (%)a
2017
n (%)a
Neonatal Resuscitation Identify Water and soap, or hand disinfectant 18 (78) 19 (83)
Stethoscope 13 (57) 17 (74)
Disposable gloves 11 (48) 14 (61)
Treat Resuscitation area with heat lamp 11 (48) 12 (52)
Ventilation bag 9 (39) 10 (44)
Mask–term / preterm sized 7 (30) 8 (35)
Suction device 7 (30) 8 (35)
Monitor-Modify Neonatal resuscitation algorithm 3 (13) 5 (22)
Thermometer 2 (9) 5 (22)
Pulse oximeter with probe 2 (9) 3 (13)
Guidelines: referral of sick newborns 2 (9) 1 (4)
Poor Feeding- Hypothermia Identify Water and soap, or hand disinfectant 18 (78) 19 (83)
Newborn weighing scale 18 (78) 17 (74)
Thermometer 17 (74) 17 (74)
Tape measure 12 (52) 15 (65)
Treat Incubator or radiant warmere [39] 9 (39) 11 (48)
KMC bed or chairf [40] 3 (13) 6 (26)
IV cannula sets 3 (13) 6 (26)
IV bags or tubing 2 (9) 1 (4)
Dextrose (IV) 2 (9) 1 (4)
Nasogastric tube (neonatal size) 2 (9) 1 (4)
Syringes / cups 2 (9) 1 (4)
Monitor-Modify Lancets (neonatal or infant size) 1 (4) 1 (4)
Glucose test strips 1 (4) 1 (4)
Glucometer 0 0
Postnatal gestational age assessment toolg 0 0
Preterm infant feeding guidelines 0 0
Ringers lactate (in 10% dextrose) or half normal saline/ 5% dextroseh [41] 0 0
Guidelines: referral of sick newborns 0 0
a For each successive item in a clinical cascade, readiness requires the simultaneous presence of all preceding items in that cascade.
b Clean, dry cord care is recommended for all neonates born in health facilities. Chlorhexidine 4% is recommended only for neonates born at home in settings with high
neonatal mortality (NMR�30), or to replace application of a harmful traditional substance to the umbilical cord (e.g., cow dung), thus it was not included.
c In settings with high HIV prevalence, PMTCT is required for neonates born to mothers with positive HIV test (not assessed in this study).
d Term (size 1) masks are required for normal-weight infants and preterm (size 0) masks are required for infants weighing<2500 grams (g) [36]. In this study, the
presence of term or preterm size masks was assessed in facilities.
e An incubator or radiant warmer is required for thermal care of neonates weighing�2000g who are: 1) clinically unstable, or 2) clinically stable, but mother/other
caregiver is not able/available to provide KMC.
f A clean cloth (may be brought by the mother), sized approximately 1 square meter, may be folded and securely tied to function as a KMC support wrap/binder. This
may later be replaced by a carrying pouch of the mother’s choice.
g Ballard, Dubowitz, or simplified postnatal gestational age assessment tool is required to calculate gestational age when last menstrual period (LMP) is unavailable,
unreliable, or incongruent with appearance.
h Ringers lactate (added to 10% dextrose in an appropriate ratio, e.g., 1:4) or half normal saline/5% dextrose is required for fluid maintenance in neonates unable to
tolerate enteral feeds after the first 2 days.
https://doi.org/10.1371/journal.pone.0207156.t002
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present in all facilities offering newborn care as this is essential to help providers identify neo-
nates who require a higher level of care (Table 2; Fig 3). In 2016, 12 facilities (52%) had water
and soap (or disinfectant), stethoscopes, and thermometers for identifying neonatal infections
(Table 3; Fig 4). Only 3 (13%) additionally had supplies to dose and administer parenteral anti-
biotics (IV cannula sets, IV bags or tubing, and weighing scale). Although 87% of facilities had
ampicillin (or penicillin) and 78% had gentamicin (S2 Table), far fewer had the resources to
identify infections and accurately administer first-line antibiotics (13% stage 2 readiness;
Table 3; Figs 2 and 4).
Clinical cascade estimates of neonatal care readiness by facility type and by
country
Among the 5 regional/district/county level facilities, the cascade model estimated mean readi-
ness of 43% (SD: 32) in 2016 and 29% (SD: 28) in 2017 across all stages and conditions (S3
Table). Overall mean readiness was 38% (SD: 31) in 2016 and 44% (SD: 37) in 2017 at the 4
Table 3. Neonatal care readiness for the respiratory distress-apnea, infection-convulsions, and jaundice clinical cascades, 2016 and 2017 (N = 23 facilities).
Stage Item 2016
n (%)a
2017
n (%)a
Respiratory Distress-Apnea Identify Water and soap, or hand disinfectant 18 (78) 19 (83)
Stethoscope 13 (57) 17 (74)
Pulse oximeter with probe 6 (26) 4 (17)
Treat Oxygen canister or concentrator 6 (26) 4 (17)
Oxygen tubing 4 (17) 4 (17)
Nasal cannula (neonatal size) 4 (17) 4 (17)
Aminophylline or caffeine citrateb 4 (17) 3 (13)
Ventilation bag 4 (17) 2 (9)
Mask—term / preterm sizec 4 (17) 2 (9)
Suction 4 (17) 2 (9)
Monitor-Modify Guidelines: oxygen therapyd 2 (9) 0
Guidelines: apnea of prematurity 0 0
Continuous positive airway pressure (CPAP) devicee 0 0
Guidelines: referral of sick newborns 0 0
Infection-Convulsions Identify Water and soap, or hand disinfectant 18 (78) 19 (83)
Stethoscope 13 (57) 17 (74)
Thermometer 12 (52) 17 (74)
Treat IV cannula sets 9 (39) 10 (44)
IV bags or tubing 3 (13) 3 (13)
Newborn weighing scalef 3 (13) 3 (13)
Ampicillin or penicillin (IV) 3 (13) 3 (13)
Gentamicin (IV) 3 (13) 3 (13)
Monitor-Modify Guidelines: neonatal sepsis 0 2 (9)
Lancets (neonatal or infant size) 0 2 (9)
Glucose test strips 0 2 (9)
Glucometer 0 0
Dextrose (IV) 0 0
Ceftriaxone or cefotaximeg 0 0
Phenobarbital (IV)h
Calcium gluconate (IV)h 0 0
Guidelines: referral of sick newborns 0 0
(Continued)
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mission/PNFP facilities (S3 Table). Comparatively, overall readiness was lower at the 10 sub-
county level facilities [2016: mean 16 (SD: 20); 2017: mean 23 (SD: 30)] and the 4 health centers
[2016: mean 19 (SD: 32); 2017: mean 27 (SD: 19); S3 Table]. Among the 17 Kenyan facilities,
overall mean readiness was 23% (SD: 23) in 2016 and 22% (SD: 28) in 2017 (S4 Table). Overall
mean readiness was increased at the 6 Ugandan facilities, ranging from 32% (SD: 28) in 2016
to 39% (SD: 31) in 2017 (S4 Table).
Readiness loss by cascade
Along the cascades, there were notable differences in readiness loss from identification (stage
1) through monitoring-modifying therapy (stage 3). At both time-points, it varied least for
neonatal resuscitation (range: 13–35) and most for respiratory distress-apnea (range: 65–74;
Table 4; Figs 1–3; S1 Fig). There was mild to moderate variability in when readiness was lost
along the cascade. In 2016, the majority of readiness was lost during the identification stage for
all cascades except essential newborn care, which lost most readiness in the treatment stage
(Table 4; Fig 4; S1 and S2 Figs). In 2017, the majority of readiness was again lost in the identifi-
cation stage for respiratory distress-apnea, jaundice, and neonatal resuscitation (Table 4; Fig
3). In contrast, the infection-convulsions, essential newborn care, and poor feeding-hypother-
mia cascades lost most readiness in the treatment stage (Table 4; S3 and S4 Figs).
Table 3. (Continued)
Stage Item 2016
n (%)a
2017
n (%)a
Jaundice Identify Water and soap, or hand disinfectant 18 (78) 19 (83)
Lancets (neonatal or infant size) 11 (48) 10 (44)
Serum bilirubin measurement or bilirubin test stripsi [42,43]
Treat Phototherapy unit 3 (13) 2 (9)
Incubator or radiant warmerj 3 (13) 2 (9)
Monitor-Modify Guidelines: neonatal jaundicek
Postnatal gestational age assessment toolk 1 (4) 2 (9)
Newborn weighing scalel 1 (4) 2 (9)
Guidelines: referral of sick newborns 1 (4) 2 (9)
a For each successive item in a clinical cascade, readiness requires the simultaneous presence of all preceding items in that cascade.
b Caffeine citrate (preferred) or aminophylline is required to help prevent and treat apnea in preterm infants.
c Term (size 1) masks are required for normal-weight infants and preterm (size 0) masks are required for infants weighing<2500g [36]. In this study, the presence of
term or preterm size masks was assessed in facilities.
d Oxygen therapy guidelines are needed to help providers modify oxygen therapy based on oxygen saturation and clinical signs.
e CPAP is required to provide respiratory support to infants with severe respiratory distress (in secondary/referral-level facilities).
f A weighing scale is required for accurate dosing of antibiotics and other medications.
g Ceftriaxone or cefotaxime is required as a second-line therapy for meningitis and other severe infections not responding to initial antibiotics within 2–3 days.
Ceftriaxone is also used as a first-line therapy with tetracycline eye ointment (in Essential Newborn Care cascade) for ophthalmia neonatorum.
h Phenobarbital is required to treat infants who are having convulsions (not assessed in this study). In addition, measurement of serum calcium should be considered (in
facilities with laboratory capacity), with calcium gluconate 10% administered for treatment of hypocalcemia.
i Bilirubin should be measured in infants with suspected hyperbilirubinemia. Serum bilirubin measurement is preferred (in facilities with laboratory capacity). Rapid
bilirubin tests may be used in facilities lacking laboratory capacity (not assessed in this study).
j An incubator or radiant warmer is required for thermal care of neonates weighing�2000g while receiving phototherapy.
k Guidelines are needed to help providers assess risk of severe hyperbilirubinemia and determine treatment threshold (not assessed in this study). Ballard, Dubowitz, or
other gestational age assessment tool is required to calculate gestational age (when LMP is unavailable, unreliable, or incongruent with appearance) for use in
determining severe hyperbilirubinemia risk and treatment threshold.
l A weighing scale is required to monitor for evidence of dehydration during phototherapy.
https://doi.org/10.1371/journal.pone.0207156.t003
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Fig 1. Comparison of overall readiness estimates by stage of care for the essential newborn care, neonatal resuscitation, and poor feeding-hypothermia clinical
cascades in 2016 and 2017.
https://doi.org/10.1371/journal.pone.0207156.g001
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Fig 2. Comparison of overall readiness estimates by stage of care for the respiratory distress-apnea, infection-convulsions, and jaundice clinical cascades in 2016
and 2017.
https://doi.org/10.1371/journal.pone.0207156.g002
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Readiness loss by stage
Across all 6 cascades, mean readiness loss by stage ranged from 43–49% for identification, 31–
40% for treatment, and 12–13% for monitoring-modifying treatment (Table 4). Across all cas-
cades and stages, there was an increasingly consistent pattern of 30% (SD: 5) to 32% (SD: 2)
overall readiness loss, with moderate variability in how loss occurred across stages (SD across
stages: 20–23; Table 4).
Comparison of readiness in facilities with and without newborn special
care units
Across both time-points, overall mean readiness was higher among facilities with a functional
NSCU (37%) compared to those without (20%). For both groups, readiness was again lowest
for respiratory distress-apnea (27% and 3%, respectively) and highest for essential newborn
care (54% and 39%, respectively; Table 5). Among facilities with a NSCU, there was
Fig 3. Neonatal resuscitation clinical cascade, 2017.
https://doi.org/10.1371/journal.pone.0207156.g003
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significantly increased identification readiness for respiratory distress-apnea (2016: 63% vs.
7%; 2017: 38% vs. 7%) and jaundice (2016: 75% vs. 33%), and treatment readiness for essential
Fig 4. Infection-convulsions clinical cascade, 2016. See Table 3 for relevant footnotes.
https://doi.org/10.1371/journal.pone.0207156.g004
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newborn care (2016: 75% vs. 20%), poor feeding-hypothermia (2016: 25% vs. 0%), respiratory
distress-apnea (2016: 38% vs. 7%; 2017: 25% vs. 0%), and infection-convulsions (2017: 38% vs.
0%; Table 5). At the monitoring-modifying stage, a significant difference was only identified
for essential newborn care (2016: 38% vs. 7%; Table 5).
Discussion
The clinical cascade model offers a novel, stepwise approach to quantitatively estimate facility
readiness for neonatal care in LMICs. Cascade-derived indicators, including overall readiness,
readiness loss by cascade, readiness loss by stage, and aggregate readiness loss, can be used by
health administrators, policy-makers, program managers, and researchers to assess and moni-
tor the availability of drugs, supplies, and equipment for facility-based neonatal care in such
contexts. By precisely identifying the timing and location of readiness loss, by stage or clinical
condition, the cascades could help guide resource allocation decisions and facilitate provision
of available, evidence-based interventions to reduce neonatal morbidity and mortality [7]. Fur-
ther, aggregate readiness loss may be utilized to evaluate and compare readiness for neonatal
care across health systems, countries, or geographic regions [33].
In contrast to health facility inventories and signal functions widely used to evaluate
EmONC capacity [16,44,45], the cascades pragmatically assess and quantify a facility’s capacity
Table 4. Readiness loss by clinical cascade and stage of care, 2016 and 2017.
Readiness loss by stagea Readiness loss by cascade
Identify Treat Monitor/Modify Mean loss across 3 stages SD Range
2016
Loss by clinical cascade
30b 20
Essential Newborn Care 22 39 0 20 20 39
Neonatal Resuscitation 52 17 22 30 19 35
Poor Feeding-Hypothermia 48 44 9 33 21 39
Respiratory Distress-Apnea 74 9 17 33 35 65
Infection-Convulsions 48 39 13 33 18 35
Jaundice 52 35 9 32 22 44
Overall loss by stage
Mean loss across cascade 49 31 12
SD 17 14 8 5
2017
Loss by clinical cascade
32b 23
Essential Newborn Care 17 48 22 29 16 30
Neonatal Resuscitation 39 26 31 32 7 13
Poor Feeding-Hypothermia 35 61 4 33 28 57
Respiratory Distress-Apnea 83 9 9 33 43 74
Infection-Convulsions 26 61 13 33 25 48
Jaundice 57 35 0 30 29 57
Overall loss by stage
Mean loss across cascade 43 40 13
SD 24 21 11 2
a n = 23 facilities
b This figure represents overall mean readiness loss across the 3 stages for all 6 cascades.
https://doi.org/10.1371/journal.pone.0207156.t004
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to identify and manage six common neonatal conditions. This is accomplished by modeling
the hierarchical and interdependent relationship among the resources required to identify a
condition, provide initial treatment, monitor clinical response, and modify treatment if indi-
cated [24,25]. Although additional signal functions for emergency newborn care were pro-
posed in 2012 [18], these have not been incorporated in recent WHO guidelines [38,39].
Further, a standardized approach to evaluate readiness for basic newborn care using existing
indicators is lacking [16,33].
To help address this gap, the cascade model provides an intuitive set of overall, condition-
specific, and health system readiness indicators for basic and comprehensive levels of newborn
care. Notably, this approach entails a negligible increase in data collection requirements com-
pared to existing facility assessment inventories [44,45]. In addition, the neonatal cascades pro-
vide detailed information about when and where readiness loss occurs. Aggregate readiness
loss can be used as a standardized indicator to quantify and compare readiness at the facility-,
health system-, or national-level. This study identified a consistent pattern of 30–32% overall
readiness loss across cascades and stages, which is comparable to that seen in the obstetric cas-
cade study in Kenya [33]. The majority of readiness loss occurred in the identification stage;
however, loss of treatment readiness increased in 2017, with this stage accounting for the
majority of overall loss for essential newborn care, poor feeding-hypothermia, and infection-
convulsions. Comparatively, the obstetric cascade study found increased variability in timing
of readiness loss. For example, most loss for hypertensive emergencies occurred in the identifi-
cation stage, whereas most loss for hemorrhage occurred in the monitoring-modifying stage
[33].
Table 5. Comparison of readiness in facilities with and without newborn special care units, 2016 and 2017.
Stage Neonatal care cascade 2016 time-point 2017 time-point
NSCU presenta NSCU absentb p-valuec NSCU presenta NSCU absentb p-valuec
Identify Essential Newborn Care (n, %) 7 (88) 11 (73) 0.2159 7 (88) 12 (80) 0.3256
Neonatal Resuscitation (n, %) 4 (50) 7 (47) 0.4400 6 (75) 8 (53) 0.1549
Poor Feeding-Hypothermia (n, %) 6 (75) 6 (40) 0.0548 6 (75) 9 (60) 0.2360
Respiratory Distress-Apnea (n, %) 5 (63) 1 (7) 0.0019 3 (38) 1 (7) 0.0318
Infection-Convulsions (n, %) 5 (63) 7 (47) 0.2350 7 (88) 10 (67) 0.1396
Jaundice (n, %) 6 (75) 5 (33) 0.0283 5 (63) 5 (33) 0.0892
Treat Essential Newborn Care (n, %) 6 (75) 3 (20) 0.0050 3 (38) 5 (33) 0.4202
Neonatal Resuscitation (n, %) 3 (38) 4 (27) 0.2960 4 (50) 4 (27) 0.1319
Poor Feeding-Hypothermia (n, %) 2 (25) 0 (0) 0.0214 1 (13) 0 (0) 0.0807
Respiratory Distress-Apnea (n, %) 3 (38) 1 (7) 0.0318 2 (25) 0 (0) 0.0214
Infection-Convulsions (n, %) 2 (25) 1 (7) 0.1074 3 (38) 0 (0) 0.0055
Jaundice (n, %) 2 (25) 1 (7) 0.1074 1 (13) 1 (7) 0.9936
Monitor-Modify Essential Newborn Care (n, %) 3 (38) 1 (7) 0.0318 0 (0.0) 3 (20.0) 0.9125
Neonatal Resuscitation (n, %) 1 (13) 1 (7) 0.3193 1 (13) 0 (0) 0.0807
Poor Feeding-Hypothermia (n, %) 0 (0) 0 (0) 1.0000 0 (0) 0 (0) 1.0000
Respiratory Distress-Apnea (n, %) 0 (0) 0 (0) 1.0000 0 (0) 0 (0) 1.0000
Infection-Convulsions (n, %) 0 (0) 0 (0) 1.0000 0 (0) 0 (0) 1.0000
Jaundice (n, %) 1 (13) 0 (0) 0.0807 1 (13) 1 (7) 0.9936
a Facilities with functional NSCU, n = 8
b Facilities without functional NSCU, n = 15
c p-values were calculated using the two-sample test of proportions, with a 95% level of confidence.
https://doi.org/10.1371/journal.pone.0207156.t005
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Using the cascade model, we found that overall readiness for neonatal care was 26% among
the 23 facilities at both time-points. In comparison, three studies using the EmONC signal
function classification to assess a total of 431 facilities in sub-Saharan Africa and South Asia
found that 0–9% and 0–23% were able to provide basic and comprehensive levels of care,
respectively [19–21]. Readiness was consistently highest for essential newborn care. This may
be related to the fact that resources required for comprehensive neonatal care are more expen-
sive or difficult to maintain than those needed for essential newborn care. Additionally, previ-
ous studies evaluating facility or health system capacity have largely focused on indicators
related to basic newborn care, including cleanliness, breastfeeding, cord care, tetracycline eye
ointment, vitamin K, and resuscitation at birth [18–22,46–48]. Conversely, readiness was con-
sistently lowest for respiratory distress-apnea, with only 17–26% of facilities having a pulse
oximeter and other supplies required for identification. Two previous studies in Kenya simi-
larly found that 14–18% of public referral hospitals had functional pulse oximeters for pediat-
ric and neonatal care in 2012 [49,50]. Not surprisingly, overall readiness was higher in
regional/district/county level and mission/PNFP facilities relative to sub-county and health
clinic level facilities. In line with the WHO guidelines on managing possible serious bacterial
infections in young infants when referral is not feasible [51], we replaced IV cannula sets with
sterile syringes and needles (for IM injection) in the neonatal infection-convulsions cascade
sub-analysis of health clinics. By country, overall readiness was higher in Uganda (32–39%)
than in Kenya (22–23%). This is likely related to the fact that 100% of Ugandan facilities had a
functional NSCU, whereas nearly 90% of Kenyan facilities did not.
Endorsed in 2014, the Every Newborn Action Plan (ENAP) is a global multi-partner initia-
tive to prevent stillbirths and reduce neonatal mortality, with national targets of 10 or fewer
deaths per 1000 livebirths by 2035 [52]. To help improve the provision of facility-based care,
ENAP has recommended defining indicators for intervention packages by level of care (basic,
special, or intensive care), noting that many small and sick neonates can be appropriately man-
aged in NSCUs [3,8,23]. A Delphi study suggested that special care, including KMC, feeding
support, IV fluids, oxygen, and management of infections and jaundice, could prevent 70% of
deaths in preterm neonates [7]. We identified increased overall readiness among facilities with
a NSCU compared to those without. Further, facilities with a NSCU had significantly increased
treatment readiness for essential newborn care, poor feeding-hypothermia, respiratory dis-
tress-apnea, and infection-convulsions, relative to facilities without a NSCU. Recognizing the
need to improve care for small and sick neonates, the Government of India scaled-up the
establishment of NSCUs in district hospitals across the country [53–55]. A study of eight
NSCUs in eight Indian states, all established within the preceding five years, demonstrated
that cause-specific mortality due to sepsis and low birthweight decreased significantly over a
two-year period [55].
Notably, poor-quality care is now considered to be a greater barrier to mortality reduction
in LMICs than insufficient access [56]. The WHO has developed a quality of care framework
for pregnant women and newborns in facilities, which highlights the overarching need for
both competent human resources and essential physical resources and additionally requires
evidence-based practices for routine and emergency care; actionable information systems;
functional referral systems; effective communication; respect and dignity; and emotional sup-
port [57]. In recent years, increased emphasis has been placed on promotion of respectful
maternity care and elimination of abuse during childbirth [58–60]. One study found that
women who experience discrimination or abuse during childbirth are less likely to seek facil-
ity-based delivery care in the future [61]; such experiences may also deter postnatal care-seek-
ing [12]. To help improve clinical outcomes for small and sick newborns, a culture of
capability should be promoted in places where fatalism on the part of healthcare providers is
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common [62,63]. Evidence from high- and middle-income countries has also demonstrated
the value of family-centered developmental care for this vulnerable population [64–66]. A
study in Colombia found that continuing education for care providers, provision of materials
for positioning of neonates, and use of an informative video for parents were helpful in pro-
moting related care practices [67].
This study has several limitations. The cascade model assesses the physical readiness of
facilities to provide newborn care, but it does not assess human resource availability or health-
care providers’ skills. Observational data from 18 LMICs, including Kenya and Uganda,
showed that providers fulfilled 45% and 64% of recommended elements of sick child and deliv-
ery care, respectively [56], highlighting the fact that provider skill assessment is also impera-
tive. These data are from 23 facilities in two regions within two countries of East Africa, which
limits generalizability to all LMIC contexts. All facility assessments were routinely conducted
as part of a broader maternal and newborn health research initiative. As a result, a few vari-
ables necessary for complete modeling of the essential newborn care, infection-convulsions,
and jaundice cascades were not available. Significant and unanticipated reductions in the avail-
ability of certain durable goods (e.g., resuscitation area with warmer, glucometer) were identi-
fied; however, we did not obtain data about potential reasons why these items were no longer
present (or functional). Certain tracer items for basic and special levels of newborn care are
poorly defined, which may slightly limit comparisons of this study with previous studies using
these indicators from the literature. For example, the EmONC tracer for basic neonatal resus-
citation does not specify the ventilation bag or mask size [16], and the ENAP tracer for IV
fluid does not specify the type of fluid [8]. Clearly defined tracer items are imperative to stan-
dardize readiness estimates for neonatal care and promote comparability across study results
and settings.
In the future, research should evaluate the neonatal cascade model in a variety of cultural,
regional, and national contexts. In addition, studies comparing this novel model of neonatal
care readiness with previous models may be indicated. Notably, the third stage (monitoring-
modifying treatment) of each cascade includes one or more guidelines related to newborn care
practices, e.g., referral of sick newborns; however, few previous studies assessing facility readi-
ness for EmONC have utilized clinical guidelines as tracer items [33,47,68]. To assess the qual-
ity of facility-based neonatal care and compare readiness estimates using different models,
inclusion of tracers for key clinical guidelines is essential. Finally, research could evaluate the
ability of the cascades, employed as one component of a broader model, to predict neonatal
mortality and morbidities related to the 6 conditions and explore the association between
aggregate readiness loss and neonatal mortality across countries or regions.
Conclusion
In conclusion, the clinical cascade model provides a novel, stepwise approach to quantitatively
assess facility readiness for neonatal care. We identified a consistent pattern of 30–32% readi-
ness loss across cascades and stages at both time-points at 23 facilities in Kenya and Uganda.
This aggregate measure could be used to monitor and compare readiness at the facility-, health
system-, or national-level. Cascade-derived estimates of readiness and capacity loss may help
guide strategies to improve care, prioritize resources, and promote neonatal survival in
LMICs.
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4. Development and validation of a simplified score to predict neonatal 
mortality risk among neonates weighing 2000 g or less (NMR-2000): an 
analysis using data from the UK and The Gambia (Paper B) 
 
4.1. Scope of this chapter 
 
Chapter 4 presents the second research paper entitled, “Development and validation of a 
simplified score to predict neonatal mortality risk among neonates weighing 2000 g or less 
(NMR-2000): an analysis using data from the UK and The Gambia.” Existing systems to quantify 
neonatal illness severity and mortality risk have primarily been developed for high-income 
settings, often requiring complex calculations and using parameters that are infrequently available 
or challenging to measure accurately in resource-constrained facilities. This paper describes the 
development and validation of a risk score, feasible for use in LMIC settings, to predict in-
hospital neonatal mortality within 24h of birth. Prompt recognition of illness and provision of 
evidence-based therapies are imperative to improve clinical outcomes amongst the smallest and 
most vulnerable newborns.  
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or less (NMR-2000): an analysis using data from the UK and 
The Gambia
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Summary
Background 78% of neonatal deaths occur in sub-Saharan Africa and southern Asia, among which, more than 80% 
are in low birthweight babies. Existing neonatal mortality risk scores have primarily been developed for high-resource 
settings. The aim of this study was to develop and validate a score that is practicable for low-income and middle-
income countries to predict in-hospital mortality among neonates born weighing 2000 g or less using datasets from 
the UK and The Gambia.
Methods This analysis used retrospective data held in the UK National Neonatal Research Database from 187 neonatal 
units, and data from the Edward Francis Small Teaching Hospital (EFSTH), Banjul, The Gambia. In the UK dataset, 
neonates were excluded if birthweight was more than 2000 g; if the neonate was admitted aged more than 6 h or 
following discharge; if the neonate was stillborn; if the neonate died in delivery room; or if they were moribund on 
admission. The Gambian dataset included all neonates weighing less than 2000 g who were admitted between 
May 1, 2018, and Sept 30, 2019, who were screened for but not enrolled in the Early Kangaroo Mother Care Trial. 
18 studies were reviewed to generate a list of 84 potential parameters. We derived a model to score in-hospital neonatal 
mortality risk using data from 55 029 admissions to a random sample of neonatal units in England and Wales from 
Jan 1, 2010, to Dec 31, 2016. All candidate variables were included in a complete multivariable model, which was 
progressively simplified using reverse stepwise selection. We validated the new score (NMR-2000) on 40 329 admissions 
to the remaining units between the same dates and 14 818 admissions to all units from Jan 1, to Dec 31, 2017. We also 
validated the score on 550 neonates admitted to the EFSTH in The Gambia.
Findings 18 candidate variables were selected for inclusion in the modelling process. The final model included 
three parameters: birthweight, admission oxygen saturation, and highest level of respiratory support within 24 h of 
birth. NMR-2000 had very good discrimination and goodness-of-fit across the UK samples, with a c-index of 
0·8859–0·8930 and a Brier score of 0·0232–0·0271. Among Gambian neonates, the model had a c-index of 0·8170 
and a Brier score of 0·1688. Predictive ability of the simplified integer score was similar to the model using regression 
coefficients, with c-indices of 0·8903 in the UK full validation sample and 0·8082 in the Gambian validation sample.
Interpretation NMR-2000 is a validated mortality risk score for hospitalised neonates weighing 2000 g or less in 
settings where pulse oximetry is available. The score is accurate and simplified for bedside use. NMR-2000 requires 
further validation using a larger dataset from low-income and middle-income countries but has the potential to 
improve individual and population-level neonatal care resource allocation.
Funding Bill & Melinda Gates Foundation; Eunice Kennedy Shriver National Institute of Child Health & Human 
Development; Wellcome Trust; and Joint Global Health Trials scheme of Department of Health and Social Care, 
Department for International Development, Medical Research Council, and Wellcome Trust.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
An estimated 2·5 million neonatal deaths occurred in 
2018, accounting for 47% of deaths among children 
younger than 5 years.1 The burden of neonatal mortality 
is unequally distributed, with nearly 80% of these 
deaths occurring in sub-Saharan Africa and southern 
Asia.1 Between 2000 and 2015, neonatal mortality 
declined more slowly than mortality among children 
aged 1–59 months. This disparity was particularly 
notable in sub-Saharan Africa, where the annual 
mortality reduction for newborn babies was less than 
half of that for 1–59 month-olds.2 Slow progress in this 
region might be related to high incidences of preterm 
birth (<37 completed weeks of gestation) and low 
birthweight (≤2000 g),3,4 poor access to care for 
neonates,5,6 and health system capacity issues, including 
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shortages of skilled providers, essential supplies, and 
basic equipment.6–8
More than 80% of neonatal deaths in sub-Saharan 
Africa and southern Asia occur in babies with a low 
birthweight.9 Low birthweight can result from being 
preterm, being small for their gestational age, or both. 
Mortality is twice as high in full-term neonates who are 
small for their gestational age than in full-term neonates 
who are of average size, and 15 times higher in preterm 
neonates who are small for their gestational age than in 
babies with either characteristic alone.10 The lower the 
birthweight and gestational age, the higher the mortality 
risk.9 Around 86% of neonates born at fewer than 
28 weeks’ gestation, and 41% of those born at 28–31 weeks, 
will die without access to intensive care;11 more than 75% 
of neonates in sub-Saharan Africa and southern Asia 
have no access to such care.7 Estimates suggest that 
neonatal special care,5,7 including resuscitation, kangaroo 
mother care, feeding support or intravenous fluids, and 
management of respiratory distress, infections, and 
jaundice, could prevent 70% of preterm deaths and 
decrease prematurity-related causes of neonatal mortality 
by 58%.12
Various systems for scoring illness severity and 
mortality risk in neonates have been developed, primarily 
for high-income settings (appendix p 6). Therapy-based 
approaches, such as the Neonatal Therapeutic Inter-
vention Scoring System (NTISS),13 categorise illness 
severity by the quantity and type of therapies 
administered. By contrast, the Score for Neonatal Acute 
Physiology (SNAP),14,15 the Transport Risk Index of 
Physiologic Stability (TRIPS),16 and other physiology-
based approaches use objective, measurable parameters 
that vary with illness severity, such as blood pressure. 
Related models, such as the Clinical Risk Index for 
Babies (CRIB),17,18 combine physiological parameters 
with perinatal factors, such as birthweight, to provide an 
overall mortality risk score. SNAP and CRIB are the 
most widely used systems and have been extensively 
validated.19
Research in context
Evidence before this study
2·5 million neonatal deaths occur each year, among which 78% 
are in sub-Saharan Africa and southern Asia. More than 80% of 
these deaths occur in babies with a low birthweight who are 
small because they are preterm, small for their gestational age, 
or both. There has been slow progress in reducing neonatal 
mortality, which accounts for nearly half of deaths in children 
younger than 5 years, highlighting the need for scale-up of 
effective interventions for neonates who are at risk. We searched 
PubMed for studies published between Jan 1, 1992, and July 31, 
2019, with the search terms “infant, newborn”, and “infant 
mortality”, or “infant, newborn, diseases, and mortality”, or 
“infant, premature, diseases, and mortality”, or “hospital 
mortality”, and “severity of illness index”, or “risk assessment”, 
or “predictive value of tests”, or “outcome assessment”. Multiple 
risk scores for neonatal mortality, illness severity, and clinical 
instability have been developed for intensive care settings. Most 
of these risk scores are not feasible for low-income and middle-
income countries, because they rely on laboratory-derived and 
therapy-derived parameters that are frequently unavailable, or 
on clinical observations that are not reliably measurable. A need 
remains for a highly predictive tool, feasible for use in resource-
constrained settings, to help providers objectively assess 
mortality risk in the most vulnerable babies.
Added value of this study
Using population-wide data from 110 176 neonates admitted 
to 187 hospitals across England and Wales, this study has 
derived and validated a mortality risk score for neonates 
weighing 2000 g or less (NMR-2000). To our knowledge, this 
is the largest dataset used to develop and validate a neonatal 
mortality risk score. NMR-2000 uses data on three 
parameters: birthweight, oxygen saturation (peripheral 
capillary oxygen) at admission, and highest level of 
respiratory support at any point within 24 h of birth. 
The model had very good discrimination and goodness-of-fit 
across the development and UK validation samples, with a 
c-index of 0·8859–0·8930 and a Brier score of 0·0232–0·0271. 
The simplified integer score, which can be measured and 
calculated at the bedside, showed predictive ability similar to 
the model using regression coefficients. In the Gambian 
dataset, which included 550 neonates at one hospital, the 
model had good discrimination and overall goodness-of-fit, 
with a c-index of 0·8170 and a Brier score of 0·1688. 
The simplified integer score showed similar performance, 
with a c-index of 0·8082. Complete data for scoring were 
available for 83% of neonates. These findings indicate that 
the NMR-2000 is valid for use in health facilities where 
pulse oximetry is available and underscore the fact that 
implementation in low-income and middle-income countries 
would require sensitisation regarding documentation of the 
three parameters used in the model.
Implications of all the available evidence
To reduce neonatal mortality worldwide, there is an urgent 
need to scale-up evidence-based interventions targeting the 
major causes of death. Our risk score could expedite 
recognition of severe illness and enable targeted delivery of 
care to small and vulnerable neonates, increasing effectiveness 
and efficiency of facility-based neonatal care in low-income 
and middle-income countries. Further research is required to 
validate NMR-2000 in low-resource settings using a larger 
sample, and to evaluate its usefulness for clinical decision 
making. The score has the potential to inform resource use, 
including nursing workload.
See Online for appendix
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Notably, none of the aforementioned systems are 
practicable for routine use in low-income and middle-
income countries (LMICs), because these systems rely 
on laboratory-derived and therapy-derived measures that 
are often not available, or on clinical observations 
that are not reliably measurable in these settings.20–22 
The simplified age-weight-sex (SAWS) score is the 
only validated neonatal mortality score designed for 
low-resource settings. Among a derivation cohort of 
428 neonates weighing 1500 g or less in Bangladesh 
and Egypt, the SAWS was reported to have moderate 
discrimination for in-hospital mortality.22 To improve the 
quality of facility-based neonatal care in LMICs, a highly 
predictive tool, which is feasible for routine use, is 
needed to help providers objectively assess mortality risk 
in small babies.
This study has two parts: (1) model development using 
data from the UK, and (2) model validation using data 
from the UK and The Gambia. The objectives were to 
evaluate existing neonatal illness severity and mortality 
risk scores to select candidate variables for use in the 
new model; develop and validate a score feasible for use 
in LMICs to predict in-hospital neonatal mortality risk 
among neonates weighing 2000 g or less within 24 h of 
birth; and compare the performance of the novel score 
(NMR-2000) with that of an existing score (CRIB-II).
Methods
Study design and participants
This retrospective study used data held in the UK 
National Neonatal Research Database (NNRD) from 
187 neonatal units to develop a model for scoring in-
hospital neonatal mortality risk in LMICs. The NNRD 
holds de-identified patient-level data, recorded by health-
care providers as part of routine care, from admissions to 
National Health Service neonatal units in England 
starting from 2008, and in Wales and Scotland starting 
from 2012. This study included neonates admitted to 
units in England and Wales between Jan 1, 2010, and 
Dec 31, 2017 (appendix p 1). The following exclusion 
criteria were also applied: birthweight more than 2000 g; 
being admitted at older than 6 h or following discharge 
home; neonates who were stillborn; neonates who died 
in the delivery room; neonates who were moribund 
(received only comfort care before death; appendix p 1).
As well as data from the NNRD, we used data on 
neonates in The Gambia. West and central Africa 
have the highest neonatal mortality worldwide (31 in 
1000 livebirths).1 In The Gambia in 2018, the neonatal 
mortality (26 in 1000 livebirths) ranked ninth among the 
16 countries of west Africa.1 An estimated 12% of 
Gambian neonates are born preterm.3 Edward Francis 
Small Teaching Hospital (EFSTH) in Banjul is the 
national referral hospital where the neo natal unit admits 
around 1400 neonates annually. From 2010 to 2013, 
case-fatality was 35% overall and prematurity-related 
complications were the leading cause of death.23
The Gambian cohort included all neonates weighing 
less than 2000 g who were admitted to EFSTH between 
May 1, 2018, and Sept 30, 2019, who were screened for 
but not enrolled in the Early KMC (eKMC) trial 
(NCT03555981). Some routine data, including mode of 
delivery and treatments administered, were collected 
from medical charts by trained study personnel. Other 
data collected as part of the screening process were 
exported from the trial database, including birthweight, 
sex, birth plurality, referral status, and peripheral 
capillary oxygen saturation (SpO2; appendix p 1).
Model development and validation using the UK dataset 
was approved by the North West–Preston Research Ethics 
Committee (17/NW/0709), the UK Health Research 
Authority, and the London School of Hygiene and Tropical 
Medicine (LSHTM; reference number 14594). Letters were 
sent to the UK Neonatal Collaborative Lead of all units 
contributing data to the NNRD, providing information 
about the study and giving each an opportunity to opt out. 
Model validation using the Gambian dataset was approved 
by research ethics committees of the Gambian Government 
and Medical Research Council Unit The Gambia at the 
LSHTM (reference number 1643) and LSHTM (reference 
number 16189). Consent was not obtained, as this was a 
retrospective study using de-identified data.
Selection of candidate variables
To select the candidate variables for the model, 18 studies 
describing existing systems for assessing neonatal 
mortality risk and illness severity were reviewed to 
generate a list of potential parameters (appendix p 6). 
Parameters that are typically unavailable, infrequently 
obtained, or unreliably measured in low-resource settings 
were excluded (appendix p 1). Remaining parameters 
were evaluated using the following exclusion criteria: low 
prevalence in the NNRD (<0·1%); high proportion of 
missing data in the development dataset (≥20%); not 
predictive of mortality in neonates who are preterm or 
have a low birthweight; low prevalence within the first 
24 h of life; little evidence to support validity; and concept 
better represented by an alternative variable (appendix 
pp 7–9).
Model development
To create the model, we used a development sample of 
neonates admitted to a random sample of neonatal units 
in England and Wales from Jan 1, 2010, to Dec 31, 2016. 
Logistic regression models were derived to model in-
hospital mortality risk. Robust standard errors allowed for 
clustering within units. All candidate variables were 
included in a complete multivariable model, which was 
progressively simplified using reverse stepwise selection, 
with the least statistically significant variable removed at 
each step. Discrimination was assessed with the c-index, 
equivalent to the area under the receiver operating 
characteristic (ROC) curve. A value of 0·5 indicates no 
predictive ability, 0·8 is considered good, and 1 is perfect.21 
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Overall goodness-of-fit was assessed with the Brier score 
and calibration using plots of observed versus predicted 
risk (appendix p 2). Multiple imputation with chained 
equations was used to assess the effect of missing 
data (appendix p 2). The logistic regression model was 
executed across the imputed datasets, and the resulting 
β coefficients and c-index were compared with original 
estimates. A sensitivity analysis excluding neonates 
whose admission age was unknown (anonymised data 
derived from calculated difference between birth time 
and admission time) was done to reassess model 
performance, because admission at more than 6 h of age 
was an exclusion criterion. Performance was additionally 
reassessed follow ing exclusion of neonates who were 
transferred for any reason because outcome data were not 
available for these babies. Performance for predicting 
mortality within 24 h of birth was evaluated in a secondary 
analysis, because 36% of neonatal deaths occur within 
this timeframe.24
Score development
To develop the score, we assigned the parameters in the 
final model points proportional to their β regression 
coefficient values. Whole numbers were used to generate 
an easily calculable score. We arbitrarily defined low-risk, 
medium-risk, and high-risk groups (appendix pp 2–3). To 
assess the calibration of the score to the model using 
regression coefficients, observed risks in groups and 
population deciles of scores were derived and compared 
with mean predicted risks in each group or population 
decile. We assessed overall predictive ability of the score 
using the c-index.
Model validation
We then evaluated both the internal and external 
validity of the model. Internal validity is the reproducibility 
of a prediction model for the underlying population from 
which the data originated.25 Bootstrap resampling with 
1000 samples from within the development sample was 
used to internally validate the model, estimating optimism-
adjusted measures of discrimination and goodness-of-fit 
in each bootstrap sample (appendix p 3). Performance of 
the refitted model in each bootstrap sample was compared 
with that of the refitted model in the original development 
84 parameters in existing neonatal risk scores
45 excluded because infeasible in LMICs
 20 infeasible or often unavailable
 17 infeasible for LMICs and not included in NNRD
 8 infeasible for LMICs and low prevalence
39 parameters remaining
8 excluded
 5 little evidence to support validity
 2 not predictive of mortality in preterm or low birthweight 
 neonates
 1 low prevalence within 24 h of birth
31 parameters remaining
18 parameters selected as candidate variables
13 excluded
 6 better represented by alternative variable
 7 <0·1% prevalence in NNRD, ≥20% missing in 
 development dataset
Figure 1: Flow chart showing filtration of parameters from existing risk 
scores to select candidate variables
LMICs=low-income and middle-income countries. NNRD=National Neonatal 
Research Database.
Panel: Candidate variables evaluated in the modelling 
process
Clinical signs and observations
• Heart rate at admission
• Respiratory rate at admission
• Temperature at admission
• Oxygen saturation (SpO2) at admission
• Convulsions within 24 h of birth, defined as the presence 
of any clinical or electrographic seizures
• Clinically relevant increase in apnoea or brachycardia 
episodes, oxygen requirement, ventilatory support, 
or respiratory rate within 24 h of birth*
Therapy-based variables
• Bag-mask resuscitation at delivery
• Intravenous fluids within 24 h of birth
• Antibiotic therapy within 24 h of birth
• Oxygen therapy within 24 h of birth†
• Highest level of respiratory support administered at any 
point within 24 h of birth‡
• Caffeine (or aminophylline) within 24 h of birth
• Anticonvulsant therapy within 24 h of birth
Perinatal factors
• Sex
• Birthweight
• Gestational age
• Small for gestational age§
• Presence of visually recognisable anomaly at birth¶
SpO2=peripheral capillary oxygen saturation. FiO2=fraction of inspired oxygen. *Defined 
as an increase that was clinically significant enough to necessitate obtaining a culture 
to evaluate for suspected sepsis, at any point within 24 h of birth. †Defined as delivery 
of supplemental oxygen (FiO2 >0·21) via any method at any point within 24 h of birth. 
‡Not including initial resuscitation at birth; level 1 defined as nasal cannula or headbox; 
level 2 defined as continuous positive airway pressure, bilevel or synchronised 
intermittent positive airway pressure, or invasive ventilation with an endotracheal tube 
or tracheostomy. §Defined as birthweight less than the 5th percentile for gestational 
age, using UK-WHO standards.26 ¶Defined as the presence of one or more of the 
following: cleft lip or palate; microcephaly; trisomy 13, trisomy 18, or trisomy 21; 
spina bifida, myelomeningocele, or meningocele; encephalocele; anencephaly; 
holoprosencephaly or prosencephaly; ambiguous genitalia; hypospadias; absent anus; 
gastroschisis; exomphalos or omphalocele; achondroplasia; Noonan syndrome.
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Development sample 
(55 029 eligible neonates; 
112 neonatal units)
External validation samples
Random (40 329 eligible 
neonates; 75 neonatal 
units)
Temporal (14 818 eligible 
neonates; 167 neonatal 
units)
Full (55 147 eligible 
neonates; 173 neonatal 
units)
Birthweight
Extremely low birthweight (<1000 g) 7518 (13·7%) 5705 (14·2%) 2238 (15·1%) 7943 (14·4%)
Very low birthweight (1000–1499 g) 15 475 (28·1%) 11 290 (28·0%) 4198 (28·3%) 15 488 (28·1%)
Low birthweight (1500–2000 g) 32 021 (58·2%) 23 324 (57·9%) 8381 (56·6%) 31 705 (57·5%)
Birthweight data missing* 15 (0·03%) 10 (0·02%) 1 (<0·01%) 11 (0·02%)
Gestational age (weeks)
Extremely preterm (<28) 6969 (12·7%) 5203 (12·9%) 1990 (13·4%) 7193 (13·1%)
Very preterm (28–31) 17 810 (32·4%) 13 108 (32·5%) 4963 (33·5%) 18 071 (32·8%)
Moderate-late preterm (32–36) 28 241 (51·3%) 20 604 (51·1%) 7470 (50·4%) 28 074 (50·9%)
Full term (37–42) 1996 (3·6%) 1408 (3·5%) 393 (2·7%) 1801 (3·3%)
Gestational age data missing 13 (0·02%) 6 (0·02%) 2 (0·01%) 8 (0·01%)
Size at gestation
Small for gestational age 11 039 (20·1%) 7965 (19·8%) 2816 (19·0%) 10 781 (19·6%)
Size at gestation data missing 16 (0·03%) 10 (0·03%) 2 (0·01%) 12 (0·02%)
Sex
Male 27 361 (49·9%) 20 307 (50·4%) 7490 (50·6%) 27 797 (50·4%)
Sex data missing 72 (0·1%) 30 (0·07%) 18 (0·1%) 48 (0·09%)
Mode of delivery
Spontaneous vaginal 16 361 (32·3%) 12 404 (32·6%) 4227 (30·5%) 16 631 (32·0%)
Caesarean section 32 473 (64·1%) 24 404 (64·0%) 9148 (66·1%) 33 552 (64·6%)
Assisted vaginal 1820 (3·6%) 1284 (3·4%) 463 (3·3%) 1747 (3·4%)
Mode of delivery data missing 4375 (8·0%) 2237 (5·5%) 980 (6·6%) 3217 (5·8%)
Multiple birth
Yes 16 933 (30·8%) 12 056 (29·9%) 4442 (30·0%) 16 498 (29·9%)
Multiple birth data missing 22 (0·04%) 8 (0·02%) 2 (0·01%) 10 (0·02%)
Location of birth
Inborn† 53 954 (98·1%) 39 481 (98·0%) 14 476 (97·9%) 53 957 (98·0%)
Location of birth data missing 7 (0·01%) 36 (0·09%) 33 (0·2%) 69 (0·1%)
Location of care
Neonatal intensive care unit‡ 24 018 (43·7%) 22 362 (55·3%) 7506 (50·7%) 29 840 (54·1%)
Local neonatal unit§ 26 276 (47·8%) 13 541 (33·5%) 6054 (40·9%) 19 541 (35·4%)
Special care baby unit¶ 4730 (8·6%) 4538 (11·2%) 1258 (8·5%) 5766 (10·5%)
Location of care data missing 5 (0·01%) 0 (0·0%) 0 (0·0%) 0 (0·0%)
Age at admission (min)
Median (IQR) 21 (13–33) 21 (13–34) 23 (15–35) 22 (14–34)
Age at admission data missing 5 (0·01%) 0 (0·0%) 0 (0·0%) 0 (0·0%)
Disposition
Died before discharge 1653 (3·0%) 1306 (3·2%) 395 (2·8%) 1701 (3·1%)
Extremely low birthweight (<1000 g) 1159 (15·4%) 929 (16·3%) 280 (12·5%) 1209 (15·2%)
Very low birthweight (1000–1499 g) 295 (1·9%) 228 (2·0%) 67 (1·6%) 295 (1·9%)
Low birthweight (1500–2000 g) 199 (0·6%) 149 (0·6%) 48 (0·6%) 197 (0·6%)
Died within 24 h of birth 207 (0·4%) 194 (0·5%) 50 (0·3%) 244 (0·4%)
Transferred to another care unit|| 12 793 (23·3%) 10 119 (25·1%) 4268 (30·3%) 14387 (26·5%)
Disposition data missing 73 (0·1%) 32 (0·1%) 726 (4·9%) 758 (1·4%)
Age at discharge (days)
Median (IQR) 22 (12–38) 21 (11–36) 19 (10–34) 20 (11–36)
Age at discharge data missing 21 (0·04%) 13 (0·03%) 740 (5·0%) 754 (1·4%)
(Table 1 continues on next page)
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sample; estimates of optimism were averaged and sub-
tracted to provide optimism-adjusted measures.
External validity is the generalisability of a model’s 
performance to related populations.25 The model was 
evaluated in three external validation samples: the random 
sample, which included neonates admitted to the units 
withheld from the development sample; the temporal 
sample, which included neonates admitted to units in 
England and Wales from Jan 1, to Dec 31, 2017; and 
the Gambian sample, which included neonates admitted 
to EFSTH between May 1, 2018, and Sept 30, 2019. Each 
sample was used to assess distinctive features of model 
performance. The random sample tested performance in 
different care settings in the UK within the same 
timeframe, whereas the temporal sample tested 
performance during a later timeframe. The Gambian 
sample was used to test performance in a LMIC care 
setting. We assessed model performance in each validation 
sample separately and in the UK full (combined random 
and temporal samples) validation sample. Discrimination 
was evaluated using the c-index, and goodness-of-fit was 
evaluated using the Brier score. Calibration was assessed 
by plotting observed versus predicted risk. We assessed the 
overall predictive ability of the risk score using the c-index. 
Development sample 
(55 029 eligible neonates; 
112 neonatal units)
External validation samples
Random (40 329 eligible 
neonates; 75 neonatal 
units)
Temporal (14 818 eligible 
neonates; 167 neonatal 
units)
Full (55 147 eligible 
neonates; 173 neonatal 
units)
(Continued from previous page)
Variables collected at time of birth
Bag-mask resuscitation at delivery 24 302 (44·2%) 18 297 (45·4%) 6131 (41·4%) 24 428 (44·3%)
Visually recognisable anomaly 1299 (2·4%) 1151 (2·9%) 309 (2·1%) 1460 (2·7%)
Variables collected at time of admission
Heart rate (beats per min), mean (SD) 153·4 (18·4) 153·8 (18·7) 154·5 (18·6) 154·0 (18·6)
Heart rate data missing 7197 (13·1%) 3557 (8·8%) 1234 (8·3%) 4791 (8·7%)
Respiratory rate (breaths per min), mean (SD) 53·3 (29·8) 52·4 (12·9) 52·5 (13·2) 52·4 (13·0)
Respiratory rate data missing 9535 (17·3%) 5377 (13·3%) 2008 (13·6%) 7385 (13·4%)
Temperature (°C), mean (SD) 36·6 (0·7) 36·6 (0·7) 36·7 (0·8) 36·6 (0·7)
Temperature data missing 589 (1·1%) 371 (0·9%) 166 (1·1%) 537 (1·0%)
SpO2 (%), median (IQR) 96 (93–98) 96 (92–99) 96 (93–99) 96 (93–99)
SpO2 data missing 7787 (14·2%) 4213 (10·4%) 1392 (9·4%) 5605 (10·2%)
Variables collected within 24 h of birth
Increased apnoea or bradycardia, oxygen, 
ventilatory support, or respiratory rate
3005 (5·5%) 2458 (6·1%) 903 (6·1%) 3361 (6·1%)
Convulsions 134 (0·3%) 81 (0·2%) 24 (0·2%) 105 (0·2%)
Convulsions data missing 579 (1·1%) 456 (1·1%) 297 (2·0%) 753 (1·4%)
Oxygen therapy 13 998 (25·4%) 10 989 (27·3%) 5178 (34·9%) 16 167 (29·3%)
Highest level of respiratory support
Nasal cannula or headbox 3722 (7·0%) 2758 (7·0%) 2035 (13·9%) 4793 (8.9%)
CPAP, BiPAP or SiPAP, or invasive ventilation 23 374 (43·8%) 16 676 (42·6%) 6427 (43·8%) 23 103 (42·9%)
Respiratory support data missing 1658 (3·0%) 1161 (2·9%) 150 (1·0%) 1311 (2·4%)
Other interventions
Intravenous fluids 41 506 (75·4%) 30 468 (75·6%) 11 697 (78·9%) 42 165 (76·5%)
Antibiotic therapy 39 774 (72·3%) 29 877 (74·1%) 11 152 (75·3%) 41 029 (74·4%)
Caffeine citrate 14 276 (25·9%) 10 862 (26·9%) 5438 (36·7%) 16 300 (29·6%)
Anticonvulsant therapy 162 (0·3%) 150 (0·4%) 45 (0·3%) 195 (0·4%)
Data are complete except where missing data are detailed; missing data are the total number of neonates for whom data are not available. Data are n (%) except where 
otherwise indicated. See panel for definitions of variables. CPAP=continuous positive airway pressure. BiPAP=bilevel positive airway pressure. SiPAP=synchronised intermittent 
positive airway pressure. SpO2=peripheral capillary oxygen saturation. *For neonates whose birthweight was missing, admission weight was used to determine eligibility. 
†Inborn is defined as birth at the hospital of neonatal unit admission. ‡Intensive care units provide care for the sickest neonates who require constant supervision and 
monitoring, including those born at fewer than 27 weeks’ gestational age: care typically includes mechanical ventilation; surgery services offered in some units; care is 
analogous to American Academy of Paediatrics levels 3 and 4.27 §Local neonatal units provide full care for the majority of babies more than 27 weeks’ gestational age, including 
short periods of intensive care; therapies provided include continuous monitoring, CPAP, and parenteral nutrition. ¶Special care units provide care for all other babies who 
could not reasonably be cared for at home; therapies provided include cardiorespiratory monitoring, nasogastric feeding, supplemental oxygen, and phototherapy. ||Transfer 
to another care unit from the initial unit of neonatal admission.
Table 1: Characteristics of the participants in the data samples from the UK National Neonatal Research Database
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In the Gambian sample, we redefined low-risk, medium-
risk, and high-risk groups to account for increased case 
fatality in this sample compared with the UK samples 
(appendix p 3). Observed risks in groups and population 
deciles of scores were derived and compared with mean 
predicted risks in each group or population decile of 
the Gambian sample.
Comparison with the CRIB II score
The NNRD did not include all the variables required for 
calculation of CRIB, SNAP, SNAP-II, SNAPPE-II, TRIPS, 
or TRIPS-II scores (appendix pp 7–9); therefore, CRIB-II 
was selected for comparison with NMR-2000 (appendix p 3). 
Because CRIB-II has only been validated for use in 
neonates born up to 32 weeks’ gestation,18 we compared 
c-indices for CRIB-II and NMR-2000 among neonates 
born at 32 weeks’ gestation or earlier in the full validation 
sample. All analyses were completed using Stata 
(version 15).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
For the selection of candidate variables, 18 studies were 
reviewed to generate a list of 84 potential parameters. 
45 (53·6%) of 84 parameters were considered infeasible 
for LMICs and were excluded, among which, 25 (55·5%) 
also had a low prevalence or were not included in the 
NNRD (figure 1). Eight (9·5%) of 84 parameters were 
excluded because the evidence was scarce, because the 
parameters had poor predictive ability in preterm 
neonates or neonates with low birthweight, or because 
the parameter had a low prevalence within 24 h of birth. 
18 candidate variables were selected for inclusion in the 
modelling process (panel).
110 176 neonates were included in the UK development 
and validation samples. Characteristics of the samples 
and participants are shown in table 1. More than half 
(56·6–58·2%) of the neonates had low birthweight 
(1500–2000 g), 28·0–28·3% had very low birthweight 
(1000–1499 g), and 13·7–15·1% had extremely low 
birthweight (<1000 g). Around half (50·4–51·3%) of the 
neonates were moderate-late preterm (32–36 weeks) and 
one-third (32·4–33·5%) were very preterm (28–31 weeks). 
Overall case-fatality was similar across samples 
(2·8–3·2%). Case-fatality of neonates with extremely low 
birthweight in the temporal sample (280 [12·5%] of 2238) 
was lower than in the other samples. No neonatal units 
declined to contribute data.
Characteristics of the 550 neonates in the Gambian 
validation sample are shown in table 2. Among 
the 550 neonates, 298 (54·2%) had a low birthweight, 
189 (34·4%) had a very low birthweight, and 63 (11·5%) 
had an extremely low birthweight. 142 (25·8%) 
of 550 neonates were multiple births (eg, twins), 
299 (54·5%) of 549 were inborn, and 215 (41·4%) of 
520 died.
The full model (18 variables) had a c-index of 0·9223 in 
the development sample (n=41 514). After stepwise 
elimination, the final model included three variables 
(table 3), with a c-index of 0·8883 and a Brier score of 
0·0232 (table 4). Complete data on all three variables 
were available for 46 108 (83·8%) of 55 029 neonates in 
the development sample. After imputation of missing 
values for predictor variables (n=54 956), the resulting 
β coefficients were nearly identical to original estimates 
(appendix p 9) and model performance was unchanged 
(c-index 0·8894; appendix p 2). Admission age was 
uncertain for 5 (0·01%) of 55 029 neonates; in a sensitivity 
analysis excluding these neonates, there was no change 
in performance (c-index 0·8886, Brier score 0·0232). 
Neonates with 
available data*
Neonates with 
characteristic
Birthweight† 550 (100%) ··
Extremely low birthweight (<1000 g) ·· 63 (11·5%)
Very low birthweight (1000–1499 g) ·· 189 (34·4%)
Low birthweight (1500 to 2000 g) ·· 298 (54·2%)
Sex† 549 (99·8%) ··
Male sex ·· 261 (47·5%)
Mode of delivery† 488 (88·7%) ··
Spontaneous vaginal ·· 342 (70·1%)
Caesarean section ·· 140 (28·7%)
Assisted vaginal ·· 6 (1·2%)
Multiple birth† 550 (100%) ··
Yes ·· 142 (25·8%)
Inborn‡† 549 (99·8%) ··
Yes ·· 299 (54·5%)
Died before discharge† 520 (94·5%) ··
Total ·· 215 (41·4%)
Extremely low birthweight (<1000 g) ·· 55/61 
(90·2%)§
Very low birthweight (1000–1499 g) ·· 93/179 
(52·0%)§
Low birthweight (1500–2000 g) ·· 67/280 
(23·9%)§
Oxygen saturation at admission 513 (93·3%) ··
SpO2 (%) at admission¶ ·· 92% (83–96)
Highest level of respiratory support 
within 24 h of birth†
494 (89·8%) ··
Nasal cannula ·· 294 (59·5%)
CPAP ventilation ·· 53 (10·7%)
Data are n (%), n/N (%), median (IQR). See panel for definition of variables. 
CPAP=continuous positive airway pressure. SpO2=peripheral capillary oxygen 
saturation. *Out of the total 550 neonates. †Information is included on routine 
admission forms. ‡Defined as birth at the study hospital. §Proportion of babies in 
each birthweight category who died (outcome data were not available for 5·5% of 
babies). ¶Information collected for the trial (eKMC trial).
Table 2: Characteristics of participants in the Gambian validation sample
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12 793 (23·3%) of 54 956 neonates were transferred from 
the unit of admission to another care unit; an analysis 
excluding these neonates showed improved performance 
(c-index 0·9150, Brier score 0·0255; appendix p 2). 
Predictive accuracy for mortality within 24 h (c-index 
0·8858, Brier score 0·0037) was nearly identical to that 
for in-hospital mortality. Because availability of SpO2 
monitoring is variable in LMIC settings, we tested a 
related variable (clinically relevant increase in apnoea or 
bradycardia, oxygen requirement, ventilatory support, or 
respiratory rate); however, this variable was not associated 
with in-hospital mortality (c-index 0·5061). A plot of 
observed versus predicted mortality risk in the develop-
ment sample is shown in figure 2.
Birthweight was the most predictive variable in the 
model (c-index 0·8540). The reciprocal of the coefficient 
for birthweight divided by 100 ([1/–0·0032]/100=–3·13) 
was used as the constant to enable retention of exact 
birthweights in score calculation (table 3),28 thereby 
improving predictive ability. The score range for low risk 
was set at 16 or more, for medium risk at 6–15, and for 
high risk at 5 or fewer points (appendix p 9). An example 
score form is shown in figure 3. Among 46 108 neonates 
from the development sample with complete data on the 
three variables included in the final model, 27 289 (59·1%) 
were designated as low risk, 17 215 (37·3%) as medium 
risk, and 1640 (3·6%) as high risk. Observed risks were 
0·3% (95% CI 0·3–0·4) for low risk, 4·1% (3·8–4·4) for 
medium risk, and 27·3% (25·2–29·5) for high risk, with 
a c-index of 0·8875. Mean predicted risks derived from 
regression coefficients were 0·2% (SD 0·2) for low risk, 
4·6% (SD 4·2) for medium risk, and 23·5% (SD 8·8) for 
high risk. Observed risks across population deciles by 
score were similar to the risks predicted with regression 
coefficients (appendix p 10).
After bootstrap resampling, optimism-adjusted 
estimates of c-index and Brier score were nearly 
identical to the original measures; thus, no adjustments 
were made to the coefficients. In the random validation 
sample, complete data on all three parameters were 
available for 35 193 (87·3%) of 40 329 neonates, for 
the temporal validation sample the data were available 
for 12 653 (85·4%) of 14 818 neonates, for the full valid-
ation sample they were available for 47 846 (86·8%) of 
55 147 neonates, and for the Gambian validation sample 
complete data on all three parameters were available for 
457 (83·1%) of 550 neonates. The model showed very 
good performance across the UK validation samples 
(c-index 0·8859–0·8930) and good performance in 
the Gambian validation sample (c-index 0·8170; Brier 
score 0·1688; table 4). Performance was similar among 
neonates weighing 1500 g or less in the Gambian 
sample (c-index 0·8069, Brier score 0·1753).
Graphical plots showed a high level of agreement 
between observed and predicted mortality risk across the 
external validation samples (figure 4). Applying the 
empirical optimal cutpoint of 3·9% based on the Youden 
Index gave moderately high sensitivity (79·1–81·6) and 
β coefficient 95% confidence interval* Integer-points† c-index
Birthweight (g) –0·0032 –0·0035 to –0·0029 Birthweight/100 0·8540
Highest respiratory support 
within first 24 h
·· ·· ·· 0·7529
Nasal cannula or headbox 0·3167 –0·1055 to 0·7389‡ –1 ··
CPAP, BiPAP or SiPAP, 
or invasive ventilation
1·6214 1·2682 to 1·9746‡ –5 ··
SpO2 at admission –0·0390 –0·0455 to –0·0326 ·· 0·6712
<80% (reference level) ·· ·· 0§ ··
80–89% –0·7694 –1·0093 to –0·5294 2§ ··
90–100% –1·3697 –1·6019 to –1·1376 4§ ··
Constant 2·6142¶ 1·7655 to 3·4629 ·· ··
n=46 108. CPAP=continuous positive airway pressure. BiPAP=bilevel positive airway pressure. SiPAP=synchronised 
intermittent positive airway pressure. SpO2=peripheral capillary oxygen saturation. *p<0·0001 for estimates for all 
variables. †Calculated by multiplying the β coefficient by a constant (–3·13) and rounding to the nearest integer. 
The reciprocal of the coefficient for birthweight divided by 100 ([1/–0·0032]/100=–3·13) was used as the constant to 
retain the exact birthweight (per 100 g) in the score. ‡p<0·0001 for overall effect of level of respiratory support. 
§The continuous SpO2 parameter was categorised into clinically meaningful categorical variables; the β coefficients of 
these variables were multiplied by the constant to obtain integer-points; the reference level (<80%) was assigned 
zero points. ¶Reflects β coefficient for constant in model including SpO2 as a continuous variable.
Table 3: Derivation logistic model for the NMR-2000 score
Development sample 
(n=46 108)
External validation samples
Original Optimism-
adjusted*
Random 
(n=35 193)
Temporal 
(n=12 653)
Full 
(n=47 846)
Gambian 
(n=457)
Brier score 0·0232 0·0233 0·0271 0·0240 0·0263 0·1688
c-index 0·8883 0·8882 0·8930 0·8859 0·8912 0·8170
*Because optimism-adjusted estimates of the c-index and Brier score were nearly identical to the original estimates, no 
adjustments were made to the model coefficients.
Table 4: Model performance in the development and validation samples
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Figure 2: Predicted versus observed death for population deciles by predicted 
risk in the development sample
n=46 108. Graph created using pmcalplot.
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specificity (81·0–82·9), with high negative predictive 
value (99·3) and low positive predictive value (11·4–12·2; 
appendix p 10).
The discriminatory ability of the simplified integer score 
was similar to the model using regression coefficients, 
with c-indices of 0·8903 in the full validation sample and 
0·8082 in the Gambian validation sample (appendix p 11). 
Among the 47 846 neonates in the UK full validation 
sample, 28 565 (59·7%) were designated as low risk, 
17 407 (36·4%) as medium risk, and 1874 (3·9%) as high 
risk. Observed risks for these categories were 0·4% 
(95% CI 0·3–0·5) for low risk, 4·8% (4·5–5·1) for medium 
risk, and 29·7% (27·7–31·8) for high risk. In the Gambian 
validation sample, the score range for low risk was set 
at 23 or more, for medium risk at 17–22, and for high 
risk at 16 or fewer points (appendix pp 3, 11). Among the 
457 neonates in the Gambian sample for whom data on 
all three parameters were available, 28 (6·1%) were 
designated as low risk, 215 (47·1%) as medium risk, and 
214 (46·8%) as high risk. Observed risks were 10·7% 
(95% CI 3·5–28·5) for low risk, 21·4% (16·4–27·4) for 
medium risk, and 68·2% (61·7–74·1) for high risk. Mean 
predicted risks derived from regression coefficients were 
9·4% (SD 1·9) for low risk, 22·3% (SD 8·5) for medium 
risk, and 67·4% (SD 18·4) for high risk. Observed risks 
across population deciles by score were similar to those 
predicted with coefficients (appendix p 11).
Comparison of areas under the ROC curves for 
NMR-2000 (c-index 0·8523 [95% CI 0·8336–0·8710]) 
and CRIB-II (c-index 0·7443 [95% CI 0·7153–0·7733]) 
among 10 812 neonates born at 32 weeks’ gestation or 
earlier (figure 5) indicated that discriminatory perfor-
mance of NMR-2000 was superior to that of CRIB-II 
(p<0·0001).
Discussion
This population-wide study, including data from 
110 176 newborn babies at 187 hospitals in the UK and 
550 newborn babies at one hospital in The Gambia, has 
derived and validated NMR-2000 for predicting in-hospital 
mortality. A strength of this work is that, to our knowledge, 
this is the largest dataset that has been used to develop 
and validate a neonatal mortality risk score. Among 
neonates born at 32 weeks’ gestation or earlier, the dis-
criminatory ability of NMR-2000 was superior to that of 
CRIB-II, one of the most widely used neonatal risk scores.
Performance of the NMR-2000 simplified integer 
score, which can be measured and calculated at the 
bedside, was similar to that of the model using regression 
coefficients. The three parameters used in the score can 
be feasibly collected in LMIC settings. Although 
sub-Saharan Africa and southern Asia account for 78% of 
the world’s neonatal deaths,1 existing risk scores have 
primarily been developed for intensive care settings and 
often require complex calculations. In LMICs, where 
parameters in widely used scores are typically not 
available nor reliably measurable,20,21 NMR-2000 could 
support shared decision making by enabling providers to 
objectively assess illness severity.29 The score could be 
used in clinical trials to assess eligibility and compare 
participants.29 Additionally, NMR-2000 could inform 
service delivery planning by identifying bottlenecks in 
care provision.6 Given that 73% of neonatal deaths occur 
within the first 7 days of life,24 early recognition of severe 
illness and rapid initiation of evidence-based inter-
ventions are crucial to promoting survival.5,9,12
The c-index was 0·8859–0·8930 across the development 
and UK validation samples, suggesting that NMR-2000 
can discriminate neonates who will die from neonates 
who will survive. This level of performance is similar to 
that of commonly used neonatal mortality scores in high-
resource settings. Discriminatory ability at the time of 
model derivation ranged from 0·87 for TRIPS-II16 to 0·92 
for CRIB-II.18 Similar to TRIPS-II, NMR-2000 can be 
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Figure 3: NMR-2000, a simplified risk score to predict mortality amongst neonates weighing 2000 g or less
(A) An example mortality risk score for clinical use. (B) Predicted risk of in-hospital mortality plotted against risk 
scores in the development sample; bar data indicate proportion of neonates; blue line indicates predicted mortality 
risk. CPAP=continuous positive airway pressure. BiPAP=bilevel positive airway pressure. SiPAP=synchronised 
intermittent positive airway pressure.
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assessed at any point within the first 24 h of life and could 
be repeated if the level of respiratory support increases. 
The performance of NMR-2000 (c-index 0·8523) was 
superior to that of CRIB-II (0·7443) among neonates born 
at 32 weeks’ gestation or earlier. The model also showed 
very good predictive ability for mortality within 24 h of 
birth (c-index 0·8858), which is notable because 37% of 
neonatal deaths in sub-Saharan Africa occur within this 
timeframe.24 The NMR-2000 model showed a high level 
of agreement between observed and pred icted deaths, as 
assessed by calibration plots, in the develop ment and 
validation samples. Calibration plots are the preferred 
method for assessing calibration.25 Previous neonatal 
scores, including NTISS,13 SNAPPE-II,15 CRIB-II,18 and 
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Figure 4: Predicted versus observed mortality risk for population deciles in the random, temporal, full, and Gambian validation samples
Graphs created using pmcalplot.
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TRIPS-II,16 were reported to have good calibration 
for predicting in-hospital mortality using the 
Hosmer-Lemeshow test. However, such results should be 
interpreted with caution given the limitations of this test, 
which include subjective and imprecise grouping of 
babies as well as inability to denote the directionality of 
miscalibration when incongruities are detected.25
In the Gambian validation sample, the NMR-2000 model 
had good discrimination and overall goodness-of-fit, with 
c-index of 0·8170 and Brier score of 0·1688. Complete data 
were available for 83% of neonates. The calibration plot 
showed a strong agreement between observed and 
predicted mortality. These findings suggest that NMR-2000 
is valid for use in LMIC settings where pulse oximetry is 
available. Discrimination of the SAWS score, developed for 
neo nates weighing 1500 g or less in low-resource settings, 
at the time of validation (c-index 0·679–0·698)22 was 
decreased relative to NMR-2000 among Gambian neonates 
weighing 1500 g or less (c-index 0·8069). Notably, neither 
goodness-of-fit nor calibration were reported for the SAWS 
score.22 Further, SAWS relies on accurate assessment of 
gestational age, which can be challenging in LMICs 
because of late presentation for antenatal care, poor recall 
of last menstrual period, and unavailability of ultra-
sonography.30 Case-fatality of Gambian neonates in this 
study is similar to that reported from a previous study at 
EFSTH (35% overall, 58% for neonates with a very low 
birthweight),23 and higher than studies at similar hospitals 
in Ghana (20% overall),31 Nigeria (14–20% overall),32,33 and 
Burkina Faso (15% overall).34
Among the three NMR-2000 parameters, all except SpO2 
are included on routine admission forms at EFSTH, 
Gambia (at time of screening),23 as well as standard forms 
at government hospitals in Kenya, Malawi, and Tanzania. 
We were able to obtain SpO2 data for the Gambian sample 
primarily because these data were being collected as part 
of the eKMC trial screening process. Variability in the 
implementation of routine pulse oximetry is a crucial gap 
in low-resource neonatal units.35,36 In a study of nearly 
7500 neonates admitted to 11 hospitals in Nigeria, 
hypoxaemia increased the adjusted odds of mortality by six 
times, and clinical signs (eg, chest in-drawing, grunting) 
poorly predicted hypoxaemia.37 Furthermore, expansion 
of neonatal inpatient care, often of variable quality 
and frequently inclusive of unmonitored 100% oxygen 
supplementation, has placed sub-Saharan Africa on the 
brink of an epidemic of retinopathy of prematurity.38 
Widespread availability of SpO2 monitoring and improved 
coverage of screening for and treatment of retinopathy of 
prematurity will be essential to control the incidence of 
visual loss in affected neonates. In LMIC settings, 
successful implementation of NMR-2000 would require 
sensitisation around recording the three parameters. 
Several studies have highlighted issues surrounding the 
collection of data on neonatal care in LMICs, including 
variable uptake of standard admission forms;36 incomplete 
documentation of assessments, monitoring, and therapies 
prescribed;20,23,36 and low capacity of data systems to capture 
information on neonates who die soon after birth or are 
transferred to another facility.4 Increasing the quality and 
coverage of data is crucial to promote actions to improve 
neonatal survival, and will require coordination across 
different levels of the health-care system.
One strength of this study is our use of a large and 
purposely-selected UK dataset, which enabled maxi-
misation of model performance. One limitation is that 
the Gambian dataset was small and limited to a single 
hospital; research is required to validate the model using 
a larger LMIC dataset. Several candidate variables in the 
development sample had a considerable pro portion of 
missing data, including admission heart rate, respiratory 
rate, and SpO2. It was not possible to compare NMR-2000 
with the CRIB, SNAP, SNAP-II, SNAPPE-II, or TRIPS-II 
scores, because the NNRD did not include all parameters 
required for their calculation. Because pulse oximetry is 
not always available in low-resource neonatal units, the 
usefulness of the NMR-2000 score in such settings could 
be limited. The NNRD did not include clinical signs of 
respiratory distress that could be tested as a potential 
proxy for SpO2. We tested a related variable (clinically 
relevant increase in apnoea or bradycardia, oxygen 
requirement, ventilatory support, or respiratory rate); 
however, this variable was not associated with mortality. 
The use of respiratory support level as a parameter could 
affect the performance of the model. Administration of 
therapies varies in line with variations in clinical practice19 
and resource availability and so might not reflect true 
therapeutic requirements.36 In LMICs, delivery systems 
for oxygen therapy and CPAP might be unavailable or 
non-functional, and related supplies (eg, nasal cannulas) 
might be out of stock.8,35,36
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Figure 5: Comparison of areas under the ROC curves for CRIB-II and NMR-2000
This analysis includes neonates born at 32 weeks’ gestation or earlier in the full 
validation sample (n=10 812). ROC=receiver operating characteristic.
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Research is required to validate the NMR-2000 score in 
low-resource settings using a sufficiently sized dataset, 
and to evaluate its usefulness for supporting clinical 
decision making.29 A follow-up study using a large, 
multihospital dataset from Kenya is planned. Nurses have 
essential roles as frontline providers of neonatal care; 
however, there is a severe shortage of neonatal nurses in 
LMICs.6,7 Future research could explore the model’s ability 
to inform resource use,13 particularly nursing workload.
The NMR-2000 is a simplified risk score, validated for 
high-resource and low-resource settings where pulse 
oximetry is available, to accurately predict in-hospital 
mortality among neonates weighing 2000 g or less. By 
enabling providers to objectively assess illness severity, 
this tool could contribute to improvements in the quality 
of care delivered in LMIC facilities. Early recognition of 
severe illness and rapid initiation of evidence-based 
interventions are crucial to promoting survival of small 
and vulnerable neonates.
Contributors
MMM, CT, DE, JEL, and EA conceived the study. MMM, HB, CT, DE, 
JEL, and EA contributed to study design. MMM and EA developed the 
analysis plan. MMM, CT, and CG were involved in curation of data from 
the NNRD. HB and AG collected data in The Gambia. MMM analysed 
the data and wrote the manuscript. MMM, HB, CT, CG, PW, DE, JEL, 
and EA interpreted the data. All authors participated in manuscript 
revision and approval of the final version.
Declaration of interests
CG has received grants from the Medical Research Council during the 
conduct of the study; grants from the National Institute for Health 
Research, Mason Medical Research Foundation, Chiesi Pharmaceuticals, 
Rosetrees Foundation, and the Canadian Institute for Health Research, 
outside the submitted work; and personal fees from Chiesi 
Pharmaceuticals, outside the submitted work. CG is also a voluntary, 
unremunerated member of the Neonatal Data Analysis Unit Steering 
Board, which oversees the UK National Neonatal Research Database. 
JEL is a member of the International Advisory Board for The Lancet Child 
and Adolescent Health. All other authors declare no competing interests.
Data sharing
Data from the UK National Neonatal Research Database is available 
upon request.
Acknowledgments
This work was supported by a grant from the Bill & Melinda Gates 
Foundation (OPP1107312) to the University of California San Francisco 
Preterm Birth Initiative. Funds from the Eunice Kennedy Shriver National 
Institute of Child Health and Human Development of the National 
Institutes of Health (K23HD092611) awarded to MMM, the Wellcome 
Trust (2000116) awarded to HB, and the Joint Global Health Trials scheme 
of the Department of Health and Social Care, the Department for 
International Development, the Medical Research Council, and the 
Wellcome Trust (MR/S004971/1) awarded to JEL also supported this study. 
The content is solely the responsibility of the authors and does not 
necessarily represent the official views of the National Institutes of Health. 
We acknowledge the invaluable assistance of Richard Colquhoun and 
Kayleigh Ougham at the Neonatal Data Analysis Unit (Imperial College 
London, London, UK), Swetlana Kapoor from the American University of 
The Gambia (Serrekunda, The Gambia), and the clinical teams from all 
contributing neonatal units who recorded data. We are grateful to all the 
families who agreed to the inclusion of their infants’ data in the UK 
National Neonatal Research Database.
References
1 UN Inter-agency Group for Child Mortality Estimation. Levels & 
trends in child mortality: report 2019. https://www.unicef.org/
media/60561/file/UN-IGME-child-mortality-report-2019.pdf 
(accessed Nov 1, 2019).
2 Liu L, Oza S, Hogan D, et al. Global, regional, and national causes 
of under-5 mortality in 2000–15: an updated systematic analysis 
with implications for the Sustainable Development Goals. Lancet 
2016; 388: 3027–35.
3 Chawanpaiboon S, Vogel JP, Moller AB, et al. Global, regional, 
and national estimates of levels of preterm birth in 2014: a systematic 
review and modelling analysis. Lancet Glob Health 2019; 7: e37–46.
4 Blencowe H, Krasevec J, de Onis M, et al. National, regional, and 
worldwide estimates of low birthweight in 2015, with trends from 
2000: a systematic analysis. Lancet Glob Health 2019; 7: e849–60.
5 Lawn JE, Davidge R, Paul VK, et al. Born too soon: care for the 
preterm baby. Reprod Health 2013; 10 (suppl 1): S5.
6 Dickson KE, Simen-Kapeu A, Kinney MV, et al. Every Newborn: 
health-systems bottlenecks and strategies to accelerate scale-up in 
countries. Lancet 2014; 384: 438–54.
7 Moxon SG, Lawn JE, Dickson KE, et al. Inpatient care of small and 
sick newborns: a multi-country analysis of health system 
bottlenecks and potential solutions. BMC Pregnancy Childbirth 2015; 
15 (suppl 2): S7.
8 Morgan MC, Spindler H, Nambuya H, et al. Clinical cascades as a 
novel way to assess physical readiness of facilities for the care of 
small and sick neonates in Kenya and Uganda. PLoS One 2018; 
13: e0207156.
9 Lawn JE, Blencowe H, Oza S, et al. Every Newborn: progress, 
priorities, and potential beyond survival. Lancet 2014; 384: 189–205.
10 Katz J, Lee AC, Kozuki N, et al. Mortality risk in preterm and 
small-for-gestational-age infants in low-income and middle-income 
countries: a pooled country analysis. Lancet 2013; 382: 417–25.
11 Blencowe H, Lee AC, Cousens S, et al. Preterm birth-associated 
neurodevelopmental impairment estimates at regional and global 
levels for 2010. Pediatr Res 2013; 74 (suppl 1): 17–34.
12 Bhutta ZA, Das JK, Bahl R, et al. Can available interventions end 
preventable deaths in mothers, newborn babies, and stillbirths, 
and at what cost? Lancet 2014; 384: 347–70.
13 Gray JE, Richardson DK, McCormick MC, Workman-Daniels K, 
Goldmann DA. Neonatal therapeutic intervention scoring system: 
a therapy-based severity-of-illness index. Pediatrics 1992; 90: 561–67.
14 Richardson DK, Gray JE, McCormick MC, Workman K, 
Goldmann DA. Score for neonatal acute physiology: a physiologic 
severity index for neonatal intensive care. Pediatrics 1993; 91: 617–23.
15 Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAP-II and 
SNAPPE-II: simplified newborn illness severity and mortality risk 
scores. J Pediatr 2001; 138: 92–100.
16 Lee SK, Aziz K, Dunn M, et al. Transport Risk Index of Physiologic 
Stability, version II (TRIPS-II): a simple and practical neonatal 
illness severity score. Am J Perinatol 2013; 30: 395–400.
17 The International Neonatal Network. The CRIB (clinical risk index 
for babies) score: a tool for assessing initial neonatal risk and 
comparing performance of neonatal intensive care units. Lancet 
1993; 342: 193–98.
18 Parry G, Tucker J, Tarnow-Mordi W. CRIB II: an update of the 
clinical risk index for babies score. Lancet 2003; 361: 1789–91.
19 Richardson D, Tarnow-Mordi WO, Lee SK. Risk adjustment for 
quality improvement. Pediatrics 1999; 103 (suppl E): 255–65.
20 Morgan MC, Nambuya H, Waiswa P, et al. Kangaroo mother care 
for clinically unstable neonates weighing ≤2000 g: is it feasible at 
a hospital in Uganda? J Glob Health 2018; 8: 010701.
21 Dorling JS, Field DJ. Value and validity of neonatal disease severity 
scoring systems. Arch Dis Child Fetal Neonatal Ed 2008; 93: F80–82.
22 Rosenberg RE, Ahmed S, Saha SK, et al. Simplified age-weight 
mortality risk classification for very low birth weight infants in 
low-resource settings. J Pediatr 2008; 153: 519–24.
23 Okomo UA, Dibbasey T, Kassama K, et al. Neonatal admissions, 
quality of care and outcome: 4 years of inpatient audit data from 
The Gambia’s teaching hospital. Paediatr Int Child Health 2015; 
35: 252–64.
24 Oza S, Cousens SN, Lawn JE. Estimation of daily risk of neonatal 
death, including the day of birth, in 186 countries in 2013: 
a vital-registration and modelling-based study. Lancet Glob Health 
2014; 2: e635–44.
25 Steyerberg EW, Vergouwe Y. Towards better clinical prediction 
models: seven steps for development and an ABCD for validation. 
Eur Heart J 2014; 35: 1925–31.
Articles
www.thelancet.com/child-adolescent   Vol 4   April 2020 311
26 Royal College of Paediatrics and Child Health. UK-WHO growth 
chart—0–4 years. https://www.rcpch.ac.uk/resources/uk-who-
growth-charts-0-4-years (accessed Jan 16, 2020).
27 Department of Health. Toolkit for high quality neonatal services. 
http://www.londonneonatalnetwork.org.uk/wp-content/
uploads/2015/09/Toolkit-2009.pdf (accessed Jan 29, 2020).
28 Malin GL, Morris RK, Riley R, Teune MJ, Khan KS. When is 
birthweight at term abnormally low? A systematic review and 
meta-analysis of the association and predictive ability of current 
birthweight standards for neonatal outcomes. BJOG 2014; 
121: 515–26.
29 Steyerberg EW, Moons KG, van der Windt DA, et al. Prognosis 
Research Strategy (PROGRESS) 3: prognostic model research. 
PLoS Med 2013; 10: e1001381.
30 Lee AC, Mullany LC, Ladhani K, et al. Validity of newborn clinical 
assessment to determine gestational age in Bangladesh. Pediatrics 
2016; 138: e20153303.
31 Owusu BA, Lim A, Makaje N, Wobil P, SameAe A. Neonatal 
mortality at the neonatal unit: the situation at a teaching hospital in 
Ghana. Afr Health Sci 2018; 18: 369–77.
32 Omoigberale AI, Sadoh WE, Nwaneri DU. A 4 year review of 
neonatal outcome at the University of Benin Teaching Hospital, 
Benin City. Niger J Clin Pract 2010; 13: 321–25.
33 Ekwochi U, Ndu IK, Nwokoye IC, Ezenwosu OU, Amadi OF, 
Osuorah D. Pattern of morbidity and mortality of newborns admitted 
into the sick and special care baby unit of Enugu State University 
Teaching Hospital, Enugu State. Niger J Clin Pract 2014; 17: 346–51.
34 Kouéta F, Yé D, Dao L, Néboua D, Sawadogo A. Neonatal morbidity 
and mortality in 2002–2006 at the Charles de Gaulle pediatric 
hospital in Ouagadougou (Burkina Faso). Sante 2007; 17: 187–91 
(in French).
35 Morgan MC, Maina B, Waiyego M, et al. Pulse oximetry values of 
neonates admitted for care and receiving routine oxygen therapy at 
a resource-limited hospital in Kenya. J Paediatr Child Health 2018; 
54: 260–66.
36 Aluvaala J, Nyamai R, Were F, et al. Assessment of neonatal care in 
clinical training facilities in Kenya. Arch Dis Child 2015; 100: 42–47.
37 Graham H, Bakare AA, Ayede AI, et al. Hypoxaemia in hospitalised 
children and neonates: a prospective cohort study in Nigerian 
secondary-level hospitals. EClinicalMedicine 2019; 16: 51–63.
38 Gilbert C, Malik ANJ, Nahar N, et al. Epidemiology of ROP 
update—Africa is the new frontier. Semin Perinatol 2019; 43: 317–22.
 
 73 
5. Current evidence regarding duration, timing, clinical impact, and causal 
pathways for clinical effects of kangaroo mother care: literature review 
5.1. Scope of this chapter 
 
Chapter 5 presents current evidence regarding the practice of KMC, including recommended 
duration and time of initiation (section 5.2), findings of relevant meta-analyses (section 5.3), and a 
literature review of RCTs examining the effect of KMC on mortality, LOS, and hypothermia 
(section 5.4). Existing evidence regarding potential causal pathways for the beneficial effects of 
KMC on mortality and other important clinical outcomes is also presented (section 5.5).  
5.2. KMC duration and time of initiation 
 
5.2.1. Current WHO recommendations 
 
WHO guidelines for preterm care recommend KMC for the “routine care of newborns weighing 
≤2000g… initiated as soon as newborns are clinically stable.”44 The WHO Practical Guide to 
KMC states that KMC should begin gradually, increasing to as close to continuous as possible.8  
 
5.2.2. KMC duration 
 
The optimal duration of KMC is unknown, and data are needed to understand the dose-response 
relationship between KMC duration and mortality.43 This must be balanced with the practicality 
of providing KMC for extended periods of time.62 Studies have shown that continuous KMC can 
be difficult to achieve; mothers may find it overwhelming, and clinicians and administrators may 
be unaware of the need for near-continuous provision.67 Adherence may be improved by 
educating clinicians and administrators, and providing comfortable beds, gowns, and KMC wraps 
for caregivers.67  
 
5.2.3. KMC time of initiation 
 
The optimal time of initiation of KMC is also unknown. In an RCT comparing early-onset (<24h) 
to late-onset (24-72h) KMC in relatively stable infants in Madagascar, the early-onset group had a 
non-statistically significant increase in neonatal mortality. However, there were no differences in 
the incidence of morbidities, adverse events, or LOS between the two groups.68  
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5.3. Effect of KMC on mortality and other clinical outcomes: evidence from meta-
analyses 
 
The most recent Cochrane review (2016) demonstrated that KMC is associated with decreased 
mortality [relative risk (RR) 0.60, 95% confidence interval (CI) 0.39-0.92 (8 trials)], sepsis [RR 
0.35, 95% CI 0.22-0.54 (5 trials)], and hypothermia [RR 0.28, 95% CI 0.16-0.49 (9 trials)] at 
discharge or 40-41 weeks postmenstrual age, compared to conventional care amongst stable 
neonates ≤2000g.42 A meta-analysis by Boundy et al (2016) found that KMC is associated with 
decreased mortality at latest follow-up among infants <2000g [RR 0.64, 95% CI 0.46-0.89 (15 
studies)], sepsis [RR 0.53, 95% CI 0.34-0.83 (8 studies), hypothermia [RR 0.22; 95% CI 0.12-
0.41 (9 studies), and hypoglycaemia [RR 0.12; 95% CI 0.05-0.32 (2 studies)].43 
 
5.4. Literature review of RCTs examining the effect of KMC on mortality, length of 
stay, and hypothermia 
 
5.4.1. Methods 
 
The objective of this literature review was to inform the planned RCT aiming to determine the 
effect of KMC initiated before stabilisation on mortality and other important clinical outcomes 
relative to standard care amongst newborns ≤2000g. This review was conducted prior to my PhD 
upgrade in November 2016. I searched MEDLINE/PubMed, Embase, and Google Scholar for 
studies published from inception through October 31, 2016. The search strategy is described in 
further detail in Annex A.5. Trials were included if they met all of the following criteria: 1) 
randomised (individually or in clusters), 2) KMC compared with standard care (incubator, radiant 
warmer, or late-onset KMC), 3) enrolled LBW infants, 4) mean/median enrolment <15d post-
birth, 5) reported mortality, LOS, or hypothermia as outcomes. Trials were excluded if they met 
any of the following criteria: 1) non-randomised or quasi-randomised, 2) enrolled infants with 
birthweight ≥2500g and did not separately report those results, 3) crossover design, 4) 
mean/median enrolment ≥15d post-birth, 5) did not report mortality, LOS, or hypothermia as 
outcomes. Notably, these eligibility criteria are more specific than those utilised in the 
aforementioned meta-analyses; for example, the Cochrane review included trials that initiated 
KMC at ≥15 days post-birth,42 and the meta-analysis by Boundy et al included both randomised 
and non-randomised studies.43 To identify relevant ongoing RCTs, I searched several clinical trial 
registries most recently in October 2019 using the terms, “kangaroo care” and “skin-to-skin 
contact” (see Annex A.5 for further details). 
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5.4.2. Results 
 
Fifteen trials, which included 2698 infants, met inclusion criteria. Table 5-1 summarises the 
characteristics of infants enrolled in the included RCTs, including the definition of clinical 
stability (if provided) and the percentage of LBW infants who were eligible. 
  
Table 5-1. Characteristics of infants in RCTs included in the review 
Study Inclusion criteria Exclusion criteria 
Mean/median 
age at time of 
enrolment 
Clinical stability 
definition 
Size, percent 
LBW infants 
eligible 
Acharya 
201469 
Stable, BW 
<2000g, admitted 
to newborn unit 
Unstable, 
chromosomal or life-
threatening 
congenital anomalies, 
mother ill or did not 
give consent  
Not provided Not requiring 
ventilatory or 
inotropic support 
or radiant warmer 
126 infants; 
87%  
Ali 200970 Stable, delivered 
vaginally, BW 
1200-1800g 
 
Delivered by 
caesarean section, 
life-threatening 
congenital 
malformations, 
severe perinatal 
complications, 
parents refuse KMC 
4.7d ± 2.9 in 
KMC group 
4.8d ± 2.4 in 
control group 
‘Hemodynamically 
stable’ 
114 infants, 
81%  
Cattaneo 
199871 
Stable, BW 1000-
1999g, ability to 
partially feed, 
mother present 
and willing to 
collaborate 
No visible major 
malformation 
10 (1-74) days 
in KMC group 
8 (1-40) days in 
control group 
Not requiring 
oxygen or IV fluids 
285 infants, 
44%  
Charpak 
199772 
Stable, BW 
≤2000g, sucks and 
swallows well, 
weight gain, 
mother/relative 
able to 
understand/follow 
instructions 
Referred, plans to 
leave Bogotá in near 
future, life-
threatening or major 
malformations, major 
conditions arising 
from perinatal 
problems, parental/ 
family refusal to 
follow-up, refusal to 
comply with KMC in 
intervention group 
4d (1-60) in 
KMC group 
3d (1-55) in 
control group 
Recovered from  
“major problems of 
adaptation to extra-
uterine life,” 
treated for 
infection and/or 
concomitant 
condition 
777 infants, 
72% 
Eka Pratiwi 
200973 
Stable, BW 1500-
2250g, Apgar 
score >6 at 5min, 
mother willing to 
follow 
instructions 
 
Major congenital 
malformations, 
cardio-pulmonary 
problems, critical 
illness (sepsis, NEC, 
ICH); twin gestation, 
complicated 
pregnancy/labour; 
maternal history of 
drug abuse, 
psychiatric disorders, 
or caesarean section, 
or inability to care for 
self or baby 
<1d Not defined 93 infants, 
37%  
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Study Inclusion criteria Exclusion criteria 
Mean/median 
age at time of 
enrolment 
Clinical stability 
definition 
Size, percent 
LBW infants 
eligible 
Gathwala 
200874 
Stable, BW 
≤1800g, Apgar 
score ≥7 at 1 and 
5min, tolerating 
enteral feeds, 
maintaining 
temperature 
Infant sick, unstable, 
or with major 
congenital 
malformations; 
mother unwell or 
refused consent 
1.7d ± 0.5  ‘Stable cardio-
pulmonary status’ 
110 infants, no 
data on percent 
of LBW 
infants eligible 
Ghavane 
201275 
Stable, BW 
≤1500g, tolerating 
feeds of 150 
mL/kg/d 
Major malformations, 
parents refuse 
consent 
14.1d ± 10.3 in 
KMC group 
13.7d ± 10.2 in 
control group 
Not receiving IV 
fluids, oxygen or 
respiratory support, 
no apnoea for 72h 
140 infants, no 
data on percent 
of LBW 
infants eligible 
Kadam 
200576 
Stable, BW 
≤1800g, Apgar 
score ≥7 at 5min, 
enteral feeds  
Infant sick and 
unstable, major 
congenital 
malformations; 
parents refuse 
consent 
3.2d (1-8)  ‘Stable cardio-
pulmonary status’ 
89 infants, no 
data on percent 
of LBW 
infants eligible 
Kumbhojkar 
201677 
Stable, BW 
<2000g 
 
Infant critically ill 
requiring ventilatory 
or inotropic support; 
chromosomal or life-
threatening 
congenital anomaly; 
mother ill; unable to 
follow-up  
3d in KMC 
group 
4d in control 
group 
Requiring 
ventilatory or 
inotropic support 
120 infants, 
52% 
Nagai 
201068 
Relatively stable, 
BW <2500g, age 
<24h, mother or 
other family 
healthy and 
willing to practice 
KMC 
Serious 
malformation, 
prolonged apnoea 
(>20 sec), IV 
infusion 
19.8h in early-
onset group, 
33.0h in late-
onset group 
SpO2 ≥95%, HR 
>100 bpm, RR <60 
breaths per min, 
capillary refill time 
<3 sec 
73 infants, 
52% 
Nimbalkar 
201478 
Stable, delivered 
vaginally, BW 
≥1800g 
Infant delivered by 
caesarean section; 
requiring 
resuscitation; 
congenital anomaly  
43 ± 13min in 
KMC group 
30-60min in 
control group 
Not defined 100 infants (45 
LBW), 43% of 
all screened 
infants eligible 
Ramanathan 
200179 
Stable, BW 
<1500g, tolerating 
enteral feeds, 
maintaining 
temperature in 
thermoneutral 
environment 
Mother unable to 
come to nursery due 
to illness or disability 
Not provided ‘Stable cardio-
pulmonary status’ 
28 infants, no 
data on percent 
of LBW 
infants eligible 
Sloan 199480 Stable 24h prior 
to enrolment, 
singleton, BW 
<2000g, tolerating 
enteral feeds, 
stable weight 
No serious congenital 
abnormalities or 
respiratory, 
metabolic, or 
infectious disease 
13.0d ± 10.5 Temperature 36.5-
37.0°C 
300 infants, 
53% 
Suman Rao 
200881 
Stable, singleton, 
BW <2000g 
 
Infant critically ill 
requiring ventilatory 
or inotropic support, 
chromosomal and 
life-threatening 
congenital anomalies, 
transfer; mother ill or 
unable to follow-up  
3.7d ± 2.8 in 
KMC group 
2.3d ± 1.9 in 
control group 
Not requiring 
ventilatory or 
inotropic support 
220 infants, 
63% 
 
 77 
Study Inclusion criteria Exclusion criteria 
Mean/median 
age at time of 
enrolment 
Clinical stability 
definition 
Size, percent 
LBW infants 
eligible 
Worku 
200560 
Unstable, BW 
<2000g, singleton 
unless 1 twin 
died; mother 
healthy and 
willing to 
participate 
No major congenital 
malformations 
10.0h in KMC 
group 
9.8h in control 
group 
Stable temperature 
and cardiovascular 
status, ability to 
suck, good general 
condition 
123 infants, 
48% 
LBW=low birthweight; BW=birthweight; IV=intravenous; NEC=necrotising enterocolitis; ICH=intracranial 
haemorrhage; HR=heart rate; RR=respiratory rate 
 
Amongst the fifteen RCTs included in the review, there was significant variability in how clinical 
stability was defined. Six defined this based on therapies,69,71,72,75,77,81 five on ‘hemodynamic 
stability,’60,70,74,76,79 and one on vital sign parameters.68 Three RCTs did not report a definition for 
stability.73,78,80  
 
Table 5-2 provides a description of the RCTs included in the review, including interventions 
provided in the standard care group, timing and duration of KMC in the KMC group, and 
outcomes assessed. 
 
Table 5-2. Description of RCTs included in the review 
Study Setting 
(country, 
facility type) 
Standard care 
group 
Continuous or 
intermittent 
KMC, initiation 
time (if provided) 
Median 
duration 
KMC per day 
Outcomes 
Acharya 
201469 
Nepal; 
newborn 
nursery at 
tertiary care 
hospital 
Radiant warmer 
only  
Intermittent ≥6h Weight/length/HC gain, 
hypothermia, apnoea, 
LOS 
Ali 200970 India; NICU at 
tertiary care 
hospital 
Radiant warmer 
or open cot in 
warm room 
Intermittent 6.3h ± 1.52 LOS, weight/HC/length 
gain, BF, nosocomial 
sepsis, hypothermia, 
infection, mortality 
Cattaneo 
199871 
Ethiopia, 
Mexico, and 
Indonesia; 
neonatal units 
at academic 
hospitals 
Radiant warmer 
or open crib in 
warm room 
(Ethiopia); 
incubator 
(Mexico, 
Indonesia) 
Continuous ≥20h Mortality, severe 
illness, weight gain, 
hypothermia, 
hyperthermia, BF, 
acceptability to health 
workers and mothers, 
cost 
Charpak 
199772 
Colombia; 
KMC ward or 
NICU of 
tertiary care 
hospital  
Incubator only 
until able to 
regulate 
temperature and 
thriving 
Continuous ≥20h Mortality, LOS, 
infection, growth 
(weight, length, HC), 
breastfeeding, mother-
infant attachment 
Eka Pratiwi 
200973 
Indonesia; 
NICU at 
public hospital 
Incubator or 
open cribs in 
warm rooms 
Intermittent; 
initiated on day of 
birth 
10.0h ± 1.8 
(range 5.3-
13.5) 
Hypothermia, BW 
regain, sepsis, mortality 
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Study Setting 
(country, 
facility type) 
Standard care 
group 
Continuous or 
intermittent 
KMC, initiation 
time (if provided) 
Median 
duration 
KMC per day 
Outcomes 
Gathwala 
200874 
India; neonatal 
unit at 
academic 
hospital 
Incubator or 
radiant warmer 
Intermittent; 
initiated at mean 
1.72d ±0.45 
10.2h ± 1.5 in 
first month 
Mother-infant 
attachment; LOS, BF, 
weight/length/HC gain 
Ghavane 
201275 
India; KMC 
ward or 
intermediate 
care unit of 
tertiary care 
hospital 
Incubator or 
radiant warmer 
Intermittent ≥8h, placed in 
open cribs 
when not in 
KMC 
Weight/length/HC gain, 
BF, LOS, hypothermia, 
sepsis, apnoea, 
hypoglycaemia 
Kadam 
200576 
India; NICU at 
tertiary care 
hospital 
Radiant warmer 
only 
Intermittent 9.8h ± 3.7 Mortality, hypothermia, 
hyperthermia, sepsis, 
apnoea, breastfeeding, 
LOS, weight gain 
Kumbhojkar 
201677 
India; NICU at 
university 
hospital 
Radiant warmer 
only 
Intermittent 11.5h, 
temporarily 
withdrawn 
from KMC if 
life-
threatening 
event or 
needed 
phototherapy  
Weight/length/HC gain; 
LOS; hypothermia; 
sepsis; apnoea; 
acceptability; BF 
Nagai 
201068 
Madagascar; 
neonatal unit 
at academic 
hospital 
Late-onset KMC 
(post- 
stabilisation, 24-
72h) 
Continuous; 
initiated within 24h 
Not provided Mortality, severe 
infection, re-admission, 
hypothermia, 
hyperthermia, BF, 
bradycardia or 
tachycardia, prolonged 
apnoea, weight gain, 
LOS, discharge ≤7d 
Nimbalkar 
201478 
India; 
maternity ward 
Radiant warmer 
only 
Intermittent; 
initiated within 1h 
post-delivery 
17.0h ± 0.3 
during first 
24h; KMC was 
discontinued at 
24h 
Hypothermia 
Ramanathan 
200179 
India; NICU at 
tertiary care 
hospital 
Incubator or 
radiant warmer 
Intermittent ≥4h Weight gain, BF, LOS 
Sloan 199480 Ecuador; 
NICU at 
maternity 
hospital 
Incubator or 
radiant warmer 
Continuous ≥20h LOS, readmission, cost, 
septicaemia, 
pneumonia, lower/ 
upper respiratory tract 
infection, urinary tract 
infection, jaundice, 
apnoea, aspiration, 
diarrhoea, dermatitis, 
growth (weight, length, 
HC, upper arm), hip 
displacement 
Suman Rao 
200881 
India; NICU at 
tertiary care 
hospital 
Radiant warmer 
only 
Intermittent 13.5h with 
mean total 
duration 33.8d 
± 15.1 
Mortality, hypothermia, 
hyperthermia, sepsis, 
LOS, hypoglycaemia, 
apnoea in <1500g, 
growth (weight, length, 
HC, chest, mid-arm, 
foot length)  
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Study Setting 
(country, 
facility type) 
Standard care 
group 
Continuous or 
intermittent 
KMC, initiation 
time (if provided) 
Median 
duration 
KMC per day 
Outcomes 
Worku 
200560 
Ethiopia; 
neonatal unit 
at academic 
hospital 
Radiant warmer 
only 
Continuous; 
initiated within 24h 
Not provided Mortality, sepsis, 
diarrhoea, pneumonia, 
aspiration, mothers’ 
feeling about KMC 
HC=head circumference; LOS=length of stay; NICU=neonatal intensive care unit; BF=breastfeeding; 
BW=birthweight 
 
Among the seven RCTs evaluating mortality, five reported decreased mortality (RR 0.20-
0.98)60,71,72,80,81 while two reported increased mortality (RR 1.02-1.95).68,76 However, both which 
found increased mortality had very few deaths (Nagai, 2 vs. 1; Kadam, 1 vs. 1) and neither 
reached statistical significance. The only RCT enrolling neonates before stabilisation reported 
major mortality reduction (RR 0.57); however, 66% of deaths and the major difference between 
arms occurred within 12 hours of birth.60 Among the eleven RCTs reporting LOS, eight found 
infants in the KMC group had decreased LOS (mean difference 0.8-7.4 days),68,70,72,74–77,79 two 
found increased LOS (mean difference 0.5-3 days),69,80 and one found no difference.81 Among the 
nine RCTs reporting incidence of hypothermia, seven found infants in the KMC group had 
decreased hypothermia (RR 0.10-0.58)69,70,73,76–78,81 and two found no difference.68,75  
 
In addition to the trials included in the review, three related RCTs are ongoing. The ‘Early KMC’ 
(eKMC) trial is evaluating the effect of KMC initiated within 24h relative to standard care 
(including KMC at >24h) on neonatal mortality amongst moderately stable newborns <2000g in 
The Gambia.82 The ‘Immediate KMC’ (iKMC) trial will compare the impact of KMC initiated 
within 2h of birth relative to standard care on mortality within 72h and 28 days amongst newborns 
1000 to <1800g at five national referral hospitals (Ghana, India, Malawi, Nigeria, Tanzania), 
where intensive care resources including CPAP are available.83 The ‘Immediate Parent-Infant 
Skin-to-Skin Study’ (IPISTOSS) is comparing the effect of continuous SSC initiated within 1h of 
birth relative to standard care on cardiorespiratory stability at 6h amongst neonates born at ≥28 to 
<33 weeks gestational age at three university hospitals in Sweden and Norway.84 
 
5.5. Potential causal pathways for clinical effects of KMC 
 
5.5.1. Thermal control and risk of intraventricular haemorrhage 
 
A variety of underlying mechanisms may be responsible for the beneficial effects of KMC on 
mortality and other important outcomes, many of which are mediated by SSC between the baby 
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and caregiver. Numerous studies have reported improved thermal control with KMC,49,69,70,76–
78,81,85 whilst two found no difference in the incidence of hypothermia.68,75 In a study of 34 
neonates receiving mechanical or nasal CPAP ventilation in the Netherlands, neonates 25 to <27 
weeks gestational age had a mean skin temperature decrease of 1.1% during SSC and 1.4% after 
SSC.86 Neonates 27 to <30 weeks gestational age had a decrease of 0.5% during SSC, which was 
not statistically significant, and a decrease of 0.8% after SSC. They concluded that SSC is safe for 
ventilated neonates <30 weeks gestational age, “as long as skin temperature is monitored and 
extra warmth is provided if necessary.”86 In a population-based study of 8,782 VLBW neonates in 
California, moderate hypothermia (32.0-35.9°C) was associated with increased odds of severe 
intraventricular haemorrhage (IVH, grade 3 or 4) on or before 28 days (odds ratio 1.3, 95% CI 
1.1-1.6).87 Hence, thermally-mediated reduction in the risk of severe IVH may represent a novel 
causal pathway for the protective effect of KMC, particularly among VLBW newborns.87  
 
5.5.2. Brain maturation and neurophysiologic organisation 
 
A growing body of evidence suggests that KMC may accelerate brain maturation and improve 
neurophysiologic organisation in preterm neonates. Maturation of circuitry in the somatosensory 
system, which is indicated by the appearance of evoked brain activity together with the departure 
of spontaneous burst activity on electroencephalogram (EEG), occurs at 35-37 weeks’ gestation.88 
In line with this, a study found that preterm infants exhibited attenuated brain responses to light 
touch at the time of NICU discharge relative to term controls, and that SSC was associated with 
increased amplitude of touch responses in preterm infants.89 A study of former LBW infants who 
participated in a KMC trial in Colombia 20 years earlier demonstrated increased volume of the 
left caudate nucleus in the KMC group.90 This is notable since several studies have shown 
reductions in basal ganglia and thalamic (Figure 5-1) volumes among preterm infants at term-
equivalence,91–94 including one that reported a 10% reduction in caudate nucleus size among 
infants <30 weeks gestational age relative to term controls.94 Larger basal ganglia volumes in 
preterm infants at term-equivalent age are associated with improved motor functioning in 
childhood,94,95 as well as higher intelligence quotient and academic outcomes at age 7 years.94,96 
The latter could be explained by an increased distribution of dopamine receptors in the caudate 
nucleus,97 leading to improved motivational control of learning and reward-seeking behaviours.98 
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Figure 5-1. Segmentation of basal ganglia nuclei and thalamus in a term infant 
 
Image source: Loh et al., 2017.94 Magnetic resonance images of basal ganglia and thalamus in (a) coronal, (b) axial, 
and (c) sagittal views. Light blue = caudate nucleus; dark blue = pallidum; fuchsia = putamen; green = thalamus. 
 
Preterm birth interrupts the normal sequence of brain development, and affected neonates may 
display disorganised sleep, reduced autonomic functioning, and increased reactivity of the 
hypothalamic-pituitary-adrenal (HPA) axis to stress.99–102 An American study reported that 
preterm neonates who received SSC exhibited more quiet sleep, improved respiratory regularity, 
and longer sleep cycles relative to term and term-equivalent controls.99 In a later paper, the same 
group showed that preterm neonates who received SSC had increased EEG sleep complexity 
relative to the non-SSC preterm group at the same postmenstrual age. Discriminant analysis 
showed that SSC neonates at term-equivalent age were closer to the non-SSC term group than to 
the non-SSC preterm group at the same age, suggesting that SSC accelerated neurophysiologic 
maturation.100 Similarly, a study in Israel showed that preterm infants receiving SSC 1h/d for ≥14 
days exhibited longer periods of quiet sleep and alert wakefulness; shorter periods of active sleep; 
higher orientation and habituation scores on the Neonatal Behavioural Assessment Scale; and 
accelerated maturation of vagal tone between 32 and 37 weeks.101 A subsequent Israeli study 
showed that children who received SSC displayed increased autonomic functioning at term-
equivalent age as well as reduced stress reactivity, improved autonomic functioning, more 
organised sleep, and better cognitive control by 10 years of age.102 
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5.5.3. Cardiorespiratory stability 
 
In line with the above findings regarding enhanced autonomic functioning, numerous studies in 
high- and middle-income settings have suggested that KMC improves cardiorespiratory 
stability.50,103–106 This may be related to attenuation of stress reactivity,107,108 potentially mediated 
by parent-baby oxytocin release during SSC.109 In Canada, a randomised crossover trial of 61 
neonates born at 28-31 weeks’ gestation and aged <10 days found that infants receiving SSC 15 
minutes before and during heel stick had lower Premature Infant Pain Profile (PIPP) scores at 90 
seconds post-procedure and faster recovery times relative to babies receiving incubator care.103 
The PIPP is a composite pain measure based on facial actions and changes in maximum heart rate 
and minimum SpO2 from baseline.103 Similarly, an American crossover trial of 14 newborns 30-
32 weeks gestational age within 9 days of birth reported that babies receiving SSC had lower 
heart rates at baseline and during heel stick, and reduced heart rate variability during 
recovery.104 Two related RCTs in Vietnam and South Africa found that LBW babies receiving 
SSC had improved cardiorespiratory stability within 6h of birth relative to babies receiving 
standard care.50,105 In both, stability was evaluated using the Stability of the Cardio-Respiratory 
system in Premature infants (SCRIP) score, a composite measure based on assessment of heart 
rate, respiratory rate, and SpO2 over a 5-minute period.110 An American study of 38 neonates born 
at 27-30 weeks’ gestation, who weighed 1000 to <1500g and were receiving nasal CPAP or nasal 
cannula flow, found that the group receiving SSC 2h/d had fewer bradycardic and oxygen 
desaturation episodes during SSC relative to time spent in incubator care between days 5-10 post-
birth.106 The SSC group also had fewer bradycardic and desaturation events relative to the 
standard care group.106 Conversely, a German study of 22 spontaneously breathing neonates born 
at <32 weeks’ gestation, with a mean chronological age of 26 days, found that the combined 
frequency of bradycardia and hypoxaemia increased from 1.5/h before to 2.8/h during SSC.111 A 
follow-up study reported that the total rate of bradycardia and desaturation was higher during SSC 
(median 3.0/h) relative to incubator care following SSC, with ambient temperature elevated by 
1°C (1.7/h).112 Notably, babies in these two studies were positioned at a 15–30° angle during 
SSC,111,112 whereas those in the aforementioned American study were held upright (45-60° 
angle).106 The authors suggested that upright positioning may reduce the risk of obstructive sleep 
apnoea,106 which is more prevalent in preterm infants;113,114 however, further research is needed to 
confirm this theory. 
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5.5.4. Breastmilk feeding and microbiome maturation  
 
Other causal pathways for KMC may be mediated by SSC as well as breastmilk feeding. RCTs in 
stable neonates have demonstrated that KMC is associated with improved daily weight gain69–
71,74,79,81 and decreased incidence of sepsis/severe infection70,72,77,81 at latest follow-up. Through 
both SSC and promotion of breastmilk feeding, KMC may stimulate lactogenesis and increase 
milk production,115,116 facilitating weight gain and overall growth. A growing number of studies 
have suggested that KMC may promote maturation of the oral and intestinal microbiome in 
preterm neonates, stimulating colonisation of bacterial flora that may be protective against 
infection.117–120 Further research is needed to understand the unique contributions of breastmilk 
feeding and SSC to microbiome establishment in this population. 
 
5.6. Analysis of existing evidence 
 
Major evidence gaps include the effect of KMC initiated prior to stabilisation on mortality and 
other important outcomes;37,43,62 a clear, consistent definition of stability; the optimal time for 
KMC initiation; and the minimum duration required to reduce mortality. In addition, few studies 
have systematically examined causal pathways by which KMC may affect outcomes, particularly 
before stabilisation. Potential mechanisms include improved thermal control;49,69,70,77,81,85 reduced 
IVH risk;87 enhanced cardiorespiratory stability;50,101,103–106 attenuation of the stress response;107–
109 increased breastmilk production;115,116 and accelerated preterm microbiome maturation.117–120  
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6. Kangaroo Mother Care for clinically unstable neonates: is it feasible at a 
hospital in Uganda? (Paper C) 
 
6.1. Scope of this chapter 
 
Chapter 6 presents the third research paper entitled, “Kangaroo Mother Care for clinically 
unstable neonates: is it feasible at a hospital in Uganda?” This paper presents the findings of a 
feasibility study conducted at Jinja Regional Referral Hospital in Uganda to inform the design of 
a randomised trial to investigate the mortality impact of initiating KMC among newborns who are 
not yet stabilised. The study aimed to determine the proportion of admitted neonates meeting the 
proposed therapy-based criteria for instability; assess the feasibility of monitoring and providing 
care therapies to unstable neonates in the KMC position; and evaluate the acceptability of this 
intervention among newborn care providers and parents of hospitalised neonates.  
 
This work was published in Journal of Global Health as an open access article in June 2018. See 
Appendix A.6.1 for the copyright. The paper was part of a six-paper supplement entitled 
‘Accelerating kangaroo mother care,’ which also included papers focusing on service readiness 
for KMC and inpatient newborn care, tracking KMC implementation and coverage, community 
perspectives on KMC in Malawi, and a systematic review of the KMC literature. 
 
In addition to the results presented in the paper, this study informed trial design by testing the 
proposed instability criteria (defined as receiving ≥2 therapies) and facilitating estimation of the 
number of eligible participants and the recruitment rates that would be required to achieve the 
target sample. Among neonates who received only one therapy, the majority received empiric 
antibiotics because they were at risk of infection, i.e., not for confirmed or suspected infection. 
This is a common practice in preterm/LBW newborns, including those who are considered stable. 
For this reason, the instability criterion for the trial was modified to receipt of ≥1 therapy 
excluding empiric antibiotics. The audit demonstrated that 89% of admitted neonates met the 
proposed instability criteria. Based on unpublished data from the Uganda Paediatric Association 
showing that approximately 480 neonates weighing ≤2000g are admitted annually, these findings 
suggest that ≥400 neonates would be eligible each year at Jinja Hospital.  
 
The study further informed trial design by exploring provider and parental willingness to 
randomise small and sick newborns within the first 48h of birth. Interview findings indicated that 
all providers and parents were eager to participate in trials. Eighty percent of providers and 50% 
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of parents expressed willingness to randomise neonates. Among parents who were unwilling, 
most had stabilised newborns who were already receiving KMC, suggesting that these parents 
may be more open to randomisation before stabilisation when neonates normally receive 
incubator care. Providers expressed confidence that most parents would be amenable with 
thorough counselling. 
 
Figure 6-1. KMC feasibility study training at Jinja Regional Referral Hospital, Uganda, 2016 
 
   Study team and newborn unit staff at Jinja Hospital         Supplies and equipment for feasibility study  
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Kangaroo mother care for clinically unstable 
neonates weighing ≤2000 g: Is it feasible at a 
hospital in Uganda?
Background Kangaroo mother care (KMC) for stable neonates 
≤2000 g (g) is associated with decreased mortality, sepsis, hy-
pothermia, and length of stay compared to conventional care. 
The World Health Organization states that KMC “should be ini-
tiated… as soon as newborns are clinically stable” [12]. Howev-
er, the majority of deaths occur in unstable neonates. We aimed 
to determine the proportion of admitted neonates meeting pro-
posed instability criteria, assess the feasibility of providing KMC 
to unstable neonates, and evaluate the acceptability of this in-
tervention to parents and providers at Jinja Regional Referral 
Hospital in Uganda.
Methods This was a mixed-methods study. We recorded data 
including birthweight, chronological age, and treatments ad-
ministered from medical charts, and calculated the percentage 
of clinically unstable neonates, defined as the need for ≥2 med-
ical therapies in the first 48 hours of admission. We enrolled a 
sample of neonates meeting pre-defined instability criteria. 
Mothers were counselled to provide KMC as close to continu-
ously as possible. We calculated the median duration of KMC 
per episode and per day. To explore acceptability, we conducted 
semi-structured interviews with parents and newborn unit care 
providers, and analysed data using the thematic content ap-
proach.
Findings We included 254 neonates in the audit, 10 neonates 
in the feasibility sub-study, and 20 participants in the accept-
ability sub-study. Instability criteria were easily implementable, 
identifying 89% of neonates as unstable in the audit. The medi-
an duration of individual KMC episodes ranged from 115 to 134 
minutes. The median daily duration ranged from 4.5 to 9.7 
hours. Seventy-five percent of interviewees felt KMC could be 
used in neonates concurrently receiving other medical therapies. 
Barriers included lack of resources (beds/space, monitoring de-
vices), privacy issues, inadequate education, and difficulties mo-
tivating mothers to devote time to KMC. Recommendations in-
cluded staff/peer counselling, resources, family support, and 
community outreach.
Conclusions There remains a need for an evidence-based ap-
proach to consistently define stability criteria for KMC to im-
prove care. We found that KMC for unstable neonates weighing 
≤2000g was feasible and acceptable at Jinja Hospital in Uganda. 
Randomised controlled trials are needed to demonstrate the ef-
fect of KMC on survival among unstable neonates in low-re-
source settings.
journal of
health
global
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Each year, 15 million babies are born preterm (<37 completed weeks gestation) and 1 million deaths oc-
cur as a direct result of complications of preterm birth [1-3]. Sub-Saharan Africa and South Asia account 
for three-quarters of the 2.7 million neonatal deaths that occur annually, and preterm birth is the leading 
cause of these deaths [4]. Progress in preventing preterm birth has been limited, but major reductions in 
mortality could be achieved by improving care in low-resource settings [1,3,5,6]. In such settings, 50% 
of neonates born at 32 to 34 weeks gestation, a time when nearly all should survive, die because newborn 
special care is not available [3,7]. Kangaroo mother care (KMC) consists of early, continuous skin-to-skin 
contact (SSC), usually with the infant’s mother; improved breastfeeding; and supportive care for neonates 
[8,9]. The most recent Cochrane review and a meta-analysis demonstrated that KMC among stable neo-
nates ≤2000g is associated with decreased mortality (relative risk (RR) 0.60-0.64) [10,11], sepsis (RR 
0.35-0.53) [10,11], hypothermia (RR 0.22-0.28) [10,11], and length of stay (LOS, mean difference -1.61 
days) [10] compared to conventional care. WHO guidelines recommend KMC for “routine care of new-
borns weighing ≤2000 grams (g)… initiated as soon as newborns are clinically stable” [12].
However, most neonatal deaths occur in clinically unstable neonates within 48 hours of birth in settings 
without intensive care [3,7]. The only randomised controlled trial (RCT) of KMC in unstable neonates 
with mortality outcomes was conducted in Ethiopia (123 neonates ≤2000g) and reported major mortal-
ity impact (RR 0.57) [13]. Notably, this trial excluded >50% of eligible neonates, did not utilise allocation 
concealment, and had an apparent imbalance in gestational age and birthweight between groups (favour-
ing KMC) at baseline [13,14]. Among 17 RCTs (14 enrolled only clinically stable neonates) comparing 
KMC with conventional care in low birthweight (LBW, <2500g) neonates aged <15 days, there was sig-
nificant variability in how clinical stability was defined. Six defined this based on therapies [15-20], five 
on ‘hemodynamic stability’ [13,21-24], and three on specific vital sign parameters [25-27], while three 
provided no definition at all [28-30]. Hence codifying stability criteria for KMC is critical. A recent WHO 
guideline for care of preterm neonates highlighted the evidence gaps regarding KMC effect on mortality 
in unstable neonates. These included absence of criteria to identify which neonates are stable enough to 
safely receive KMC; the optimal time for initiation; and the duration required to reduce mortality [12].
Compared to other regions of the world, sub-Saharan Africa has experienced slow progress towards re-
ducing neonatal mortality, particularly mortality due to preterm birth [2]. This is likely due to higher 
preterm prevalence and lower access to care [3,7], and shortages in health workers [31,32]. Further, many 
interventions are introduced to low-resource settings without adequate evidence of their effectiveness in 
such settings [3,31]. Incubators, the standard mode of thermal support for small and preterm neonates, 
are often unavailable or fail to function due to resource-related difficulties such as inconsistent electricity 
supply or access to replacement parts. Further, they require regular disinfection; however, this is often 
not done in resource-constrained settings [33]. Other potential issues include risk of cross-infection from 
other neonates when incubators are shared, and cost [34-36].
In Uganda alone, an estimated 45 000 newborn deaths occur annually, a quarter of which are due to com-
plications of prematurity [37]. As a result, “national attention for maternal and child health has been clear 
and authorised from the highest levels” [38]. In 2006, the Ugandan government established a Newborn 
Steering Committee, which advised immediate action to increase the scale-up of KMC in facilities [38].
The purpose of this study was to explore the feasibility and acceptability of KMC for clinically unstable 
neonates weighing ≤2000g at Jinja Regional Referral Hospital in Uganda. Specifically, we aimed to:
1)  determine the proportion of admitted neonates meeting proposed clinical instability criteria,
2)  assess the feasibility of monitoring and providing interventions to unstable neonates ≤2000g in the 
KMC position, and
3)  evaluate the acceptability of KMC for unstable neonates ≤2000g to parents and healthcare providers.
METHODS
Study setting
This study was conducted at Jinja Regional Referral Hospital, a facility in southeastern Uganda with a 
catchment area of 4 million. Jinja Hospital has ~ 6500 deliveries annually [39], and preterm birth is com-
mon. Sick and preterm/LBW neonates are cared for in the newborn unit, which admits approximately 
1200 neonates annually. This unit is distinct from the postpartum ward, where healthy newborns receive 
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care. KMC is employed for neonates deemed stable by newborn unit staff. Mothers participate in the care 
of their babies by providing KMC, feeding (breastfeeding and nasogastric/cup feeds), and checking tem-
perature. The standard mode of thermal support for unstable neonates is incubators, frequently with sev-
eral neonates sharing an incubator.
Study design
This was a mixed-methods study consisting of three parts: an admissions audit, a feasibility sub-study, 
and an acceptability sub-study.
1) Admissions audit
Clinical instability was defined a priori as need for ≥2 medical therapies (oxygen, continuous positive air-
way pressure (CPAP), intravenous (IV) fluids, IV antibiotics, aminophylline, phenobarbital, or photother-
apy) during the first 48 hours after birth. The audit aimed to determine the percentage of admitted neo-
nates meeting the proposed criteria. A study coordinator and research assistant were trained on audit 
objectives and procedures. The target sample size was 250 neonates, based on the suggestion of Sackett 
et al [40] that 10 charts per variable are needed to obtain accurate and clinically useful results in a retro-
spective audit. Records were randomly selected across the 12-month audit period (June 2015 to May 
2016). We retrospectively recorded data from the medical charts of neonates who were born at Jinja Hos-
pital and admitted to the newborn unit within 48 hours of birth. The research assistant recorded birth-
weight, date and time of birth and admission, and treatments administered during the first 48 hours of 
admission. We excluded charts that were not satisfactorily complete, defined as including both birthweight 
and medical therapies administered, and those with birthweight >2000g from the analysis. To ensure data 
quality, the study coordinator randomly selected 10% of neonatal charts included in the audit, and dou-
ble-entered data from those charts into data collection forms. We calculated the frequency and percentage 
of medical therapies received during the first 48 hours with 95% confidence intervals (CI), and the per-
centage of neonates meeting the proposed therapy-based instability criteria in that period.
2) Feasibility sub-study
Using instability criteria defined in the audit, we sought to demonstrate the feasibility of monitoring and 
providing clinical care and interventions (such as oxygen, IV fluids) to unstable neonates in the KMC po-
sition. The research team (paediatrician, nurse, study coordinator) and newborn unit nurses had training 
on the study objectives and procedures. Between July and December 2016, we enrolled a purposive sam-
ple of 10 neonates meeting the following eligibility criteria: 1) live-born at Jinja Hospital; 2) birthweight 
≥700g and ≤2000g; 3) singleton; 4) chronological age <48 hours; 5) mother able and willing to participate 
in KMC; 6) infant unstable (defined as in the audit) at the time of enrolment, and followed them until 
discharge (up to a maximum of 14 days). We selected a small sample size due to the exploratory nature 
of the intervention and the inherent clinical risks in this vulnerable population. A KMC overview hand-
out was provided and the study nurse counselled mothers during the consent process and throughout the 
study to provide KMC as close to continuously as possible with a goal of 18 hours per day. For purposes 
of this study, we defined a KMC episode as beginning when skin-to-skin contact (SSC) commenced and 
ending when SSC stopped. For interruptions due to mothers carrying out activities like bathing, a family 
member was encouraged to take over KMC. If none were available, the baby was placed in an incubator 
until the mother returned. Neonates were managed according to unit guidelines. The study paediatrician 
oversaw clinical decisions about enrolled neonates. All neonates received continuous monitoring of oxy-
gen saturation (SpO
2
) and heart rate (HR) using Masimo Rad-8 pulse oximeters. Monitoring was com-
menced at the time of KMC initiation and was continued throughout enrolment. To avoid interruption of 
KMC, a Bilisoft® phototherapy blanket (GE Healthcare, Chicago, IL, USA) was utilised to treat jaundice. 
The study nurse and unit nurses completed a data collection form, which recorded date and time of birth 
and admission, gestational age, birthweight, admission and discharge diagnoses, treatments administered, 
timing and duration of KMC episodes, date of breastfeeding initiation, LOS, and discharge disposition. 
Gestational age was calculated by last menstrual period (LMP). When LMP was unavailable, the study 
nurse conducted a Ballard examination [41]. We calculated the median duration of KMC per episode 
(minutes) and per day (hours) with interquartile ranges (IQR), and the mean number of concurrent med-
ical interventions delivered per day with standard deviation (SD). Statistical analyses for the admissions 
audit and feasibility study were carried out using Stata 13 (StataCorp LP, College Station, TX, USA).
3) Acceptability sub-study
We assessed the acceptability of KMC for unstable neonates ≤2000g to parents and providers at Jinja Hos-
pital. The sub-study utilised qualitative research methodology through semi-structured interviews with 
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20 key stakeholders. In qualitative research, the correct sample size is one that satisfactorily answers the 
research question [42]. Purposive sampling was utilised to select 10 parents of singleton neonates that 
were alive and hospitalised in the newborn unit at the time of the interview. All 10 newborn unit provid-
ers were included. Interviews took place between May and July 2016. Two interview guides were devel-
oped in English – one for parents and one for providers. The guide for parents was translated from En-
glish to Lusoga, the local dialect, and translated back to English to ensure accuracy and equivalence [43]. 
Interviews with parents were conducted in the language with which they were more comfortable. Inter-
views with providers were conducted in English. The interview guide employed open-ended questions 
about a broad range of potential factors while allowing the interviewer to ask additional questions on 
emerging themes. One female interviewer conducted the interviews in a private setting in the language 
of the participant’s choice. Data validity was supported by the fact that the interviewer was a local wom-
an who spoke the local language. The interviewer was familiar with techniques of qualitative research and 
had previous experience interviewing parents in a hospital setting. The protocol and interview guide were 
discussed in detail with the interviewer to ensure she understood the study objectives. Pilot interviews 
were conducted to identify and revise unclear interview questions and provide additional training on ar-
eas of weakness. Consent was requested to audiotape the interview. Interviews were held in a private room 
to provide confidentiality.
Thematic analysis
Interview data were transcribed and, where necessary, translated to English. The interviewer performed 
transcription with the assistance of an experienced Ugandan transcriptionist based at Makerere Univer-
sity. To improve quality control, a sample of early transcripts was compared to the audiotaped interviews 
to detect transcription errors and correct them. Data were analysed using the thematic content approach 
[44,45], which consisted of four steps: 1) familiarisation; 2) identifying codes and themes; 3) developing 
a coding scheme and applying it to the data; and 4) organising codes and themes. The principal investi-
gator (PI) and interviewer read all transcripts and developed the preliminary coding scheme together. Two 
interviews were double coded by the PI and the interviewer, and any discrepancies were discussed and 
resolved to develop the final coding framework. The PI coded the remaining interviews. New themes that 
emerged outside the coding framework were also included in the analysis [46,47].
Ethical issues
All participants in the feasibility study received standard care available in the newborn unit at Jinja Hos-
pital, including oxygen, CPAP, IV fluids, antibiotics, phototherapy, nasogastric feeds, and anti-convulsant 
and other medications as clinically indicated and available. Mechanical ventilation was not available. Fol-
lowing a full explanation about the study by the trained nurse (feasibility study) or interviewer (accept-
ability study) who spoke the local language, written informed consent was obtained from a parent/guard-
ian (feasibility study) or the participant (acceptability study). Ethics Committee approvals were obtained 
from Makerere University, the Uganda National Council for Science and Technology, the London School 
of Hygiene and Tropical Medicine (LSHTM), and the University of California, San Francisco (UCSF).
RESULTS
1) Admissions audit
A total of 268 charts were reviewed, among which 255 were satisfacto-
rily complete and 254 met birthweight criteria (Figure 1).
Among the 254 included neonates, the mean birthweight was 1477g (SD 
318g, range 500-2000g) and 139 (60%) were female. Table 1 shows the 
frequency and percentage of all neonates, very low birthweight (VLBW, 
1001-1500g) neonates, and extremely low birthweight (ELBW, 500-
1000g) neonates with 95% CI by the number of medical therapies re-
ceived during the first 48 hours after birth. Among all enrolled neonates, 
226 (89%, 95% CI: 84.5-92.5) met the proposed instability criteria (≥2 
medical therapies). Similarly, 99 (90%, 95% CI: 82.8-94.9) of VLBW ne-
onates and 26 (90%, 95% CI: 72.6-97.8) of ELBW neonates met criteria 
for instability (Table 1).
Figure 1. Flowchart showing inclusions and 
exclusions for admissions audit.
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The instability criteria were easily implementable, leading to clear 
and timely identification of a substantial proportion of admitted 
neonates as unstable.
2) Feasibility sub-study
Table 2 shows the participant characteristics. Among the 10 neo-
nates enrolled, median birthweight was 1310g, median gestational 
age was 28 weeks, median age at enrolment was 25.3 hours, and 
median LOS was 10 days. Eight neonates were discharged to home, 
all of whom were breastfeeding (3 with supplemental expressed 
breastmilk) at the time of discharge. Two neonates died during the 
study period; both were extremely premature (26-27 weeks) and 
extremely low birthweight (700-750g).
Amongst the 10 participants, we observed 315 KMC episodes over 102 person-days. The median age at 
KMC initiation was 30.3 hours (IQR: 19.6-95.2 hours). The provider was the mother in 298 (94.6%), 
the father in 2 (0.6%), and another family member in 15 (4.8%). Amongst the 8 participants that breast-
fed during the first 14 days of admission, the median age at breastfeeding initiation was 4.5 days (IQR: 
2.0-7.5 days). The mean number of concurrent medical interventions was relatively constant across the 
first 14 days of admission, ranging from 3.7 to 4.1 interventions per day (Table 3). The median duration 
of individual KMC episodes was stable across this time period, ranging from 115 to 134 minutes. The 
median daily duration of KMC ranged from 4.5 hours (day 3) to 9.7 hours (day 13) with a slight upward 
trend over time (Figure 2). Two neonates received the target duration of 18 hours on day 1 (18.1 and 
21.6 hours) and one neonate received the target duration on day 5 (18.3 hours). The number of concur-
rent medical interventions an infant was receiving did not affect the daily duration of KMC (Figure 3).
Table 1. Number of medical therapies received among neonates in admissions audit (N = 254)
Number of medical 
therapies received*
frequeNcy (%) of all 
NeoNates, N = 254 95% ci
frequeNcy (%) of vlbW 
NeoNates, N = 110 95% ci
frequeNcy (%) of elbW 
NeoNates, N = 29 95% ci
0 to 1 29 (11.4) 7.8-16.0 11 (10.0) 5.1-17.2 3 (10.3) 2.2-27.4
2 73 (28.7) 23.3-34.7 32 (29.1) 20.8-38.5 4 (13.8) 3.9-31.7
3 105 (41.3) 35.2-47.7 47 (42.7) 33.3-52.5 19 (65.5) 45.7-82.1
4 to 5 47 (18.5) 13.9-23.8 20 (18.2) 11.5-26.7 3 (10.3) 2.2-27.4
CI – confidence interval, VLBW – very low birth weight, ELBW – extremely low birth weight
*Oxygen, CPAP, IV fluids, IV antibiotics, aminophylline, phenobarbital, phototherapy.
Table 3. Concurrent interventions and KMC duration by study day (N = 10)
study day meaN (sd) Number 
of iNterveNtioNs
raNge Number of 
iNterveNtioNs
meaN (raNge) Number of 
Kmc episodes
mediaN (iqr) duratioN of Kmc 
episodes (miNutes)
mediaN (iqr) daily duratioN 
of Kmc (hours)
1 (n = 10) 4.0 (0.67) 3-5 2.4 (0-5) 120 (108-146.5) 5.1 (3.0-8.6)
2 (n = 10) 3.9 (0.88) 2-5 2.6 (0-5) 115 (65-140) 5.1 (0-8.4)
3 (n = 10) 4.1 (0.99) 2-5 2.0 (0-5) 120 (65-168) 4.5 (1.0-7.0)
4 (n = 9) 4.0 (1.0) 2-5 3.3 (0-4) 131 (120-196) 8.5 (6.7-9.5)
5 (n = 9) 4.0 (1.0) 2-5 3.3 (2-5) 120 (60-148) 7.4 (5.0-8.3)
6 (n = 9) 3.9 (1.05) 2-5 3.0 (0-5) 130 (100-156) 6.1 (5.0-7.3)
7 (n = 9) 3.7 (1.22) 1-5 3.4 (0-6) 120 (108-202) 8.1 (6.0-11.9)
8 (n = 9) 3.7 (1.41) 1-5 3.0 (0-4) 120 (108-146.5) 6.7 (4.4-10.3)
9 (n = 8) 3.5 (1.41) 1-5 3.1 (1-6) 120 (88-138) 6.3 (2.4-9.6)
10 (n = 4) 4.0 (0.82) 3-5 4.0 (2-5) 120 (75-146) 8.3 (6.0-9.8)
11 (n = 4) 4.0 (0.82) 3-5 4.0 (3-5) 129 (92-162.5) 9.3 (7.2-10.1)
12 (n = 4) 3.8 (0.96) 3-5 4.0 (3-5) 134 (80-155) 7.5 (6.5-10.8)
13 (n = 4) 3.8 (0.96) 3-5 4.5 (3-6) 132 (90-160) 9.7 (8.4-11.4)
14 (n = 4) 3.8 (0.96) 3-5 3.0 (2-4) 120 (84-163) 5.6 (4.1-8.4)
KMC – kangaroo mother care, SD – standard deviation, IQR – interquartile range
Table 2. Feasibility study participant characteristics 
(N = 10)
participaNt characteristics mediaN (iqr) raNge
Birthweight (g) 1310 (820-1600) 700-1800
Gestational age (weeks) 28 (26-31) 26-35
Age at enrolment (hours) 25.3 (4.8-43.9) 1.7-47.1
LOS (days) 10 (9-14) 3-40
Number Percent
Female 7 70
Discharged 8 80
Died 2 20
IQR – interquartile range, LOS – length of stay
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3) Acceptability sub-study
We enrolled 20 key stakeholders (10 parents, 10 pro-
viders). Table 4 shows the participant characteristics.
We use the main themes emerging from the data to 
structure the presentation of material from the inter-
views, with themes broadly classified as facilitators or 
barriers, as below.
Facilitators
General knowledge about KMC and its benefits
All parents and providers knew KMC is a method to 
provide warmth to preterm babies through SSC, usu-
ally with the mother.
“It’s a traditional or African way of keeping a baby 
warm; it is usually for babies that are born preterm. You put the baby on the chest of the mothers. It cre-
ates love between the mum and child.” (Father, age 28)
While most parents reported that the mother is the KMC provider, several health care providers stated 
that other family members could also deliver KMC. Parents and providers agreed that KMC promotes 
breastfeeding and infant bonding. One mother also said KMC promotes connection between parents.
“As a KMC father myself, I felt that there was a lot of bonding between myself and my daughter. She is 9 
years old now. I feel like I have bonded with her more than my other children. Each time I meet someone, 
I proudly tell them, ‘This is my daughter.’ When people say, ‘so what,’ I tell them that she was 900 grams 
and look at how she has grown.” (Paediatrician, age 52)
Half of providers mentioned that KMC promotes immunity and overall health in unstable preterm and 
LBW neonates. One provider described how they encourage mothers to practice KMC to help stabilise 
neonates when oxygen is unavailable.
“When the power has gone, we encourage mothers to do it to help stabilize the breathing when the oxygen 
is off.” (Midwife, age 29)
Improved monitoring of unstable neonates
The majority of providers felt that KMC leads to improved monitoring of unstable neonates, compared 
to incubator care.
“While the baby is on KMC, the monitoring is better because the mum is always there. However, if the baby 
is an incubator, the nurse may not be able to check on the baby frequently because of the limited human 
resources available.” (Paediatrician, age 55)
Figure 2. Daily kangaroo mother care (KMC) duration (median, 
IQR, 5th-95th percentiles) by study day (N = 10).
Figure 3. Daily kangaroo mother care (KMC) duration by 
number of concurrent medical interventions (N = 10).
Table 4. Acceptability study participant characteristics (N = 20)
pareNt characteristics, N = 10 provider characteristics, N = 10
Age (median, range) 27 (22-35) Age (median, range) 48.5 (29-55)
Demographic characteristics Role in Newborn Unit
Mother 8 (80%) Paediatrician 2 (20%)
Married 7 (88%) Charge nurse/nurse officer 2 (20%)
Resides in rural area 5 (63%) Midwife 6 (60%)
Father 2 (20%) Educational level
Married 2 (100%) Diploma 6 (60%)
Resides in urban area 2 (100%) Certificate 2 (20%)
Educational level Master’s degree 2 (20%)
Primary 3 (30%)
Secondary 5 (50%)
College 2 (20%)
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The majority of parents also felt that KMC leads to improved infant monitoring. Three mothers and one fa-
ther additionally described how practicing KMC gave them a sense of responsibility in caring for their ba-
bies.
“Because I want my baby to be looked after properly, I start to become responsible for my child and I find 
myself looking to see what’s wrong and letting the doctor know.” (Mother, age 27)
Almost half of providers stated that improved availability of monitoring devices would help facilitate KMC 
provision amongst unstable neonates.
“If it’s there, it would work. Something preferably with lights that’s easier for mums to remember.” (Charge 
nurse, age 50)
Provision of medical interventions in the KMC position
Seventy-five percent of parents and providers felt that medical therapies (eg, oxygen, IV fluids) can be 
provided to neonates while in the KMC position.
“I don’t think there are any concerns because the baby can face either side of the mother’s chest while they 
are receiving oxygen and IV fluids.” (Midwife, age 51)
KMC initiation
The majority of parents and providers felt KMC could be used in the first 48 hours after birth.
“I think it’s a good idea because that skin-to-skin contact will stabilise the baby’s temperature faster than 
an incubator.” (Midwife, age 51)
Staff and peer counselling
All providers and the majority of parents agreed that staff counselling is essential to promote KMC amongst 
unstable neonates. Three providers and three parents stated that peer counselling is a valuable approach 
to promote KMC in the hospital. One provider suggested a follow-up club where mothers could talk to 
each other about KMC and preterm care.
“Peer counselling is key because another mum in the ward can share her experience; we have found that 
peer counselling is more important and effective than counselling from a doctor or nurse.” (Paediatrician, 
age 55)
“We like the follow-up clinic on Friday because it gives the mums a chance to talk amongst each other. You 
will often hear them ask “I put my child like this, is this the right way?” They also compare and contrast. 
We also encourage mothers to teach each other on the proper way to do it.” (Paediatrician, age 52)
Family support and meal provision
Almost half of providers discussed the importance of family support, with two specifically commenting 
on the role of the mother in law in influencing KMC practice in facilities.
“The management of the baby is a combination of the mum, the nurses and the doctors, but also the relatives. 
The mothers need support from the relatives to survive in the hospital.” (Charge nurse, age 50)
One provider and one mother mentioned that provision of meals in the newborn unit would be helpful 
to mothers who lack family support and money.
Concerns related to incubators
Half of parents expressed concerns that incubators were unsafe, some stating they cause brain damage.
“Sometimes I think an incubator can harm the baby’s brain. There is no love, just heat, in the incubator.” 
(Mother, age 22)
One provider and one mother mentioned the shortage of incubators in the newborn unit.
“The incubators are not enough because sometimes your baby could be there and then the doctor comes in 
with a much sicker baby and they remove yours and the cycle continues like that until your baby never 
goes back to the incubator.” (Mother, age 32)
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Cost savings and sustainability of KMC
Three providers stated that KMC is less costly than incubator care. One mother mentioned the sustain-
ability of KMC and one provider discussed the applicability of KMC across different income and educa-
tion levels.
“It is appropriate in every household regardless of someone’s level of civilization. We believe it has bigger 
advantages which is less cost and sophistication and less risks in terms of temperature and it is sustainable.” 
(Paediatrician, age 52)
Community outreach and education
Three providers and two parents felt that provision of KMC education in antenatal clinics and elsewhere 
in local communities would help promote KMC practice amongst hospitalised neonates. One provider 
suggested that such outreach could involve mothers of former preterm neonates teaching members of 
their local community about KMC.
“Some mums don’t have sheets and hats to do KMC… they come unprepared. We provide the hats, but the 
sheets we don’t have anymore. Some counselling and training on KMC needs to be done in the antenatal 
ward to prepare mums.” (Nursing officer, age 50)
“I believe KMC training should start as far as the rural areas; there are some health workers there I’m sure 
don’t know about it. It would be beneficial; this training would then extend to health centre-3s [lowest level 
facility in Uganda at which deliveries are allowable] and go to antenatal care as well.” (Father, age 28)
Barriers
Stigma and guilt related to prematurity
Several providers mentioned that stigma and guilt about having a preterm infant are common in the local 
communities.
“The mothers that are getting preterm babies for the first time are reluctant to help because they don’t be-
lieve that these babies can survive.” (Charge Nurse, age 50)
“Acceptability of this baby is an issue; some mums accept their babies while others, especially those that 
have had normal births in the past, are torn up about it.” (Paediatrician, age 55)
Several mothers described personal observations about the high risk of death in preterm babies.
“I have seen some babies die, especially those that range between 5 and 5.5 months. These babies are at a 
higher risk of dying than those that are 6 or even 7 months. They usually pass away.” (Mother, age 32)
Concerns related to infant monitoring
Providers agreed that monitoring unstable neonates in the KMC position can be challenging due to staff 
shortages and/or lack of monitoring devices.
“I worry sometimes because these mothers may not observe the baby; in some situations, the baby may fall 
inside without the mother noticing… we have to pay extra attention to these mums in the event they aren’t 
monitoring their baby.” (Midwife, age 51)
One mother expressed concern that her baby might be monitored less closely, but agreed that KMC al-
lows mothers to learn more about the care of preterm neonates.
“I’m very worried that doing KMC would not allow my baby to be monitored as much because the baby 
can change colour at any time and you aren’t sure what’s wrong. Sometimes as mothers, we don’t know the 
difference in colour change. However, it also allows the mother to learn more about her baby and update 
the doctor or nurse.” (Mother, age 32)
Concerns related to pain and dislodgement of tubing
A few mothers expressed concern that doing KMC while receiving oxygen or IV fluids could be painful 
for the baby or could lead to accidental dislodgement of tubing.
“I want to be close to him and I feel like those tubes would hurt him as we are doing KMC.” (Mother, 
age 26)
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One mother discussed the difficulties of KMC provision following a caesarean delivery.
“I had a caesarean section and I couldn’t move properly or even hold a baby for at least 3 or even 4 days 
so I wasn’t able to do KMC immediately.” (Mother, age 30)
Lack of family support, finances, and time away from work
One mother stated that lack of family support and lack of money for mothers to buy food are common 
in the newborn unit. A father discussed difficulties with KMC related to cost and increased time away 
from work.
“I was supposed to work but I had to get the day off and come here so that they could be discharged from 
the hospital because it’s becoming very expensive. The more time we are here, the more money I have to 
spend.” (Father, age 25)
Lack of beds, space, and privacy
All providers and 80% of parents felt that lack of beds and space in the newborn unit was a barrier to 
KMC practice. Twenty percent of providers and 80% of parents, including both fathers, perceived lack of 
privacy to be an issue.
“You are a man and they are making you take off your shirt; I know men are shy. If there was a place with 
less people and you are free, that would be good.” (Father, age 25)
Lack of KMC education
Half of parents felt that lack of education was a barrier to KMC provision in facilities.
“Sometimes there are students here and they don’t tell us about KMC and then by the time we are learning 
it has been three days after!” (Mother, age 23)
Lack of motivation amongst parents
Three providers described how it can be difficult to motivate mothers to devote sufficient time to KMC.
“Some of these mothers don’t find it realistic to sit with their babies for that period of time and ultimately 
don’t enjoy it. They want it to be quick.” (Midwife, age 29)
DISCUSSION
To our knowledge, this is the first study to evaluate the incidence of clinical instability, as well as the fea-
sibility and acceptability of KMC in this vulnerable population.
Instability criteria
We found that the majority of neonates weighing ≤2000g admitted within 48 hours of birth in this re-
gional hospital met our criteria for clinical instability. Based on a review of currently available evidence, 
we defined instability by the need for ≥2 medical therapies. For public health impact, it was crucial to 
select criteria that would permit inclusion of the majority of vulnerable neonates, who face the highest 
risk of mortality, while still ensuring safety. Importantly, these therapy-based criteria identified 89% of all 
LBW neonates and 90% of VLBW and ELBW neonates as unstable within 48 hours of birth. We hypoth-
esised that these criteria would identify all ELBW neonates as unstable; however, it is possible that some 
administered therapies were not properly recorded in medical charts. There remains a need for an evi-
dence-based approach to consistently define stability criteria in order to improve clinical care and facili-
tate research in this population [12,48].
Feasibility
We found that it is feasible to monitor and provide medical interventions to unstable neonates in the KMC 
position. Underlining the vulnerability of these preterm neonates, two of the 10 enrolled neonates died 
during the 14-day enrolment period. Both were extremely premature and extremely low birthweight, thus 
at very high risk of death, particularly in a low-resource setting given the lack of ventilatory support and 
other intensive care usually required for survival at this gestational age. The median age at enrolment was 
25.3 hours, and neonates received a median duration of KMC ranging from 4.5 to 9.7 hours per day with 
a slight upward trend over time. This is comparable to findings from several RCTs, which reported me-
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dian daily durations of ≥4 to 10 hours with mean/median age at enrolment ranging from <1 to 4.7 days 
[15,21-24,28]. Notably, despite nurse counselling, few neonates achieved the target KMC duration of 18 
hours per day (two on day 1 and one on day 3). Three RCTs evaluating continuous KMC reported dura-
tions of ≥20 hours per day with mean/median age at enrolment of 4 days [17], 10 days [16], and 13 days 
[30]. Studies have shown that continuous KMC can be difficult to achieve as mothers may find it over-
whelming, and clinicians and administrators may be unaware of the need for near-continuous provision 
[49]. In this study, the number of concurrent medical therapies an infant was receiving did not affect the 
daily duration of KMC. The median duration of individual KMC episodes was approximately 2 hours 
across the study period. Experts have suggested that a minimum episode duration of 2 hours is import-
ant [9] because it provides the stimulation needed to increase milk volume and facilitate let-down; facil-
itates the infant spontaneously awakening, self-regulating feeding, and completing a sleep cycle [50,51]; 
and reduces the number of transfers into and out of the KMC position [52].
Acceptability
We found that stigma and guilt related to having a preterm baby is common in local communities in 
southeastern Uganda. Another study in this region found that most of the mothers interviewed believed 
that preterm babies could survive if treated properly. However, that study also found that some mothers 
wished their preterm neonates had never been born [53]. Other studies have also reported stigma, fear, 
shame, or guilt in association with having a preterm infant [54–56]. All participants knew that KMC pro-
vides warmth to small or preterm neonates. Participants were also aware that KMC promotes breastfeed-
ing, stimulates breathing, and promotes infant bonding. Other studies in low-resource settings have also 
reported knowledge of these benefits [56-58]. In particular, the effect of KMC on parent-infant bonding 
has been widely reported [9,59-63]. In this study, most parents stated that the mother is the KMC pro-
vider. In another Ugandan study, most men interviewed felt that women were the sole KMC providers 
[53]. The majority of parents and providers found use of KMC among neonates who are receiving con-
current medical therapies in the first 48 hours after birth acceptable. A few mothers expressed concern 
that KMC might cause pain or displace IV/oxygen tubing, worries that have also been seen in neonatal 
units in high- and upper middle-income settings [64-67]. The majority of parents and providers felt that 
KMC leads to improved infant monitoring. Other studies have also found that parents feel more respon-
sible for the health of their neonates when providing KMC [9,56].
Our study found that lack of beds/space, privacy issues, insufficient staff and devices for monitoring, in-
adequate KMC education, and difficulties motivating mothers to devote time were the most common 
barriers to KMC practice. Other studies have also reported that lack of space, privacy, and KMC resourc-
es hindered KMC practice [54,68-72]. A study in Malawi found that lack of recreational activities was an 
obstacle [57]. Parents and providers suggested that KMC practice could be improved through staff and 
peer counselling, more beds/space, improved availability of monitoring devices, family support, and com-
munity outreach. Several studies have noted the importance of staff training and counselling on KMC 
[73,74], and a related RCT demonstrated the efficacy of peer counselling in promoting breastfeeding 
amongst admitted preterm neonates [75]. Other studies have noted the importance of family support, 
particularly from the father and mother in law [49,57,63,76], and other social support, such as from peers 
and nurses, in promoting KMC [49,77,78]. In support of the recommendation for community outreach, 
a study found that zero of 16 health centres in two districts of eastern Uganda promoted KMC practice. 
Further, local community members had minimal knowledge about KMC [53].
Limitations
This study has limitations. Audit findings are limited especially by incomplete records, a common issue 
in low-resource contexts. To address the latter, we excluded charts that were not satisfactorily complete, 
which were defined as including both birthweight and medical therapies administered. Our feasibility 
findings are based on a sample of only 10 neonates, which is too small to draw firm conclusions. Impor-
tantly, however, we continuously observed clinical care and KMC practice from the time of enrolment to 
discharge, up to a maximum of 14 days. In a recent systematic review, only 12% of included studies re-
ported the duration of KMC [79]. For the acceptability sub-study, we interviewed 10 parents (8 mothers 
and 2 fathers) and 10 providers who had experienced a preterm birth or cared for preterm neonates, re-
spectively. Participants were assured that their responses were confidential in nature, and would not affect 
the care of their infant in any way; however, social desirability bias may have influenced the responses of 
some parents.
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CONCLUSIONS
This study demonstrates that KMC for neonates meeting criteria for clinical instability, defined as the need 
for ≥2 medical therapies in the first 48 hours, was feasible in a small sample of neonates weighing ≤2000g 
and acceptable to parents and providers at Jinja Hospital in Uganda. To improve clinical care and facili-
tate research, there remains a need for an evidence-based approach to consistently define stability criteria 
for KMC. Further, RCTs are crucial to examine the effect of KMC on survival in this vulnerable popula-
tion. Such evidence would have broad applicability, especially in low-resource settings where most neo-
natal deaths occur.
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7. Operationalising kangaroo Mother care before stabilisation amongst low 
birth Weight Neonates in Africa (OMWaNA): protocol for a randomised 
controlled trial to examine mortality impact in Uganda (Paper D) 
 
7.1. Scope of this chapter 
 
Chapter 7 presents the fourth research paper entitled, “Operationalising kangaroo Mother care 
before stabilisation amongst low birth Weight Neonates in Africa (OMWaNA): protocol for a 
randomised controlled trial to examine mortality impact in Uganda.” This paper describes the 
protocol for the OMWaNA trial and provides an overview of the accompanying economic and 
process evaluations. The primary aim of the trial is to determine the effect of KMC initiated 
before stabilisation on mortality within 7 days relative to standard care amongst neonates ≤2000g 
at four government hospitals in Uganda (Entebbe, Jinja, and Masaka Regional Referral Hospitals 
and Iganga District Hospital). The OMWaNA trial is funded by the Joint Global Health Trials 
scheme of the Department of Health and Social Care, the Department for International 
Development, the Medical Research Council, and the Wellcome Trust.  
 
This work was published in Trials as an open access article in January 2020. See Appendix A.7.1 
for the copyright.  
 
The OMWaNA Inception Meeting was held in February 2019 (Figure 7-1) and the Trial 
Implementation Meeting was held in August 2019 (Figure 7-2). Following completion of 
renovations (Figure 7-3) and a pilot phase, the trial commenced recruitment in January 2020. 
 
Figure 7-1. OMWaNA Inception Meeting in Entebbe with hospital directors, paediatricians, and 
nurse matrons from the four Ugandan trial sites, February 2019 
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Figure 7-2. Members of the OMWaNA team participating in the ‘KMC Challenge’ at the Trial 
Implementation Meeting in Entebbe, August 2019 
   
 
Figure 7-3. OMWaNA team members and collaborators visiting the newly refurbished neonatal unit 
at Entebbe Regional Referral Hospital, August 2019 
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Figure 1- Map of Uganda showing location of the four OMWaNA trial hospitals  
Figure 2- OMWaNA trial schedule of enrolment, interventions, and assessments 
Figure 3- Overview of trial flow including routine procedures and key criteria for eligibility 
screening, assessing severe illness, and stopping KMC 
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Figure 4- OMWaNA intervention (KMC) and control (standard incubator care) arms  
Figure 5- Study site participant flow for the OMWaNA trial 
Figure 6- CONSORT flow diagram for the OMWaNA trial 
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Abstract
Background: There are 2.5 million neonatal deaths each year; the majority occur within 48 h of birth, before stabilisation.
Evidence from 11 trials shows that kangaroo mother care (KMC) significantly reduces mortality in stabilised neonates;
however, data on its effect among neonates before stabilisation are lacking. The OMWaNA trial aims to determine the
effect of initiating KMC before stabilisation on mortality within seven days relative to standard care. Secondary objectives
include exploring pathways for the intervention’s effects and assessing incremental costs and cost-effectiveness between
arms.
Methods: We will conduct a four-centre, open-label, individually randomised, superiority trial in Uganda with two parallel
groups: an intervention arm allocated to receive KMC and a control arm receiving standard care. We will enrol 2188
neonates (1094 per arm) for whom the indication for KMC is ‘uncertain’, defined as receiving ≥ 1 therapy (e.g. oxygen).
Admitted singleton, twin and triplet neonates (triplet if demise before admission of ≥ 1 baby) weighing ≥ 700–≤ 2000 g
and aged ≥ 1–< 48 h are eligible. Treatment allocation is random in a 1:1 ratio between groups, stratified by weight and
recruitment site. The primary outcome is mortality within seven days. Secondary outcomes include mortality within 28
days, hypothermia prevalence at 24 h, time from randomisation to stabilisation or death, admission duration, time from
randomisation to exclusive breastmilk feeding, readmission frequency, daily weight gain, infant–caregiver attachment and
women’s wellbeing at 28 days. Primary analyses will be by intention-to-treat. Quantitative and qualitative data will be
integrated in a process evaluation. Cost data will be collected and used in economic modelling.
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Discussion: The OMWaNA trial aims to assess the effectiveness of KMC in reducing mortality among neonates before
stabilisation, a vulnerable population for whom its benefits are uncertain. The trial will improve understanding of
pathways underlying the intervention’s effects and will be among the first to rigorously compare the incremental cost
and cost-effectiveness of KMC relative to standard care. The findings are expected to have broad applicability to hospitals
in sub-Saharan Africa and southern Asia, where three-quarters of global newborn deaths occur, as well as important
policy and programme implications.
Trial registration: ClinicalTrials.gov, NCT02811432. Registered on 23 June 2016.
Keywords: Preterm, Low birthweight, Newborn, Kangaroo care, Skin-to-skin contact, Neonatal mortality, Randomised
controlled trial, Pragmatic
Background
An estimated 2.5 million neonatal deaths occurred in
2018, accounting for nearly half of all deaths in children
aged < 5 years [1]. Within the neonatal period, 36% of
deaths occur on the day of birth and 73% occur in the
first week [2]. Over 80% of neonatal deaths occur in low
birthweight (LBW; weighing < 2500 g) babies, of which
two-thirds are born preterm (≤ 37 weeks gestational age)
[3]. Complications of prematurity are the leading cause
of neonatal and under-5 mortality [1]. Approximately
two-thirds of the 21 million LBW and 15 million pre-
term babies born each year are born in sub-Saharan Af-
rica or southern Asia [4–6]. Together, these two regions
are responsible for 78% of neonatal deaths [1]. With
rates of preterm birth rising or stagnant across the globe
[5, 6], finding ways to improve survival and reduce mor-
bidity in preterm babies is a growing imperative.
Substantial progress could be achieved by improving
facility-based care of small and sick babies in low- and
middle-income countries (LMIC) [7, 8], Estimates suggest
that available interventions could reduce prematurity-
related mortality by 58% [9]. Kangaroo mother care (KMC)
is an intervention consisting of early skin-to-skin contact,
promotion of exclusive breastmilk feeding, early hospital
discharge, and adequate support and close follow-up at
home [10]. The latest Cochrane review (21 trials) and a
meta-analysis (124 studies) demonstrated that KMC among
stable neonates ≤ 2000 g is associated with decreased mor-
tality [11, 12], sepsis [11, 12], hypothermia [11, 12],
hypoglycaemia [12] and length of stay [11] compared to
conventional care. WHO guidelines recommend KMC for
‘routine care of newborns weighing ≤ 2000g… initiated as
soon as newborns are clinically stable’ [13]; however, there
is significant variability in how stability has been defined in
previous randomised controlled trials (RCT) of KMC [14].
The majority of neonatal deaths occur within 48 h of
birth [2], and before stabilisation. The only RCT of KMC
initiated before stabilisation with mortality outcomes was
conducted in Ethiopia, enrolling 123 newborns weighing
< 2000 g [15]. It reported a 43% reduction in mortality;
however, 66% of deaths and the major difference between
arms occurred within 12 h of birth [15, 16]. Further, this
trial excluded > 50% of eligible neonates, did not utilise al-
location concealment and had an apparent group imbal-
ance at baseline (favouring KMC) [15], compromising
robustness. Hence, the effect of initiating KMC before sta-
bilisation remains an unaddressed research priority and a
well-designed RCT, with clear criteria for stability, is war-
ranted to examine mortality impact in non-intensive care
settings [16, 17]. The OMWaNA trial aims to determine
the effect of KMC initiated before stabilisation on mortal-
ity within 7 and 28 days relative to standard care at four
hospitals in Uganda.
There are few published economic evaluations of
KMC, and none conducted rigorously in low-resource
settings from a societal perspective or with systematic
equity assessment. Several studies in LMIC settings have
found that KMC resulted in cost savings for the hospital
or provider [18–21]; however, none has considered
whether KMC may increase costs to households nor
purposely evaluated KMC initiated before stabilisation.
Evidence gaps remain with regards to estimation of the
incremental cost, cost-effectiveness, budget impact and
equity of KMC before stabilisation, particularly consider-
ing the household and societal perspectives. An eco-
nomic evaluation embedded within the trial will
compare the incremental cost and cost-effectiveness of
KMC relative to standard care.
Rigorous studies examining causal pathways for the ef-
fects of KMC on neonatal health outcomes have not
been conducted; thus, scientific understanding is limited.
Potential underlying mechanisms may include improved
thermal control [11, 12], enhanced cardiorespiratory sta-
bility [22, 23], increased breastmilk volume [24, 25],
oxytocin-mediated attenuation of the stress response
[26, 27] and thermally mediated reduction in the risk of
intraventricular haemorrhage (IVH) [28]. The relevance
of these hypothesised causal pathways in neonates for
whom KMC is initiated before stabilisation is unclear,
particularly IVH risk among very low birthweight
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(VLBW; < 1500 g) newborns. Incubators, which are the
standard alternative to KMC, may increase the risk of
nosocomial infections, particularly in newborn units
with ineffective cleaning standards or where incubators
are shared [29, 30]. Thus, further research is warranted
to improve scientific understanding of the physiological
processes underlying the effect of KMC relative to stand-
ard care in this vulnerable population.
Methods/design
This manuscript has been prepared according to the
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) statement (Additional file 1).
Objectives
The primary objective of the OMWaNA trial is to deter-
mine the effect of KMC initiated before stabilisation on
mortality within seven days relative to standard care among
neonates weighing ≤ 2000 g. Secondary objectives include:
1. Determining the effect of KMC initiated before
stabilisation on other important clinical outcomes
relative to standard care among neonates weighing
≤ 2000 g;
2. Estimating the incremental costs and cost-
effectiveness of KMC initiated before stabilisation
relative to standard care from the societal
perspective;
3. Exploring hypothesised causal pathways for the
clinical effects of KMC initiated before stabilisation
relative to standard care among neonates weighing
≤ 2000 g;
4. Examining the barriers and facilitators to initiating
KMC before stabilisation to inform uptake and
sustainability in Uganda.
Study design
This is a four-centre, open-label, individually rando-
mised, superiority trial with two parallel groups: an
intervention arm allocated to receive KMC and a control
arm allocated to receive standard care. Treatment alloca-
tion is random in a 1:1 ratio between groups.
Study setting
The host institution for the trial is the Medical Research
Council/Uganda Virus Research Institute (MRC/UVRI)
and London School of Hygiene & Tropical Medicine
(LSHTM) Uganda Research Unit in Entebbe. The trial is
being undertaken in collaboration with Makerere Uni-
versity and LSHTM. The trial is being conducted at four
Ugandan government hospitals: Entebbe, Jinja and
Masaka Regional Referral Hospitals and Iganga District
Hospital (Fig. 1).
Uganda has a population of 42.9 million and is ranked
162/189 on the Human Development Index (2017) [31].
The population is predominately rural (76%) and the pov-
erty incidence is 27% nationally [32]. Poverty rates vary
considerably, with the highest rates occurring in rural
areas where subsistence farming is the primary source of
income. The Busoga sub-region, where Jinja and Iganga
are located, has the third highest incidence of poverty in
the country (42.1%), while the Wakiso sub-region, where
Entebbe is located, has the second lowest (7.5%) [32].
In Uganda, the neonatal mortality rate is estimated at
19.9 per 1000 live births, with a resultant 32,296 deaths
in 2018 [1]. Complications of prematurity are respon-
sible for 27% of neonatal deaths [33], as compared to
35% globally [1]. An estimated 107,921 (7%) Ugandan
babies were born preterm in 2014 [5].
Characteristics of the four trial hospitals are shown in
Table 1. Each hospital has a neonatal special care unit,
which accepts referrals from their respective region/dis-
trict. The level of equipment in these government facil-
ities differs, but all have: bag-mask resuscitation;
incubators and/or overhead radiant heaters for thermal
support; intravenous (IV) fluids, nasogastric tubes and
syringes for feeding support; oxygen supply (concentra-
tors or cylinders) and nasal prongs for respiratory sup-
port; IV and oral antibiotics; phototherapy for jaundice;
aminophylline for prematurity-associated apnoea; and
phenobarbital for seizures. Pulse oximetry and impro-
vised bubble continuous positive airway pressure (CPAP)
ventilation are available at some of the trial hospitals. In-
vasive ventilation and surfactant are unavailable at all
sites. Standard care at the four sites involves provision of
intermittent KMC to neonates weighing ≤ 2000 g once
stable, in line with current WHO guidelines.
Study population
The trial will include admitted neonates weighing ≤
2000 g for whom the indication for KMC is ‘uncertain’
according to WHO guidelines concerning clinical stabil-
ity [10]. Eligibility criteria are listed below.
Inclusion criteria:
 Neonate admitted to trial hospital (inborn or
outborn);
 Singleton, twin or triplet (if triplet pregnancy
resulted in demise or stillbirth of ≥ 1 fetus);
 Birthweight ≥ 700 g and ≤ 2000 g;
 Chronological age ≥ 1 h and < 48 h at time of
screening;
 Alive at time of recruitment;
 Parent/caregiver able and willing to provide KMC;
 Parent/caregiver willing to attend follow-up visit;
 Indication for KMC ‘uncertain’ according to WHO
guideline concerning clinical stability: pragmatically
defined as receiving ≥ 1 therapy: oxygen; CPAP; IV
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fluids; therapeutic antibiotics (for suspected or
confirmed infection); phenobarbital.
Exclusion criteria:
 Result of triplet or higher-order multifetal pregnancy
(unless triplet pregnancy resulted in demise or still-
birth of ≥ 1 fetus);
 Indication for KMC ‘certain’ according to WHO
guidelines: pragmatically defined as clinically well
neonates receiving none of the above therapy-based
criteria;
 Severely life-threatening instability defined as oxygen
saturation (SpO2) < 88% in oxygen and ≥ 1 of:
– Respiratory rate < 20 or > 100 breaths/min;
– Apnoea requiring bag-mask ventilation;
– Heart rate (HR) < 100 or > 200 beats/min;
 Severe jaundice requiring immediate management;
 Active neonatal seizures;
 Major congenital malformation;
 Parent does not provide written informed consent to
participate in trial.
Study procedures
The schedule of procedures for the OMWaNA trial is
outlined in Fig. 2.
Figure 3 describes the flow of participants from the
time of screening through follow-up at 28–30 days.
Screening
All admitted neonates weighing ≤ 2000 g at the four trial
hospitals will be screened for eligibility by a study nurse
or medical officer (Fig. 3a, ‘Screening for eligibility’). Eli-
gibility will be assessed as soon as possible after admis-
sion and once the baby is aged ≥ 1 h to allow for
transition immediately after birth. This is in recognition
of the large physiological changes that take place follow-
ing delivery and that the stability of a newborn aged < 1
h may change rapidly and not accurately reflect their
subsequent clinical trajectory. Trained study staff will as-
certain chronological age and relevant pregnancy details
by examining source documents and/or conducting a
standardised maternal interview. Weight will be mea-
sured using the Seca™ 384 electronic weighing scale. A
focused examination will be conducted to assess for the
presence of major congenital malformations, severe
jaundice and seizures.
Neonates for whom KMC is indicated per WHO guide-
lines (i.e. are considered ‘stable’) will be excluded and re-
ceive KMC as part of standard care (Fig. 3a, ‘Stable to
receive KMC’). Neonates for whom the indication for
Fig. 1 Map of Uganda showing location of the four OMWaNA trial hospitals. Source of map data: Google Maps©, 2019
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KMC is ‘uncertain’ per WHO guidelines (i.e. are ‘prior to
stability’) will be further assessed. For those neonates who
are found to meet eligibility criteria (Fig. 3a, ‘Screening for
eligibility’), a trained member of the study staff will moni-
tor HR and SpO2 using a Masimo Rad-8© pulse oximeter
for 10min and measure respiratory rate manually by
counting breaths for 1 min. Those found to meet the cri-
teria for ‘life-threatening instability’ (Fig. 3a, ‘Too un-
stable’), or who have seizures or jaundice requiring
treatment, will not be eligible for immediate recruitment
and will enter a cycle of reassessment every 3 h. All will
continue to receive clinically indicated treatments and car-
diorespiratory monitoring at the discretion of the on-duty
paediatrician, medical officer or nurse. If, during any re-
assessment within the first 48 h, a neonate is found to
have improved and no longer meets exclusion criteria, re-
cruitment may proceed. Neonates who continue to have
life-threatening instability or meet other exclusion criteria
by 48 h will be permanently excluded.
Informed consent
Written informed consent will be sought from the par-
ents of all participants for the following: neonatal
inclusion in the study; collection of sociodemographic
and clinical data; and randomisation to a study arm.
Consent will also be obtained for the possibility that the
caregiver will provide continuous skin-to-skin contact, if
randomised to that arm. Additionally, consent will be
obtained for the collection of household socioeconomic
and cost data, as well as data on infant–caregiver attach-
ment and women’s wellbeing. Study medical officers or
nurses will request informed consent. The preferred per-
son to provide informed consent for neonatal involve-
ment is the mother. If a mother is unavailable or too ill
to provide consent, consent can be obtained from the
father. Once the mother is available and feeling well
enough, the informed consent process will be repeated
to confirm her consent for her baby’s continued partici-
pation. An impartial and literate witness will be used
during consent for non-literate parents, as per Inter-
national Council for Harmonisation-Good Clinical Prac-
tice (GCP) guidance.
Collection of baseline data
Study staff will be trained in infection prevention and
standard operating procedures (SOP) will detail infection
Table 1 Characteristics of Ugandan trial hospitals, with resource availability in February 2019
Entebbe Hospital Iganga Hospital Jinja Hospital Masaka Hospital
Facility level of care Regional District Regional Regional
Catchment area [32] Semi-urban 86% rural 86% rural 65% rural
Local poverty incidence (%) [32] 7.5 42.1 42.1 24.3
Live births (2018) 5706 6894 5287 9588
Neonatal admissions (2018) 597 933 698 2016
Born at an outside facility (n (%)) 12 (2) 32 (3) 98 (14) 504 (25)
Birthweight < 2500 g (n (%)) 248 (42) 421 (45) 234 (34) NAa
Birthweight < 1500 g (n (%)) 229 (38) 114 (12) 115 (17) NAa
Average length of stay (days) 21 3–4 7 4
Paediatrician 1 1 3 2
Nurses in neonatal unit 8b 5 9 6
Overhead radiant heater 3 functional 1 functional 4 functional 2 functional
Incubator 2 functional 4 functional 3 functional, 6
non-functional
3 functional
Open cots 0 7 10 8
Oxygen supply 2 concentrators,
2 cylinders
1 concentrator,
1 cylinder
4 concentrators,
3 cylinders
2 non-functional
concentrators, 1 cylinder
Bubble CPAP (improvised) 1 1 1 0
Pulse oximeter 0 1 4 1
Phototherapy 2 functional 1 functional, 1 non-functional 3 functional 4 functional
KMC beds, chairs 4 beds (KMC room),
no chairs
5 beds (3 KMC room, 2
postnatal corner), no chairs
4 beds (KMC room),
20 chairs (neonatal unit)
4 beds (KMC room),
no chairs
CPAP continuous positive airway pressure, KMC kangaroo mother care, NA not applicable
a Neonatal admissions data were not available for Masaka Hospital
b The neonatal unit at Entebbe Hospital has six government-employed nurses and two volunteer nurses
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control measures for the use of study equipment to avoid
contamination between participants. Axillary temperature
will be measured with a digital thermometer in degrees
Celsius; three measurements will be taken to enable calcu-
lation of the mean value. Respiratory rate will be measured
manually by counting breaths for 1 min. Blood glucose
will be measured with a capillary sample using the study
glucometer. Head circumference (HC) will be measured
and a physical examination will be conducted. Baseline
clinical and anthropometric data will be collected as soon
Fig. 2 OMWaNA trial schedule of enrolment, interventions and assessments 1. The start of trial procedures (time 0) is defined as when the pulse
oximeter is attached for cardio-respiratory monitoring 2. All participants are reviewed daily while admitted to the hospital 3. All participants
receive continuous monitoring of heart rate (HR) and oxygen saturation (SpO2) for 72 h after randomisation. Continuous monitoring continues
until participants no longer require any form of respiratory support 4. HR, SpO2, axillary temperature and respiratory rate are measured every 6 h
until stability criteria are met, after which the frequency transitions to daily 5. Blood glucose is measured daily and may be discontinued once the
participant tolerates full enteral feeds 6. Participants are weighed on day 5, then daily until discharge (unless deemed too unstable by site study
staff) 7. Socioeconomic data, including household details, are collected within 48 h of enrolment. During this time, study staff also inform families
that they will be asked about their household expenditures and activities over the coming month 8. For participants at Entebbe and Jinja
Hospitals, cranial ultrasounds are performed on days 1, 3 and 7 of hospitalisation (or as an outpatient if discharged before day 7) and on follow-
up at day 28–30 9. The Women’s Capabilities Index (WCI) is administered to all mothers within 48 h of enrolment and on days 28–30 to assess
women’s wellbeing 10. The Maternal Infant Responsiveness Instrument (MIRI) is administered on days 28–30 to assess infant-caregiver attachment
11. Duration of admission is measured as the mean time (days and hours) from hospital admission to discharge
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Fig. 3 (See legend on next page.)
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as possible after enrolment, with the exception of gesta-
tional age and crown-foot length, which may be delayed
to within 48 h of enrolment. Gestational age will be esti-
mated using Ballard score [34], last menstrual period and
foot length [35]. Length will be measured using the Seca™
210 neonatal measuring mat.
Socioeconomic data, including household details,
will be collected within 48 h of enrolment using stan-
dardised parent interviews. The Women’s Capabilities
Index (WCI) questionnaire will also be administered
to mothers during this timeframe. Study staff will also
inform families that, over the coming month, they
will be asked about their expenditures and the activ-
ities of members of their household in order to evalu-
ate the economic impact of KMC relative to standard
care.
Randomisation, allocation and blinding
Treatment allocation is random in a 1:1 ratio between
groups using permuted blocks of varying block sizes. The
allocation sequence was computer-generated centrally at
MRC/UVRI by an independent statistician, stratified by
birthweight (< 1000, 1000–1499 or ≥ 1500 g) and recruit-
ment site. The random allocation sequence is uploaded
onto the REDCap (Research Electronic Data Capture,
Nashville, TN, USA) platform [36] and accessed using a
computer with Internet access at each site. The random-
isation server and research database are hosted at the
MRC/UVRI and LSHTM Unit data centre. This precludes
any possibility of study staff viewing the allocation se-
quence. Allocation is revealed only after the study medical
officer or nurse has entered all required screening data
into REDCap. The mother is the unit of randomisation;
twin and triplet participants will be allocated to the same
arm. Each site has one spare computer in case of break-
down or theft; if both fail, the site will revert to random al-
location using telephone as the back-up option. Given the
nature of the KMC intervention, blinding parents/care-
givers is not possible. Process and outcome data will be
anonymised and all analyses will be blinded. Analyses will
be unblinded for the Data and Safety Monitoring Board
(DSMB) at their request.
Intervention arm
Neonates in the intervention group will receive KMC
initiated as soon as possible after randomisation.
Neonates will be naked except for hat and diaper, and
will be secured to the exposed chest of the caregiver
using a KMC wrap (Fig. 4a). The caregiver is seated or
lying on a bed, while the neonate receives any clinically
indicated therapies (e.g. IV fluids, antibiotics, oxygen).
Caregivers will be encouraged to provide KMC as close
to continuously as possible, aiming for at least 18 h per
day. If the primary caregiver is unavailable, another fam-
ily member (e.g. father, grandmother) or close friend
(helper) will be encouraged to provide KMC. If a family
member or helper is not available to continue KMC, the
neonate will be placed into an incubator or under a radi-
ant heater until the caregiver returns. KMC will con-
tinue to be encouraged until discharge and at home after
discharge, as per WHO guidelines. KMC is commonly
practiced until the baby is 2500 g or resists the KMC
position, which is often at 4–10 weeks after birth.
Neonates who meet any of the criteria for stopping
KMC (Fig. 3d, ‘Criteria for stopping KMC’) will be tem-
porarily withdrawn from the intervention and cared for
in an overhead heater or incubator at the discretion of
the on-duty paediatrician. KMC may be restarted once
all of the following criteria are met: (1) no longer meet
any of the stopping criteria; (2) no apnoea requiring bag-
mask ventilation for 24 h; (3) not on phototherapy; (4)
no seizures for 24 h; (5) no abdominal distension; (6)
caregiver available and willing to do KMC; (7) no health-
care worker concerns about clinical condition.
Control arm
Neonates in the control group will be cared for in an in-
cubator (Fig. 4b) or under a radiant heater. Caregivers
are able to touch, hold and feed their baby, but may not
provide any skin-to-skin contact until the neonate meets
WHO criteria for KMC, i.e. are considered ‘stable’. Neo-
nates will be considered stable when the following cri-
teria have been met for a continuous period of ≥ 24 h:
(1) breathing spontaneously with SpO2 > 90% in room
air; (2) no need for supplemental oxygen or CPAP; (3)
respiratory rate 40–< 60 breaths/min; (4) no apnoea; (5)
HR 80–< 180 beats/min; (6) axillary temperature 36.0–
37.4 °C; and (7) no need for IV fluids. These criteria are
consistent with those being used in the WHO-led Im-
mediate KMC (I-KMC) trial [37]. Once stable, neo-
nates can transition to routine (intermittent) KMC
with the caregiver in line with standard care at the
(See figure on previous page.)
Fig. 3 Overview of trial flow including routine procedures and key criteria for eligibility screening, assessing severe illness and stopping KMC 1.
Refusal to feed, feed intolerance or abdominal distension (after starting feeds) 2. Increased respiratory support defined as new oxygen or CPAP
requirement 3. Axillary temperature < 35.5°C after 1 h of observed skin-to-skin contact, not associated with environment or with hypoglycaemia 4.
For participants at EH and JH, cranial ultrasounds will be performed on days 1, 3 and 7 of hospitalisation (or as an outpatient if discharged before
day 7) and on follow-up at days 28–30. CPAP continuous positive airway pressure, EH Entebbe Hospital, HC head circumference, JH Jinja Hospital.
a Screening for eligibility. b Signs of severe illness. c Suspected infection criteria. d Criteria for stopping KMC
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trial sites. As in the intervention arm, neonates in the
control arm who meet any of the criteria for stopping
KMC (Fig. 3d, ‘Criteria for stopping KMC) will be
cared for in an overhead heater or incubator until re-
start criteria are met.
Participant flow around study sites
Participant flow around the study sites is illustrated in
Fig. 5, using Entebbe Hospital as an example. All neo-
nates are initially stabilised and assessed at a radiant
heater. While clinically ‘unstable’, neonates allocated to
KMC are cared for in a study bed and those allocated to
standard care are cared for in an incubator or radiant
heater. Participants in both arms are transferred to the
KMC step-down unit once they meet stability criteria.
Neonatal care capacity building
Substantial expansion of neonatal care capacity and
infrastructure at all trial sites has been embedded
within the OMWaNA trial. This includes enlargement
of the KMC areas within the neonatal units to ensure
Fig. 4 OMWaNA intervention (KMC) and control (standard incubator care) arms. Images: University of California San Francisco Preterm Birth
Initiative, with caregiver consent for publication (a); Melissa Medvedev (b)
Fig. 5 Study site participant flow for the OMWaNA trial. Inc incubator, RH radiant heater
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that all neonates, whether in KMC or not, can be
cared for safely. Additional infrastructure improve-
ments include sinks to provide an optimal environ-
ment for infection control, bathrooms/toilets for
mothers/caregivers and office space for clinical staff.
One study medical officer and 4–5 study nurses have
been recruited to join the clinical teams at each site.
Further, each site will be provided with the following
supplies and equipment: six Masimo Rad-8© oxi-
meters with neonatal sensors; one oxygen concentra-
tor; two thermometers; one glucometer with blood
glucose testing strips; one neonatal ventilation bag
and mask; one Seca™ 384 neonatal weighing scale;
one Seca™ 210 neonatal measuring mat; 2–3 paediat-
ric stethoscopes; and a minimum of four adjustable
beds. In addition, KMC wraps will be provided to
support practice in each unit.
Clinical care for neonates in both arms
Clinical monitoring
All participants will be evaluated at least once by a study
paediatrician or medical officer during the first 24 h after
randomisation. All participants will receive continuous
monitoring and recording of HR and SpO2 for 72 h after
randomisation. Continuous monitoring will continue
until participants no longer require any form of respira-
tory support. HR, SpO2, axillary temperature and re-
spiratory rate will be measured and recorded by a study
nurse every 6 h until stability criteria are met, after
which the frequency will transition to daily. According
to the same frequency, a study nurse will observe and
record the presence or absence of clinical signs of re-
spiratory distress, including chest in-drawing, nasal flar-
ing and grunting. Blood glucose will be measured every
6 h during the first 24 h after randomisation unless it is
< 2.6 mmol/L, in which case it will be measured hourly
until two or more consecutive readings are in normal
range (2.6–6.9 mmol/L). Subsequently, blood glucose
will be measured daily until a participant is tolerating
full enteral feeds.
Medical therapies
All enrolled neonates will receive clinically indicated
treatments, including but not limited to oxygen, IV
fluids (given by bolus or burette), antibiotics, aminophyl-
line, anticonvulsant medicines and phototherapy. Stan-
dardised clinical guidelines will be followed for common
neonatal conditions, including preterm fluids/feeding
(including breastfeeding), suspected and proven sepsis,
respiratory distress, jaundice and seizures. Bubble CPAP
will be provided at the discretion of the on-duty paedia-
trician at sites where this is the standard of care. Jaun-
dice will be treated with phototherapy for neonates in
both arms. All caregivers will be trained in KMC regard-
less of study arm.
Clinical deterioration
Neonatal unit staff at all sites will be trained to recognise
signs of severe illness (Fig. 3b, ‘Signs of severe illness)
and to inform study staff if a participant meets any of
these criteria. The study paediatrician or medical officer
(or study nurse if neither is present) will examine the
neonate as soon as possible to assess whether signs of
early-onset (< 72 h of age) or late-onset (≥ 72 h of age)
infection (Fig. 3c, ‘Suspected infection criteria’) are
present. Neonates will be reassessed for signs of severe
illness and infection during daily rounds. Where avail-
able, a blood culture will be obtained as soon as possible
if a neonate meets criteria for suspected infection; how-
ever, this will not delay administration of antibiotic ther-
apy. Study staff will also assess if the neonate meets
criteria for temporary withdrawal from KMC (Fig. 3d,
‘Criteria for stopping KMC’). At the discretion of the
study paediatrician, neonates may be referred to a
higher-level facility for more specialised care; however,
existing data indicate that this is an uncommon
occurrence.
Discharge and follow-up
At the time of discharge, all caregivers will be provided
with an illustrated handout on neonatal danger signs
and instructed to contact the site study team or seek
medical help if their baby becomes unwell. Caregivers of
babies in both arms will be encouraged to continue
KMC at home. All participants will be given an appoint-
ment to attend the follow-up clinic at the respective
study site on days 28–30. At this visit, cranial ultrasound
(Entebbe and Jinja Hospitals only) and anthropometry
will be performed, feeding practices and outcomes (alive,
dead, readmitted) will be documented, and the WCI and
Maternal Infant Responsiveness Instrument (MIRI)
questionnaires will be administered to mothers.
If participants are discharged before day 7, additional
follow-up will be arranged according to study site. If par-
ticipants do not attend the follow-up visit, a telephone
call will be made the same day to ascertain outcome and
feeding practices and to arrange follow-up, either in the
clinic or at the families’ home, as soon as possible. Rou-
tine follow-up beyond the planned study follow-ups will
be provided by the study staff according to standard
practice and based upon the clinical need of the baby.
Safety reporting and study monitoring
Adverse events (AE) are medical events or laboratory
findings, which result in a change in clinical manage-
ment after randomisation and until 28 days after birth. A
serious adverse event (SAE) is defined as an event that
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results in death, is life-threatening, requires hospitalisa-
tion or prolongation of hospitalisation, results in persist-
ent or significant disability, or requires intervention to
prevent permanent impairment or damage [38]. Study
medical officers and nurses will inform the site paediatri-
cian about any SAE occurrence within 24 h. SAEs will
be followed up by the paediatrician until their resolution
or stabilisation, or until causality is determined to be un-
related to the trial intervention. If a serious but unex-
pected AE occurs, which might be related to the trial
intervention, a SAE report will be submitted to the Re-
search Ethics Committees (REC) at UVRI and LSHTM
within 48 h of the investigators becoming aware of the
event, with a follow-up report provided within a further
five working days. This expedited reporting will be lim-
ited to those outcomes not already listed as primary or
secondary outcomes, yet which might reasonably occur
as a consequence of the trial intervention. All SAEs will
be reported to the Sponsor and RECs as part of their re-
spective annual progress and safety report.
The DSMB will oversee the overall integrity of the
study, its safety and its continued relevance and ability
to answer the primary objective. DSMB members in-
clude a perinatal epidemiologist/statistician (chair), a
South African neonatologist and a neonatal bioethicist.
The DSMB will receive a summary of SAEs after one
month of recruitment, then move to every three or six
months; the DSMB will decide the frequency following
the first report. An interim analysis will be performed on
the primary outcome when approximately half of neo-
nates have been randomised. An independent statistician
will perform the interim analysis, blinded to treatment
allocation and report to the DSMB. Analyses will be un-
blinded at the request of the DSMB. In light of these
data and other evidence from relevant studies, the
DSMB will inform the Trial Steering Committee (TSC)
if in their view: it is evident that no clear outcome will
be obtained with the current trial design; they have a
major ethical or safety concern; or it is evident that the
intervention is clearly superior and continuing the trial
would be unethical to those in the control arm. The
TSC will make the final decision on study continuation.
The study will be monitored by the Reciprocal Moni-
toring Scheme of the East African Consortium for Clin-
ical Research in collaboration with the Research
Compliance and Quality Assurance section of the MRC/
UVRI and LSHTM Unit. Dedicated study monitors, in-
dependent of the study team, will oversee progress and
ensure the trial is conducted and data are handled in ac-
cordance with the protocol, SOPs and applicable ethical
and regulatory requirements. In addition, the UVRI REC
will conduct initial site visits with neonatal specialists
from the Uganda Paediatrics Association and the Ugan-
dan Ministry of Health Newborn Steering Committee.
The trial may be subject to audit by LSHTM under their
remit as Sponsor, the Study Coordination Centre and
other regulatory bodies to ensure adherence to GCP.
Outcome measures
The primary outcome is all-cause early neonatal mortality
(within seven days). Estimates suggest that three-quarters
of neonatal deaths occur in the first week of life [2].
Secondary outcomes are as listed below.
1. Prevalence of hypothermia (axillary temperature <
36.5 °C) at 24 h after randomisation
Axillary temperature will be assessed using a digital
thermometer.
2. Time from randomisation to clinical stabilisation
(days and hours)
The date and time of randomisation and clinical
stabilisation will be prospectively recorded. Stability
is defined as having met all of the following criteria
for a continuous period of at least 24 h:
 Breathing spontaneously with SpO2 > 90% in
room air;
 No need for supplemental oxygen or CPAP;
 Respiratory rate 40– < 60 breaths/min;
 No apnoea;
 HR 80– < 180 beats/min;
 Axillary temperature 36.0–37.4 °C;
 No need for IV fluids.
3. Time from randomisation to death (days and hours)
The date and time of death will be prospectively
recorded from the death certificate for in-hospital
deaths. For deaths occurring after discharge, the
date will be recorded according to verbal report by
the parent/caregiver.
4. Time from randomisation to exclusive breastmilk
feeding (days and hours)
The date and time of randomisation and initiation
of exclusive breastmilk feeding will be prospectively
recorded. Exclusive breastmilk feeding is defined as
receiving breastmilk, either directly from the breast
or by nasogastric tube, bottle, cup or spoon after
expression from the breast, as the sole source of
nutrition [39].
5. Mean duration of hospital admission (days and
hours)
The date and time of admission and discharge will
be documented prospectively for the first admission
episode.
6. All-cause mortality within 28 days
This outcome will be documented at the follow-up
visit on days 28–30. If participants do not attend, a
telephone call will be made the same day to
ascertain outcome.
7. Mean frequency of readmission at 28 days
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Episodes in which a neonate who had been
discharged from a hospital is readmitted to the
same hospital during the first 28 days will be
prospectively recorded. Episodes in which a neonate
is readmitted to a different hospital will be recorded
according to verbal report by the parent/caregiver
on follow-up at days 28–30.
8. Mean daily weight gain (g/day) at 28 days
Mean daily weight gain will be calculated as the
difference between weight at enrolment and on
follow-up at days 28–30, as measured by the study
scale.
9. Women’s wellbeing at 28 days
Women’s wellbeing will be assessed using the WCI,
a capability-based composite measure of quality of
life that will capture the broader effects to the
mother of practicing KMC. The WCI includes six
domains (physical strength, inner wellbeing,
household wellbeing, community relations,
economic security, happiness), with a total of 26
sub-dimensions [40]. Developed and validated in
Malawi, the WCI was recently adapted for use in
Uganda [41].
10. Infant–caregiver attachment at 28 days
Infant–caregiver attachment will be assessed using
the MIRI, a 22-item questionnaire that measures
maternal recognition of responsiveness to infant
cues, maternal recognition of infant responsiveness
and difficulties in responsiveness [42]. The MIRI
was developed and validated in the United States,
and is now being used in Uganda [43].
Process outcomes
Understanding the hypothesised causal pathways for
clinical effects of the intervention (objective 3) will be
achieved by measurement of the following process out-
comes, which are categorised as providing very early
(within 24 h), early (within 72 h) or late clinical impact.
1. Cardiorespiratory stability within 24 h, 72 h after
randomisation
Proportion of time spent with suboptimal HR (<
100 bpm) and SpO2 (< 85%) over the first 24 h and
72 h after randomisation, measured and recorded
continuously using the study pulse oximeter.
2. Prevalence of hypothermia (axillary temperature <
36.5 °C) at 24 h, 72 h after randomisation
Axillary temperature will be assessed using a digital
thermometer.
3. Hypothermia density within 24 h, 72 h after
randomisation
Hypothermia density is defined as the proportion of
time the axillary temperature is < 36.5 °C during a
defined time period. Axillary temperature will be
measured every 6 h during the first 24 h after
randomisation and until clinically stable, after
which it is measured daily.
4. Prevalence of hypoglycaemia (blood glucose < 2.6
mmol/L) within 24 h, 72 h after randomisation
Blood glucose will be measured using a study
glucometer and glucose testing strips.
5. Presence and severity of IVH at 72 h, seven days
after randomisation; presence of late intracerebral
sequelae of prematurity at days 28–30
IVH is a complication of prematurity characterised
by bleeding within the cerebral ventricles, typically
originating from the periventricular germinal
matrix; severity ranges from grade 1 (mild) to grade
4 (severe) [44]. Late intracerebral sequelae include
cystic degeneration, post-haemorrhagic hydrocephalus
and cerebral atrophy. The study paediatrician or
medical officer at two of the four hospitals (Entebbe
and Jinja) will perform cranial ultrasounds using a
Sonosite Edge II© portable ultrasound machine. Both
standard and linear probes will be used to assess for
abnormalities according to a defined protocol and will
include ≥ 11 coronal and sagittal views. Images will be
read by an independent expert.
Data collection, management and security
Trial data will be electronically entered into trial-specific
case report forms on tablets using an offline, mobile
REDCap application, with inbuilt ranges and consistency
checks. Data from tablets will be synchronised once daily
over a secure connection with the web-based REDCap
database, hosted at the MRC/UVRI and LSHTM Unit
data centre. Cardiorespiratory data from Masimo Rad-
8© oximeters will be downloaded using Stowood Visi-
Download™ software, captured in CSV files, securely
transmitted to MRC/UVRI, analysed with PROFOX™
software and reconciled with the trial database. Cranial
ultrasound images will be stored in OsiriX Dicom™ soft-
ware and interpreted blind to allocation and clinical de-
tails. Logs linking parent/caregiver names and residence
location will be stored separately on password-protected
computers, with a hard copy stored in locked cabinets in
secure rooms at all sites.
All data will be stored in institutional servers at the
MRC/UVRI and LSHTM Unit during the study. Data
from the web-based REDCap database will be down-
loaded and stored on institutional servers at LSHTM in
London for access by the PIs and independent statisti-
cian for analysis and preparation of reports for the
DSMB, respectively. These secure, password-protected
servers are only accessible within the LSHTM network
and activity is fully audited, recording both login details
and file system access. Access will be limited to essential
research personnel.
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Sample size
Assuming a control mortality rate of 25% across the four
recruitment sites, 1750 neonates (875 per arm) would
enable us to detect a relative difference between arms of
22.4% (5.6% absolute difference) with 80% power and a
significance level of 5%. If the control mortality rate
were in fact as low as 18%, we would still be able to de-
tect a relative difference of 27% (absolute difference of
4.8%). We plan to recruit 2188 neonates (1094 per arm)
in order to allow for 10% withdrawal due to clinical de-
teriorations and consent withdrawal, and 10% dilution
due to non-compliance and loss to follow-up. This sam-
ple size would enable us to detect absolute reductions of
6.3% and 5.4% from control rates of 25% and 18%, re-
spectively, with 90% power.
Statistical analyses
Summary of baseline data and flow of patients
Baseline characteristics of enrolled neonates will be sum-
marised by treatment arm. Descriptive statistics for con-
tinuous variables will include mean, standard deviation,
median, range and number of observations. Categorical
variables will be summarised as counts and proportions.
Participant flow through screening, randomisation, alloca-
tion and follow-up will be illustrated in a CONSORT dia-
gram (Fig. 6), with reasons for exclusion, non-adherence,
loss to follow-up and non-analysis documented.
Primary and secondary outcome analyses
Primary and secondary outcome analyses will be carried
out on all neonates as randomised (‘intention-to-treat’).
The rate of loss to follow-up will be reported. We will re-
port risk ratios for mortality within seven days (primary
outcome) and 28 days (secondary outcome) for interven-
tion versus control with associated 95% confidence inter-
vals (CI). Time from randomisation to death, time from
randomisation to exclusive breastmilk feeding and length
of stay will be analysed using Kaplan–Meier plots and haz-
ard ratios, with accompanying 95% CI calculated using
Cox proportional hazards regression. All other secondary
outcomes will be analysed using appropriate regression
models accounting for the nature of the distribution of the
outcome, and results will be presented as appropriate ef-
fect sizes with a measure of precision (95% CI). Both un-
adjusted analyses and analyses adjusted for stratification
factors will be carried out. Additional exploratory analyses
will control for any baseline measures that appear to be
imbalanced between arms.
Subgroup and adjusted analyses
Subgroup analyses are planned to explore between-
group differences in the impact of KMC relative to
standard care on mortality by gestational age (< 28, 28–
32 or > 32 weeks), birthweight (< 1000, 1000–1499 or ≥
1500 g) and recruitment site. Gestational age is an im-
portant predictor of newborn survival. In settings with
newborn special care without intensive care, such as the
four trial hospitals, neonatal mortality rates are 86% in
neonates born at < 28 weeks and 41% in neonates born
at 28–31 weeks [45]. Further exploratory analyses will be
carried out to explore the association between mortality
and time of initiation (< 12, 12– < 24 or ≥ 24 h), and
continuity of KMC (median hours per day: < 6, 6– < 12,
12– < 18 or 18–24 h).
Process evaluation
The process evaluation is being conducted to strengthen
understanding of KMC initiation before stabilisation on
neonatal health outcomes, considering both intended
(beneficial) and unintended (negative) clinical effects.
Changes in neonatal care between hospitals and from
before the trial will also be assessed. This evaluation will
be conducted in accordance with the MRC guidance on
process evaluation of complex interventions [46], and
will integrate quantitative and qualitative data. Quantita-
tive outputs will include data related to causal pathways
for clinical effects, neonatal admissions data, and health
system- and facility-level survey data. Quantitative data
will be summarised using descriptive statistics. Qualita-
tive data will be collected though in-depth interviews,
focus group discussions and workshops with parents/
caregivers, healthcare providers and other key stake-
holders to identify experiences of KMC and explore fa-
cilitators and barriers to inform uptake and
sustainability. These data will be analysed using a the-
matic content approach. An iterative methodology will
be used with data collected at several time points and
then used to inform later explorations. Intervention
reporting will follow the template for intervention de-
scription and replication (TIDieR) [47], which will en-
sure a shared understanding of all activities related to
the trial intervention and, if shown to be effective,
how these relate to any proposed scale-up activities.
In addition, the TIDieR will facilitate thoughtful con-
sideration regarding the transferability of findings out-
side a trial setting and to other hospitals in Uganda
and elsewhere.
Economic evaluation
The incremental cost, cost-effectiveness, budget impact
and equity of KMC for neonates before stabilisation rela-
tive to standard care will be examined from both an ag-
gregated and a disaggregated societal perspective
(provider and household combined), in accordance with
the reference case [48]. Effects of the intervention on
neonatal health and maternal wellbeing will be assessed.
Both financial costs, which reflect actual monies paid,
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Fig. 6 CONSORT flow diagram for the OMWaNA trial
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and economic costs, which reflect the full value of re-
sources used, will be examined. Multiple data sources
will be triangulated to arrive at best estimates. Where
possible, resource use and unit costs will be collected
and presented separately, although some costs, such as
out-of-pocket payments for transport, do not permit
this. Household costs will be collected through surveys
amongst a sample of caregivers at the time of discharge
and during follow-up visits. Costs to providers will be
collected prospectively and retrospectively using project
accounts, key informant interviews, facility audits, direct
observations and time-use surveys. As necessary, sec-
ondary data on costs of treating subsequent conditions
may be supplemented with limited primary data collec-
tion in the trial hospitals. Costs and effects will be mod-
elled using a lifetime time horizon.
Discussion
Deaths in the neonatal period are responsible for 47% of
mortality in children aged < 5 years [1]. Complications
of prematurity are the leading cause, accounting for 35%
of neonatal deaths and 16% of under-5 deaths [1]. The
majority of neonatal deaths occur before stabilisation in
settings without intensive care [2]. The OMWaNA trial
will measure the impact of KMC initiated before stabil-
isation on mortality within seven days at four neonatal
units in Uganda, where intensive care is not available.
With rates of preterm birth and institutional delivery on
the rise globally [5, 6, 49], this intervention has the
potential to benefit an ever-growing number of neonates.
This trial was designed with an aim to align clinical
criteria and data definitions to facilitate future opportun-
ities for pooled analyses with related RCTs, including
the eKMC trial in The Gambia [50] and the multi-
country I-KMC trial led by WHO [37]. Several chal-
lenges were identified over the course of designing the
OMWaNA trial, the most notable of which are related
to informed consent and recruitment, non-adherence
and contextual resource limitations.
Challenge 1: timely recruitment with informed consent
Obtaining timely informed consent for this RCT may be
challenging given the involvement of sick neonates [51,
52], the fact that KMC needs to be started as soon as
possible after birth and the fact that some women may
be too ill, especially within the first 24 h, to provide con-
sent or participate. In addition, some of these women
may not be literate. Parental stress is compounded by
the fact that complications may be unexpected, espe-
cially in low-resource settings, where knowledge of
preterm birth is generally low. To help address these is-
sues, the OMWaNA trial utilises the continuous consent
approach [53], which involves providing information at
multiple time points both before and after recruitment.
Studies have found that the validity of consent improves
when discussion continues after recruitment [53]. This
approach has three main elements:
1. Parents will be given preliminary information
during neonatal eligibility screening;
2. If the neonate is eligible, a comprehensive
information sheet will be provided, and further
discussion will take place. If the parents express
willingness and ability to participate, written
informed consent will be obtained and the neonate
will be randomised;
3. During the intervention period, study staff will meet
with parents to ensure that they understand the
trial procedures and wish to continue to participate
in the trial. It will be made clear that they may
withdraw their baby from the trial at any time.
Audit data from the feasibility study at Jinja Hospital
suggest that ~ 400 eligible neonates are admitted annually
[14]. Preliminary data suggest that ~ 500 eligible neonates
each are admitted to Iganga and Entebbe Hospitals per
year and ~ 800 eligible neonates are admitted to Masaka
Hospital per year. Thus, a total population of ~ 4400 eli-
gible neonates is expected over the 24-month recruitment
period, which means a recruitment rate of ~ 50% will be
required to achieve the target sample of 2188. The feasibil-
ity study findings suggest that this is realistic and achiev-
able [14]. The trial timeline includes a three-month buffer
period in the event that recruitment is delayed or slower
than expected. Further, training of study staff emphasised
the importance of timely reporting and responsiveness to
recruitment issues.
Challenge 2: non-adherence to allocated treatment,
especially continuous KMC
Among neonates in the control group, non-adherence
with allocation (e.g. parents demanding early KMC) is a
potential issue; however, this has not been reported in
other trials [11]. Adherence in both arms, particularly the
KMC arm, could be affected by parents witnessing a death
(e.g. in the KMC position). Some babies will die regardless
of the trial arm to which they are randomised. Preterm ne-
onates can die quickly, even in settings with intensive care,
and such deaths are a recognised impediment to KMC
[54]. Stigma regarding preterm birth is common in
Uganda, but has not impeded KMC practice for stable
babies [55]. Study staff will counsel parents about the
potential for mortality at the time of enrolment as well as
counsel parents of neonates who die and those who wit-
ness a death. In addition, prompt reporting of all SAEs
and trial monitoring through regular site visits will further
facilitate timely identification of and responsiveness to any
compliance issues, should they arise.
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Adherence to the target duration of KMC (≥ 18 h/day)
may be challenging [56]. Among five RCTs that pro-
moted continuous KMC, three reported durations of ≥
20 h/day [18, 57, 58] and two did not report duration
[15, 59]. Among 16 RCTs evaluating intermittent KMC
in stable neonates, one reported mean/median duration
of 17 h/day, five reported 10–14 h/day and nine reported
< 10 h/day [60]. The OMWaNA trial will employ a
comprehensive approach to improve adherence. An il-
lustrated KMC handout will be provided to caregivers at
the time of enrolment. Study staff will counsel mothers
about the benefits of KMC throughout the hospital stay,
including the time of discharge. Studies have noted the
importance of staff training and counselling for KMC
[61, 62], and a related RCT demonstrated the efficacy of
peer-counselling in promoting breastfeeding among hos-
pitalised preterm neonates [63]. We will establish KMC
peer-counselling programmes at each site, enlisting
mothers who practiced KMC as participants when they
return for follow-up. Peer counselling will address many
maternal concerns and may help facilitate longer dura-
tions of KMC. We will also engage hospital administra-
tors about KMC guidelines. Adjustable beds and KMC
wraps will be provided, as these have been shown to
improve adherence [56]. Lack of privacy and inadequate
space for beds and equipment were identified as signifi-
cant barriers to KMC practice in the feasibility study [14].
Provision of increased space within the four neonatal units
may facilitate caregiver privacy as well as help improve
clinical providers’ ability to safely care for at-risk neonates.
Despite these measures, this is a pragmatic trial and some
non-adherence is inevitable. The effect of non-adherence
might be to dilute the size of the effect of KMC (assuming
it ‘works’) and this has been factored into the sample size
calculations. Biannual neonatal quality of care surveys,
including progress monitoring of KMC provision/services,
will be conducted at the four sites as part of the process
evaluation.
Challenge 3: context including infrastructure, supplies
and equipment
Over the six months preceding the start of the trial, the
study team has made extensive efforts to expand neonatal
care capacity at the four hospitals. Improvements include
increased space and water supply in the neonatal units,
office space for clinical staff, bathrooms/toilets for care-
givers, adjustable beds for KMC, and various equipment
and supplies. Despite these efforts, context-related re-
source constraints are inevitable. In government facilities,
such as the four trial hospitals, supply/medication short-
ages are common and repair of malfunctioning equipment
(e.g. incubators, oxygen concentrators) is often protracted.
Triannual (every four months) surveys of staffing,
equipment, supply and medication availability, and
infrastructure across the sites are included in the process
evaluation. In addition to the supplies and equipment pro-
vided before trial commencement, the budget includes a
small allowance to help cover the cost of necessary com-
modities for each participating neonate.
Electrical power is required for incubators, radiant
warmers, oxygen concentrators and phototherapy. Lack
of access to reliable electricity is a problem in many
LMICs, including Uganda, where a 2007 national survey
showed that only 19% of government hospitals had
reliable electricity (during working hours) or a backup
generator with fuel [64]. In 2014, a study at Jinja
Hospital recorded 120 episodes of power failure (mean
of 13 times/week), with a median duration of 30 min
each, over a 64-day period [65]. The four trial hospitals
have reliable power supply, with occasional brief power
outages (e.g. when back-up generators run out of fuel).
Daily communication between staff at the MRC/UVRI
and LSHTM Unit and the sites will facilitate timely iden-
tification and resolution of any significant power outages
impacting patient care. Frequency and duration of power
outages will be recorded by site staff.
Conclusion
The OMWaNA trial will assess the effectiveness of
KMC in reducing mortality among neonates before sta-
bilisation, a population where the benefits of KMC are
currently uncertain. These findings are expected to have
broad applicability to hospitals in low-resource settings
and important policy and programme implications. The
trial will be among the first to rigorously compare the
incremental cost and cost-effectiveness of KMC and
standard care, taking into account family members’ time,
which will be crucial to ensure the sustainability of this
intervention. Additionally, OMWaNA will advance un-
derstanding of the underlying mechanisms for the effects
of KMC before stabilisation, including prematurity-
associated brain injury, which could help inform preven-
tion of disability as well as guide further innovation to
improve survival for preterm newborns in the highest
mortality settings.
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8. Discussion and implications 
8.1. Scope of this chapter 
 
In the preceding chapters, this thesis has presented the results of three studies and the protocol for 
a RCT that was informed by these studies, and discussed how they contribute to the existing 
evidence base. This chapter summarises the findings of the PhD and outlines the implications for 
inpatient care of small and sick newborns in the sub-Saharan African context, with a focus on 
KMC practice. Recommendations for policy, programmes, and future research will be presented 
in the final chapter. 
 
8.2. Main findings of this PhD 
 
The overall aim of this PhD has been to improve risk prediction amongst small and sick newborns 
and inform the design of a trial of KMC initiated before stabilisation in a sub-Saharan African 
context. Globally, there are 2.5 million neonatal deaths each year,20 among which more than 80% 
occur in LBW babies who are small because they are preterm, SGA, or both.23–25 Sub-Saharan 
Africa has experienced slow progress in reducing newborn deaths,20 especially those due to 
complications of preterm birth.15,30 The ARR for neonatal mortality in sub-Saharan Africa 
between 2000 and 2018 (2.1%) was less than half of the global ARR (4.3%) that will be required 
to achieve the SDG and ENAP targets by 2030 (Figure 1-1),17–19 underscoring the need for 
improved quality of inpatient care and scale-up of effective interventions for small and sick 
newborns. Assessment of individual risk, using a simplified score feasible for use in LMIC 
facilities, could expedite recognition of severe illness and contribute to improvements in the 
effectiveness and efficiency of care delivered in such settings. Further, the effect of initiating 
KMC before stabilisation remains an unaddressed research priority and a well-designed RCT is 
needed to examine mortality impact,37,62 particularly in settings without intensive care where the 
burden of neonatal death and disability is highest.20,121,122  
 
The first objective of this PhD focused on utilising a clinical cascade model to assess facility 
readiness for neonatal care in East Africa. Cascades were developed for six common neonatal 
conditions and used to assess 23 health facilities in Kenya and Uganda. The second objective 
focused on quantifying in-hospital mortality risk among neonates weighing 2000g or less. A 
logistic model was derived and validated using data from 187 neonatal units in the UK 
(n=110176) and one hospital in The Gambia (n=550). The NMR-2000 score, which includes three 
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parameters that can be feasibly collected in LMICs, demonstrated very good discrimination and 
goodness-of-fit. The third objective of this PhD focused on evaluating the feasibility of initiating 
KMC before stabilisation amongst neonates ≤2000g at a Ugandan hospital. The study showed that 
it was feasible to monitor and provide care in the KMC position (n=10), and demonstrated the 
acceptability of this intervention amongst parents and care providers (n=20). An audit of 
admissions to the neonatal unit (n=254) found that the proposed therapy-based instability criteria 
were easily implementable. The fourth objective drew upon the findings of the first three 
objectives to inform the design of a RCT, which aims to determine the effect of KMC initiated 
before stabilisation on mortality within 7 days relative to standard care. The OMWaNA trial is 
now ongoing at four government hospitals in Uganda.  
 
8.3. Cascade model to assess facility readiness for neonatal care in Kenya & Uganda 
 
The clinical cascade model provides a novel approach to quantitatively assess the physical 
readiness of facilities to provide care for small and sick newborns. In contrast to widely used 
facility inventories and EmONC signal functions,123–125 this model employs a stepwise approach 
that assesses the availability of resources needed to identify and manage six common neonatal 
conditions,126,127 with a negligible increase in data collection requirements.123,124 The cascade 
study estimated overall mean readiness of 26% across conditions and stages of care at the 23 
facilities in Kenya and Uganda. Readiness was consistently lowest for the respiratory distress-
apnoea cascade, with only 17-26% of facilities having all supplies required for identification. This 
was primarily due to the fact that a functional pulse oximeter was only available in 22-44% of 
facilities at both timepoints. In 2015, a study at 11 district hospitals in eastern Uganda similarly 
found that only one paediatric ward had a pulse oximeter, additionally reporting that 89% of 
paediatric nurses failed to demonstrate adequate skills in pulse oximetry.128 In contrast, a recent 
evaluation at nine teaching hospitals across southern Asia and sub-Saharan Africa, including three 
in Kenya and one in Uganda, found that all facilities had pulse oximeters for neonatal care.129 
Overall readiness was higher amongst facilities with a NSCU (37%) relative to those without 
(20%), and facilities with a NSCU had significantly increased treatment readiness for essential 
newborn care, poor feeding-hypothermia, respiratory distress-apnoea, and infection-convulsions. 
These findings have implications for KMC practice and neonatal care more broadly, specifically 
the need to define physical resource requirements for facilities by level of care. This is in line with 
ENAP recommendations regarding indicators for neonatal inpatient care.26,34,130 The cascade 
model identified a consistent pattern of 30-32% overall readiness loss across the 23 facilities. The 
majority of loss occurred in the identification stage; however, the poor feeding-hypothermia, 
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infection-convulsions, and essential newborn care cascades lost most readiness during the 
treatment stage in 2017. Together with low overall readiness, this variability underscores the need 
for improved supply chain management systems to enable more timely detection of resource 
shortages. The cascade model provides an intuitive set of overall, condition-specific, and health 
system indicators for neonatal care that can be used to track the availability of essential drugs, 
supplies, and equipment; aggregate readiness loss could be used to compare readiness across 
health systems, countries, or geographic regions. The low overall readiness among facilities in the 
cascade study additionally highlights the importance of introducing interventions for small and 
sick newborns as part of a broader care package. This suggestion is illustrated by a recent study at 
24 government hospitals in Malawi that reported improved survival to discharge among neonates 
weighing 1000-2499g who were treated for respiratory illness after CPAP implementation, but 
found that 77% of babies with documented admission temperatures were hypothermic and those 
whose mean temperature was hypothermic during CPAP treatment had reduced survival rates.131 
 
8.4. Score to predict mortality amongst hospitalised newborns ≤2000g (NMR-2000) 
 
A variety of scoring systems for predicting mortality risk amongst hospitalised neonates have 
been developed, primarily for high-resource settings. The NMR-2000 was derived and validated 
using data from 187 neonatal units in the UK (n=110176) and one hospital in The Gambia 
(n=550). The final model, which includes three parameters (birthweight, admission SpO2, highest 
level of respiratory support within 24h of birth), showed good discrimination in the development 
and UK validation samples (c-index 0.89) and in the Gambian validation sample (c-index 0.82). 
Complete scoring data were available for 83% of Gambian neonates. Table 8-1 compares the 
characteristics and findings of development studies for scoring systems to predict in-hospital 
mortality amongst admitted neonates.132–141 Scores developed to predict mortality in neonates who 
have been transported from another facility (e.g., MINT, TRIPS, TREMS),142–144 or to enable 
quality of care comparisons across hospitals, necessitating inclusion of delivery room deaths (e.g., 
VON-RA),145 are not presented. As shown in Table 8-1, only one of these scores was designed for 
use in low-resource settings (SAWS). The SAWS score had moderate discriminatory ability 
amongst neonates ≤1500g, with c-indices of 0.70-0.71 at the time of derivation and 0.68-0.70 at 
the time of validation.132 Importantly, the validation sample for this study was very small (n=39) 
and solely comprised of neonates from a community-based study in Nepal.132 A study in Jamaica 
compared SAWS, CRIB-II, birthweight, and gestational age in a cohort of 109 hospitalised 
neonates with VLBW and found that birthweight alone was the strongest predictor of mortality 
(p<0.01), with an area under the ROC curve of 0.91 (95% CI: 0.85-0.96).146 Table 8-1 also 
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highlights key differences with regard to eligibility criteria, complexity of data collection and 
scoring, and suitability for use in LMIC settings. NTISS, TRIPS-II, and the various forms of the 
SNAP score were developed for all NICU admissions; studies of other scoring systems limited 
enrolment based on birthweight, gestational age, or both. Several systems require a 12 to 24h 
period for data collection (e.g., CRIB, SNAP-II), while others are not practicable for bedside use 
due to their length and complexity (e.g., NTISS, SNAP). In contrast to other scores, TRIPS-II and 
NMR-2000 can be assessed at any point within the first 24h and may be repeated as a baby’s 
clinical condition changes. As discussed in Chapter 4, most of these systems rely on laboratory- 
and therapy-derived measures (e.g., blood gas) that are typically unavailable or on clinical 
observations that are not routinely collected or reliably measurable (e.g., urine output) in low-
resource neonatal units.58,65,132 In addition, the NMR-2000 score does not rely on gestational age, 
which is an advantage relative to the SAWS score given the challenges associated with accurately 
assessing this measure in LMIC settings (e.g., limited availability of early antenatal ultrasound).59 
Taken together, the findings of this study indicate that the NMR-2000 score is valid for use in 
health facilities where pulse oximetry is available. These findings also underscore the need to 
strengthen the quality and coverage of routine health information systems in sub-Saharan Africa. 
The NMR-2000 score could facilitate individual risk assessment, enabling targeted delivery of 
care, and has potential to inform neonatal care resource utilisation. 
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Table 8-1. Scoring systems for predicting in-hospital mortality amongst admitted neonates: Characteristics and findings of development studies 
 
Medvedev 
et al64 
Gray et 
al133 
Horbar et 
al134 
Intl. 
Neonatal 
Network135 
Richardson 
et al136,137 
Maier et 
al138 
Richardson 
et al139 
Parry et 
al140 
Rosenberg 
et al132 
Lee et 
al141 
Scoring system NMR-2000 NTISS NICHHD CRIB SNAP, SNAPPE Unnamed 
SNAP-II, 
SNAPPE-II CRIB-II SAWS TRIPS-II 
Study design Retrospective Prospective Retrospective Retrospective Prospective Mixed* Prospective Retrospective Retrospective Prospective 
Year of birth 2010-19 1989-90 1987-89 1988-90 1989-90 1978-87 1996-97 1998-99 1998-2003 2006-08 
Geographical 
location 
England and 
Wales, UK; 
Banjul, GM 
US 
(locations 
unspecified) 
US (locations 
unspecified) 
UK (locations 
unspecified) Boston, US 
Berlin, 
Germany 
Canada and US 
(New England, 
California) 
UK (nationally 
representative 
sample) 
Bangladesh, 
Egypt, Nepal† 
Canada  
(15 distinct 
regions) 
Care setting 
187 neonatal 
units (UK), 
1 NSCU (GM)  
3 teaching 
hospital 
NICUs 
7 teaching 
hospital 
NICUs 
4 teaching 
hospital 
neonatal units 
3 teaching 
hospital NICUs 1 NICU 
17 NICUs in 
Canada, 13 
NICUs in US 
54 neonatal 
units 
1 NICU in 
Cairo, 1 NSCU 
in Dhaka† 
15 tertiary 
NICUs 
Inclusion 
criteria 
BW ≤2000g; 
not enrolled in 
eKMC (GM) 
Admitted to 
NICU 
BW 501-
1500g; inborn 
GA <31 weeks 
or BW ≤1500g 
Admitted to 
NICU 
BW 
<1500g 
Admitted to 
NICU GA ≤32 weeks 
GA ≤33 weeks; 
BW ≤1500g; 
age ≤72h 
Admitted to 
NICU 
Exclusion 
criteria 
UK datasets: 
Admitted at 
>6h of age or 
post-discharge; 
stillborn; died 
in delivery 
room; 
moribund 
Moribund None reported Inevitably 
lethal 
congenital 
anomalies 
Died in 
delivery room; 
moribund on 
admission 
GA >33 
weeks; 
missing 
>10% of 
required 
data 
Died in delivery 
room; admitted 
at age >48h or 
post-discharge; 
transferred to 
normal nursery 
in <24h;  
moribund 
Stillborn; lethal 
congenital 
anomaly or 
metabolic 
disorder; death 
due to organ 
transplant or 
heart surgery 
Congenital 
malformations; 
critically ill 
infants deemed 
unlikely to 
survive beyond 
initial 48h of 
hospitalisation 
Moribund; 
missing GA 
at birth 
Statistical 
methods 
Reverse step-
wise logistic 
regression, 
initially 
including all 
candidate 
variables. 
Assessed 
discrimination 
using c-index, 
goodness-of-fit 
with Brier 
score, and 
calibration 
using plots of 
observed vs. 
predicted 
mortality risk. 
Expert panel 
reviewed 
therapy 
items and 
assigned 
weights 
based on 
intensity. 
Assessed 
association 
between 
NTISS and 
mortality 
using Mantel 
Haenzel 
extension of 
X2 test, and 
goodness-of-
fit with H-L. 
Reverse 
stepwise 
logistic 
regression, 
initially 
including 
variables 
associated 
with death on 
univariate 
analyses. 
Assessed 
predictive 
ability using 
ROC and 
goodness-of-
fit with H-L 
test.  
Reverse 
stepwise 
logistic 
regression, 
initially 
including 
variables 
associated with 
death on 
univariate 
analyses. 
Assessed 
discrimination 
with ROC and 
goodness-of-fit 
with H-L. 
Experts 
selected 
physiologic 
items, assigned 
weights by 
item severity. 
Tested SNAP 
using X2. 
Logistic 
regression 
including BW, 
tested variables 
to select best 
model (+PE). 
Assessed 
discrimination 
with ROC and 
goodness-of-fit 
with H-L test. 
Forward 
stepwise 
logistic 
regression 
to identify 
variables 
associated 
with death. 
Assessed 
predictive 
ability 
using ROC 
and 
goodness-
of-fit with 
H-L test. 
Logistic 
regression, 
starting with 
SNAP variables 
associated with 
death on 
univariate 
analyses. Chose 
best physiologic 
model. Perinatal 
variables then 
added to select 
best combined 
model. Assessed 
discrimination 
using ROC and 
goodness-of-fit 
with H-L test. 
Logistic 
regression 
including log-
odds of death 
by BW, sex, 
and gestation 
derived from 
Draper Grid.147 
Candidate 
variables were 
then added, 
with selection 
of best model 
using Akaike 
information 
criteria.148 
Categorical 
GA, weight, 
and sex 
variables were 
combined into 
SAWS model. 
Compared 
predictive 
ability using 
ROC of SAWS 
alone vs. with 
addition of 
other candidate 
variables, then 
calculated 
mortality risk 
for each SAWS 
category. 
Reverse 
stepwise 
logistic 
regression, 
initially 
including 
variables 
associated 
with death 
on univariate 
analyses. 
Assessed 
predictive 
ability using 
ROC and 
goodness-of-
fit with H-L 
test. 
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Medvedev 
et al64 
Gray et 
al133 
Horbar et 
al134 
Intl. 
Neonatal 
Network135 
Richardson 
et al136,137 
Maier et 
al138 
Richardson 
et al139 
Parry et 
al140 
Rosenberg 
et al132 
Lee et 
al141 
Derivation 
sample size 55029 1768 1823 812 
SNAP: 1643 
+PE: 1089 396 10819 1886 428
† 11383 
Validation 
sample size 55697 NA 1780 488 SNAPPE: 532 176 14610 1065 39
† 5692 
Deaths in 
derivation 
sample, n (%) 
1653 (3.0) 114 (6.5) 890 (24.7)‡ 201 (24.8) 
SNAP:  
114 (6.9) 
+PE: 59 (5.4) 
106 (26.8) 418 (3.9) 240 (7.9)‡ 262 (61.2) 411 (3.6) 
Deaths in 
validation 
sample, n (%) 
UK: 1701 (3.1) 
GM: 215 
(41.4) 
NA 890 (24.7)‡ 111 (22.7) SNAPPE:  33 (6.2) 55 (31.0) 548 (3.8) 240 (7.9)
‡ 24 (61.5) 199 (3.5) 
Parameters in 
final model 
(number, type) 
1 perinatal, 
1 physiologic, 
1 therapy  
62 therapies 5 perinatal 
2 perinatal,  
1 diagnosis, 
3 physiologic 
34 physiologic 
(SNAP) + 3 
perinatal (+PE) 
2 perinatal, 
1 diagnosis, 
1 therapy, 1 
physiologic  
6 physiologic 
(SNAP-II) + 3 
perinatal (+PE) 
3 perinatal, 
2 physiologic 3 perinatal 
4 
physiologic 
Timeframe for 
collection of 
scoring data 
Anytime 
within 24h  
of birth  
Up to 24h 
after 
admission 
At time of 
birth or 
admission 
Up to 12h after 
admission 
Up to 24h after 
admission 
At time of 
admission 
Up to 12h after 
admission 
Up to 1h after 
admission 
At time of birth 
or admission 
Anytime 
within 24h 
of admission 
Simplified for 
bedside use? Yes 
No- long and 
complex tool 
No- logistic 
model only 
No- lengthy 
data collection  
No- long and 
complex tool Yes 
No- lengthy  
data collection Yes Yes Yes 
Suitability for 
LMIC settings 
Yes, if SpO2  
is available 
Therapies 
unavailable 
Black race not 
explanatory 
Blood gas, 
FiO2 required 
Blood gas, OI, 
FiO2 required 
 Blood gas 
required 
Blood gas, FiO2, 
UOP required 
Blood gas 
required 
Yes, if GA  
is accurate  
Neonatal BP 
not routine  
Discrimination 
in derivation 
sample 
0.89 
X2: 158.3 
p-value: 
<0.001 
0.82 0.92 
X2 p<0.001 
(reported only 
for SNAP) 
Not 
reported 
0.91  
(reported only 
for SNAPPE-II) 
Not reported 
0.70 (GA ≤33 
weeks); 0.71 
(≤32 weeks)   
Not reported 
Discrimination 
in validation 
sample 
UK: 0.89¶ 
GM: 0.82 NA 0.82 0.90 
0.93 
(reported only 
for SNAPPE) 
0.86 
0.89-0.93§ 
(reported only 
for SNAPPE-II) 
0·92 
0.68 (GA ≤33 
weeks); 0.70 
(≤32 weeks)   
0.87 
Goodness-of-
fit in derivation 
sample 
0.02 Close agreement 
H-L X2: 14.3 
p=0.07# Not reported Not reported p=0.56# 
p=0.62# 
(reported only 
for SNAPPE-II) 
Not reported Not reported Not reported 
Goodness-of-
fit in validation 
sample 
Brier score-
UK: 0.03¶ 
GM: 0.17 
NA H-L X
2: 15.4 
p=0.06# 
H-L X2: 16.8 
p=0.08# 
H-L X2: 7.5§ 
p=0.11#& p=0.99# 
p=0.19-0.66§# 
(reported only 
for SNAPPE-II) 
H-L X2: 4.3 
p=0.83# Not reported 
H-L X2: 8.3 
p=0.14# 
NMR-2000=Neonatal Mortality Risk among newborns weighing 2000 grams or less; NTISS= Neonatal Therapeutic Intervention Scoring System; NICHHD=National Institute of Child Health and 
Human Development; CRIB=Clinical Risk Index for Babies; SNAP= Score for Neonatal Acute Physiology; SNAPPE=SNAP Perinatal Extension; SAWS= Simplified age-weight-sex; TRIPS= 
Transport Risk Index of Physiologic Stability; GM=Gambia; NSCU=neonatal special care unit; NICU=neonatal intensive care unit; BW=birthweight; eKMC=Early KMC trial; GA=gestational age; 
ROC=area under receiver operating characteristic curve; H-L=Hosmer-Lemeshow; NA=not applicable; FiO2=fraction of inspired oxygen; OI=oxygenation index; UOP=urine output; BP= blood 
pressure. *Data collected retrospectively from 1978 to 1986, and prospectively in 1987. †Derivation sample comprised of hospitalised neonates in Cairo, Egypt and Dhaka, Bangladesh; validation 
sample comprised of neonates from a community-based study in Sarlahi District, Nepal. ‡Figure represents deaths in the combined derivation and validation samples. ¶Figure represents model 
performance in the UK full validation sample. §Ranges represent model performance in the Canadian (n=5588), California (n=5530), and New England (n=3492) validation samples. #P-value for 
Hosmer-Lemeshow statistic (p<0.05 represents poor goodness-of-fit). &Figures represent goodness-of-fit for the SNAPPE score in the combined derivation and validation samples.
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8.5. Feasibility study of KMC initiated before stabilisation in Uganda 
 
This study demonstrated that continuous cardiorespiratory monitoring and provision of concurrent 
therapies were feasible among neonates receiving KMC before stabilisation at Jinja Hospital.65 
Enrolled neonates received an average of four concurrent therapies per day over the first 14 days 
of admission. A related study in India similarly reported no adverse events (e.g., extubation, loss 
of venous access) nor significant changes in temperature, respiratory rate, or SpO2 among LBW 
infants receiving CPAP (n=15) or mechanical ventilation (n=5) in the KMC position.149 A recent 
study in China found that ELBW infants receiving KMC had significantly shorter durations of 
CPAP (29.5 versus 20.5 days) and nasal intermittent positive pressure ventilation (21.0 versus 
13.5 days), relative to infants receiving standard care.150 In the feasibility study, the median daily 
duration of KMC ranged from 4.5 to 9.7h. Despite nurse counselling, few neonates received the 
target duration of 18h per day.65 An observational study at Jinja Hospital (see Annex A.2) found 
that the mean daily duration of SSC over the first week of life was 3.0h (SD 2.1) among stabilised 
newborns weighing 2000g or less; barriers to SSC continuity included maternal illness, lack of 
privacy, unavailability of chairs for caregivers, and overcrowding in the newborn unit.151 A RCT 
of KMC among term infants in Zambia reported that KMC continuity within 24h of birth was 
negatively affected by postpartum fatigue, maternal illness, routine postpartum checks, and 
essential newborn care practices.152 A related study in India identified multiple barriers affecting 
KMC continuity among hospitalised preterm infants (Figure 8-1).153 Taken together, these studies 
emphasise the need for targeted strategies addressing underlying barriers in order to promote 
KMC uptake and continuity in health facilities. 
 
Figure 8-1. Barriers to KMC continuity amongst preterm infants in an Indian NICU 
  
Source: Joshi et al, 2018.153 
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The audit of admissions found that the proposed therapy-based instability criteria were easily 
implementable. As described in Chapter 5, significant variability exists with regard to how 
previously published trials of KMC have defined clinical stability.60,68,70–72,74–76,79,81 These 
inconsistencies highlight the need for a standardised stability definition as well as uniform criteria 
for SSC initiation to help health workers determine eligibility for KMC. The qualitative sub-study 
demonstrated the acceptability of initiating KMC before stabilisation and found that most parents 
and providers felt monitoring was improved in the KMC position relative to incubator care.65 
Similarly, a study in Zimbabwe reported that mothers felt anxious and helpless when their baby 
was in an incubator; all mothers preferred KMC because it facilitated close monitoring and on-
demand feeding.154 In Sweden, a related study found that staff in a NICU designed to enable 
continuous KMC were more comfortable about its use among neonates who were not yet 
stabilised, including those receiving CPAP or mechanical ventilation.155 The qualitative sub-study 
at Jinja Hospital also highlighted challenges related to shortages of staff and monitoring devices, 
lack of beds and space, insufficient KMC education, and prevalent stigma surrounding preterm 
birth in local communities.65 Recommendations to improve KMC practice included staff and peer 
counselling, family support, and improved availability of beds and monitoring devices.65 Variable 
availability of pulse oximetry and scarcities of skilled providers, especially nurses, are critical 
gaps in LMIC neonatal units.34–36,156–158 An ethnographic study of neonatal nursing at three 
Kenyan government hospitals found that standard routines (Figure 8-2) were often interrupted by 
emergency admissions, care of acutely ill babies, and unanticipated staff shortages; as a result, 
nurses were habitually burdened with making decisions regarding allocation of inadequate human 
resources.159 As shown in Figure 8-2, nurses characteristically prioritised technical tasks (e.g., IV 
fluids, medications), delegating more basic tasks to student nurses (e.g., vital signs, weighing), 
mothers (e.g., cup and nasogastric tube feeding), and/or support staff (e.g., bathing and feeding 
babies, cleaning incubators).159 
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Figure 8-2. Organisation of neonatal nursing work in three Kenyan government hospitals 
 
Source: Nzinga et al, 2019.159 Tasks in each shift listed in order of nurses’ perceived priority. Tasks in adjacent boxes 
denote lower priority tasks, often delegated to students, mothers, or support staff. Top-tailing=head to toe cleaning. 
 
A related study utilised ergonomics methods to identify the nature and clinical importance of 
possible errors of nasogastric tube feeding with Kenyan neonatal nursing experts, and found that 
training and procedural checklists were key strategies for supporting mothers to safely perform 
this task.160 Hence, contextually tailored strategies, such as KMC with linked family-integrated 
neonatal care, are urgently required to address human resource constraints in LMIC settings, e.g., 
by empowering mothers and caregivers to safely engage in the provision of inpatient care (Figure 
8-3).161–163 In addition, educational outreach programmes in local communities are necessary to 
address stigma, raise awareness of KMC, and promote social support for mothers and caregivers. 
 
Figure 8-3. Mothers feeding preterm babies by cup and nasogastric tube in Kenya and Afghanistan 
   
Image source: Melissa Medvedev, 2016.      Image source: Médecins San Frontières, 2016.164 
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8.6. Randomised trial of KMC initiated before stabilisation in Uganda (OMWaNA) 
 
The primary aim of the OMWaNA trial is to determine the effect of KMC initiated before 
stabilisation on early neonatal mortality (within 7 days of birth) relative to standard care at four 
hospitals in Uganda. In the introductory chapter, I described why the early neonatal period 
represents a critical window of opportunity to improve neonatal and child survival; estimates 
suggest that deaths in this timeframe are responsible for 73% of neonatal deaths and 34% of 
under-5 deaths.11,20 To date, only one published RCT has examined the impact of KMC on 
mortality amongst neonates prior to stabilisation relative to standard care.60 In addition to 
OMWaNA,66 three other ongoing RCTs are evaluating the clinical effects of KMC initiated 
before stabilisation.82–84 Table 8-2 describes and compares the design of these trials, illustrating 
several notable discrepancies. These include inconsistencies in outcomes, level of care, stability 
definition, age at recruitment, and eligibility criteria. The iKMC, eKMC, and OMWaNA trials are 
investigating the mortality impact of this intervention in East Africa (Tanzania, Uganda); West 
Africa (Gambia, Ghana, Nigeria); southern Africa (Malawi); and southern Asia (India). These 
three trials will contribute outcome data on deaths occurring within 72h (iKMC, n=4200), 7 days 
(OMWaNA, n=2188), and 28 days (iKMC, OMWaNA, eKMC; pooled n=6780) of birth. In 
contrast, the primary outcome of the IPISTOSS trial is cardiorespiratory stability at 6h of life. The 
IPISTOSS and iKMC trials are being conducted in hospitals with neonatal intensive care, while 
the eKMC and OMWaNA trials are taking place in hospitals that provide special care for small 
and sick newborns. The OMWaNA trial is utilising the same stability criteria as the iKMC trial, 
while eKMC and IPISTOSS employ distinct stability definitions. The IPISTOSS trial employs 
gestational age to assess eligibility, while the eKMC, iKMC, and OMWaNA trials use weight. 
This is likely to be related to the fact that IPISTOSS is being conducted in Scandinavia, where 
antenatal ultrasonography is widely available. Further, these trials utilise divergent minimum 
thresholds for weight (e.g., 700g in OMWaNA versus 1000g in iKMC). Notably, some neonates 
with ELBW do survive with KMC in non-intensive care settings.26 If the OMWaNA trial suggests 
mortality reduction in this subgroup, further research will be warranted to assess the impact of 
KMC in this population in additional LMIC contexts, integrating thoughtful consideration about 
physical and human resource requirements. 
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Table 8-2. Randomised controlled trials examining the clinical effects of KMC initiated prior to neonatal stabilisation 
 OMWaNA66 Worku et al60 eKMC82 iKMC83 IPISTOSS84 
Geographic 
location(s) 
Uganda Ethiopia The Gambia Ghana, India, Malawi, 
Nigeria, Tanzania 
Norway, Sweden 
Description of trial 
hospital(s) 
3 regional referral hospitals, 
1 district hospital 
1 university hospital 1 national referral 
hospital 
5 national referral hospitals 3 university hospitals 
Level of care34 Special care Special care Special care Intensive care Intensive care 
Trial design Parallel, two-arm, 
superiority trial 
Parallel, two-arm, 
superiority trial 
Parallel, two-arm, 
superiority trial 
Parallel, two-arm, 
superiority trial 
Parallel, two-arm, superiority 
trial 
Recruitment period 2019-2021 2001-2002 2018-2020 2017-2020 2018-2020 
Sample size Target: 2188 (1094/arm) Actual: 123 (62 KMC 
arm, 61 control arm) 
Target: 392 (196/arm) Target: 4200 (2100/arm) Target: 150 (75/arm) 
Definition of 
clinical stability 
SpO2 >90% (no oxygen); 
respiratory rate 40-<60*; no 
apnoea; heart rate 80-179†; 
temperature 36.0-37.4°C‡; 
no CPAP or IV fluids 
Stable temperature; 
stable cardiovascular 
status; satisfactory 
ability to suck; good 
general condition 
SpO2 ≥88% (no 
oxygen); respiratory rate 
20-60*; no apnoea; no 
severe chest in-drawing 
SpO2 >90% (no oxygen); 
respiratory rate 40-60*; no 
apnoea; heart rate 80-160†; 
temperature 36-37.4°C‡; 
no CPAP or IV fluids 
Stability of the Cardio-
Respiratory System In 
Preterms (SCRIP) score;110 
higher score indicates greater 
physiological stability 
Age at recruitment Within 48h of birth Mean: 10h (both arms) Within 24h of birth Within 2h of birth Within 1h of birth 
Inclusion criteria Birthweight 700 to ≤2000g; 
age 1 to <48h; indication 
for KMC uncertain, defined 
as receiving ≥1 therapy 
(oxygen, CPAP, IV fluids, 
therapeutic antibiotics, 
phenobarbital); caregiver 
able and willing to provide 
KMC and attend follow-up 
Birthweight <2000g; 
no major congenital 
malformation; 
singleton unless one 
twin died; mother 
healthy and willing to 
participate 
Admission weight 
<2000g; age 1-24h; 
availability of study bed; 
caregiver available and 
willing to provide KMC 
 
Weight 1000 to <1800g; 
age 0 to 2h; mother able to 
provide KMC 
Gestational age 28 to <33 
weeks; born in maternity 
ward at study centre; 
caregiver available to start 
SSC within 1h of birth 
Exclusion criteria Triplets or more (unless ≥1 
triplet died); severely life-
threatening instability; 
severe jaundice requiring 
immediate treatment; active 
seizures; major congenital 
malformation 
 Not reported Triplets or more; stable; 
severely unstable; life-
threatening congenital 
malformation; jaundice 
requiring treatment; 
seizures; enrolled in 
another study 
Triplets or more; baby 
unable to breathe 
spontaneously within 1h of 
birth; congenital 
malformation precluding 
KMC; mother <15 years, 
resides outside study area 
Outborn; triplets or more; 
known malformation 
requiring immediate surgery; 
known congenital infection; 
ongoing resuscitation or 
intensive care (mechanical 
ventilation or inotropy) 
 
 137 
 OMWaNA66 Worku et al60 eKMC82 iKMC83 IPISTOSS84 
Intervention arm Continuous KMC until 
discharge (target duration 
≥18h/day), with continued 
KMC at home 
Continuous KMC 
initiated within 24h of 
birth (duration not 
reported) 
Continuous KMC until 
discharge (target 
duration 18h/day), with 
continued KMC at home 
Continuous KMC until 
discharge (target duration 
≥20h/day) 
SSC with 1 caregiver 
continuously during first 6h 
after birth and as much as 
possible during first 72h 
Control arm Incubator/radiant warmer 
until clinically stable, then 
intermittent KMC (per 
routine care at study sites) 
Radiant heater in 
heated room until 
clinically stable, then 
routine KMC 
Incubator/radiant heater 
until clinically stable, 
then intermittent or 
continuous KMC 
Separation of mother and 
baby until baby is 
clinically stable, then 
continuous KMC 
Incubator/radiant warmer 
during first 72h after birth 
Primary outcome Mortality within  
7 days of birth  
In-hospital mortality Mortality within  
28 days of birth 
Mortality within 72h,  
28 days of birth 
Cardiorespiratory stability  
at 6h of life 
Secondary 
outcomes 
Mortality within 28 days of 
birth; prevalence of 
hypothermia at 24h of life; 
time from randomisation to 
clinical stabilisation; time 
from randomisation to 
death; time from 
randomisation to exclusive 
breastmilk feeding; duration 
of hospital admission; 
frequency of readmission; 
daily weight gain, infant-
caregiver attachment, 
women’s wellbeing at  
28 days 
Temperature§; weight 
gain4; type of feeding§; 
episodes of minor and 
major illness§; 
episodes of serious 
illness§ (diarrhoea, 
sepsis, pneumonia, 
aspiration pneumonia); 
duration of hospital 
admission; mothers’ 
feelings about method 
of care 
Time from start of 
intervention/control 
procedures to death; 
cardio-respiratory 
stability (SCRIP score) 
at 24h; prevalence of 
hypothermia within 24h; 
exclusive breastfeeding 
at discharge; duration of 
hospital admission; 
weight gain, incidence of 
suspected late-onset  
(>3 days) infection, 
prevalence of intestinal 
carriage of extended-
spectrum β-lactamase-
producing Klebsiella 
pneumoniae within  
28 days 
 
Incidence of hypothermia, 
suspected sepsis, probable 
sepsis, hypoglycaemia; 
time to stabilisation; time 
to full breastfeeding; 
exclusive breastmilk 
feeding at 28d; maternal 
satisfaction; maternal 
depression 
Days on respirator, number 
of surfactant doses, days on 
CPAP, days on oxygen, 
number of sepsis episodes, 
days of antibiotics from birth 
to discharge; temperature 
within 6h; breastfeeding 
status; time to full enteral 
nutrition; duration of 
nasogastric tube feeding; 
time to recovered birth 
weight; weight gain; 
epigenetic/telomere profiling 
in buccal cells/blood; infant 
EEG maturation; infant 
structural/functional brain 
maturation; mother brain 
responsiveness; mother-
infant microbiota, bonding, 
attunement in regulating 
stress; parents’ experiences; 
child neuro behaviour 
CPAP=continuous positive airway pressure; IV=intravenous; SpO2=peripheral capillary oxygen saturation; SCRIP=Stability of the Cardiorespiratory System in Preterms; 
SSC=skin-to-skin contact; EEG=electroencephalogram. *Respiratory rate in breaths per minute. †Heart rate in beats per minute. ‡Axillary temperature in degrees Celsius. 
§Outcome measure listed in methods section of manuscript, but not reported.
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The OMWaNA trial implementation meeting was held in Entebbe in August 2019. Following 
completion of neonatal unit renovations and an initial pilot phase, the trial commenced official 
recruitment in January 2020. An economic evaluation embedded within the trial will compare the 
incremental cost and cost-effectiveness of KMC relative to standard care from the societal 
perspective. Findings of the economic evaluation could help guide allocation of resources for 
newborn care and potential strategies to address opportunity costs for families. The accompanying 
process evaluation will explore hypothesised causal pathways for the clinical effects of KMC 
initiated before stabilisation and examine barriers and facilitators to inform the uptake and 
sustainability of this intervention in Uganda and related contexts, if shown to be effective. The 
process evaluation will include triannual surveys of staff, supply, medication, and equipment 
availability as well as biannual neonatal quality of care surveys, including progress monitoring of 
KMC services. As KMC provision in Ugandan health facilities is not routinely recorded, the 
process evaluation may have important implications regarding the need for a standardised system 
to track national coverage and quality of KMC services. Improved understanding of potential 
underlying mechanisms, including brain injury following preterm birth, could inform programmes 
and interventions to help prevent disability and related downstream effects on human capital and 
wellbeing, in line with the post-2015 SDG agenda.18  
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8.7. Strengths and limitations of this PhD 
 
8.7.1. Strengths 
 
An important strength of this PhD is the utilisation of primary data collected from sub-Saharan 
Africa to evaluate three objectives (facility assessment data from Kenya and Uganda, the risk 
score validation data from The Gambia, and the feasibility study data from Uganda), which 
together informed design of the OMWaNA trial in Uganda (Table 8-3).  
 
Table 8-3. Informing the design of the OMWaNA trial using mixed methods 
 Study finding(s) Impact on trial design 
Chapter 3 (clinical cascades 
to assess facility readiness 
for neonatal care) 
Among the 23 Kenyan and Ugandan 
facilities, the model estimated overall 
readiness of 27% in 2016 and 26% in 
2017; mean readiness by cascade 
ranged from 12% (respiratory distress-
apnoea) to 48% (essential newborn 
care) across both time-points 
Site staff completed training on 
standardised clinical guidelines 
(including signs of severe illness), 
pulse oximetry monitoring, KMC, 
and Ballard scoring prior to start 
of the trial, plus ongoing refresher 
training on guidelines and KMC 
Across 23 Kenyan and Ugandan health 
facilities, 22-44% had a functional 
pulse oximeter with neonatal probe, 
26-30% had KMC beds or chairs, and 
4-35% had a functional glucometer 
Provision of 6 Masimo Rad-8© 
pulse oximeters with neonatal 
probes, 4-5 adjustable KMC beds, 
and 1 glucometer with blood 
glucose testing strips at each site 
Variability in the timing of readiness 
loss, with increased loss in treatment 
stage for essential newborn care, poor 
feeding-hypothermia, and infection-
convulsion cascades in 2017 vs. 2016 
Process evaluation will assess 
changes in care between hospitals 
and from before trial, including 
baseline and triannual surveys of 
staffing, supplies, and equipment 
Chapter 4 (NMR-2000 risk 
score development and 
validation) 
NMR-2000 is a validated mortality 
score for hospitalised neonates ≤2000g 
in settings where pulse oximetry is 
available; NMR-2000 demonstrated 
good discrimination, goodness-of-fit, 
and calibration across the UK and 
Gambian external validation samples 
Data needed for score calculation 
are collected as part of the trial; 
subgroup analysis will explore 
between-group difference in the 
impact of KMC vs. standard care 
on mortality, by level of predicted 
risk based on NMR-2000 score 
As the Gambian sample was small and 
limited to a single site, NMR-2000 
requires further validation using a 
larger dataset from LMIC settings 
Follow-up validation study using 
pooled data from the OMWaNA 
trial and a large, multi-hospital 
study in Kenya is planned 
Chapter 6 (KMC feasibility 
study at Jinja Hospital) 
Audit found that the instability criteria 
were easily implementable; among 
neonates who received only 1 therapy, 
majority received empiric antibiotics 
because they were at risk of infection 
Instability criteria were modified 
to 1 or more therapies, excluding 
empiric antibiotics, for the trial 
Audit estimated ≥400 eligible neonatal 
admissions per year at Jinja Hospital 
Estimate informed sample size 
calculations for the trial 
Table 8-3 continues on the following page.  
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 Study finding(s) Impact on trial design 
Chapter 6 (KMC feasibility 
study at Jinja Hospital) 
Continuous monitoring of heart rate 
and SpO2 was feasible among 
neonates in the KMC position 
All neonates receive continuous 
monitoring of heart rate and SpO2 
for 72 hours; monitoring continues 
until participants no longer require 
any form of respiratory support 
Qualitative sub-study identified 
staffing shortages in the neonatal unit 
as a key barrier to KMC practice 
One study medical officer and 4-5 
nurses were recruited at each site; 
process evaluation comprises 
triannual staffing and biannual 
quality of care surveys, including 
progress monitoring of KMC 
provision/services (Annex A.9) 
Qualitative sub-study identified 
shortages of monitoring devices, beds 
and space; insufficient KMC 
education; and stigma surrounding 
preterm birth in local communities as 
key barriers to KMC practice 
Staff and peer counselling on 
KMC and care of preterm/LBW 
neonates; substantial infrastructure 
improvements in newborn units 
(increased space, sinks, bathrooms 
for caregivers); provision of pulse 
oximeters, beds, and KMC wraps 
 
By employing mixed methods, including collection of both quantitative and qualitative data, this 
work facilitated a greater understanding of the barriers and facilitators affecting KMC provision 
and inpatient care amongst small and sick newborns before stabilisation in these sub-Saharan 
African contexts. Given the involvement of a highly vulnerable population, this detailed level of 
understanding was invaluable during the process of preparing a successful funding application for 
the Joint Global Health Trials scheme, developing the trial protocol, and planning and 
implementing the trial across the four Ugandan government hospitals. In particular, these findings 
underscored the need for substantial infrastructure improvements within the neonatal units in 
advance of trial commencement and comprehensive capacity building. Another strength is that the 
NMR-2000 study represents the largest dataset utilised to develop and validate a neonatal 
mortality risk score (Table 8-1). In addition, to our knowledge, the NMR-2000 is the only score 
for predicting in-hospital neonatal mortality that has been validated in a low-resource (i.e., non-
intensive care) facility setting. 
 
8.7.2. Limitations 
 
The main overall limitation of this PhD is the small size of the sub-Saharan African samples 
utilised in the studies that informed the design of the trial, since the Gambian validation and 
Ugandan feasibility studies were each limited to a single hospital. Further research is required to 
validate the NMR-2000 score in LMIC settings using larger, multi-site datasets. Similarly, the 
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cascade study assessed 23 facilities within two regions of East Africa; thus, future work is needed 
to evaluate this model in different geographic and cultural contexts. The feasibility audit and the 
NMR-2000 study were both limited by the presence of missing data in routine hospital records. 
Several studies have described issues regarding collection of data on neonatal inpatient care in 
LMICs,65,157,165 underscoring the fact that effective implementation of the NMR-2000 score in 
such settings would require sensitisation among health workers. As demonstrated by the findings 
of the cascade study and related studies in sub-Saharan Africa,63,156–158 the usefulness of the 
NMR-2000 score could be limited by variable availability of pulse oximetry in low-resource 
neonatal units. The cascade model assesses the physical readiness of facilities; however, it does 
not evaluate knowledge or skills among newborn care providers. A study at 11 Ethiopian facilities 
reported that providers performed 62% and 57% of the recommended tasks of immediate and 
postnatal newborn care, respectively,166 while a multi-country African study showed that neonatal 
asphyxia was correctly diagnosed by fewer than half of providers.167 In Tanzania, a Helping 
Babies Breathe programme evaluation found that the proportion of providers passing the clinical 
examination declined from 87% immediately after training to 56% at 4-6 months.168 These studies 
emphasise the critical importance of routinely assessing provider knowledge and skills alongside 
regular monitoring of physical and human resource availability across levels of the health system. 
 
Other important limitations relate to challenges that have been identified during the design and 
implementation of the OMWaNA trial. The involvement of small and sick newborns before 
stabilisation, together with the fact that a caregiver must be available to provide KMC within 48h 
of birth, could present difficulties in obtaining timely and valid informed consent. Parental 
capacity to give valid consent may be affected by emotional state and level of understanding, as 
well as by the time available to process the information and make a decision.169–172 Adherence to 
near-continuous KMC may be challenging for a variety of reasons, such as maternal illness, lack 
of privacy, and insufficient family or social support.65,67,151–153 Intervention adherence could also 
be diminished by parents or caregivers witnessing a death, especially one occurring in the KMC 
position.161 As some degree of non-adherence is unavoidable, the potential for resultant dilution 
of the effect size of KMC was taken into account during the sample size calculations. Finally, 
although substantial efforts were undertaken to improve neonatal care capacity, government 
hospitals in Uganda often experience human resource constraints, drug and supply shortages,34,63 
delayed repair of equipment, and periodic interruptions to the electrical supply,158,173 which is 
necessary to power radiant warmers, incubators, oxygen concentrators, and phototherapy.  
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9. Recommendations and conclusion 
9.1. Scope of this chapter 
 
This PhD has developed a cascade model to evaluate facility readiness, validated a score to assess 
individual risk and guide resource provision, and demonstrated the feasibility of initiating KMC 
before stabilisation. These studies have informed the design of a RCT that will determine the 
mortality impact of this intervention relative to standard care, resulting in development of the 
protocol for an ongoing four-centre trial in Uganda. In this final chapter, I use the findings of this 
PhD to provide recommendations for policy, programmes, and future research. 
 
9.2. Recommendations for policy and programmes 
 
In line with current WHO guidelines, recommendations for policy and programmes pertain to 
facility-initiated KMC among stable neonates, except where otherwise noted. If evidence from 
ongoing trials demonstrates the effectiveness of KMC among neonates prior to stabilisation, these 
recommendations could also be applied to KMC practice in this population. 
 
Table 9-1. Summary of recommendations for policy and programmes 
 Actions for policy and programmes 
Individual/household-level 
(babies, mothers, families, 
local communities)  
Operationalise strategies in health facilities to promote KMC uptake 
and continuity throughout hospitalisation and at home after discharge 
Engage peer counsellors and local champions to support KMC practice 
including at home after discharge 
As part of Universal Health Coverage and financial protection, address 
opportunity costs for families, particularly those of neonates requiring 
prolonged hospitalisation 
Raise awareness about KMC, enhance social support for caregivers, 
and address stigma surrounding preterm birth in local communities 
Health system-level 
(facilities, administrators, 
care providers) 
Employ individual risk assessment in routine care to inform planning 
Estimate the budget impact of KMC relative to standard care to inform 
allocation of resources for neonatal care across levels of the health 
system 
Develop, implement, and monitor comprehensive newborn care 
packages, including space, health workers, and essential devices and 
equipment (e.g., NEST360°) 
Implement family-integrated neonatal care in health facilities, 
contextualising evidence from other settings 
Table 9-1 continues on the following page.  
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 Actions for policy and programmes 
National-level (e.g., Uganda 
Ministry of Health, Uganda 
Paediatric Association) 
Promote national scale-up of inpatient care for small and sick 
newborns, including KMC 
Introduce national system for routine monitoring of KMC provision and 
services in health facilities  
Strengthen routine health information systems, integrating collection of 
neonatal inpatient data across levels of care 
Enhance supply chain management systems, incorporating cascade-
derived indicators to track the availability of supplies and equipment 
International-level (e.g., 
WHO, UNICEF) 
Establish consensus regarding standardised criteria for KMC initiation, 
incorporating a clear and uniform definition of clinical stability  
Develop evidence-based guidelines on building suitable environments 
for KMC provision across levels of neonatal care 
Promote KMC implementation and scale-up in all countries 
Take actions to further scientific understanding of underlying pathways 
for the clinical effects of KMC initiated before stabilisation 
 
9.2.1. Individual/household-level 
 
9.2.1.1. Promotion of KMC uptake and continuity in facilities 
 
To promote KMC uptake and continuity throughout hospitalisation and at home after discharge, 
targeted strategies should be employed within facilities across the healthcare system. Sensitisation 
efforts should be conducted in antenatal clinics and maternity wards to raise awareness about 
KMC. Numerous studies have demonstrated the importance of positive perceptions among 
parents and families regarding the benefits of KMC to both babies and caregivers.174–176 
Healthcare workers should clearly explain and discuss these benefits with parents, families, and 
other involved individuals,175 taking time to thoughtfully address their questions and concerns. An 
Indian study found that a KMC improvement initiative, including comprehensive counselling for 
families, weekly nurse champions, emphasis of SSC duration in the daily treatment order, and 
unlimited visitation for family members, increased the mean daily duration of SSC from 3h to 6h 
over a 7-week period.153 Evaluations at 6 and 12 months post-implementation suggested sustained 
improvements in SSC duration of up to 9h per day.153 A related study in the US reported that a 
KMC pathway, integrated within a training program comprised of clinical champions (e.g., 
nurses, respiratory therapists) and a simulated educational video for NICU staff and parents, 
increased the frequency of SSC 2.4-fold overall and 1.8-fold among neonates receiving invasive 
respiratory support.177  
  
 
 144 
9.2.1.2. Peer counsellors and KMC champions  
 
In LMIC settings, where awareness of KMC and preterm birth are generally low, health workers 
and caregivers may be engaged to share success stories about small and vulnerable babies who 
received KMC and survived.174,175 In the acceptability study at Jinja Hospital, parents and 
newborn unit providers agreed that peer counselling is a valuable tool for supporting KMC 
practice.65 Studies in Malawi, Mozambique, and South Africa also found that new mothers had 
positive perceptions of learning about KMC from peers who had personal experience.178–180 In 
line with the suggestion of a provider at Jinja Hospital,65 nurses in Mozambique felt that follow-
up visits were an opportunity for mothers who had practiced KMC to share their experiences.178 
Further, Malawian mothers who had KMC experience were enthusiastic about acting as KMC 
champions in the future.179  
 
9.2.1.3. Programmes to address opportunity costs for families 
 
Targeted programmes are also needed to reduce the financial burden and address opportunity 
costs for families, particularly those of neonates who require prolonged hospitalisation. Potential 
barriers to KMC continuity include competing work and household responsibilities, including 
care of other children,175,176,181,182 and transport time and costs.175,176,182 Approaches to address 
these issues may include transportation vouchers; unlimited visitation hours; home follow-up 
visits by trained nurses or community health workers; directed financial assistance; and financing 
schemes to help reduce out-of-pocket expenses.161,175,176 For example, Colombia offers public and 
private health insurance plans covering all costs for LBW babies receiving KMC, including 
follow-up though 12 months corrected-age.161 In LMICs that lack universal insurance coverage, 
community-based or mutual health insurance is an alternative funding mechanism. A population-
wide study in Rwanda found that mutual health insurance was associated with reduced household 
financial burden as well as increased utilisation of healthcare services.183    
 
9.2.1.4. Initiatives to raise awareness of KMC, promote social support, and address stigma 
 
Perceptions of fatalism and stigma around having a preterm baby are prevalent in LMIC 
settings.178,179,184,185 Societal and cultural norms may dictate that fathers should not play a major 
role in newborn or child care.67,176,179 A study in South Africa found some fathers felt 
uncomfortable learning about KMC from anyone other than their partner,186 while one in Brazil 
reported that some mothers and traditional birth attendants felt uncomfortable when fathers 
practiced KMC.187 Community-based programmes may be leveraged to raise awareness about 
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KMC, enhance social support for caregivers, and address stigma regarding preterm birth. Such 
efforts could include provision of information about KMC through print media, drama, or 
discussions on radio or television; promotion of activities to celebrate a baby’s graduation from 
KMC; and peer- and elder-led community education programmes;154,175,188 as well as context-
specific programmes to encourage paternal involvement in KMC and newborn care.189 For 
example, the Ekendeni Agogo Programme in Malawi trained 4100 respected grandparents to 
educate new and expectant mothers and their families about maternal and newborn care practices 
through group and individual counselling, using songs, poems, and drama to convey key 
messages.190 Training included an overview of KMC and its benefits; demonstration of the KMC 
position; and discussion about the role of family members in supporting KMC.191 An evaluation 
of the programme reported increased facility-based care seeking and exclusive breastfeeding, and 
reduced use of harmful traditional practices.190 In a related study, community leaders in Malawi 
identified several key actions to address stigma and raise awareness about KMC. These included 
promoting counselling among families of preterm infants; instituting public meetings to discuss 
preterm birth and KMC; and creating local leadership networks focused on these issues.179 
 
9.2.2. Health system-level 
 
9.2.2.1. Clinical monitoring and care provision, informed by individual risk assessment 
 
Enabling clinical monitoring and care of neonates in the KMC position is critical. The feasibility 
study demonstrated that cardiorespiratory monitoring and therapy provision were practicable in 
the KMC position, but highlighted challenges related to shortages of monitoring devices and 
healthcare providers.65 The cascade study similarly found that more than half of the facilities did 
not have a functional pulse oximeter and neonatal probe at both timepoints. In line with these 
findings, numerous studies have reported that LMIC facilities frequently lack sufficient nurses or 
pulse oximeters to enable continuous monitoring of all neonates receiving supplemental oxygen 
therapy.158,192–195 Studies in The Gambia, Kenya, and Nigeria have reported that hypoxaemia on 
neonatal admission increased the odds of mortality by three-fold to eight-fold.156,196,197 Thus, 
inconsistent availability of routine pulse oximetry in neonatal units is a crucial gap that must be 
addressed. Assessment of individual risk using the NMR-2000 score could inform neonatal care 
delivery planning,33 and support shared decision-making among providers.198 Further, the NMR-
2000 may help expedite recognition of severe illness and enable targeted provision of 
interventions to help promote neonatal survival.18,26,199  
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9.2.2.2. Estimating the budget impact of KMC relative to standard care to inform allocation of 
resources for neonatal care 
 
Incubators are currently the standard of care for maintaining normothermia in preterm and LBW 
neonates prior to stabilisation. Costs associated with incubators include purchase price, electricity 
requirements, and maintenance for mechanical dysfunction. Medical costs may arise as a result of 
nosocomial infections, particularly in neonatal units with ineffective cleaning standards or where 
incubators are shared,48,52 a common practice in low-resource settings.45 The OMWaNA trial will 
estimate the budget impact of KMC relative to standard care, which could help guide decision-
making and inform allocation of resources for neonatal care across levels of the health system. 
Further, estimation of running costs may inform planning at individual health facilities. 
 
9.2.2.3. Comprehensive newborn care packages, including space, health workers, and essential 
devices and equipment 
 
In LMICs, an urgent need remains to scale-up effective interventions targeting the major causes 
of neonatal mortality and morbidity. Findings of the cascade study and the aforementioned study 
of CPAP implementation in Malawi have underscored the value of introducing interventions for 
small and sick newborns as part of a broader care package.63,131 One example of such an approach 
is NEST360° (Newborn Essential Solutions and Technologies), an initiative that is developing 
and implementing a comprehensive newborn care package in hospitals across Kenya, Malawi, 
Nigeria, and Tanzania, with an overarching aim to reduce neonatal mortality in sub-Saharan 
African hospitals by 50%.200 NEST360° is employing a strategy that addresses four key gaps in 
neonatal care by: 1) optimising a bundle of rugged and affordable technologies (Figure 9-1), with 
ongoing support and maintenance; 2) training clinicians and biomedical engineers on technology 
implementation and innovation; 3) collecting data to improve quality of care and facilitate wider 
adoption; and 4) developing a market to enable sustainable distribution of devices and equipment 
to health systems across Africa.200 
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Figure 9-1. NEST360° (Newborn Essential Solutions and Technologies) 
 
Source: Rice360°, 2019.200  
 
9.2.2.4. Family-integrated care  
 
As described in Chapter 8, family-integrated care (FIC) represents a potential approach to help 
address human resource shortages in LMIC neonatal units. The aims of FIC are to promote parent 
competence and confidence, enhance family well-being, and improve infant health outcomes at 
the time of hospital discharge.162 The core components of FIC include family-centred neonatal 
unit design and policies (e.g., family spaces, unlimited visitation); staff training on how to teach 
parents to safely provide neonatal care; parent psychoeducational support (e.g., group classes, 
nurse and/or peer mentorship); delivery of neonatal care by parents as much as able (targeting ≥6h 
per day); and frequent provider-parent communication with shared decision-making.162,201–204 A 
cluster RCT in 25 NICUs across Canada, Australia, and New Zealand found that FIC for preterm 
neonates resulted in improved infant weight gain at day 21, decreased parental stress and anxiety 
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at day 21, and increased breastmilk feeding incidence at discharge relative to standard care.163 A 
study of a FIC intervention bundle including a parent support mobile application in two UK 
neonatal units showed that, relative to historical controls, preterm infants who received FIC were 
discharged earlier (corrected gestational age 36 versus 37 weeks), had reduced overall LOS, and 
reached full enteral and full suck feeds earlier.205 A pre-post FIC intervention study in two 
Chinese NICUs found that infants who received FIC had increased breastfeeding incidence, 
breastfeeding duration, enteral nutrition duration and weight gain, and reduced duration of 
respiratory support relative to controls.206 A follow-up study reported that FIC infants scored 
higher on the Bayley Mental and Psychomotor Developmental Indices at 18 months of age.207 
Although studies are needed to assess its impact in LMIC contexts, existing evidence suggests 
that practicing KMC and linked family-integrated neonatal care could empower mothers and 
families, reduce nursing workload, promote earlier discharge, and improve newborn survival.  
 
9.2.3. National-level 
 
9.2.3.1. National scale-up of KMC in health facilities  
 
In 2006, the Ugandan Ministry of Health established a Newborn Steering Committee, which 
advised scale-up of KMC for stable neonates.208 KMC has now been implemented in all Ugandan 
district hospitals; however, further efforts will be required to achieve national coverage in all 
facilities. Studies in South Africa have demonstrated that KMC can be successfully implemented 
in facilities by introducing a multimedia training package in combination with group facilitation 
sessions, either on-site or at a centre of excellence, highlighting the importance of administrative 
support and endorsement by local opinion leaders.209,210 Establishing regional, district, and 
institutional KMC steering committees was a key component of a successful implementation 
initiative at 38 hospitals in Ghana.211 These committees convened regularly to monitor progress, 
plan activities, and discuss issues affecting project execution.211 Several countries in sub-Saharan 
Africa and southern Asia have engaged neonatologists, paediatricians, and related professionals as 
champions to advocate for KMC.161,212–215 In Uganda, the Ministry of Health’s Newborn Steering 
Committee and the Uganda Paediatric Association should be involved throughout the scale-up 
process. Further, neonatal and maternal health experts from these organisations could facilitate 
identification of suitable individuals to serve as national or regional KMC champions.  
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9.2.3.2. National system for routine monitoring of KMC provision and services in facilities  
 
Efforts should be made to establish a countrywide system for routine monitoring of KMC 
provision and services in health facilities. Key stakeholders in Uganda have recognised the 
scarcity of KMC coverage data within the existing health information system as a major barrier to 
scale-up efforts.161 Bergh et al developed a KMC assessment instrument based on a staged model 
of progress monitoring that includes three phases (pre-implementation, implementation, 
institutionalisation), beginning with creation of awareness and culminating in sustainable practice 
(Figure 9-2).216 This comprehensive tool (Annex A.9) is being utilised to monitor KMC provision 
and services biannually across the four sites as part of the OMWaNA process evaluation.  
 
Figure 9-2. KMC progress monitoring model 
 
Source: Bergh et al, 2005.216 
 
9.2.3.3. Improved quality and coverage of routine health information systems  
 
Enhancing the quality and coverage of routine health information systems is critical to promote 
actions to improve neonatal survival.157,217 This will require coordinated efforts across levels of 
the health system, including post-discharge follow-up care. Particular attention should be directed 
to improving the capacity of these systems to collect inpatient data on babies who die shortly after 
birth or are transferred to another facility,23 as well as longer-term follow-up data on preterm and 
VLBW babies who face an elevated risk of neurodevelopmental impairment in childhood.218–220  
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9.2.3.4. Strengthening of existing supply chain management systems  
 
Strengthening of existing healthcare supply chain management systems should also be prioritised, 
including incorporation of cascade-derived indicators to monitor facility readiness and track the 
availability of essential drugs, supplies, and equipment. A multi-country analysis of bottlenecks 
affecting neonatal inpatient care highlighted the fact that inadequate and imprecise logistics 
systems often limit the capacity of health systems to predict demand for oxygen, supplies, and 
equipment maintenance in facilities.34 Stakeholders in sub-Saharan Africa and southern Asia have 
reported limited availability of special care equipment, including CPAP systems, and frequent 
shortages of key commodities, including cannulas, antibiotics, and preterm feeding supplies.34,161 
The cascade study similarly revealed low availability of CPAP, nasal cannulas, nasogastric tubes, 
and certain antibiotics; additionally noting that IV bags and tubing, glucose test strips, KMC beds 
and chairs, and functional phototherapy devices were available in fewer than one-third of the 
facilities.63 The cascade model provides a set of indicators for neonatal inpatient care that can be 
used to evaluate individual facilities and compare readiness estimates across health systems, 
countries, or geographic regions.63,221 Further, by precisely identifying the timing and location of 
readiness loss, the cascade model could help guide resource allocation decisions and facilitate 
improved quality of care for small and sick newborns.199   
 
9.2.4. International-level 
 
9.2.4.1. Standardised criteria for KMC initiation, including clear definition of stability 
 
A key priority at the international-level is to establish consensus regarding standardised criteria 
for KMC initiation. These criteria should incorporate a clear and uniform definition of clinical 
stability. This process should take into consideration the findings of ongoing trials, including 
eKMC, iKMC, IPISTOSS, and OMWaNA. Taking these actions to harmonise guidance would 
support clinical decision-making by enabling care providers to more consistently and objectively 
determine which newborns are stable enough to safely receive KMC.  
 
9.2.4.2. Guidelines on suitable environments for KMC provision across levels of care 
 
Policymakers and technical agencies should also prioritise the development of harmonised 
guidelines on building suitable environments for KMC practice at each level of neonatal care. 
These guidelines may include provision of beds, chairs, and KMC wraps, as well as infrastructure 
improvements (e.g., sinks, toilets, private space for caregivers).176,222 Clinical monitoring devices, 
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such as pulse oximeters, may additionally be advised for facilities that provide ongoing care to 
small and sick newborns (i.e., special and intensive neonatal care). Incorporation of estimated 
financing requirements by level of care across different geographic regions could help facilitate 
wider adoption and implementation of such guidelines.  
 
9.2.4.3. Implementation and scale-up of facility-initiated KMC in all countries 
 
The United Nations Children’s Fund (UNICEF) is committed to wider implementation of 
newborn care in priority countries, including Uganda, and has highlighted KMC as a key 
intervention.223 The ENAP has prioritised KMC implementation across all levels of the health 
system.19 A recent WHO report estimated that KMC could save nearly 70,000 newborn lives in 
81 high-burden countries in 2025, if 95% of facility deliveries have access to comprehensive 
EmONC and newborn special care.39 The International Network on KMC was established to 
support programme implementation, promote knowledge sharing, and provide training to 
healthcare institutions, professional associations, and governmental and non-governmental 
agencies.224 Together, these stakeholders can help facilitate widespread and effective scale-up of 
KMC in facilities, including KMC initiated before stabilisation (if proven to be effective).  
 
9.2.4.4. Scientific understanding of causal pathways for beneficial effects of KMC 
 
Key stakeholders, policymakers, and technical agencies should also prioritise actions to advance 
scientific understanding regarding potential causal pathways for the beneficial clinical effects of 
KMC, including KMC before stabilisation. Heightened understanding of underlying mechanisms 
for these effects could inform specific approaches to improve inpatient care and health outcomes 
for small and sick neonates. Further, such knowledge could guide innovative strategies to help 
prevent early childhood disability, empowering these vulnerable babies to survive and thrive. 
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9.3. Implications for research 
 
Table 9-2. Summary of implications for future research  
 Research questions to address remaining evidence gaps 
Description  
Determine minimum dose per 24h required to achieve beneficial effects on neonatal 
survival and other important clinical outcomes, or potential threshold for time in 
intermittent KMC 
Long-term follow-up to assess neurodevelopmental outcomes and early childhood 
disability after KMC, adjusting for gestational age 
Follow-up to evaluate the effects of KMC on mental health and wellbeing among both 
mothers and babies 
Discovery  
Further explore underlying physiological mechanisms by which KMC may affect 
clinical outcomes, including KMC initiated prior to stabilisation 
Develop cheap and robust devices to accurately capture and record time spent in the 
KMC position  
Develop cost-effective approaches for retinopathy screening and treatment in LMIC 
settings, incorporating contextually-appropriate screening criteria 
Delivery  
Validate and integrate indicators to track KMC coverage and quality through routine 
health management information systems  
Further validate the NMR-2000 score in LMIC settings and explore its utility to support 
clinical decision-making and inform resource utilisation, including nursing workload 
Compare the clinical cascade model with other facility readiness assessment tools, and 
explore the association between aggregate readiness loss and neonatal mortality  
Evaluate the incremental cost and cost-effectiveness of KMC, including additional costs 
of KMC initiated before stabilisation, relative to standard care from the societal 
perspective, considering impact on women and households, in other LMIC contexts 
 
9.3.1. Description 
 
9.3.1.1. Minimum dose required to achieve beneficial clinical effects of KMC 
 
The most recent WHO guidelines for preterm care highlighted the lack of evidence regarding the 
dose-response relationship between KMC duration and mortality reduction as a key research 
priority.12 Hence, research is needed to determine the minimum dose of continuous KMC per 24h 
that is required to achieve beneficial effects on neonatal survival and other important clinical 
outcomes. Future research should also evaluate the potential threshold for time in intermittent 
KMC that may be needed to attain positive impacts on newborn health. 
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9.3.1.2. Impact of KMC on early childhood disability and neurodevelopmental outcomes 
 
Further research is required to advance scientific understanding concerning the effects of KMC on 
early childhood disability and neurodevelopmental outcomes, including cognitive, motor, 
language, social, and emotional skills and capabilities. Several studies have suggested that KMC 
is associated with improved cognitive development. A case-control study in Israel found that 
infants who received KMC had improved cognitive development at 6 months of age, scoring 
higher on the Bayley Mental and Psychomotor Developmental Indices relative to controls.225 A 
later study by the same group found that infants who received KMC scored higher on the Bayley 
Mental Developmental Index at 6, 12, and 24 months, and had better executive functioning at 5 
and 10 years of age.102  Evidence from high-income settings has demonstrated the beneficial 
effects of family-centred developmental care, including cue-based caregiving and KMC, on 
cognitive and behavioural outcomes in preterm and VLBW babies.226–229 A 20-year follow-up 
study of former LBW infants in Colombia who participated in a KMC trial demonstrated that 
KMC had long-lasting social and behavioural protective effects.90 These included reduced school 
absenteeism and decreased hyperactivity, aggressiveness, and socio-deviant conduct as young 
adults.90 Further long-term studies are needed to assess the effects of KMC on early childhood 
disability and neurodevelopmental outcomes through adolescence, especially in sub-Saharan 
Africa and southern Asia where evidence is scarce. 
 
9.3.1.3. Long-term impact of KMC on mental health and wellbeing in mothers and babies 
 
Preterm babies exhibit heightened stress as a result of increased HPA reactivity together with 
exposure to stressful environments, painful procedures, and maternal separation.107–109 Mothers of 
preterm babies experience higher levels of stress and mental health issues, including a two- to 
three-fold increased risk of postpartum depression relative to mothers of term babies.230 Further, 
several studies in high-income settings have reported that postpartum depression and maternal 
stress negatively impact neurocognitive outcomes among children born preterm.231–234 Several 
studies have suggested that KMC may improve mental health and wellbeing outcomes, including 
postpartum depression;225,235–237 maternal anxiety;102,236,238 mother-infant stress;102,107–109,239,240 and 
mother-infant attachment.74,102,225,239,241 A recent meta-analysis demonstrated that KMC was 
associated with a 1% reduction in standardised postpartum depression scores among mothers of 
preterm or LBW neonates relative to standard care; however, high heterogeneity existed among 
the eight included studies.242 Hence there remains a need for additional research, including long-
term follow-up studies, to improve understanding regarding the effects of KMC on mental health, 
stress, and wellbeing among both mothers and infants. 
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9.3.2. Discovery 
 
9.3.2.1. Exploration of underlying physiological mechanisms for the clinical effects of KMC 
 
Further research is needed to explore the underlying physiological pathways by which KMC may 
affect clinical outcomes, including KMC initiated before stabilisation. Potential mechanisms 
include improved thermal control;49,69,70,77,81,85 reduced risk of IVH and late intracerebral sequalae 
of prematurity;87 accelerated brain maturation and neurophysiologic organisation;89,90,99–102 
enhanced cardiorespiratory stability;50,103–106 attenuated HPA response to stress;107–109 increased 
breastmilk production;115,116 and augmented microbiome maturation.117–120 The OMWaNA trial 
will further understanding regarding the effects of KMC on thermal control and prevalence of 
IVH and late intracerebral sequelae of prematurity,66 while the IPISTOSS trial will provide 
valuable data on infant EEG and brain maturation, mother-infant stress attenuation, and mother-
infant microbiota (Table 8-2).84 All four ongoing trials are evaluating impact on cardiorespiratory 
stability, with eKMC and IPISTOSS using the SCRIP score,110 and iKMC and OMWaNA using 
the WHO’s stability definition.83 The eKMC trial will also contribute novel data regarding the 
infection prevention effects of KMC by conducting microbiological tests for suspected infections 
and examining impact on intestinal carriage of extended-spectrum β-lactamase-producing 
Klebsiella pneumoniae,82 a major cause of invasive neonatal infections in sub-Saharan Africa.243 
 
9.3.2.2. Cheap and robust devices to accurately capture and record time in the KMC position 
 
Cheap and robust devices to accurately capture and record time spent in the KMC position are 
greatly needed, as current methods typically involve increased workload (nurse report) or direct 
costs (observation), and may introduce bias (caregiver/nurse report, observation). Development of 
such a device would help facilitate research to determine the minimum dose of KMC required to 
achieve clinical benefits. For example, an existing neonatal wireless vital sign monitoring device 
could potentially be adapted to additionally track movement (e.g., between an incubator and the 
KMC position) by incorporating an accelerometer.244 I am currently working with a team at the 
University of Cambridge who recently developed such a device to explore this possibility. 
 
9.3.2.3. Cost-effective approaches for retinopathy screening and treatment in LMIC settings 
 
An estimated 184,700 babies were affected by retinopathy of prematurity (ROP) in 2010, among 
which 32,300 developed visual impairment or blindness as a result (Figure 9-3).195 In high-
income countries, development of severe disease requiring treatment typically occurs only in 
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extremely preterm and ELBW babies.245,246 In LMICs, severe ROP may develop in larger and 
more mature infants, e.g., those with birthweights of 1500-2000g or gestational ages of 32-36 
weeks.247,248 ROP requiring treatment is characterised by the presence of ‘plus disease,’ which is 
defined as arterial tortuosity and venous dilation of the posterior retinal vessels.249 Sub-Saharan 
Africa is currently on the brink of an epidemic of ROP due to improved preterm survival coupled 
with neonatal care of inadequate quality, often inclusive of unmonitored and unblended oxygen 
therapy.250–255 Expanded coverage of ROP screening and treatment services, together with 
improved quality of care, including pulse oximetry monitoring to maintain safe oxygen levels, 
will be essential to control the incidence of associated visual loss.195,256  
 
Figure 9-3. Retinopathy of prematurity and associated visual impairment among survivors of 15 
million preterm births in 2010 
 
Source: Blencowe et al, 2013.195 a <1% of survivors following preterm birth at 32-36 weeks gestational age. 
 
Most ROP screening and treatment programmes are led by ophthalmologists, who conduct 
frequent visits to neonatal units to examine at-risk infants, with clinical decisions at each visit 
(Figure 9-4).257 Challenges of such programmes include shortages of ophthalmologists, travel 
burden, medicolegal concerns, poor reimbursement, and scheduling complexity.257,258 Studies in 
the US, Canada, and India have demonstrated the validity of telemedicine platforms employing 
trained technicians or neonatal nurses to capture wide-angle digital retinal images, which can be 
interpreted at the bedside or remotely (Figure 9-4).248,259–261  
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Figure 9-4. Comparison of ophthalmology-led and neonatology-led approaches to detecting and 
monitoring progression of retinopathy of prematurity 
 
Source: Gilbert et al, 2016.257 
 
One US study found that a tiered approach utilising a telemedicine platform and a postnatal 
growth model for predicting severe ROP risk reduced the number of imaging sessions and 
ophthalmologist examinations more than either approach alone.261 Notably, all studies included in 
the American Academy of Paediatrics Joint Technical Report on Telemedicine for the Evaluation 
of ROP utilised the RetCam™ imaging system (Clarity Medical Systems, Pleasanton, California, 
US),262 which costs around US$100,000.263 More recently, studies have demonstrated that fully 
automated image analysis algorithms using convolutional neural networks can accurately 
diagnose plus disease and quantitatively characterise pathological features of ROP.264,265 Despite 
the considerable progress that has been made, there remains a pressing need for low-cost, high-
resolution imaging technology that is suitable for ROP screening, as well for cost-effective 
approaches to expand coverage of ROP treatment services, especially in LMIC settings where 
ophthalmologists are few and the burden of resultant visual loss is high.193,266 Importantly, such 
approaches should incorporate contextually-appropriate screening criteria that are wide enough to 
capture the majority of infants developing severe disease.247,250  
 
9.3.3. Delivery 
 
9.3.3.1. Validate and integrate indicators to track KMC coverage and quality 
 
To improve care and facilitate research, indicators to track KMC coverage and quality through 
routine health information systems should be validated and integrated across levels of the health 
system. Such indicators should integrate clear definitions for the individual components of KMC, 
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including SSC, breastfeeding, early discharge, and follow-up. Progress in operationalising KMC 
has been hindered by the fact that previous studies have employed heterogeneous definitions, as 
well as by the scarcity of existing evidence on the effects of these individual components alone or 
in combination.62 Future research and implementation programmes should prioritise collecting 
data on all aspects of KMC practice, including initiation criteria; target and actual duration of SSC 
per day (or per session, if intermittent KMC); caregiver involvement; IV fluids and feeding 
support, including breastmilk volume and mode of delivery; hospital discharge criteria; and 
follow-up guidelines.  
  
9.3.3.2. Further validate the NMR-2000 score in LMICs and evaluate its utility to support clinical 
decision-making and inform resource allocation  
 
Future research is required to further validate the NMR-2000 score in low-resource settings, using 
adequately powered samples. Studies employing large, multi-hospital datasets from Kenya and 
Uganda are being planned to address this gap. As discussed in the previous chapter, facilities in 
LMICs frequently experience human resource constraints, especially shortages of trained neonatal 
nurses.33,34 In the aforementioned bottleneck analysis, 10 of 12 countries identified scarcities of 
skilled newborn care providers as a significant issue; recommendations included comprehensive 
mapping of the neonatal workforce and shifting of physician tasks that could be performed by 
lower level health workers (e.g., prescribing antibiotics) to maximise available resources.34 Future 
research should explore the usefulness of the NMR-2000 score for supporting clinical decision-
making and informing resource allocation,133,198 including nursing workload. If found to be 
effective, this tool could be employed alongside other contextually-appropriate approaches, such 
as task shifting, to help address provider shortages in LMIC neonatal units.  
 
 9.3.3.3. Compare the clinical cascade model with other facility readiness assessment tools 
 
Future research is also needed to compare the clinical cascade model with other facility readiness 
assessment tools, such as facility inventories and signal functions, across levels of neonatal care. 
Some tracer items for neonatal care are poorly defined (e.g., type of IV fluid, size of ventilation 
bag and mask),34,125 and few previous studies evaluating EmONC readiness have employed 
clinical guidelines as tracer items.221,267,268 To standardise readiness indicators and facilitate 
comparability across studies and settings, use of clearly defined tracers and inclusion of core 
clinical guidelines are essential. In addition, future research should explore the association 
between aggregate readiness loss and neonatal mortality in a variety of LMIC contexts. 
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9.3.3.4. Rigorous economic evaluations of KMC, including KMC before stabilisation, relative to 
standard care from the societal perspective, considering impact on women and households 
 
Published economic and costing evaluations have consistently found that KMC resulted in cost 
savings for the hospital or provider relative to standard care. Such studies have included a multi-
centre RCT in Mexico, Ethiopia, and Indonesia,71 a RCT at one hospital in Colombia,269 and 
implementation studies in one Nicaraguan270 and one Brazilian hospital,271 all of which compared 
KMC and incubator care among LBW neonates. An evaluation at 18 neonatal units in the UK 
estimated that providing KMC to 800 additional babies, initiated according to pre-defined clinical 
criteria,272 could generate potential cost savings of £668,000 to £2 million annually, primarily as a 
result of reduced LOS.273 More recently, an analysis of maternal and neonatal heath interventions 
in Ethiopia reported that achieving a 20% increase in KMC coverage relative to baseline would be 
highly cost-effective, with an incremental cost-effectiveness ratio of US$8 per disability-adjusted 
life year averted.274 Notably, none of these studies has considered whether KMC may increase 
costs to households nor specifically evaluated the cost implications of initiating KMC prior to 
stabilisation. The OMWaNA economic evaluation will compare the incremental costs and cost-
effectiveness of KMC and standard care from the societal perspective (provider and household 
combined),275 considering variation in household costs and health outcomes across socioeconomic 
groups, as well as cost variation between hospitals and how these may differ outside the trial 
setting. Rigorous economic analyses of KMC, including the costs of initiating KMC before 
stabilisation, are warranted to examine incremental cost and cost-effectiveness relative to standard 
care from the societal perspective, particularly considering impact on women and households, in 
additional LMIC contexts.  
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9.4. Conclusion 
 
Improved quality and coverage of inpatient care for small and sick newborns is urgently needed to 
reduce the estimated annual burden of 2.5 million neonatal deaths, the majority of which occur 
before stabilisation in settings without intensive care. Sub-Saharan Africa and south Asia account 
for around two-thirds of the 21 million LBW and 15 million preterm babies born every year, and 
together these regions are responsible for nearly 80% of newborn deaths. KMC is an evidence-
based intervention that reduces mortality and morbidity among stable neonates weighing 2000g or 
less; however, its impact among newborns prior to stabilisation remains uncertain. This PhD has 
developed a clinical cascade model to assess facility readiness for neonatal care, validated a score 
to assess individual mortality risk and guide resource provision, and demonstrated the feasibility 
and acceptability of initiating KMC before stabilisation in sub-Saharan African contexts. These 
studies have informed the design and implementation of the OMWaNA trial, which aims to 
determine the mortality impact of KMC initiated before stabilisation relative to standard care at 
four hospitals in Uganda. The findings of this RCT are expected to have broad applicability to 
hospitals in LMICs and could inform policies and programmes to promote survival and prevent 
disability among small and sick newborns, particularly in settings where intensive care is not 
available. The economic evaluation will compare the incremental costs and cost-effectiveness of 
KMC and standard care, taking into consideration opportunity costs for families, which will be 
important to promote KMC continuity. The process evaluation will strengthen understanding of 
KMC initiation before stabilisation through exploration of barriers, facilitators, and pathways 
underlying clinical effects, with implications for the transferability of results and, if shown to be 
effective, future scale-up efforts. Follow-up work is needed to advance scientific understanding of 
neurodevelopmental outcomes after KMC as well as the effects of KMC on mental health and 
wellbeing among both mothers and babies. Investment in improving coverage of comprehensive 
intervention packages for inpatient newborn care is required to address the growing global burden 
of death and disability following neonatal conditions. Wider implementation of KMC coupled 
with high quality, family-integrated neonatal care could alleviate nursing workload, empower 
mothers and caregivers, and enable the most vulnerable newborns to survive and thrive.  
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ABSTRACT
Aim: Kangaroo mother care (KMC) is a safe and effective method of reducing neonatal
mortality in resource-limited settings, but there has been a lack of data on the duration of skin-
to-skin contact (SSC) in busy, low-resource newborn units. Previous studies of intermittent
KMC suggest the duration of SSC ranged from 10 minutes to 17 hours per day.
Methods: This was an observational study of newborn infants born weighing less than
2000 g, which collected quantitative data on SSC over the first week after birth. The study
took place in July 2016 in the newborn unit of a low-resource facility in Uganda.
Results: The mean daily duration of SSC over the first week after birth was three hours. This
differed significantly from the World Health Organization recommendation of at least
20 hours of SSC per day. SSC was provided by mothers most of the time (73.5%), but
other family members also took part, especially on the day of birth.
Conclusion: Our study found a disappointingly low daily duration of SSC in this Ugandan
newborn unit. However, advocacy and community education of SSC may help to decrease
the stigma of KMC, improve overall acceptance and reduce the age at SSC initiation.
INTRODUCTION
Nearly half of all deaths in children under five occur during
the neonatal period. Complications of preterm birth,
defined as birth before 37 completed weeks of gestation,
were responsible for 35% of the 2.7 million neonatal deaths
across the globe in 2015 (1). Low-birthweight, defined by
the World Health Organization (WHO) as weighing less
than 2500 g at birth, irrespective of gestational age, has
been used as a surrogate for preterm birth (2,3) and is
correlated with neonatal survival (2,4,5). Estimates suggest
that at least 75% of global neonatal deaths occur in low-
income and middle-income countries (6), where neonatal
intensive care is often not available (7).
Kangaroo mother care (KMC) is an alternative to
conventional thermal care for infants considered to be
clinically stable (7). Key features of KMC are early,
continuous and prolonged skin-to-skin contact (SSC)
between the infant and the mother or another caregiver,
frequent and exclusive breastfeeding, early discharge from
hospital, whenever possible, and postdischarge follow-up
(2,3). KMC provides the infant with thermal support,
protection from infection, appropriate stimulation and a
nurturing environment (3,8,9).
Evidence supports KMC as a safe and effective way of
reducing neonatal mortality (2,7,9,10). In 2015, the WHO
issued a strong recommendation that KMC should be part
of the routine care of newborn infants weighing up to
2000 g at birth and that it should be initiated in healthcare
facilities as soon as infants were clinically stable (11). The
WHO recommendations advocate continuous KMC,
defined as at least 20 hours of SSC per day. Where
Abbreviations
KMC, Kangaroo mother care; SSC, Skin-to-skin contact; WHO,
World Health Organization.
Key notes
 Data on Kangaroo mother care (KMC) and the duration
of skin-to-skin contact (SSC) in busy, low-resource
newborn units are lacking.
 This study found that the mean daily duration of SSC
provided to low-birthweight infants admitted to a
newborn unit in Uganda was three hours.
 SSC was mostly provided by mothers (73.5%), but
other family members also took part, especially on the
day of birth.
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continuous KMC is not feasible, intermittent SSC is prefer-
able to conventional thermal care (11).
Prolonged direct SSC between infants and caregivers is
the cornerstone of KMC (12). Most studies of KMC have
taken place in dedicated KMC wards (13–18), where staff
were trained to care for both newborn infants and post-
partum women. Intermittent SSC may occur in the absence
of a KMC ward or where adequate space to practice
continuous SSC does not exist or is not used.
The 2016 Cochrane Review of KMC included 21 ran-
domised controlled trials (RCT), three of which evaluated
continuous KMC in stabilised infants (Table 1) (7). These
three studies took place in neonatal intensive care units
(NICU)orKMCwardsatmaternity, universityor tertiarycare
hospitals. The review also evaluated 16 RCTs of intermittent
KMC in stabilised infants and found that the mean daily
duration of SSC in these trials ranged from 10 minutes to
17 hours per day (Table 2). Most of these studies also took
place inNICUs, intermediate nurseries ormaternitywards in
tertiary care hospitals. When infants were not receiving SSC,
they were kept in incubators or under radiant warmers. The
remaining two RCTs included in the Cochrane Review
evaluated KMC in infants prior to stabilisation.
None of the RCTs of intermittent KMC took place in sub-
Saharan Africa, and none of the studies evaluated KMC in
an environment without a KMC ward or other dedicated
space for KMC. Quantitative descriptions of the duration of
SSC have rarely been reported (3). Many studies have only
stated whether KMC is practised in a facility (19) or how
health workers promote KMC, such as advising mothers to
provide SSC to their infants at all times, except for brief
interruptions to use the bathroom (15). Other studies have
described KMC as irregular (20) or almost continuous (21).
On the rare occasions when the hours of SSC are recorded,
details on whether the data were obtained through obser-
vation, self-report or other methods were not provided (13).
Lack of data on the duration of SSC in routine practice
has been cited as a limitation in the current evidence (3),
and poor-quality data on low-birthweight infants are a
significant barrier to KMC success (12). This study aimed to
address the knowledge gap surrounding the continuity of
facility-based KMC through direct observation of SSC in a
busy newborn unit at a resource-limited hospital in Uganda.
The objectives were to quantify the daily duration of SSC
over the first week of life and to compare these findings
with the data collected on SSC continuity by the existing
literature.
METHODS
This was an observational study of newborn infants that
collected quantitative data on SSC practices in July 2016. A
sample of participants was recruited after birth using the
following inclusion criteria: inborn, born weighing up to
2000 g, deemed clinically stable by the admitting clinician
and the mother was willing and able to participate in KMC.
Infants were excluded from study if they were outborn, born
outside the study period, born weighing greater than 2000 g,
born with congenital anomalies or severe medical problems
that precluded the safe use of KMC or the mother was
unwilling or unable to participate in KMC. Ethical approval
for this study was obtained from the London School of
Hygiene and Tropical Medicine, Makerere University and
the Uganda National Council of Science and Technology.
Study site
The study took place at Jinja Regional Referral Hospital in
south-eastern Uganda. The hospital serves a catchment area
of four million people and has approximately 6600 deliv-
eries per year (22). Sick newborn infants are cared for in a
newborn special care unit, adjacent to the labour ward.
Common admitting diagnoses include prematurity, birth
asphyxia, sepsis, respiratory distress syndrome and jaun-
dice. During the study, the approximate daily occupancy
was 10–15 patients and the unit had 13 cots, three radiant
warmers and one incubator. A total of eight midwives and
nurses staffed the newborn unit on a rotating day–night
schedule, with one or two working per shift.
Data collection
A data collection tool, based upon the WHO’s KMC guide
(2) was specifically designed for this study. When eligible
newborn infants were admitted to the newborn unit, we
immediately obtained informed consent from the mother or
father. When no family members accompanied the patient
on admission, we visited the mother in the labour ward to
Table 1 Randomised controlled trials of the Cochrane Review* evaluating continuous KMC (20 hours) in stabilised newborn infants
Study Setting (country; type of facility) Mean age at recruitment
Source of temperature control for
conventional care (control) group
Cattaneo et al. (1998)
(23) (n = 285)
Ethiopia, Mexico and Indonesia;
neonatal units of university hospitals
Median age 10 days (1–74) in
KMC group (n = 149); 8 days
(1–40) in control group (n = 136)
Radiant warmer or open crib in warm
room in Ethiopia; Incubators in
Mexico and Indonesia
Charpak et al. (1997)
(24) (n = 777)
Colombia; Kangaroo Mother Care
ward or neonatal intensive care
unit of tertiary care hospital
Median age 4 days (1–60) in
KMC group (n = 396); 3 days
(1–55) in control group (n = 381)
Incubator until able to regulate
temperature and thriving
Sloan et al. (1994)
(25) (n = 300)
Ecuador; neonatal intensive care
unit of maternity hospital
13.0 days  10.5 in KMC (n = 140)
and control (n = 160) groups
Incubator or radiant warmer
*Conde-Agudelo and Dıaz-Rossello JL (7).
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obtain consent. Thus, continuous observation of infants
began as soon as possible after birth and continued until the
end of day of life seven, discharge or death, whichever came
first. The lead researcher was present in the newborn unit
during daytime hours, and trained study personnel were
responsible for the data collection at night. The unit was
small, so it was possible to monitor multiple subjects
simultaneously. The characteristics of the mothers and
infants were documented using hospital records or by
asking the mother when information was not documented.
For each day of life, the total duration of hours spent in
SSC was calculated by adding together the duration of all
individual SSC sessions on that day. If an infant received at
least 20 hours of SSC, it was considered continuous KMC,
and any fewer hours of SSC per day was documented as
intermittent KMC (7). If the practice was intermittent, one
of the following reasons was recorded: mother ill, infant
unstable, caregiver not available or environmental chal-
lenges.
The date and time of birth and of the first SSC session in
the newborn unit were recorded and, from this, the age in
hours at SSC initiation was determined. We recorded the
hours spent in SSC, the caregiver providing SSC, the infant
position and infant clothing for every session of SSC.
Table 2 Randomised controlled trials of the Cochrane Review* evaluating intermittent KMC in stabilised newborn infants
Study Setting (country, type of facility) Mean age at recruitment
Source of thermal care
for control group Mean daily hours of KMC
Nimbalkar et al. (2014)
(26) (n = 45)
India; maternity ward 43 minutes  13 in KMC group
(n = 22); 30–60 minutes in control
group (n = 23)
Radiant warmer 17.0  0.3 during first
24 hours; KMC
discontinued at
24 hours
Suman et al. (2008)
(27) (n = 220)
India; neonatal intensive care unit
of tertiary care hospital
3.7 days  2.8 in KMC group
(n = 108); 2.3 days  1.9 in control
group (n = 112)
Radiant warmer 13.5
Kumbhojkar et al. (2016)
(28) (n = 120)
India; neonatal intensive care unit
of university hospital
3 days in KMC group (n = 60);
4 days in control group (n = 60)
Radiant warmer 11.5
Gathwala et al. (2008)
(29) (n = 110)
India; neonatal unit of university
hospital
1.7 days  0.5 in KMC (n = 50) and
control (n = 50) groups
Incubator or radiant
warmer
10.2  1.5 in the first
month
Eka Pratiwi et al. (2009)
(30) (n = 93)
Indonesia; neonatal intensive care
unit of public hospital
Not provided (n = 48 KMC group;
n = 45 control group)
Incubator or open crib
in warm room
10.0  1.8 (range 5.3
–13.5)
Kadam et al. (2005)
(31) (n = 89)
India, neonatal intensive care unit
of tertiary care hospital
3.2 days (1–8) for KMC (n = 44) and
control (n = 45) groups
Radiant warmer 9.8  3.7
Ghavane et al. (2012)
(32) (n = 140)
India; Kangaroo Mother Care ward
(KMC group), neonatal intensive/
intermediate care unit (control
group) of tertiary care hospital
14.1 days  10.3 in KMC group
(n = 71); 13.7 days  10.2 in
control group (n = 69)
Incubator or radiant
warmer
≥8, placed in open
cribs when not in
KMC
Ali et al. (2009)
(33) (n = 114)
India; neonatal intensive care unit
of tertiary care hospital
4.7 days  2.9 in KMC group
(n = 58); 4.8  2.4 in control group
(n = 56)
Radiant warmer or
open cot in warm
room
6.3  1.52 (range 4–
12)
Acharya (et al.) (2014)
(34) (n = 126)
Nepal; newborn nursery of tertiary
care hospital
Not provided (n = 63 KMC group;
n = 63 control group)
Radiant warmer ≥6
Neu and Robinson (2010)
(35) (n = 60)
United States; initially neonatal
intensive care unit of hospitals,
then at home
15.0 days  6.7 for KMC group
(n = 31); 15.0 days  4.9 for
control group (n = 29)
Incubator while in
hospital
4.81  2.12
(participant reported
data)
Ramanathan et al. (2001)
(36) (n = 28)
India; neonatal intensive care unit
of tertiary care hospital
Median age at KMC initiation
11.8 days for KMC (n = 14) group
Incubator or radiant
warmer
≥4
Roberts et al. (2000)
(37) (n = 30)
Australia; neonatal intensive care
units of university or tertiary care
hospitals
31.5 days  2.7 for KMC (n = 16)
and control (n = 14) groups
Incubator 1.6  0.9, 5 days a
week
Rojas et al. (2003)
(38) (n = 60)
United States; neonatal intensive
care unit of tertiary care hospital
19.6 days in KMC group (n = 33);
18.2 days in control group (n = 27)
Incubator 1.3  0.7
Boo and Jamli (2007)
(39) (n = 128)
Malaysia; neonatal intensive care
unit of tertiary care hospital
Median age 24.5 days in KMC group
(n = 65); 20.5 days in control group
(n = 63)
Incubator until infant
reached 1750 g
1.0 (median)
Whitelaw et al. (1988)
(40) (n = 71)
United Kingdom; neonatal
intensive care unit of a university
or tertiary care hospital
16 days (1–66) for KMC (n = 35)
and control (n = 36) groups
Incubator 0.6 (0–1.5)
Blaymore Bier et al.
(1996) (41) (n = 50)
United States; special care nursery
of a tertiary care hospital
29 days in KMC group (n = 25);
30 days in control group (n = 25)
Incubator 0.2
*Conde-Agudelo and Dıaz-Rossello JL (7).
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A well-positioned infant was defined as an infant meeting
four of the following five criteria: upright, between the
mother’s breasts, abdomen and chest touching the mother’s
bare chest, head turned to one side, legs flexed and abducted.
Appropriate clothing meant the infant’s chest and abdomen
were exposed and the infant was wearing a hat.
Data analysis
All the data collected on written data collection forms were
entered using EpiData 3.1 (EpiData Association, Odense,
Denmark). Data were double-entered, checked for any
incongruence and exported to Stata 14 (Stata Corp, College
Station, TX, USA) for analysis. The primary outcome was
the cumulative daily duration of SSC over the first week of
life. This was compared to the WHO recommendations
using a t-test. The secondary outcomes were age at SSC
initiation, the duration of individual SSC sessions, the
reason for intermittent KMC, the SSC provider, the infant’s
position and infant’s clothing. Descriptive statistics for
continuous variables included the means, standard devia-
tions (SD) and ranges. Categorical variables were analysed
and presented as frequencies and proportions. We consid-
ered conducting a survival analysis of KMC per day per
baby still in hospital, but we decided against this given the
small sample size.
RESULTS
Sample
Of the 68 newborn infants admitted to the unit during the
study period, 12 met the inclusion criteria. None of the
parents who were approached refused to participate. The
average age of the mothers was 24  5 years; the enrolled
infants had a mean birthweight of 1664  300 g and a
mean completed gestational age of 31  3 weeks deter-
mined by last menstrual period. Half of enrolled infants
were male, and 67% were delivered vaginally.
Of the 12 participants, eight were observed for the entire
first week of life, one died on day of life two and one left
against medical advice on day of life four. In total, 117
individual SSC sessions were observed, and information on
daily totals was gathered 76 times.
Outcomes
The mean daily duration of SSC over the first week of life
was 3.0  2.1 hours (range 0–9). When compared to the
WHO recommendation for at least 20 hours of SSC per
day, the resulting p value was <0.0001. This was evidence of
a significant difference between the practice at this facility
and the WHO recommendations.
We found that the mean daily duration of SSC, age at SSC
initiation and total number of SSC sessions varied by
participant and was not related to birthweight (Table 3).
The mean age at SSC initiation in the newborn unit was
21.6  9.8 hours (range 5.5–44.5). The mean duration of
individual SSCepisodeswas1.9  0.5 hours (range1.0–3.5).
None of the infants received continuous KMC. We
explored reasons for the lack of KMC continuity. The
mother was ill 23.7% of the time, and the infant was
considered too unstable for KMC 1.3% of the time. Most of
the time (75.0%), however, the reason for intermittent SSC
was environmental challenges, such as overcrowding, lack
of privacy or shortage of chairs for caregivers. Although a
small KMC room exists just outside the newborn unit, it was
not used frequently. Caregivers sat in plastic chairs or on
the floor of the crowded unit while providing SSC and
privacy screens were not available.
Skin-to-skin contact was mainly provided by mothers
(73.5%), but other family members also took part, especially
on the day of birth (Fig. 1). Newborn infants were well-
positioned and wearing appropriate clothing during all SSC
sessions.
DISCUSSION
The most SSC occurred on the second day of life and this
was the only day where every infant received at least one
session of SSC. Infants received the least SSC on the day of
birth. Infants who received the greatest number of SSC
sessions over the first week had higher mean daily durations
of SSC compared to infants receiving fewer sessions.
Unfortunately, the duration of SSC did not increase over
the first week, as some literature has suggested (8,11). The
shortest SSC sessions were one hour and the longest were
3.5 hours. While many studies on KMC conclude that SSC
should be practiced for no less than one hour (7), two hours
is ideal (8).
Most the time, both the mother and the infant were stable
enough for KMC and a potential SSC provider was nearby
and available. Once they were discharged from the labour
ward, most mothers spent the day in the outdoor area
adjacent to the newborn unit and other family members
frequently visited.
Previous research suggests that many physical and
cultural barriers to KMC exist. Physical barriers include
issues such as lack of space, overcrowding, lack of privacy,
absence of chairs or beds and the time needed to provide
SSC (8,42–46). Existing customs, such as carrying the infant
on the back, stigma surrounding the birth of a preterm
infant and general poor involvement and support from the
community may affect KMC. Beliefs that incubator care is
more effective than SSC and ambivalence by medical staff
may also influence the duration of SSC (12,43,45).
Mothers provided the most SSC, but grandmothers and
aunts played an important role on the day of birth, while the
mother was recovering from labour. One father participated
in KMC and this infant had one of the highest mean daily
durations of SSC. This finding must be interpreted with
caution, as this infant was only observed for two days, but it
presents an interesting argument for whether paternal
involvement in KMC significantly affects the duration of
SSC. Very little data regarding fathers and KMC exist from
both low-income and high-income countries, and one of the
key barriers to KMC adoption for men is lack of opportu-
nity to practice (42). Men could have a significant direct
impact on KMC initiation, by providing SSC themselves,
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and indirectly, by supporting the mother practically and
emotionally (12).
STRENGTHS AND LIMITATIONS
The main strength of our study is that this was one of the
few studies to examine KMC continuity and SSC in detail.
Through direct observation, our study provided a descrip-
tion of numerous episodes of SSC at a low-resource facility
in Uganda, where KMC is often poorly documented.
During the discussion of the study objectives and proce-
dures, parents were provided with a brief description of KMC
and its benefits. In some instances, they were hearing about
KMC for the first time. Parents’ awareness of the study
objectives and thepresenceof anobserver in thenewbornunit
could have had an impact on SSC practices, but the results do
not suggest that these factors played a significant role.
The data collection tool was not piloted or tested prior to
use, but the newborn unit paediatrician provided feedback
during the protocol and tool development.
Another study of KMC (46) was occurring at the facility
while our data were being collected for this study. The
purpose, outcomes and data collected for these studies
differed, but it is possible that one study may have
influenced the other.
Studies evaluating routine KMC practice in resource-
limited newborn units are scarce. Although the WHO
endorses intermittent KMC, little is known about the dose–
response relationship between the duration of SSC and
clinical outcomes such as mortality, length of hospitalisa-
tion and feeding practices (3,9,11,42). More studies are
needed to determine whether intermittent KMC, without
conventional thermal care, confers the mortality impact
described in a Cochrane Review (7). If a threshold for KMC
is determined, recommendations could be more precise (42)
and the demand placed on caregivers may be reduced (43).
CONCLUSION
Kangaroo mother care is a safe and effective way to decrease
neonatal mortality, and there is increasing global attention
being paid to KMC programmes. Our study found a disap-
pointingly low daily duration of SSC and demonstrated that
SSC was not practiced according to the current WHO
recommendations in this Ugandan newborn unit. However,
the nurses and midwives provided excellent education to
caregivers on proper SSC techniques, as all the infants were
positioned and clothed appropriately. While the mothers
provided themost SSC, other family members, including one
father, also participated. Further advocacy and community
education on the care of preterm infants with SSC may help
decrease the stigma of KMC, improve its overall acceptance
and reduce the age at SSC initiation.
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A.3. Clinical cascades to assess physical readiness of facilities for the care of small 
and sick neonates in Kenya and Uganda. PLoS One 2018. 
A.3.1. Copyright and permissions 
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 
International License (CC-BY), which permits unrestricted use, distribution, and reproduction in 
any medium, provided the original authors and source are credited, a link to the license is 
provided (http://creativecommons.org/licenses/by/4.0/), and any changes are indicated. 
A.3.2. Web appendix with supplementary tables and figures 
The web appendix with supplementary tables and figures is available on the following pages. 
S1 Table. Frequency and proportion of facilities with durable goods for neonatal care 
Category Item 
2016 
n (%)a 
2017 
n (%)a 
Percentage 
point change 
p-
valueb 
Physical exam 
supplies 
Thermometer 21 (91) 21 (91) 0 1.0000 
Stethoscope 15 (65) 21 (91) 26 0.0578 
Functional pulse oximeter with probe 10 (44) 5 (22) -22 0.0588 
Tape measure 16 (70) 21 (91) 21 0.0956 
Newborn weighing scale 23 (100) 21 (91) -9 0.1573 
Testing and 
treatment 
supplies 
Clean blade 22 (96) 19 (83) -13 0.1797 
Clean cloth / towel (may be brought by mother) 12 (52) 4 (17) -35 0.0325 
Resuscitation area with warmer / heat lamp 22 (96) 17 (74) -22 0.0253 
Neonatal ventilation bag 18 (78) 15 (65) -13 0.2568 
Mask – term or preterm size 15 (65) 17 (74) 9 0.5637 
Oxygen tubing 15 (65) 15 (65) 0 1.0000 
Suction device 21 (91) 20 (87) -4 0.6547 
Glucometer 8 (35) 1 (4) -31 0.0082 
Vitamin K (IM) 13 (57) 9 (39) -18 0.2059 
Equipment 
Functional incubator or radiant warmer 19 (83) 15 (65) -18 0.1025 
KMC beds or chairs 6 (26) 7 (30) 4 0.7055 
Filled oxygen cylinder or functional concentrator 18 (78) 18 (78) 0 1.0000 
Continuous positive airway pressure (CPAP) 
device 
10 (44) 5 (22) -22 0.0956 
Functional phototherapy unit 6 (26) 7 (30) 4 0.6547 
Guidelines-
assessment 
and treatment 
Guidelines: referral of sick newborns 6 (26) 10 (44) 18 0.2059 
Neonatal resuscitation algorithm 7 (30) 15 (65) 35 0.0209 
Gestational age assessment tool 3 (13) 8 (35) 22 0.0588 
Preterm infant fluid / feeding guidelines 6 (26) 7 (30) 4 0.6547 
Guidelines: oxygen therapy 3 (13) 6 (26) 13 0.2568 
Guidelines: apnea of prematurity 1 (4) 9 (39) 35 0.0047 
Guidelines: treatment of neonatal sepsis 3 (13) 9 (39) 26 0.0339 
Guidelines: neonatal jaundicec 
a Data represent resource availability across all 23 health facilities at one time-point. 
b Individual facilities were paired and p-values for resource availability by facility were calculated using McNemar’s test. 
c Presence of guidelines for neonatal jaundice was not assessed in this study. 
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S2 Table. Frequency and proportion of facilities with consumable supplies for neonatal care 
Stage Item 
2016 
n (%)a 
2017 
n (%)a 
Percentage 
point change 
p-valueb 
Examination 
and testing 
supplies 
Water & soap (or hand disinfectant) 18 (78) 19 (83) 5 0.7055 
Disposable gloves 17 (74) 19 (83) 9 0.4142 
Lancets (neonatal or infant size) 13 (57) 11 (48) -9 0.5271 
Glucose test strips 7 (30) 4 (17) -13 0.2568 
Serum bilirubin measurement or bilirubin test stripsc 
Medications 
Tetracycline eye ointment 16 (70) 17 (74) 4 0.7055 
PMTCT in line with national policyc 
Dextrose (IV) 22 (96) 18 (78) -18 0.1025 
Ringers lactate or half normal saline/5% dextrose 21 (91) 21 (91) 0 1.0000 
Caffeine citrate or aminophylline 21 (91) 18 (78) -13 0.2568 
Ampicillin or penicillin (IV) 20 (87) 14 (61) -26 0.0578 
Gentamicin (IV) 18 (78) 17 (74) -4 0.7389 
Ceftriaxone or cefotaxime (IV) 13 (57) 15 (65) 8 0.5271 
Phenobarbital (IV)c 
Calcium gluconate (IV) 9 (39) 9 (39) 0 1.0000 
Other 
treatment 
supplies 
IV cannula sets (minimum size: 24 gauge) 17 (74) 15 (65) -9 0.4795 
IV bags / tubing 6 (26) 4 (17) -9 0.3173 
Nasogastric tube (neonatal size) 13 (57) 13 (57) 0 1.0000 
Syringes / feeding cups 19 (83) 20 (87) 4 0.6547 
Nasal cannula (neonatal size) 12 (52) 10 (44) -8 0.5930 
a Data represent resource availability across all 23 health facilities at one time-point. 
b Individual facilities were paired and p-values for resource availability by facility were calculated using McNemar’s test. 
c Presence of these supplies and medications was not assessed in this study. 
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S3 Table. Neonatal care readiness in Kenyan and Ugandan health facilities by facility level, 
2016 and 2017 
Clinical 
cascade 
Stage Regional/district/ 
county level, n=5 
Mission/PNFP 
level, n=4 
Sub-county 
level, n=10 
Health center 
level, n=4 
2016 
n (%) 
2017 
n (%) 
2016 
n (%) 
2017 
n (%) 
2016 
n (%) 
2017 
n (%) 
2016 
n (%) 
2017 
n (%) 
Essential 
Newborn Care 
Identify 5 (100) 4 (80) 3 (75) 4 (100) 6 (60) 9 (90) 4 (100) 2 (50) 
Treat 4 (80) 1 (20) 3 (75) 3 (75) 2 (20) 3 (30) 0 1 (25) 
Monitor-
Modify 
2 (40) 0 2 (50) 1 (25) 0 1 (10) 0 1 (25) 
Neonatal 
Resuscitation 
Identify 2 (40) 3 (60) 3 (75) 3 (75) 4 (40) 6 (60) 2 (50) 2 (50) 
Treat 2 (40) 2 (40) 2 (50) 2 (50) 3 (30) 3 (30) 0 1 (25) 
Monitor-
Modify 
1 (20) 1 (20) 1 (25) 0 0 0 0 0 
Poor Feeding- 
Hypothermia 
Identify 5 (100) 3 (60) 2 (50) 4 (100) 3 (30) 6 (60) 2 (50) 2 (50) 
Treat 2 (40) 1 (20) 0 0 0 0 
Monitor-
Modify 
0 0 0 0 0 0 0a 2 (50)a 
Respiratory 
Distress-Apnea 
Identify 3 (60) 1 (20) 3 (75) 2 (50) 0 1 (10) 0 0 
Treat 2 (40) 0 2 (50) 2 (50) 0 0 0b 0b 
Monitor-
Modify 
0 0 0 0 0 0 0a 0a 
Infection-
Convulsions 
Identify 3 (60) 4 (80) 3 (75) 3 (75) 3 (30) 8 (80) 3 (75) 2 (50) 
Treat 1 (20) 1 (20) 1 (25) 2 (50) 1 (10) 0 1 (25)c 1 (25)c 
Monitor-
Modify 
0 0 0 0 0 0 0a 1 (25)a 
Jaundice 
Identify 4 (80) 3 (60) 2 (50) 3 (75) 5 (50) 3 (30) 0 1 (25) 
Treat 2 (40) 1 (20) 0 3 (75) 1 (10) 1 (10) 
Monitor-
Modify 
1 (20) 1 (20) 0 0 0 1 (10) 0d 1 (25)d 
a Modified to include only guidelines for referral of sick newborns. 
b Modified to include only mask, ventilation bag, and suction. 
c Modified to include only newborn weighing scale, ampicillin (or penicillin) and gentamicin, with addition of 
sterile syringe and 23-25 gauge needle (for intramuscular injection) 
d Modified to include only newborn weighing scale and guidelines for referral of sick newborns. 
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S4 Table. Neonatal care readiness in Kenyan and Ugandan health facilities by country, 
2016 and 2017 
Clinical cascade Stage of care Kenyan facilities, n=17 Ugandan facilities, n=6 
2016 
n (%) 
2017 
n (%) 
2016 
n (%) 
2017 
n (%) 
Essential Newborn Care 
Identify 13 (76) 14 (82) 5 (83) 5 (83) 
Treat 5 (29) 5 (29) 4 (67) 3 (50) 
Monitor-Modify 3 (18) 3 (18) 1 (17) 0 
Neonatal Resuscitation 
Identify 9 (53) 10 (59) 2 (33) 4 (67) 
Treat 6 (35) 4 (24) 1 (17) 4 (67) 
Monitor-Modify 2 (12) 0 0 1 (17) 
Poor Feeding- 
Hypothermia 
Identify 7 (41) 11 (65) 5 (83) 4 (67) 
Treat 0 0 2 (33) 1 (17) 
Monitor-Modify 0 0 0 0 
Respiratory Distress-
Apnea 
Identify 3 (18) 1 (6) 3 (50) 3 (50) 
Treat 3 (18) 0 1 (17) 2 (33) 
Monitor-Modify 0 0 0 0 
Infection-Convulsions 
Identify 9 (53) 12 (71) 3 (50) 5 (83) 
Treat 1 (6) 0 2 (33) 3 (50) 
Monitor-Modify 0 0 0 0 
Jaundice 
Identify 7 (41) 5 (29) 4 (67) 5 (83) 
Treat 2 (12) 1 (6) 1 (17) 1 (17) 
Monitor-Modify 0 1 (6) 1 (17) 1 (17) 
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S1 Figure. Respiratory distress-apnea clinical cascade, 2016 
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S2 Figure. Jaundice clinical cascade, 2016 
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S3 Figure. Essential newborn care clinical cascade, 2017 
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S4 Figure. Poor feeding-hypothermia clinical cascade, 2017 
202 
203 
A.3.3. Ethical approvals 
This work was covered within the broader research efforts of the UCSF Preterm Birth Initiative-
East Africa, which received ethical approval from the Institutional Review Boards of UCSF, 
Makerere University, UNCST, and the Kenya Medical Research Institute. Letters of approval 
from UCSF, Makerere University, UNCST, and the Kenya Medical Research Institute are 
available on the following pages. 
Human Research Protection Program
Institutional Review Board (IRB)
Expedited Review Approval
Principal Investigator: Dilys Walker, MD
Type of Submission: Submission Correction for Initial Review Submission Packet
Study Title: Strengthening selected interventions to improve birth outcomes and reduce morbidity 
and mortality of preterm infants in health facilities in Migori County, Kenya and Busoga Region, Uganda: An 
implementation science study
IRB #: 16-19162
Reference #: 161307
Committee of Record: San Francisco General Hospital Panel
Study Risk Assignment: Minimal
Approval Date: 03/29/2016 Expiration Date: 03/28/2017
This research satisfies the following condition(s) for the involvement of children:
45 CFR 46.404, 21 CFR 50.51: Research not involving greater than minimal risk.
Parental Permission and Assent:
The permission of one parent or guardian is sufficient.
The research meets all of the conditions of 45 CFR 46.204 for the involvement of pregnant women or fetuses.
The requirement for individual Research HIPAA Authorization is waived for some subjects, as detailed in the 
application. The use or disclosure of the requested information does not adversely affect the rights and welfare 
of the individuals and involves no more than a minimal risk to their privacy based on, at least, the presence of 
the following elements:
(1) an adequate plan to protect the identifiers from improper use and disclosure; (2) an adequate plan to destroy 
the identifiers at the earliest opportunity consistent with conduct of the research, unless there is a health or 
research justification for retaining the identifiers or if such retention is otherwise required by law;
(3) adequate written assurances that the requested information will not be reused or disclosed to any other 
person or entity, except as required by law, for authorized oversight of the research study, or for other research 
for which the use or disclosure of the requested information would be permitted by the Privacy Rule;
(4) the research could not practicably be conducted without the waiver; and (5) the research could not 
practicably be conducted without access to and use of the requested information.
A waiver of HIPAA Authorization and consent is acceptable for the recruitment procedures to identify potential 
subjects. The recruitment procedures involve routine review of medical or other records, do not adversely affect 
the rights and welfare of the individuals, and pose minimal risk to their privacy, based on, at least, the presence 
of the following elements:
(1) an adequate plan to protect the identifiers from improper use and disclosure; (2) an adequate plan to destroy 
the identifiers at the earliest opportunity consistent with conduct of the research, or a health or research 
justification for retaining the identifiers was provided or such retention is otherwise required by law;
(3) adequate written assurances that the requested information will not be reused or disclosed to any other 
person or entity, except as required by law, for authorized oversight of the research study, or for other research 
for which the use or disclosure of the requested information would be permitted by the Privacy Rule;
(4) the research could not practicably be conducted without the waiver; and (5) the study recruitment could not 
practicably be conducted without access to and use of the requested information. Study participants will sign a 
consent form prior to participation in the study.
A waiver of the requirement to obtain a signed consent form is acceptable for this study because, as detailed in 
the application, the research presents no more than minimal risk of harm to subjects and involves no procedures 
for which written consent is normally required outside of the research context.
The waiver applies to some subjects, as detailed in the application.
A waiver or alteration of informed consent is acceptable because, as detailed in the application: (1) the research 
involves no more than minimal risk to the subjects; (2) the waiver or alteration will not adversely affect the rights 
and welfare of the subjects; (3) the research could not practicably be carried out without the waiver or alteration; 
and (4) whenever appropriate, the subjects will be provided with additional pertinent information after 
participation.
The waiver or alteration of informed consent applies to some subjects, as detailed in the application.
This submission was eligible for expedited review as: 
Category 5: Research involving materials (data, documents, records, or specimens) that have been collected, or 
will be collected solely for nonresearch purposes (such as medical treatment or diagnosis)
Category 6: Collection of data from voice, video, digital, or image recordings made for research purposes
Category 7: Research on individual or group characteristics or behavior (including, but not limited to, research 
on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social 
behavior) or research employing survey, interview, oral history, focus group, program evaluation, human factors 
evaluation, or quality assurance methodologies 
All changes to a study must receive UCSF IRB approval before they are implemented. Follow the 
modification request instructions. The only exception to the requirement for prior UCSF IRB review and approval 
is when the changes are necessary to eliminate apparent immediate hazards to the subject (45 CFR 46.103.b.4, 
21 CFR 56.108.a). In such cases, report the actions taken by following these instructions.  
Expiration Notice: The iRIS system will generate an email notification eight weeks prior to the expiration of this 
study’s approval.  However, it is your responsibility to ensure that an application for continuing review approval 
has been submitted by the required time. In addition, you are required to submit a study closeout report at the 
completion of the project.
Documents Reviewed and Approved with this Submission (includes all versions – final approved 
versions are labeled ‘Approved’ in the Outcome column): 
 
Consent Documents
Other Study Documents
For a list of all currently approved documents, follow these steps: Go to My Studies and open the study – Click 
on Informed Consent to obtain a list of approved consent documents and Other Study Documents for a list of 
other approved documents. 
San Francisco Veterans Affairs Medical Center (SFVAMC): If the SFVAMC is engaged in this research, you 
must secure approval of the VA Research & Development Committee in addition to UCSF IRB approval and 
follow all applicable VA and other federal requirements. The UCSF IRB website has more information. 
MAKERERE	 UNIVERSITY
 
Tel: 256414532207/543872/543437 P.O. Box 7072 Kampala Uganda 
Website: www.musph.ac.ug	 Fax: 256414531807 
COLLEGE OF HEALTH SCIENCES 
SCHOOL OF PUBLIC HEALTH 
HIGHER DEGREES, RESEARCH AfiD ETHICS COMMITTEE 
Dr. Peter Waiswa 
Principal Inves tigator, Protocol (395) 
Makerere University, School o f Public Health 
Rc: Approval of Proposal ti tled: Strengthening selected interventions to improve birth 
Outcomes and reduce morbidity and mortality of preterm infants in health facilities in 
Migori County, Kenya a nd Busoga Region, Uganda : An implementation science study 
This is to inform 'ou that, the Highe r Degrees , Research and Ethics Committee (HD RE C) has 
granted approval to the above referenced study, the HDREC reviewed the proposal during the 138th 
HDREC meeting held on April 12[\ 2016 and provided suggestions and comments which you have 
adequately inc rpo rat d: 
Please note that your study protocol number With HDR :C is 395 . Please be sure to reference this 
number in any correspondence with HDREC. ote tha t the initial approval date f r your proposal 
by HDREC is 17'h / 06/2016, and therefore approval expires at every annual anniversary o f this 
approval date . The current approval is therefore valid until: 17th / 0612017. 
Continued approval is conditional upon your compliance with the following requirements : 
1) No ot her consent form(s), questionnaire and/or advertisement documents sho uld be used. 
The con sent form(s) mus t be signed by each sub ject prior to initiation of any pro tocol 
procedures. In addition, each subject must be given a copy of the signed consent form. 
2)	 All protocol amendments and changes to o ther app roved do cuments must be submitted to 
HDREC and not be impleme nted un til approved by HDREC excep t where necessary to 
eliminate apparent immedia te hazards to the study subjects. 
3)	 Significant changes to the study site and significant deviations fro m the research protocol and 
all unanticipated problems that may invo l 'e risks or affect the safety or welfare of sub jects or 
o ther , or tha t may affect the integrity of the research mus t be promptly reponed to HDRE C. 
4)	 All deaths, life threatening problems or serious or unexpected a dv:m:s~t s , whether related to 
the stucfy or not, mus t be reported to HDREC in a timely ~ett~ sS~i%~ in the 1 ational 
Guidelines for Research Involving Humans as Research ~];'ticip a nts. ,oG-6 
~ ~. 
~ Valid Thru' ('l~ 
ttl
.:E 
• '" 
~ 
1 7 JUN l017 :T 
• Please complete and submit reports to HDRE C as follows: 
a) For renewal of the study approval - complete and retu rn the continuing Review Report -
Renewal Request (Form 404A) at least 60 days prior to the expiration of the approval period . 
The stud y cannot continue un til re-app roved by HDREC. 
b) Completion, termination, or if not renewing the project - send a final report within 90 days 
upon completion o f the study. 
Finally, the legal requir eme nt in Uganda is tha t all research activities must be registered with 
the N ational Co uncil o f Science and Te chnology. T he forms for this registration can be 
obtained from their website www.uncst.go .ug. Please contact the Administrative Assis tant of 
the Higher D eg~.-Rcs~ch and E thics Commi ttee at wtusiimc@musph.ac.ug or 
telephon e nu mb {) *,~6') Lt.3 95' ,*%~9 7 if you encounter any problems. 
,~ 0,.-
q,' .<J 
..,' ~6
Yours sincerely ~ Va/j Tf-. _ ~ 
~ ·"U:-;r:. 
(\) 
~ 
7 JUN 2011 :T 
Chairperson: H ighe r D egrees, Research and E thics Committee 
Enclosures: 
a) A stamped, app roved study docume nts (informed consen t do cuments): 
2 


210 
A.4. Development and validation of a simplified score to predict neonatal mortality 
risk among neonates weighing 2000 g or less (NMR-2000): an analysis using data 
from the UK and The Gambia. The Lancet Child and Adolescent Health 2020. 
A.4.1. Copyright and permissions 
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Noncommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0), which permits 
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does not permit distribution of the Article if it is changed or edited in any way.  
A.4.2. Methods appendix with supplementary tables and figures 
The methods appendix with supplementary tables and figures is available on the following pages. 
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Methods appendix with supplementary tables and figures 
Selection of candidate variables 
Studies describing existing scoring systems for assessing neonatal mortality risk, illness severity, and clinical instability were 
reviewed to generate a list of potential parameters (Table S1). Parameters that are typically unavailable (e.g., oxygenation 
index), infrequently obtained (e.g., haematocrit), or unreliably measured (e.g., urine output) in low-resource settings were 
excluded (Table S2). Remaining parameters were evaluated using the following exclusion criteria: low prevalence in the 
NNRD (<0·1%); high prevalence of missing data in the development dataset (≥20%); not predictive of mortality in preterm 
or low birthweight neonates (e.g., thermoregulated environment); low prevalence within 24 hours (h) of birth (e.g., 
phototherapy); limited evidence to support validity (e.g., black race); concept better represented by an alternative variable 
(Table S2). Selection of candidate variables was conducted by members of the research team, which includes three 
neonatologists (one from US, two from UK), two of whom have extensive experience working in neonatal care in East 
Africa; a UK paediatrician based in The Gambia working in neonatal care; Gambian and Ugandan medical doctors with 
experience in neonatal care; and a UK paediatrician who is a global expert on newborn care and has an extensive background 
in neonatal care in LMICs, including throughout sub-Saharan Africa.    
Study participants and data acquisition 
UK samples 
This study utilised data from 187 neonatal units in the UK National Neonatal Research Database (NNRD). The NNRD holds 
electronic patient-level data, recorded by health professionals as part of routine clinical care, from admissions to National 
Health Service (NHS) neonatal units in England from 2008, and Wales and Scotland from 2012. Data in the NNRD are de-
identified and critical data items are fed back to and validated by treating clinicians. A formal comparison of NNRD data 
items against those recorded in case report forms of a randomised controlled trial demonstrated a high level of agreement 
(>95%).1  Items in the National Neonatal Data Set are held within the NHS Data Dictionary.2 This study included data on 
newborns admitted to neonatal units in England and Wales between January 2010 and December 2017. 
The NNRD includes a total of approximately 140000 neonates born weighing ≤2000 grams (g) who were admitted to 
participating neonatal units in England and Wales from January 2010 to December 2017. For model development, 5 to 10 
outcome events per predictor variable are required to obtain accurate and clinically useful results.3 Using this guidance, the 
dataset was divided into the following samples: 
• Development sample – all neonates ≤2000g admitted to a random sample of participating neonatal units in England
and Wales from January 2010 to December 2016 
• Random validation sample – all neonates ≤2000g admitted to the remaining participating neonatal units in England
and Wales from January 2010 to December 2016 
• Temporal validation sample – all neonates ≤2000g admitted to all neonatal units in England and Wales from January
to December 2017 
The following exclusion criteria were applied: birthweight >2000g; admitted at >6h of age or following discharge home; 
stillborn; died in the delivery room; moribund (received only comfort care prior to in-hospital death). Comfort care was 
defined as not receiving intubation, mechanical ventilation, vasopressors, or chest compressions. 
Gambian sample 
The Gambian validation sample included all neonates <2000g who were admitted to the neonatal unit at Edward Francis 
Small Teaching Hospital in Banjul between May 2018 and September 2019, and who were screened but not enrolled in the 
‘Early KMC’ (eKMC) trial (NCT03555981). 
Routine data, including mode of delivery and treatments administered during the first 24h post-birth, were collected from 
routine medical charts and recorded in an Excel spreadsheet by trained study personnel. Other routine and non-routine data, 
collected as part of the eKMC trial screening process, were exported from the trial database and transferred to the 
spreadsheet. These data included birthweight, sex, birth plurality (singleton or multiple), referral status (inborn or outborn), 
and oxygen saturation (SpO2) at admission (%). Due to the stepwise nature of the eKMC screening process, SpO2 was not 
required for those neonates who were deemed ineligible. Accordingly, if a neonate’s SPO2 measurement was not recorded in 
the trial database, study personnel attempted to collect this data from routine medical charts.  
Outcome measure 
The primary outcome was in-hospital mortality. Mortality has been utilised as the outcome against which most neonatal 
intensive care risk scores have been designed and validated.4,5,14,6–13 Mortality is clearly and directly related to illness 
severity, objectively measured, and reliably ascertainable.9   
A.4.2. Methods appendix
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Missing data 
Missing data were excluded from the analysis for continuous variables. In this study, categorical variables include therapy-
based risk factors (e.g., IV fluids) and clinical signs that are non-continuous (e.g., convulsions). Recording the absence of 
categorical variables is not mandatory in the data sources from which the NNRD is extracted; thus, these fields are often left 
blank to indicate absence. Therefore, there are several reasons why a neonate may not have such a variable recorded.15 First is 
the possibility that the neonate was healthy and, thus, did not require the therapy or have the clinical sign. This is the 
assumption that was made in the development of this score; the same assumption was made in the development of the widely 
used SNAP and CRIB scores. The second possibility is that the therapy was given or the clinical sign was present, but this 
information was not documented in the medical record. Given that a comparison of NNRD data items against those recorded 
for a randomised trial demonstrated >95% agreement,1 this was considered to be unlikely. Other possibilities include that the 
clinician should have ordered the therapy or noted the clinical sign, but failed to do so as a result of inadequate knowledge or 
skill. This was thought to be unlikely in UK neonatal units, which are staffed by neonatologists and/or paediatricians 
experienced in neonatal care. The data sources from which the NNRD data are drawn are summary data describing the 
treatments received or the signs detected on a particular day; therefore, treatments ‘ordered’ but not administered will not be 
recorded and, thus, will not be included in the NNRD. This was confirmed in the aforementioned NNRD validation study.1 
Model development 
Continuous data were presented using means and standard deviations (SD) for parametric data and medians and interquartile 
ranges (IQR) for non-parametric data. Categorical data were presented as counts and proportions. Logistic regression models 
were derived to model the risk of in-hospital mortality. Robust standard errors were used to allow for clustering within 
neonatal units. All candidate variables were included in a complete multivariable model, which was progressively simplified 
using reverse stepwise selection, with the least statistically significant variable being removed at each step. Model 
discrimination was assessed with the c-index,16 equivalent to the area under the receiver operating characteristic curve, which 
ranges from 0·5 (no predictive ability) to 1 (perfect discrimination).17 Overall goodness-of-fit was assessed with the Brier 
score, which ranges from 0 (perfect fit) to a maximum value dependent upon outcome incidence (0·25 for 50% 
incidence).18,19 Calibration was evaluated using graphical plots of observed versus predicted risk; perfect predictions lie on 
the 45 degree line.19 Locally weighted scatterplot smoothing was used to estimate the relationship between observed and 
predicted probabilities.20 A sensitivity analysis excluding neonates whose admission age was uncertain (anonymised data 
derived from calculated difference between time of birth and time of admission) was conducted to reassess performance, as 
admission at >6h of birth was an exclusion criterion. Model performance was additionally reassessed following exclusion of 
neonates who were transferred for any reason since outcome data were not available for these babies. Performance for 
predicting mortality within 24h of birth was evaluated in a secondary analysis, as 36% of neonatal deaths globally occur 
within this timeframe.21   
Multiple imputation 
Methods 
We employed multiple imputation (MI) with chained equations to impute missing values for incomplete predictor variables 
in the development sample. The imputation model included the primary outcome, predictor variables, and candidate variables 
believed to be associated with missing data values and/or patterns of missingness. Candidate variables were added in a 
stepwise process to assess model convergence and compatibility; those resulting in convergence failure were excluded. Stata 
version 15 was used to perform all imputation analyses (mi impute chained, mi estimate). Continuous variables were imputed 
using predictive mean matching (k=10) due to non-normality and restricted range; categorical variables were imputed using 
logistic regression.22 Variables were analysed in sequence from the most observed to the least observed. Fifteen imputed 
datasets were generated, with 10 iterations per dataset. The logistic regression model was executed across the 15 datasets and 
results were combined to create a single set of inferential statistics, using Rubin’s rules.23 MI estimates of the β coefficients 
and c-index were compared to original estimates. Monte Carlo errors were examined to assess statistical reproducibility.23  
Results 
Following imputation of missing values for incomplete predictor variables (n=54956), β coefficient estimates were nearly 
identical to original estimates (Table S3), thus no adjustments were made to the model coefficients. Discriminatory 
performance of the model was unchanged, with a c-index of 0·8894 (95% CI: 0·8818-0·8969). Estimates of Monte Carlo 
errors for β coefficients, standard errors, and p-values suggested that the MI process could be statistically reproduced. The 
average relative variance increase was 0·0457 and the largest fraction of missing information was 0·0902. 
Risk score development 
We assigned the parameters in the final model points proportional to their β regression coefficient values.24–26 Whole 
numbers were used in order to generate an easily calculable score.  
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Logistic regression equation relating the risk model to in-hospital mortality: 
Log odds of mortality = 2.6142 – (0.0032*birthweight) + (0.3167*nasal cannula/headbox) 
 + (1.6214*CPAP/mechanical ventilation) – (0.0390*admission SpO2) 
Logistic regression equation relating the risk score to in-hospital mortality: 
Log odds of mortality = 0.1901 – (0.3256*NMR-2000) 
A risk score was calculated for each patient and predictive margins with 95% confidence intervals (CI) were computed across 
a broad range of risk score percentiles (Table S4). Using these margins as a guide, the development sample was arbitrarily 
divided into three groups: neonates at low risk, medium risk, and high risk for mortality. To assess the calibration of the 
integer score to the model using regression coefficients, observed risks in risk groups and population deciles of the risk score 
were derived and compared with the mean predicted risks in each group or population decile (Figure S1). We assessed 
overall predictive ability of the integer score using the c-index. 
Internal validation 
Internal validity refers to the reproducibility of a risk prediction model for the underlying population from which the data 
originated.27 Bootstrap resampling, with 1000 samples within the development sample, was used to internally validate the 
final model at the two time-points and to estimate optimism-adjusted measures of model discrimination and overall fit in each 
bootstrap sample.28 Overfitting is a phenomenon whereby the process of generating a model that has optimal fit for the 
development dataset results in reduced fit when the model is applied to other datasets and, thus, provides an optimistic 
evaluation of its predictive ability.29 Performance of the refitted model in each bootstrap sample was compared to that of the 
refitted model in the original development sample. Estimates of optimism for the c-index and Brier score were averaged and 
subtracted to provide optimism-adjusted measures.  
External validation 
External validity refers to the generalisability of a model’s performance to related populations.27 The final model was 
evaluated in three external validation samples, each selected to assess distinctive features of performance. The random 
validation sample, drawn from the neonatal units withheld from the development sample, tested the performance of the 
model when applied to different neonatal care settings in the UK within the same timeframe. The temporal validation sample, 
drawn from all units in the development and random validation samples during the final twelve months of data collection, 
tested performance in the same neonatal units over time. The Gambian sample tested performance in a LMIC neonatal care 
setting. We assessed model performance in each validation sample separately and in the UK full (combined) validation 
sample. Discrimination and overall goodness-of-fit were evaluated using the c-index and Brier score, respectively. 
Calibration was assessed using graphical plots of observed versus predicted risk. Sensitivity, specificity, positive predictive 
value, and negative predictive value were calculated across a wide range of possible cut-points in the UK development and 
full validation samples (Table S5).  
We assessed overall performance of the simplified integer score using the c-index and Brier score in all external validation 
samples (Table S6). In the Gambian sample, we re-defined low-, medium-, and high-risk groups to account for increased case 
fatality in this setting. To assess the calibration of the integer score to the model using regression coefficients, observed risks 
in groups and population deciles of risk scores were derived and compared with mean predicted risks in each group or 
population decile of the Gambian sample (Figure S2). A risk score was calculated for each neonate and predictive margins 
with 95% CIs were computed across a broad range of score percentiles (Table S7). Using these margins as a guide, the 
Gambian sample was arbitrarily divided into three groups: neonates at low-, medium-, and high-risk for mortality.  
Comparison with the CRIB-II score 
The Clinical Risk Index for Babies (CRIB, CRIB-II),5,8 the Score for Neonatal Acute Physiology (SNAP, SNAP-II),6,9 and 
the SNAP Perinatal Extension (SNAPPE, SNAPPE-II)7,9 are the most widely used neonatal intensive care risk scores. The 
Transport Risk Index of Physiologic Stability (TRIPS, TRIPS-II) is a related physiology-based approach that can be assessed 
at any point within the first 24h and repeated as a baby’s clinical condition changes.13,14 The NNRD did not include all of the 
variables required for calculation of CRIB, SNAP, SNAP-II, SNAPPE-II, TRIPS, or TRIPS-II (Table S2); hence, CRIB-II 
was selected for comparison. CRIB-II includes 5 variables (sex, birthweight, gestational age, temperature, base excess), all 
collected within 1h of admission.8 As CRIB-II has only been validated for use in neonates up to 32 weeks gestational age, we 
compared the c-index and Brier score for CRIB-II and NMR-2000 amongst neonates ≤32 weeks in the full validation sample. 
All statistical analyses for this study were completed using Stata version 15 (College Station, Texas, United States). 
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Table S1. Characteristics of development studies reviewed to generate list of potential parameters 
Model Approach Dates Setting Sample 
sizea 
In-hospital 
mortalitya 
Gray, 19924 NTISSb Therapy-based 1989-90 3 NICUc, USA 1768 114 
Horbar, 199330 NICHHDd Perinatal factors 1987-89 7 NICUc, USA 3603 890 
International 
Neonatal Network, 
19935 
CRIBe Physiology-based + perinatal factors 1988-90 4 NICU
c, UK 812 201 
Richardson, 19936 SNAPf Physiology-based 1989-90 3 NICUc, USA 1643 114 
Richardson, 19937 SNAPPEg Physiology-based + perinatal factors 1989-90 3 NICU
c, USA 1089 59 
Maier, 199731 Unnamed 
Physiology-based + 
perinatal factors + 1 
therapy measure 
1978-87 1 NICUc, Germany 396 106 
Fischer, 199832 SCRIPh Physiology-based Not reported 1 NICU
c, Germany 20 Not reported 
Richardson, 20019 SNAP-II
f, 
SNAPPE-IIg 
Physiology-based (SNAP) 
+ perinatal factors 
(SNAPPE) 
1996-97 17 NICUc, Canada 10819 418 
Lee, 200113 TRIPSi Physiology-based 1996-97 8 NICU
c, Canada 
(transport service) 1115 Not reported 
Parry, 20038 CRIB-IIe Physiology-based + perinatal factors 1998-99 54 NICU
c, UK 3027 240 
Broughton, 200411 MINTj Physiology-based + perinatal factors 1992-2001 
Neonatal transport service 
in Australia 1252 138 
Zupancic, 200710 VON-RAk Physiology-based + perinatal factors 2002 
>500 NICUc, Vermont 
Oxford Network 10439 1072 
Rosenberg, 200833 SAWSl Perinatal factors 1998-2003 2 NICU
c, Egypt and 
Bangladesh 428
j 262 
Lee, 201314 TRIPS-IIi Physiology-based 2006-08 15 NICUc, Canada 11383 411 
Sutcuoglu, 201512 TREMSm Physiology-based 2011 1 NICU
c, Turkey (transport 
service) 306 56 
Shah, 201534 Unnamed Therapy-based + perinatal factors 2010-12 23 NICU
c, Canada 9978 650 
Rathod, 201635 SNSn Physiology-based 2012-13 1 NICU
c, India (transport 
service) 303 60 
Morgan, 201836 Unnamed Therapy-based 2015-16 1 neonatal unit (regional referral hospital), Uganda 264
o 2o 
a Total sample size and number of in-hospital deaths in the development cohort. 
b Neonatal Therapeutic Intervention Scoring System (NTISS) 
c Neonatal intensive care unit (NICU) 
d National Institute of Child Health and Human Development (NICHHD) 
e Clinical Risk Index for Babies (CRIB, CRIB-II) 
f Score for Neonatal Acute Physiology (SNAP, SNAP-II) 
g Score for Neonatal Acute Physiology Perinatal Extension (SNAPPE, SNAPPE-II) 
h Stability of the Cardio-Respiratory System in Premature Infants (SCRIP) 
i Transport Risk Index of Physiologic Stability (TRIPS, TRIPS-II) 
j Mortality Index for Neonatal Transportation (MINT) 
k Vermont Oxford Network-Risk Adjustment (VON-RA)  
l Simplified age-weight-sex (SAWS); sample comprised of neonates enrolled in clinical trials of topical emollient therapy at 
two tertiary care hospitals (one in Egypt, one in Bangladesh). 
m Transport Related Mortality Score (TREMS)  
n Sick Neonate Score (SNS) 
o Sample comprised of 254 neonates in a retrospective audit and 10 in a prospective study evaluating the feasibility of
kangaroo mother care for clinically unstable neonates; in-hospital mortality is reported for the feasibility study. 
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Table S2. Parameters evaluated for potential inclusion in the modelling process 
Model(s) Inclusion/exclusion 
Perinatal factors NAa NAa 
Birthweight 
CRIBb, SNAPPE-IIc, 
CRIB-IIb, MINTd, 
SAWSe, NICHHDf, 
Maierg 
Included 
Gestational age CRIB, CRIB-II
b, SAWSe, 
VON-RAh Included 
Sex CRIB-II
b, SAWSe, 
NICHHDf, VON-RAh Included 
Postnatal age MINTd Excluded- only validated as a binary risk factor (0-1 vs. >1 hour) among neonates transported within 72 hours (h)11 
Small-for-gestational age SNAPPE-IIc, NICHHDf Included 
Apgar score at 1 minute MINT
d, NICHHDf, 
VON-RAh 
Excluded- often unavailable in LMIC facilities, especially 
for babies born at home or transferred from another facility 
Apgar score <7 at 5 minutes, Apgar score at 5 minutes SNAPPE-II
c,  Maierg, 
VON-RAh Excluded- as above 
Congenital anomalyi CRIB
b, MINTd, VON-
RAh 
Unreliable diagnosis in LMIC settings- modified to 
‘presence of visually recognisable anomaly at birth’ using a 
predefined list of conditions 
Black race NICHHDf Excluded- limited evidence; only validated in 1 study (published in 1993) 
Outborn status VON-RAh Excluded- only validated in combination with SNAP-II10 
Multiple gestation VON-RAh Excluded- as above 
Caesarean delivery VON-RAh Excluded- as above, plus not available in many LMIC facilities 
Therapy-based NAa NAa 
Cardiopulmonary resuscitation in first 24h NTISSj Modified to ‘bag-mask resuscitation at time of delivery’ 
Surfactant administration in first 24h NTISSj Excluded- infeasible for LMIC settings 
Oxygen therapy in first 24/48h NTISSj, KMCk Included as ‘oxygen therapy within 24h of birth’ 
Continuous positive airway pressure in first 24/48h NTISSj, KMCk Modified to ‘highest level of respiratory support within 24h of birth’ 
Mechanical/high frequency ventilation in first 24h, at 
admission NTISS
j, Maierg Excluded- better represented by alternative variable (‘highest level of respiratory support within 24h of birth’) 
Tracheostomy in first 24h NTISSj Excluded- infeasible for LMIC settings 
Extracorporeal membrane oxygenation in first 24h NTISSj Excluded- infeasible for LMIC settings 
Endotracheal intubation in first 24h NTISSj 
Excluded- better represented by alternative variable 
(‘highest level of respiratory support within 24h of birth’), 
low data completeness in NNRD 
PaO2/FiO2 ratio in first 12/24h SNAP-II/SNAPl 
Excluded- not included in NNRD, infeasible for LMIC 
settings 
Oxygenation index in first 24h SNAPl Excluded- not included in NNRD, infeasible for LMIC settings 
Minimum/maximum FiO2 in first 12h CRIBb Excluded- not included in NNRD, infeasible for LMIC settings 
Indomethacin administration in first 24h NTISSj Excluded- infeasible for LMIC settings 
Vasopressor administration in first 24h NTISSj Excluded- infeasible for LMIC settings 
Pacemaker therapy in first 24h NTISSj Excluded- not included in NNRD, infeasible for LMIC settings 
Antibiotic therapy in first 24/48h NTISSj, KMCk Included as ‘antibiotic therapy within 24h of birth’ 
Diuretic therapy in first 24h NTISSj Excluded- infeasible for LMIC settings 
Steroid administration in first 24h NTISSj Excluded- infeasible for LMIC settings 
Anticonvulsant therapy in first 24/48h NTISSj, KMCk Included as ‘anticonvulsant therapy within 24h of birth’ 
Caffeine (or aminophylline) in first 24/48h NTISSj, KMCk Included as ‘caffeine or aminophylline within 24h of birth’ 
Treatment of metabolic acidosis in first 24h NTISSj Excluded- infeasible for LMIC settings 
Potassium binding resin administration in first 24h NTISSj Excluded- infeasible for LMIC settings 
Frequent vital signs/cardiorespiratory monitoring in first 24h NTISSj Excluded- unreliable, infeasible for LMIC settings 
Frequent phlebotomy in first 24h NTISSj Excluded- infeasible for LMIC settings 
Thermoregulated environment in first 24h NTISSj 
Excluded- not useful to predict mortality risk amongst 
neonates ≤2000g, as all require some form of thermal 
support (KMC, incubator, or radiant warmer) 
Arterial, central venous pressure monitoring in first 24h NTISSj Excluded- not included in NNRD, infeasible for LMIC settings 
Urinary catheter in first 24 hours NTISSj Excluded- not included in NNRD, infeasible for LMIC settings 
Gavage feeding NTISSj 
Excluded- not useful to predict mortality risk amongst 
neonates ≤2000g, as those born at <35 weeks may require 
gavage feeding until coordinated suck and swallow 
develops (typically around 32 to 34 weeks) 
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Intravenous (IV) amino acid administration, IV potassium 
infusion within first 24h NTISS
j Modified to ‘IV fluids within 24h of birth’ 
IV fluids within 48h of birth KMCk Excluded- better represented by alternative variable (‘IV fluids within 24h of birth’) 
Insulin administration in first 24h NTISSj Excluded- low prevalence, infeasible for LMIC settings 
Phototherapy in first 24/48h NTISSj, KMCk Excluded- low prevalence within 24h of birth 
Blood product transfusion in first 24h NTISSj Excluded- infeasible for LMIC settings 
Exchange transfusion in first 24h NTISSj Excluded- infeasible for LMIC settings 
Patient transport in first 24h NTISSj Excluded- infeasible in many LMIC settings 
Chest tube in first 24h NTISSj Excluded- low prevalence in NNRD, infeasible for LMIC settings 
Pericardial tube in first 24h NTISSj Excluded- low prevalence in NNRD, infeasible for LMIC settings 
Operation in first 24h NTISSj Excluded- low prevalence in NNRD, infeasible for LMIC settings 
Thoracentesis in first 24h NTISSj Excluded- low prevalence in NNRD, infeasible for LMIC settings 
Pericardiocentesis in first 24h NTISSj Excluded- low prevalence in NNRD, infeasible for LMIC settings 
Dialysis in first 24h NTISSj Excluded- low prevalence in NNRD, infeasible for LMIC settings 
Vascular access in first 24hm NTISSj Excluded- low prevalence in NNRD, arterial and central venous access infeasible for LMIC settings 
Clinical signs/observations NAa NAa 
Blood pressure in first 12/24h, at admission 
SNAP-II/SNAPl, TRIPS, 
TRIPS-IIn, TREMSo,
SNSp 
Excluded- high proportion of missing data (30·3%) in 
development set 
Heart rate in first 24h, at admission SNAPl, MINTd, SNSp Included as ‘Heart rate at admission’ 
Respiratory rate in first 24h, at admission SNAPl, SNSp Modified to ‘Respiratory rate at admission’ 
Temperature at admission (within first hour) CRIB-II
b, TREMSo, 
TRIPS, TRIPS-IIn, SNSp Included as ‘temperature at admission’ 
Temperature in first 12/24h SNAP-II/SNAPl Excluded- better represented by alternative variable (‘temperature at admission’) 
Oxygen saturation in first 24h, at admission NTISSj, TREMSo, SNSp Included as ‘Oxygen saturation at admission’ 
Urine output in first 12/24h, quantitative intake and output in 
first 24h SNAP-II/SNAP
l, NTISSj Excluded- unreliable measure, infeasible for LMIC settings 
Number of seizures in first 12/24h SNAP-II/SNAPl Number not included in NNRD- modified to ‘any seizures within 24h of birth’  
Apnoeic episodes in first 24h SNAPl 
Unreliable measure in present form- modified to ‘clinically 
relevant increase in apnoea/bradycardia episodes, oxygen 
requirement, or ventilatory support’ 
Respiratory status/effort, severity of respiratory distress at 
admission 
TRIPS, TRIPS-IIn, 
Maierg, SNSp 
Excluded- better represented by alternative variables (‘RR 
at admission,’ ‘SpO2 at admission’ ‘clinically relevant 
increase in apnoea/bradycardia episodes, oxygen 
requirement, ventilatory support, or respiratory rate’) 
Response to noxious stimuli TRIPS, TRIPS-IIn Excluded- not included in NNRD 
Capillary refill time at admission SNSp Excluded- prevalence <0.1% in NNRD 
Episodes of apnoea, bradycardia, or oxygen desaturation 
measured over 5-minute periods 13 times throughout the 
first 6h 
SCRIPq 
Excluded- infeasible for routine clinical use; better 
represented by alternative variable (‘clinically relevant 
increase in apnoea/bradycardia episodes, oxygen 
requirement, ventilatory support, or respiratory rate’)  
Laboratory measures NAa NAa 
Serum pH in first 12/24h, at admission SNAP-II/SNAPl, MINTd Excluded- infeasible for routine use in LMIC settings 
PaO2 in first 24h, at admission SNAPl, MINTd Excluded- not included in NNRD, infeasible for LMIC settings 
pCO2 in first 24h, at admission SNAPl, TREMSo Excluded- infeasible for routine use in LMIC settings 
Base excess in first 12h, within 1h, on admission CRIB, CRIB-IIb, Maierg Excluded- infeasible for routine use in LMIC settings 
Haematocrit in first 24h SNAPl Excluded- not included in NNRD 
White blood cell count in first 24h SNAPl Excluded- not included in NNRD 
Immature total ratio in first 24h SNAPl Excluded- not included in NNRD, infeasible for LMIC settings 
Absolute neutrophil count in first 24h SNAPl Excluded- not included in NNRD, infeasible for LMIC settings 
Platelet count in first 24h SNAPl Excluded- not included in NNRD, infeasible for routine use in LMIC settings 
Blood urea nitrogen in first 24h SNAPl Excluded- not included in NNRD, infeasible for routine use in LMIC settings 
Creatinine in first 24h SNAPl Excluded- not included in NNRD, infeasible for routine use in LMIC settings 
Bilirubin in first 24h SNAPl Excluded- not included in NNRD, infeasible for routine use in LMIC settings 
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Sodium in first 24h SNAPl Excluded- not included in NNRD, infeasible for routine use in LMIC settings 
Potassium in first 24h SNAPl Excluded- not included in NNRD, infeasible for routine use in LMIC settings 
Calcium in first 24h SNAPl Excluded- not included in NNRD, infeasible for routine use in LMIC settings 
Blood glucose in first 24h, on admission SNAPl, TREMSo, SNSp Excluded- high proportion of missing data (23·9%) in development set 
Serum bicarbonate in first 24h SNAPl Excluded- not included in NNRD, infeasible for routine use in LMIC settings 
Stool guaiac in first 24h SNAPl Excluded- not included in NNRD 
a Not applicable (NA). 
b Clinical Risk Index for Babies (CRIB, CRIB-II). 
c Score for Neonatal Acute Physiology Perinatal Extension (SNAPPE, SNAPPE-II). 
d Mortality Index for Neonatal Transportation (MINT). 
e Simplified age-weight-sex (SAWS). 
f National Institute of Child Health and Human Development (NICHHD). 
g Unnamed mortality risk score for VLBW neonates, published by Maier et al. 
h Vermont Oxford Network-Risk Adjustment (VON-RA).  
i  The CRIB score stratified the risk of congenital anomalies into 3 categories: 1) none; 2) non-acutely life threatening; 3) 
acutely life threatening.5 The MINT score categorized this variable solely by its presence or absence, as recorded at the 
time of the referral call.11 The VON-RA score defined congenital anomalies using a predefined list of conditions.37  
j Neonatal Therapeutic Intervention Scoring System (NTISS). 
k Therapy-based clinical instability criterion used in study exploring KMC feasibility amongst unstable neonates in Uganda.36 
l Score for Neonatal Acute Physiology (SNAP, SNAP-II). 
m The NTISS defined vascular access to include peripheral IV, arterial, and central venous lines, with higher therapeutic 
intensity weights assigned to arterial and central venous access (subscore: 2) than peripheral IV access (subscore: 1).4 
n Transport Risk Index of Physiologic Stability (TRIPS, TRIPS-II). 
o Transport Related Mortality Score (TREMS).
p Sick Neonate Score (SNS). 
q Stability of the Cardio-Respiratory System in Premature Infants (SCRIP). 
Table S3. NMR-2000 logistic model following multiple imputation versus original estimates in development sample 
Multiple imputation (n=54956) Original estimates (n=46108) 
β Coefficient 95% Confidence interval β Coefficient 95% Confidence interval 
Birthweight -0.0032 -.0035 to -.00289a -0·0032 -0·0035 to -0·0029a 
Highest respiratory support within first 24h ··, NAb ··, NAb ··, NAb ··, NAb 
Nasal cannula or headbox 0.3896 0.0014 to 0.7778c 0·3167 -0·1055 to 0·7389a 
CPAP, Bi/SiPAP, or invasive ventilation 1.4977 1.1909 to 1.8045a 1·6214 1·2682 to 1·9746a 
SpO2 at admission (%) -0.0386 -0.0449 to -0.0322a -0·0390 -0·0455 to -0·0326a 
Constant 2.8229 1.9410 to 3.7047a 2·6142f 1·7655 to 3·4629a 
a Estimate significant to p-value <0·0001. 
b Not applicable. 
c Estimate significant to p-value <0·05. 
Table S4. Predicted mortality risk across score percentiles in the development sample (n=46108) 
Percentile Score Mean predicted mortality riska 95% Confidence intervala 
1% 3·9 34·1 29·1 - 39·0 
5% 6·1 18·5 15·6 - 21·4 
10% 7·9 11·1 9·3 - 12·8 
25% 12·0 4·7 3·9 - 5·4 
50% 17·2 1·1 0·9 - 1·3 
75% 21·1 0·2 0·2 - 0·3 
90% 22·9 0·1 0·06 - 0·1 
a All predictions significant to p-value <0.0001. 
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Figure S1. Predicted versus observed risk of death for pre-defined categories and population deciles by risk score in 
the development sample (n=46108). Predicted risk of death derived from exact regression model (dotted lines) versus 
observed risk of death (solid bars). 
Table S5. Sensitivity and specificity based on predicted mortality risk in the development (n=46108) and full 
validation samples (n=47846) 
Sensitivity (95% CI) Specificity (95% CI) PPVa (95% CI) NPVb (95% CI) 
Development NAc NAc NAc NAc 
0·5% 96·1 (94·8-97·1) 52·9 (52·4-53·3) 5·4 (5·1-5·7) 99·8 (99·7-99·8) 
1% 91·9 (90·2-93·4) 64·4 (63·9-64·8) 6·7 (6·3-7·1) 99·7 (99·6-99·7) 
3·9%d 79·1 (76·7-81·3) 82·9 (82·5-83·2) 11·4 (10·7-12·1) 99·3 (99·2-99·4) 
5% 75·3 (72·8-77·7) 85·7 (85·4-86·0) 12·8 (12·0-13·5) 99·2 (99·1-99·3) 
10% 60·1 (57·4-62·9) 93·1 (92·9-93·3) 19·5 (18·2-20·8) 98·8 (98·7-98·9) 
20% 26·1 (23·7-28·7) 98·4 (98·3-98·5) 31·3 (28·5-34·3) 98·0 (97·8-98·1) 
Full validation NAc NAc NAc NAc 
0·5% 96·5 (95·5-97·4) 52·0 (51·5-52·4) 6·1 (5·8-6·4) 99·8 (99·7-99·8) 
1% 91·7 (90·2-93·1) 63·4 (63·0-63·9) 7·5 (7·1-7·9) 99·6 (99·5-99·7) 
3·9%d 81·6 (79·6-83·6) 81·0 (80·7-81·4) 12·2 (11·6-12·9) 99·3 (99·2-99·4) 
5% 78·4 (76·2-80·4) 83·9 (83·5-84·2) 13·6 (12·9-14·4) 99·2 (99·1-99·3) 
10% 65·6 (63·1-68·0) 91·3 (91·1-91·6) 19·7 (18·6-20·9) 98·8 (98·7-98·9) 
20% 34·6 (32·2-37·1) 97·7 (97·6-97·8) 32·8 (30·5-35·2) 97·9 (97·7-98·0) 
a Positive predictive value (PPV). 
b Negative predictive value (NPV). 
c Not applicable (NA). 
d Empirical optimal cutpoint based on the Youden Index.38 
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Table S6. Risk score performance in the external validation samples 
Random validation 
n=35193 
Temporal validation 
n=12653 
Full validation 
n=47846 
Gambian validation 
n=457 
Brier score 0·0272 0·0237 0·0263 0·1715 
C-index 0·8910 0·8872 0·8903 0·8082 
Table S7. Predicted mortality risk across score percentiles in the Gambian validation sample (n=457) 
Percentile Score Mean predicted mortality riska 95% Confidence intervala 
1% 4·2 96·8 94·0 - 99·6 
5% 7·0 92·5 88·3 - 96·7 
10% 9·0 89·2 84·3 - 94·2 
25% 12·5 73·8 67·3 - 80·4 
50% 17·0 48·1 42·7 - 53·5 
75% 20·0 25·3 20·3 - 30·2 
90% 22·0 14·5 10·0 - 18·9 
a All predictions significant to p-value <0.0001. 
Figure S2. Predicted versus observed risk of death for pre-defined categories and population deciles by risk score in 
the Gambian validation sample (n=457). Predicted risk of death derived from exact regression model (dotted lines) versus 
observed risk of death (solid bars). 
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A.4.3. Ethical approvals 
Model development and validation in the UK was approved by the UK Health Research Authority 
and the Research Ethics Committees (REC) of North West–Preston (17/NW/0709) and LSHTM 
(#14594). The Gambian validation study was approved by RECs of the Gambian 
Government/Medical Research Council (MRC) Unit The Gambia at LSHTM (#1643) and 
LSHTM (#16189). Letters of approval from LSHTM, North West–Preston, the UK Health 
Research Authority, and the Gambian Government/MRC Unit The Gambia are available on the 
following pages. 
Observational / Interventions Research Ethics Committee
Dr Melissa Morgan 
LSHTM
14 February 2018 
Dear Dr Morgan
Study Title: The OMWaNA Study: Operationalising kangaroo Mother care among unstable low birth Weight Neonates in Africa: Developing and validating a clinical stability index to help
providers determine eligibility 
LSHTM Ethics Ref: 14594 
Thank you for your application for the above research project which has now been considered by the Observational Committee via Chair’s Action.
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting
documentation, subject to the conditions specified below.
Conditions of the favourable opinion
Approval is dependent on local ethical approval having been received, where relevant. 
Approved documents
The final list of documents reviewed and approved is as follows:
Document Type File Name Date Version
Local Approval Chris Gale - NDAU Board Approval email 19/10/2017 1.0
Local Approval 238074 17.NW.0709 favourable opinion 30.11.2017 11/11/2017 1.0
Protocol / Proposal OMWaNA study_NDAUprotocol_v3 15/11/2017 3.0
Local Approval LSHTM Sponsorship Letter_QA1081_MMorgan_20.11.17 20/11/2017 1.0
Local Approval 238074; 17NW0709 - Letter of HRA Approval - 14.12.2017 14/12/2017 1.0
Investigator CV Morgan CV_Jan 2018_UK 29/01/2018 1.0
Investigator CV Cally Tann_CV 29/01/2018 1.0
Investigator CV Joy Lawn CV 2018 29/01/2018 1.0
Investigator CV Diana Elbourne_CV 29/01/2018 1.0
Investigator CV Peter Waiswa_CV 29/01/2018 1.0
Investigator CV Elizabeth Allen_CV 29/01/2018 1.0
After ethical review
The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application.  These must be submitted to the committee for review
using an Amendment form.  Amendments must not be initiated before receipt of written favourable opinion from the committee.
The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the project
by submitting a Serious Adverse Event form. 
An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study.  
At the end of the study, the CI or delegate must notify the committee using the End of Study form.
All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk.
Further information is available at: www.lshtm.ac.uk/ethics.
Yours sincerely,
Page 1 of 2
Professor John DH Porter
Chair
ethics@lshtm.ac.uk
http://www.lshtm.ac.uk/ethics/ 
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North West - Preston Research Ethics Committee 
Barlow House 
3rd Floor 
4 Minshull Street 
Manchester 
M1 3DZ 
 
Telephone: 020 71048008 
 
 
 
 
 
 
 
 
 
 
30 November 2017 
 
Dr Melissa Morgan 
Keppel Street 
London 
WC1E 7HT 
 
 
Dear Dr Morgan  
 
Study title: The OMWaNA Study: Operationalising kangaroo Mother 
care among unstable low birth Weight Neonates in 
Africa: Developing and validating a clinical stability 
index to help providers determine eligibility 
REC reference: 17/NW/0709 
Protocol number: QA1079 
IRAS project ID: 238074 
 
The Proportionate Review Sub-committee of the North West - Preston Research Ethics 
Committee reviewed the above application in correspondence.   
 
We plan to publish your research summary wording for the above study on the HRA 
website, together with your contact details. Publication will be no earlier than three months 
from the date of this favourable opinion letter.  The expectation is that this information will 
be published for all studies that receive an ethical opinion but should you wish to provide a 
substitute contact point, wish to make a request to defer, or require further information, 
please contact hra.studyregistration@nhs.net outlining the reasons for your request. Under 
very limited circumstances (e.g. for student research which has received an unfavourable 
opinion), it may be possible to grant an exemption to the publication of the study.  
 
 
 
Please note:  This is the 
favourable opinion of the 
REC only and does not allow 
you to start your study at NHS 
sites in England until you 
receive HRA Approval  
 
 Page 2 
Ethical opinion 
 
On behalf of the Committee, the sub-committee gave a favourable ethical opinion of the 
above research on the basis described in the application form, protocol and supporting 
documentation, subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the start 
of the study. 
 
Management permission must be obtained from each host organisation prior to the start of 
the study at the site concerned. 
 
Management permission should be sought from all NHS organisations involved in the study 
in accordance with NHS research governance arrangements. Each NHS organisation must 
confirm through the signing of agreements and/or other documents that it has given 
permission for the research to proceed (except where explicitly specified otherwise). 
 
Guidance on applying for HRA Approval (England)/ NHS permission for research is 
available in the Integrated Research Application System, www.hra.nhs.uk or at 
http://www.rdforum.nhs.uk.  
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of management permissions from host 
organisations. 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database. This should be before the first participant is 
recruited but no later than 6 weeks after recruitment of the first participant. 
  
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment.  We will audit the registration details as 
part of the annual progress reporting process. 
  
To ensure transparency in research, we strongly recommend that all research is registered 
but for non-clinical trials this is not currently mandatory. 
  
If a sponsor wishes to request a deferral for study registration within the required timeframe, 
they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials 
will be registered, however, in exceptional circumstances non registration may be 
permissible with prior agreement from the HRA. Guidance on where to register is provided 
on the HRA website.  
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It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable). 
 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see “Conditions of the favourable opinion”). 
 
Summary of discussion at the meeting (if applicable) 
 
The members had no ethical issues with this application. 
 
Approved documents 
 
The documents reviewed and approved were: 
 
Document   Version   Date   
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only)  
    
IRAS Application Form [IRAS_Form_28112017]    28 November 2017  
IRAS Application Form XML file [IRAS_Form_28112017]    28 November 2017  
Research protocol or project proposal  3  15 November 2017  
Summary CV for Chief Investigator (CI)      
Summary CV for supervisor (student research)      
Summary CV for supervisor (student research)      
 
Membership of the Proportionate Review Sub-Committee 
 
The members of the Sub-Committee who took part in the review are listed on the attached 
sheet. 
 
Statement of compliance  
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
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User Feedback 
 
The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received 
and the application procedure. If you wish to make your views known please use the 
feedback form available on the HRA website: http://www.hra.nhs.uk/about-the-
hra/governance/quality-assurance/    
 
HRA Training 
 
We are pleased to welcome researchers and R&D staff at our training days – see details at 
http://www.hra.nhs.uk/hra-training/   
 
With the Committee’s best wishes for the success of this project. 
 
17/NW/0709 Please quote this number on all correspondence 
 
Yours sincerely 
 
Dr Rob Monks  
Chair 
 
Email: nrescommittee.northwest-preston@nhs.net 
 
 
Enclosures: List of names and professions of members who took part in the review  
 
“After ethical review – guidance for researchers”  
 
Copy to: Mrs Patricia Henley 
Dr Essam Ramhamadany, Chelsea and Westminster NHS Foundation 
Trust  
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Dr Melissa Morgan 
Keppel Street 
London 
WC1E 7HT 
 
Email: hra.approval@nhs.net 
 
14 December 2017 
 
Dear Dr Morgan     
 
 
Study title: The OMWaNA Study: Operationalising kangaroo Mother care 
among unstable low birth Weight Neonates in Africa: 
Developing and validating a clinical stability index to help 
providers determine eligibility 
IRAS project ID: 238074  
Protocol number: QA1079 
REC reference: 17/NW/0709   
Sponsor London School of Hygiene & Tropical Medicine 
 
I am pleased to confirm that HRA Approval has been given for the above referenced study, on the 
basis described in the application form, protocol, supporting documentation and any clarifications 
noted in this letter.  
 
Participation of NHS Organisations in England  
The sponsor should now provide a copy of this letter to all participating NHS organisations in England.  
 
Appendix B provides important information for sponsors and participating NHS organisations in 
England for arranging and confirming capacity and capability. Please read Appendix B carefully, in 
particular the following sections: 
 Participating NHS organisations in England – this clarifies the types of participating 
organisations in the study and whether or not all organisations will be undertaking the same 
activities 
 Confirmation of capacity and capability - this confirms whether or not each type of participating 
NHS organisation in England is expected to give formal confirmation of capacity and capability. 
Where formal confirmation is not expected, the section also provides details on the time limit 
given to participating organisations to opt out of the study, or request additional time, before 
their participation is assumed. 
 Allocation of responsibilities and rights are agreed and documented (4.1 of HRA assessment 
criteria) - this provides detail on the form of agreement to be used in the study to confirm 
capacity and capability, where applicable. 
Further information on funding, HR processes, and compliance with HRA criteria and standards is also 
provided. 
 
Letter of HRA Approval 
IRAS project ID 238074 
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It is critical that you involve both the research management function (e.g. R&D office) supporting each 
organisation and the local research team (where there is one) in setting up your study. Contact details 
and further information about working with the research management function for each organisation 
can be accessed from the HRA website.  
 
Appendices 
The HRA Approval letter contains the following appendices: 
 A – List of documents reviewed during HRA assessment 
 B – Summary of HRA assessment 
 
After HRA Approval 
The document “After Ethical Review – guidance for sponsors and investigators”, issued with your REC 
favourable opinion, gives detailed guidance on reporting expectations for studies, including:  
 Registration of research 
 Notifying amendments 
 Notifying the end of the study 
The HRA website also provides guidance on these topics, and is updated in the light of changes in 
reporting expectations or procedures. 
 
In addition to the guidance in the above, please note the following: 
 HRA Approval applies for the duration of your REC favourable opinion, unless otherwise 
notified in writing by the HRA. 
 Substantial amendments should be submitted directly to the Research Ethics Committee, as 
detailed in the After Ethical Review document. Non-substantial amendments should be 
submitted for review by the HRA using the form provided on the HRA website, and emailed to 
hra.amendments@nhs.net.  
 The HRA will categorise amendments (substantial and non-substantial) and issue confirmation 
of continued HRA Approval. Further details can be found on the HRA website. 
 
Scope  
HRA Approval provides an approval for research involving patients or staff in NHS organisations in 
England.  
 
If your study involves NHS organisations in other countries in the UK, please contact the relevant 
national coordinating functions for support and advice. Further information can be found through IRAS. 
  
If there are participating non-NHS organisations, local agreement should be obtained in accordance 
with the procedures of the local participating non-NHS organisation. 
 
User Feedback 
The Health Research Authority is continually striving to provide a high quality service to all applicants 
and sponsors. You are invited to give your view of the service you have received and the application 
IRAS project ID 238074 
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procedure. If you wish to make your views known please use the feedback form available on the HRA 
website. 
 
HRA Training 
We are pleased to welcome researchers and research management staff at our training days – see 
details on the HRA website.  
 
Your IRAS project ID is 238074. Please quote this on all correspondence. 
 
Yours sincerely 
 
Maeve Ip Groot Bluemink 
Assessor 
 
Email: hra.approval@nhs.net  
 
 
Copy to: Mrs Patricia Henley, London School of Hygiene & Tropical Medicine – Sponsor 
Contact 
Dr Essam Ramhamadany, Chelsea and Westminster NHS Foundation Trust – 
Lead R&D Contact & Participating NHS organisations in England 
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Appendix A - List of Documents 
 
The final document set assessed and approved by HRA Approval is listed below.   
 
 Document   Version   Date   
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only)  
  20 November 2017  
HRA Statement of Activities   1 (HRA 
final) 
14 December 2017  
IRAS Application Form [IRAS_Form_28112017]    28 November 2017  
Other [data sharing agreement]      
Research protocol or project proposal  3  15 November 2017  
Summary CV for Chief Investigator (CI)      
Summary CV for supervisor (student research) [Joy Lawn]     
Summary CV for supervisor (student research) [Elizabeth Allen]     
 
   
 
                                 Observational / Interventions Research Ethics Committee
Dr Helen Brotherton  
LSHTM
10 January 2019 
Dear Helen,
Study Title:  Developing and validating a mortality risk score for neonates weighing less than 2000 grams to help providers determine eligibility for kangaroo mother care
in low-resource settings 
LSHTM  ethics ref:  16189  
Thank you for your application for the above research, which has now been considered by the Observational Committee.
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting
documentation, subject to the conditions specified below.
Conditions of the favourable opinion
Approval is dependent on local ethical approval having been received, where relevant. 
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document Type File Name Date Version
Protocol / Proposal Neonatal clinical stability scoring system_NDAUprotocol_v3 15/11/2017 3
Investigator CV CV HB June 2018 01/06/2018 1.0
Investigator CV Morgan CV_Oct2018_UK 01/10/2018 1.0
 
After ethical review
The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application.  These must be submitted to the Committee for
review using an Amendment form.  Amendments must not be initiated before receipt of written favourable opinion from the committee.  
The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the
project by submitting a Serious Adverse Event form. 
An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study. 
At the end of the study, the CI or delegate must notify the committee using an End of Study form. 
All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk
Additional information is available at: www.lshtm.ac.uk/ethics
Yours sincerely,
Professor John DH Porter
Chair
ethics@lshtm.ac.uk
http://www.lshtm.ac.uk/ethics/  
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235 
A.4.4. Accompanying Comment in The Lancet Child and Adolescent Health 
A.4.4.1. Citation  
Lee SK, Zhou Q. Neonatal risk adjustment in low-resource settings. Lancet Child Adolesc Health 
2020; 4: 256-257. doi: 10.1016/S2352-4642(20)30039-0. 
A.4.4.2. Copyright and permissions 
This is an open access article distributed under the terms of the Creative Commons Attribution-
Noncommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided this is not done for 
commercial purposes, the original authors and source are credited, a link to the license is provided 
(https://creativecommons.org/licenses/by-nc-nd/4.0/), and any changes are indicated, and further 
does not permit distribution of the Article if it is changed or edited in any way.  
RESEARCH PAPER COVER SHEET 
Please note that a cover sheet must be completed for each research paper included within a thesis. 
SECTION A – Student Details 
Student ID Number 131393 Title Dr 
First Name(s) Melissa Morgan 
Surname/Family Name Medvedev 
Thesis Title 
Informing the design of a trial of kangaroo mother care initiated 
before stabilisation amongst small and sick newborns in a sub-
Saharan African context using mixed methods  
Primary Supervisor Elizabeth Allen 
If the Research Paper has previously been published please complete Section B, if not please move 
to Section C. 
SECTION B – Paper already published 
Where was the work published? 
The Lancet Child and Adolescent Health as: 
Lee SK, Zhou Q. Neonatal risk adjustment in low-resource 
settings. Lancet Child Adolesc Health 2020; 4: 256-257. doi: 
10.1016/S2352-4642(20)30039-0. 
When was the work published? 28 February 2020 
If the work was published prior to 
registration for your research degree, 
give a brief rationale for its inclusion 
Not applicable 
Have you retained the copyright for the 
work?* No 
Was the work subject 
to academic peer 
review? 
Yes 
*If yes, please attach evidence of retention. If no, or if the work is being included in its published format,
please attach evidence of permission from the copyright holder (publisher or other author) to include this 
work. 
SECTION C – Prepared for publication, but not yet published 
Where is the work intended to be 
published? 
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Please list the paper’s authors in the 
intended authorship order: 
Stage of publication Choose an item. 
SECTION D – Multi-authored work 
For multi-authored work, give full details of 
your role in the research included in the 
paper and in the preparation of the paper. 
(Attach a further sheet if necessary) 
This is a Comment piece that accompanied the NMR-
2000 risk score paper (Chapter 4); both were published 
in The Lancet Child and Adolescent Health in February 
2020. The linked Comment was authored by Shoo Lee 
and Qi Zhou; I played no role in its preparation. The 
Comment is included as a supplementary annex (A.4.4). 
SECTION E 
Student Signature Melissa Medvedev 
Date 3 August 2020 
Supervisor Signature Elizabeth Allen 
Date 05/08/2020 
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www.thelancet.com/child-adolescent   Published online February 28, 2020   https://doi.org/10.1016/S2352-4642(20)30039-0 1
Neonatal risk adjustment in low-resource settings
Risk adjustment is the process of sorting patients 
into different risk groups to permit fair comparisons 
of outcomes.1 This is important because although 
randomisation in clinical trials evenly distributes risk 
among the comparison groups, this is not possible 
when comparing real-world outcomes among different 
hospitals or groups of patients. Consequently, risk 
adjustment is an indispensable tool for real-world 
comparisons of outcomes. These comparisons are 
essential for quality improvement because they 
permit valid examination of variations in outcomes. 
If particular practices are associated with unusually 
good or poor outcomes, then clinical trials can be done 
to find out which treatments are the cause. Many 
therapies are used on the basis of experience rather than 
randomised clinical trials, and effectiveness might differ 
when applied to different populations and combined 
with untested therapies. Thus, field effectiveness is 
as important to evaluate as experimental efficacy, 
and risk adjustment is an indispensable tool for 
comparative effectiveness studies, collaborative quality 
improvement, and policy research.
Most risk adjustment instruments use a combination 
of variables that measure biological risks (eg, respiratory 
distress syndrome, congenital anomalies), vulnerability 
(eg, birthweight), or that are proxies for other risks 
(eg, socioeconomic status), and the selection of 
variables is determined by the desired outcome. For 
neonatal mortality, several well validated and widely 
used risk adjustment scores exist, including Clinical 
Risk Index for Babies (CRIBS), Score for Neonatal Acute 
Physiology version II (SNAP-II), Neonatal Therapeutic 
Intervention Scoring System (NTISS), Transport Risk 
Index of Physiologic Stability version II (TRIPS-II), and 
the Simplified Age-Weight-Sex (SAWS).2–6 So, why 
produce another neonatal risk adjustment score? 
Melissa Medvedev and colleagues7 rightly point out that 
existing neonatal risk adjustment scores were mostly 
created for use in high-resource settings and require 
data that are not easy to collect in low-resource settings, 
which limits their usability. SAWS is an exception in that 
it was designed specifically for low-resource settings, 
but this score has been reported to have only moderate 
discrimination for in-hospital mortality.6 Medvedev 
and colleagues’ new score, NMR-2000, is intended 
to fill this gap and to provide low-resource settings 
with a tool that can facilitate efforts in benchmarking, 
quality improvement, and research. This laudable 
goal might spur quality improvement efforts in low-
resource settings that could lead to substantial system-
wide improvements and better patient outcomes, as 
has been amply shown by existing networks in high-
resource settings, such as the Vermont-Oxford Neonatal 
Network, California Perinatal Quality Care Collaborative, 
and the Canadian Neonatal Network.8–10
Medvedev and colleagues7 used retrospective, 
observational data from the large UK National 
Neonatal Research Database (187 neonatal units) to 
derive the NMR-2000 score by including only variables 
that were considered easily available in low-resource 
settings. They then validated the score using data from 
the database (more than 55 000 neonates admitted 
to any unit between Jan 1, 2010 and Dec 31, 2017) 
and data from a Gambian cohort (550 neonates 
weighing less than 2000 g who were admitted to the 
Edward Francis Small Teaching Hospital, Banjul, The 
Gambia, between May 1, 2018, and Sept 30, 2019). 
Their approach is innovative because low-resource 
settings are often restricted by an absence of large 
cohorts with reliable data. The results showing that 
NMR-2000 compares favourably with other neonatal 
risk adjustment scores for prediction of mortality 
in both the UK (c-index of 0·8859–0·8930 and a 
Brier score of 0·0232–0·0271) and Gambian cohorts 
(c-index of 0·8170 and a Brier score of 0·1688) is 
heartening. However, it is perhaps not surprising, 
because the three variables selected were birthweight, 
admission oxygen saturation, and highest level of 
respiratory support during the first 24 h of admission.7 
Birthweight is the single most predictive variable 
of neonatal mortality, and respiratory status is the 
most common source of neonatal physiological 
instability. What is surprising is the choice of oxygen 
saturation as an eligible variable because many 
hospitals in low-resource settings might have no 
ready access to oxygen saturation monitors, which 
limits the usefulness of the NMR-2000. The TRIPS-II 
score might be more practical because it uses clinical 
observations that are easy to make without the need 
for instrumentation.5 Additionally, because NMR-2000 
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uses measurements made over 24 h, interventions 
during the initial 24 h can influence the outcome 
and bias the results, whereas TRIPS-II is measured 
almost instantly, and can be used sequentially so that 
mortality risks can be revised as the condition of the 
infant changes. However, the TRIPS-II has not been 
validated in low-resource settings.
Medvedev and colleagues7 should be commended 
because NMR-2000 might stimulate benchmarking and 
collaborative quality improvement efforts in countries 
where outcome improvements are badly needed at 
affordable costs, and the effect could be substantial. 
Indeed, such efforts should be encouraged and funding 
made available. However, it should be remembered that 
risk prediction models come with important caveats. 
Quality of care should consider not only mortality, but 
also factors such as morbidity, quality of life, access 
to care, and cost of care. In addition, even when risk 
prediction models based on routinely collected health 
data work well for populations, they do not reliably 
predict individual risks and should not be applied to 
individuals.
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A.5. Search strategy for literature review of randomised controlled trials examining 
the effect of KMC on mortality, length of stay, and hypothermia 
 
I searched PubMed for studies published from inception through October 31, 2016 using the 
following search terms. Equivalent dates and search terms were used for EMBASE and 
Google Scholar. Only relevant articles were retrieved.  
 
Kangaroo care 
(kangaroo-mother care method[MeSH] OR kangaroo mother care OR kangaroo care OR skin-to-
skin care OR skin-to-skin contact)  
 
AND  
 
Newborn 
(infant, newborn[MeSH] OR newborn OR new-born OR neonate OR neonatal OR infant, 
premature/ OR infant, preterm/ OR infant, low birth weight/ OR LBW OR infant, very low birth 
weight/ OR VLBW OR infant, extremely low birth weight/ OR ELBW OR infan* OR neonat*)  
 
AND  
 
Randomised controlled trial 
(randomised controlled trial OR controlled clinical trial OR clinical trials as topic[MeSH] OR 
Clinical Trial[ptyp] OR randomised[tiab] OR [tiab] OR trial[ti]).  
 
 
To identify relevant ongoing trials, I searched the following databases most recently in 
October 2019 using the terms, “kangaroo care” and “skin-to-skin contact.”    
 
• Australian and New Zealand Clinical Trials Registry: www.anzctr.org.au  
• European Union Clinical Trials Register: www.clinicaltrialsregister.eu 
• US National Institutes of Health Clinical Trials Registry: www.clinicaltrials.gov  
• WHO International Clinical Trials Registry platform: www.who.int/trialsearch  
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A.6. Kangaroo Mother Care for clinically unstable neonates: is it feasible at a 
hospital in Uganda? Journal of Global Health 2018. 
 
A.6.1. Copyright and permissions  
 
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 
International License (CC-BY), which permits unrestricted use, distribution, and reproduction in 
any medium, provided the original authors and source are credited, a link to the license is 
provided (http://creativecommons.org/licenses/by/4.0/), and any changes are indicated. 
A.6.2. Ethical approvals 
 
Ethical approval was obtained from the Institutional Review Boards at LSHTM, Makerere 
University, and UNCST. Letters of approval from LSHTM, Makerere University, and UNCST are 
available on the following pages. 
 
  
 
                                             
Observational / Interventions Research Ethics Committee
 
 
 
Dr Melissa Morgan 
LSHTM
9 May 2016 
Dear Melissa
Study Title: The OMWaNA Study: Feasibility and acceptability of an individually randomised trial of kangaroo mother care for clinically unstable infants weighing ≤2000g in Uganda 
LSHTM Ethics Ref: 10597 
Thank you for responding to the Interventions Committee’s request for further information on the above research and submitting revised documentation.
The further information has been considered on behalf of the Committee by the Chair. 
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation
as revised, subject to the conditions specified below.
Conditions of the favourable opinion
Approval is dependent on local ethical approval having been received, where relevant. 
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document Type File Name Date Version
Investigator CV Morgan CV Jan 2016_UK 28/01/2016 1.0
Investigator CV Harriet Nambuya_CV 28/01/2016 1.0
Investigator CV Peter Waiswa_CV 28/01/2016 1.0
Investigator CV Joy Lawn CV 28/01/2016 1.0
Investigator CV Elizabeth Allen CV 28/01/2016 1.0
Investigator CV Janet Seeley CV 28/01/2016 1.0
Investigator CV Mike English CV 28/01/2016 1.0
Investigator CV Cally Tann CV 28/01/2016 1.0
Protocol / Proposal OMWaNA Study Feasibility and Acceptability Protocol_v3_3May2016 03/05/2016 3.0
Information Sheet Feasibility Part 2 Consent Form_v2_3May 2016 03/05/2016 2.0
Information Sheet Feasibility Study Part 3 Consent Form_v2_3May2016 03/05/2016 2.0
Information Sheet Acceptability Study Consent Form_v2_3May2016 03/05/2016 2.0
Covering Letter LSHTM Ethics Response_Morgan_v1.0_4May2016 04/05/2016 1.0
Local Approval Makerere University_KMC Study Approval 3740001 04/05/2016 1.0
 
After ethical review
The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application.  These must be submitted to the Committee for review
using an Amendment form.  Amendments must not be initiated before receipt of written favourable opinion from the committee.  
The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the project
by submitting a Serious Adverse Event form. 
An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study. 
Page 1 of 2
At the end of the study, the CI or delegate must notify the committee using an End of Study form. 
All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk
Additional information is available at: www.lshtm.ac.uk/ethics
Yours sincerel ,
Professor John DH Porter
Chair
ethics@lshtm.ac.uk
http://www.lshtm.ac.uk/ethics/ 
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A.7. Operationalising kangaroo Mother care before stabilisation amongst low birth 
Weight Neonates in Africa (OMWaNA): protocol for a randomised controlled trial 
to examine mortality impact in Uganda. Trials 2020. 
A.7.1. Copyright and permissions 
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 
International License (CC-BY), which permits unrestricted use, distribution, and reproduction in 
any medium, provided the original authors and source are credited, a link to the license is 
provided (http://creativecommons.org/licenses/by/4.0/), and any changes are indicated.  
A.7.2. Web appendix of published paper 
Available at: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-4044-6 
A.7.3. Ethical approvals 
Ethical approval for the study was obtained from the Research Ethics Committees of LSHTM 
(#16972), MRC/UVRI and LSHTM Uganda Research Unit (GC/127/19/06/717), and UNCST 
(HS 2645). Letters of approval from LSHTM, MRC/UVRI and LSHTM Uganda Research Unit, 
and UNCST are available on the following pages. 
Observational / Interventions Research Ethics Committee
Prof Joy Lawn 
LSHTM
11 July 2019 
Dear  Prof Joy Lawn  ,
Study Title:  The OMWaNA Study: Operationalising kangaroo Mother care before stabilisation amongst low birth Weight Neonates in Africa: a multi-site randomised
controlled trial to examine mortality impact in Uganda 
LSHTM  ethics ref:  16972  
Thank you for your application for the above research, which has now been considered by the Interventions Committee.
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting
documentation, subject to the conditions specified below.
Conditions of the favourable opinion
Approval is dependent on local ethical approval having been received, where relevant. 
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document Type File Name Date Version
Other GCP_GCP Certificate (R2)_CT_12Dec17 12/11/2017 n/a
Other RETC_Certificate_2019 09/01/2019 n/a
Information Sheet ICFphotography_OMWaNA_V1.0_8.2.19 08/02/2019 1.0
Information Sheet ICFquali_OMWaNA_V1.0_English_8.02.19 08/02/2019 1.0
Other Melissa Medvedev_GCP Certificate_5May2019 05/05/2019 n/a
Investigator CV Cally Tann_CV 30/05/2019 n/a
Investigator CV Melissa Medvedev_CV 30/05/2019 n/a
Investigator CV Peter Waiswa_CV 30/05/2019 n/a
Investigator CV Joy Lawn_CV 30/05/2019 n/a
Investigator CV Liz Allen_CV 30/05/2019 n/a
Sponsor Letter 2019-MUU-234_Sponsor Confirmation 31/05/2019 n/a
Protocol / Proposal OMWaNA protocol_V1.2_31.05.19_clean 31/05/2019 1.2
Information Sheet ICF_OMWaNA_V1.1_English_31.05.19_clean 31/05/2019 1.1
After ethical review
The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application.  These must be submitted to the Committee for
review using an Amendment form.  Amendments must not be initiated before receipt of written favourable opinion from the committee.
The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the
project by submitting a Serious Adverse Event form. 
An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study.
At the end of the study, the CI or delegate must notify the committee using an End of Study form. 
All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk
Additional information is available at: www.lshtm.ac.uk/ethics
Page 1 of 2
Yours sincerely,
Professor Jimmy Whitworth
Chair
ethics@lshtm.ac.uk
http://www.lshtm.ac.uk/ethics/  
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SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related 
documents* 
Section/item Item 
No 
Description Addressed 
on page 
number 
Administrative information 
Title 1 Descriptive title identifying the study design, population, interventions, 
and, if applicable, trial acronym 
__1____ 
Trial 
registration 
2a Trial identifier and registry name. If not yet registered, name of 
intended registry 
__2, 5 __ 
2b All items from the World Health Organization Trial Registration Data 
Set 
__2, 3 __ 
Protocol 
version 
3 Date and version identifier __35 ___ 
Funding 4 Sources and types of financial, material, and other support __37 ___ 
Roles and 
responsibilities 
5a Names, affiliations, and roles of protocol contributors _37-39__ 
5b Name and contact information for the trial sponsor __36____ 
5c Role of study sponsor and funders, if any, in study design; collection, 
management, analysis, and interpretation of data; writing of the 
report; and the decision to submit the report for publication, including 
whether they will have ultimate authority over any of these activities 
_36, 37__ 
5d Composition, roles, and responsibilities of the coordinating centre, 
steering committee, endpoint adjudication committee, data 
management team, and other individuals or groups overseeing the 
trial, if applicable (see Item 21a for data monitoring committee) 
_37, 38__ 
Introduction 
Background 
and rationale 
6a Description of research question and justification for undertaking the 
trial, including summary of relevant studies (published and 
unpublished) examining benefits and harms for each intervention 
__6, 7 __ 
6b Explanation for choice of comparators __6, 7___ 
Objectives 7 Specific objectives or hypotheses __8_____ 
Trial design 8 Description of trial design including type of trial (eg, parallel group, 
crossover, factorial, single group), allocation ratio, and framework (eg, 
superiority, equivalence, noninferiority, exploratory) 
__8_____ 
A.7.4. SPIRIT Checklist
255 
Methods: Participants, interventions, and outcomes 
Study setting 9 Description of study settings (eg, community clinic, academic hospital) 
and list of countries where data will be collected. Reference to where 
list of study sites can be obtained 
__8-10__ 
Eligibility 
criteria 
10 Inclusion and exclusion criteria for participants. If applicable, eligibility 
criteria for study centres and individuals who will perform the 
interventions (eg, surgeons, psychotherapists) 
_10, 11__ 
Interventions 11a Interventions for each group with sufficient detail to allow replication, 
including how and when they will be administered 
_16-18__ 
11b Criteria for discontinuing or modifying allocated interventions for a 
given trial participant (eg, drug dose change in response to harms, 
participant request, or improving/worsening disease) 
_17, 18__ 
11c Strategies to improve adherence to intervention protocols, and any 
procedures for monitoring adherence (eg, drug tablet return, 
laboratory tests) 
_31, 32__ 
11d Relevant concomitant care and interventions that are permitted or 
prohibited during the trial 
_19, 20__ 
Outcomes 12 Primary, secondary, and other outcomes, including the specific 
measurement variable (eg, systolic blood pressure), analysis metric 
(eg, change from baseline, final value, time to event), method of 
aggregation (eg, median, proportion), and time point for each 
outcome. Explanation of the clinical relevance of chosen efficacy and 
harm outcomes is strongly recommended 
_22-25__ 
Participant 
timeline 
13 Time schedule of enrolment, interventions (including any run-ins and 
washouts), assessments, and visits for participants. A schematic 
diagram is highly recommended (see Figure) 
__12____ 
Sample size 14 Estimated number of participants needed to achieve study objectives 
and how it was determined, including clinical and statistical 
assumptions supporting any sample size calculations 
__26____ 
Recruitment 15 Strategies for achieving adequate participant enrolment to reach 
target sample size 
_30, 31__ 
Methods: Assignment of interventions (for controlled trials) 
Allocation: 
Sequence 
generation 
16a Method of generating the allocation sequence (eg, computer-
generated random numbers), and list of any factors for stratification. 
To reduce predictability of a random sequence, details of any planned 
restriction (eg, blocking) should be provided in a separate document 
that is unavailable to those who enrol participants or assign 
interventions 
__16____ 
256 
Allocation 
concealment 
mechanism 
16b Mechanism of implementing the allocation sequence (eg, central 
telephone; sequentially numbered, opaque, sealed envelopes), 
describing any steps to conceal the sequence until interventions are 
assigned 
_17, 18__ 
Implementatio
n 
16c Who will generate the allocation sequence, who will enrol participants, 
and who will assign participants to interventions 
__16____ 
Blinding 
(masking) 
17a Who will be blinded after assignment to interventions (eg, trial 
participants, care providers, outcome assessors, data analysts), and 
how 
__16____ 
17b If blinded, circumstances under which unblinding is permissible, and 
procedure for revealing a participant’s allocated intervention during 
the trial 
_16, 22__ 
Methods: Data collection, management, and analysis 
Data collection 
methods 
18a Plans for assessment and collection of outcome, baseline, and other 
trial data, including any related processes to promote data quality (eg, 
duplicate measurements, training of assessors) and a description of 
study instruments (eg, questionnaires, laboratory tests) along with 
their reliability and validity, if known. Reference to where data 
collection forms can be found, if not in the protocol 
15,16,22-
25 
18b Plans to promote participant retention and complete follow-up, 
including list of any outcome data to be collected for participants who 
discontinue or deviate from intervention protocols 
_20, 21__ 
Data 
management 
19 Plans for data entry, coding, security, and storage, including any 
related processes to promote data quality (eg, double data entry; 
range checks for data values). Reference to where details of data 
management procedures can be found, if not in the protocol 
__26____ 
Statistical 
methods 
20a Statistical methods for analysing primary and secondary outcomes. 
Reference to where other details of the statistical analysis plan can be 
found, if not in the protocol 
__27____ 
20b Methods for any additional analyses (eg, subgroup and adjusted 
analyses) 
_27, 28__ 
20c Definition of analysis population relating to protocol non-adherence 
(eg, as randomised analysis), and any statistical methods to handle 
missing data (eg, multiple imputation) 
__27____ 
Methods: Monitoring 
Data 
monitoring 
21a Composition of data monitoring committee (DMC); summary of its role 
and reporting structure; statement of whether it is independent from 
the sponsor and competing interests; and reference to where further 
details about its charter can be found, if not in the protocol. 
Alternatively, an explanation of why a DMC is not needed 
21, 22, 38 
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21b Description of any interim analyses and stopping guidelines, including 
who will have access to these interim results and make the final 
decision to terminate the trial 
__22____ 
Harms 22 Plans for collecting, assessing, reporting, and managing solicited and 
spontaneously reported adverse events and other unintended effects 
of trial interventions or trial conduct 
__21____ 
Auditing 23 Frequency and procedures for auditing trial conduct, if any, and 
whether the process will be independent from investigators and the 
sponsor 
__22   __ 
Ethics and dissemination 
Research 
ethics 
approval 
24 Plans for seeking research ethics committee/institutional review board 
(REC/IRB) approval 
__36____ 
Protocol 
amendments 
25 Plans for communicating important protocol modifications (eg, 
changes to eligibility criteria, outcomes, analyses) to relevant parties 
(eg, investigators, REC/IRBs, trial participants, trial registries, 
journals, regulators) 
__36____ 
Consent or 
assent 
26a Who will obtain informed consent or assent from potential trial 
participants or authorised surrogates, and how (see Item 32) 
__15____ 
26b Additional consent provisions for collection and use of participant data 
and biological specimens in ancillary studies, if applicable 
__15____ 
Confidentiality 27 How personal information about potential and enrolled participants will 
be collected, shared, and maintained in order to protect confidentiality 
before, during, and after the trial 
__26____ 
Declaration of 
interests 
28 Financial and other competing interests for principal investigators for 
the overall trial and each study site 
__37____ 
Access to data 29 Statement of who will have access to the final trial dataset, and 
disclosure of contractual agreements that limit such access for 
investigators 
__26____ 
Ancillary and 
post-trial care 
30 Provisions, if any, for ancillary and post-trial care, and for 
compensation to those who suffer harm from trial participation 
__36____ 
Dissemination 
policy 
31a Plans for investigators and sponsor to communicate trial results to 
participants, healthcare professionals, the public, and other relevant 
groups (eg, via publication, reporting in results databases, or other 
data sharing arrangements), including any publication restrictions 
_36, 37__ 
31b Authorship eligibility guidelines and any intended use of professional 
writers 
_36, 37__ 
31c Plans, if any, for granting public access to the full protocol, participant-
level dataset, and statistical code 
__36____ 
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Appendices 
Informed 
consent 
materials 
32 Model consent form and other related documentation given to 
participants and authorised surrogates 
These are 
available 
from the 
correspond-
ing author 
on request. 
Biological 
specimens 
33 Plans for collection, laboratory evaluation, and storage of biological 
specimens for genetic or molecular analysis in the current trial and for 
future use in ancillary studies, if applicable 
Biological 
specimens 
will not be 
collected 
for use in 
the current 
trial or in 
future 
ancillary 
studies. 
*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation &
Elaboration for important clarification on the items. Amendments to the protocol should be tracked and 
dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons 
“Attribution-NonCommercial-NoDerivs 3.0 Unported” license. 
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A.8. Presentations resulting from this work and related work 
1. Medvedev M (on behalf of the NMR-2000 team). An example of how the National Neonatal
Research Database has been used to help develop a risk scoring tool for use in low- and
middle-income countries. National Neonatal Audit Programme and Neonatal Data Analysis
Unit Collaborators’ Meeting 2020 March (postponed due to COVID-19 pandemic); London,
UK. Platform presentation.
2. Medvedev M (on behalf of the OMWaNA team). The OMWaNA Trial: Operationalising
kangaroo Mother care among unstable low birth Weight Neonates in Africa. Impact Now:
Improving maternal, newborn and child health in Africa 2019 November; Stellenbosch, South
Africa. Platform presentation and panel discussion.
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A.9. KMC progress monitoring tool 
From: Bergh AM et al. Acta Paediatr 2005; 94: 1102-8
Implementation
construct
(and score) Progress marker (indicator)
Instrument items related to progress marker
(with scores)
1 Creating awareness
(maximum=2 points)
1-1 Number and type of (senior)
managers involved in
implementation process
(in relation to size of hospital)
! Special persons who take specific effort in promoting KMC
– Management (manager, CEO, nursing service manager,
ward manager, other)
– Professionals (doctors, nurses, allied health workers)
– Driving forces (contact person, KMC committee, other
individuals or group)
(1.5 points)
! Impressions regarding the intensity of involvement of senior
management in establishing KMC (past or future) (a lot,
some, little/neutral/resistant)
(0.5 points)
2 Adopting the concept
(maximum=2 points)
2-1 Minuted decision to
implement KMC or recall
by leaders of occasion and
date of decision
! Knowledge of original decision to implement (e.g. occasion,
date, minutes, who was involved)
! Impression of recall of history of implementation (good,
some, none)
(1 point)
! If KMC is not implemented yet: Has a formal decision in
this regard been made?
(1 point)
2-2 Signing of baseline
datasheet to enrol in the
outreach
! Baseline data sheet together with permission from the CEO
or medical superintendent to participate in the outreach has
been submitted
(1 point)
3 Taking ownership
(mobilization of
resources)
(maximum=6 points)
3-1 Allocation of space ! Practice of intermittent KMC in the neonatal unit
(nursery/NICU)
(1 point)
! Special area or ward for continuous KMC 24 h per day
(1 point)
3-2 Ability to lodge mothers ! Existence of a lodger mother facility for mothers to stay
while infants are still in incubators (0.5 points)
3-3 Procurement of equipment ! Special equipment or facilities enhancing the practice of
KMC in the neonatal unit or KMC ward:
– Comfortable chairs
– Wrappers to hold infant in KMC position
– Low beds
– Other (e.g. back rests)
(0.5 points)
3-4 Removal of cribs ! All cribs removed from KMC ward
(1 point)
3-5 Information for mothers ! Availability of brochures and information sheets
! Posters on display
! Other (e.g. videos)
(1 point)
3-6 Other resources ! Allocations from the hospital budget to establish KMC facility
(0.5 points)
! Other sponsors
(0.5 points)
4 Evidence of practice
(maximum=7 points)
4-1 Evidence of the KMCposition ! Intermittent KMC practised in high care
(1 point)
! Number of infants doing intermittent KMC in neonatal unit
– Observed
– Verified from records
– Verified other (e.g. from mothers)
(1 point)
! Separate KMC ward or area
(1 point)
! Number of mother–infant pairs enrolled for continuous KMC in
separate KMCward or area in another ward (e.g. postnatal ward)
– Number of mothers observed having infants in KMC
position
(1 point)
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construct
(and score) Progress marker (indicator)
Instrument items related to progress marker
(with scores)
4-2 Orientation for new staff ! Face-to-face oral orientation
! Written orientation
! Other (e.g. video)
(0.5 points)
(All types of staff orientation to be verified from
in-service training or other records)
4-3 Records that document KMC ! Records in use and nature thereof (ward register, special
form for every single KMC infant, special collective record
kept for all infants who receive(d) KMC, any other
relevant record)
(1 point)
4-4 Ability to provide figures
of number of infants going
through KMC
! Records can be used for calculation of
– number of infants receiving intermittent and continuous
KMC
– length of intermittent and continuous KMC of outreach
infant
– weight on admission to intermittent and continuous
KMC
– weight gain while in intermittent and continuous
KMC
(1.5 points)
5 Evidence of routine
and integration
(maximum=7 points)
5-1 Further evidence of
KMC position
! Kangaroo position (skin-to-skin contact) is practised by
HIV+ mothers of infants in the neonatal unit and KMC
ward
(1 point)
5-2 Evidence of KMC
nutrition
! There is a written feeding policy in the neonatal ward for
intermittent KMC and in the KMC ward for continuous
KMC
(1 point)
5-3 Evidence of KMC discharge
and ambulatory KMC
(follow-up system)
! Follow-up arrangements (infants return to ward,
outpatients, clinic, home care/visits)
! Written evidence of follow-up system
! Written evidence of record-keeping
(3 points)
5-4 Evidence of KMC included
in policy and protocol
documents
! Statements and policies in which KMC appears (vision,
mission, declaration of quality of service)
(0.5 points)
! Guidelines and protocols regarding the practice
of KMC (for nursing staff, doctors, ward clerk,
allied health workers)
(1.5 points)
6 Sustainable practice
(maximum=6 points)
6-1 Audit results for at least 1 y ! Audit figures containing evidence of ongoing KMC practice
for at least 1 y can be provided
(2 points)
6-2 Evidence of staff development
policy
! Special plan to ensure that all staff get adequate training in
KMC
(0.5 points)
! Evidence of a written plan
(0.5 points)
(Also evaluate against the requirements of the
South African Skills Development Act)
6-3 Evidence of staff training
(additional to facilitation
that is part of the
outreach)
! Whether one or more staff members got special training
in past year
(1 point)
6-4 Score on first five constructs
(divided by 12)
(The score on the first five constructs will influence
sustainabililty)
(2 points)
Maximum total score 30 points
A.9. KMC progress monitoring tool - continued 
From: Bergh AM et al, Acta Paediatr 2005; 94: 1102-8
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